aspirin has been researched along with Recrudescence in 1237 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this prospective cohort study, we randomly assigned patients with PFO who had a cryptogenic stroke, in a 1:1 ratio, to dabigatran or aspirin group." | 9.51 | Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study. ( Cai, D; Chen, S; He, J; Huang, P; Lai, Y; Sun, H; Wu, Q; Zhou, L, 2022) |
| " Approach and Results: The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) randomized patients with acute minor ischemic stroke or high-risk transient ischemic attack to clopidogrel plus aspirin or aspirin alone from October 1, 2009, to July 30, 2012, in China." | 9.34 | Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial. ( Li, H; Li, J; Lin, J; Liu, L; Wang, A; Wang, Y; Zhao, X; Zuo, Z, 2020) |
| "The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it substantially reduces stroke risk in patients with atrial fibrillation (AF)." | 9.30 | Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. ( Arauz, A; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Eckstein, J; Endres, M; Epstein, AE; Gladstone, DJ; Haeusler, KG; Hankey, GJ; Hart, RG; Healey, JS; Karlinski, M; Kasner, SE; Lutsep, H; Mikulik, R; Molina, CA; Mundl, H; Ntaios, G; Pagola, J; Perera, K; Santo, G; Shuaib, A; Swaminathan, B; Toni, D; Uchiyama, S; Yang, X, 2019) |
| "We conducted a multicenter, randomized, double-blind trial of dabigatran at a dose of 150 mg or 110 mg twice daily as compared with aspirin at a dose of 100 mg once daily in patients who had had an embolic stroke of undetermined source." | 9.30 | Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. ( Bernstein, RA; Brueckmann, M; Chernyatina, M; Cotton, D; Cronin, L; Diener, HC; Donnan, G; Easton, JD; Ferro, JM; Granger, CB; Grauer, C; Grond, M; Kallmünzer, B; Kreuzer, J; Krupinski, J; Lee, BC; Lemmens, R; Masjuan, J; Odinak, M; Sacco, RL; Saver, JL; Schellinger, PD; Toni, D; Toyoda, K; Uchiyama, S, 2019) |
| "Exploratory analyses of 7213 participants in the NAVIGATE ESUS international trial who were randomized to aspirin 100 mg/day or rivaroxaban 15 mg/day and followed for a median of 11 months, during which time there were 309 first recurrent ischemic strokes (4." | 9.30 | Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. ( Ameriso, SF; Bangdiwala, SI; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Gagliardi, RJ; Hankey, GJ; Hart, RG; Kasner, SE; Lindgren, A; Mundl, H; Ntaios, G; Perera, KS; Peters, G; Sharma, M; Sheridan, P; Shoamanesh, A; Shuaib, A; Toni, D; Veltkamp, RC, 2019) |
| "For this industry-independent, double-blind, double-dummy, randomised trial done in one academic hospital in Hong Kong, we screened patients with arthritis and cardiothrombotic diseases who were presenting with upper gastrointestinal bleeding, were on NSAIDs, and require concomitant aspirin." | 9.24 | Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. ( Au, KWL; Chan, FKL; Chan, H; Cheong, PK; Ching, JYL; Kee, KM; Kyaw, MH; Lam, K; Lee, V; Lo, A; Ng, SC; Suen, BY; Tse, YK; Wong, GLH; Wong, VWS; Wu, JCY, 2017) |
| "Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis." | 9.24 | Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is effective in preventing recurrent strokes after minor ischemic stroke or transient ischemic attack (TIA)." | 9.22 | Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis. ( Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Zitikyte, G, 2022) |
| "To examine whether combined treatment with low-molecular-weight heparin (LMWH) and aspirin reduces recurrent hypertensive disorders of pregnancy (HD: pre-eclampsia, eclampsia or HELLP syndrome) in women with antiphospholipid antibodies (aPLA) and a previous delivery for HD and/or small-for-gestational-age (SGA) birthweight before 34 weeks gestation." | 9.22 | Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 9.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 9.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| "An individual patient data analysis of these trials was planned, before their results were known, to assess the effect of aspirin versus placebo on recurrent VTE, major vascular events (recurrent VTE, myocardial infarction, stroke, and cardiovascular disease death) and bleeding, overall and within predefined subgroups." | 9.19 | Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. ( Agnelli, G; Becattini, C; Brighton, TA; Eikelboom, JW; Kirby, AC; Mister, R; Prandoni, P; Simes, J, 2014) |
| "We investigated whether CYP2C9 genotype was associated with risk of colorectal adenoma and/or modified associations with aspirin treatment or cigarette smoking in a cohort of 928 participants in a randomized trial of aspirin chemoprevention." | 9.17 | CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment. ( Ahnen, DJ; Baron, JA; Barry, EL; Bresalier, RS; Makar, KW; McKeown-Eyssen, GE; Mott, LA; Poole, EM; Sandler, RS; Ulrich, CM, 2013) |
| "To investigate the prevalent of aspirin resistance (AR) in Chinese stroke patients and its association with recurrent stroke and other vascular events, including cardiovascular disease and death." | 9.17 | Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events. ( Chi, L; Lin, J; Yi, X; Zhou, Q, 2013) |
| "To determine the effect of aspirin on ulcer healing rate in patients with chronic venous insufficiency, and to establish prognostic factors that influence ulcer evolution." | 9.16 | Influence of aspirin therapy in the ulcer associated with chronic venous insufficiency. ( Antonio, J; del Río Solá, ML; Fajardo, G; Vaquero Puerta, C, 2012) |
| "Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase the risk of bleeding and death." | 9.16 | Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. ( Benavente, OR; Coffey, CS; Hart, RG; McClure, LA; Pearce, LA; Szychowski, JM, 2012) |
| "After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 9.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| "In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries, 3491 patients stabilised after an acute coronary syndrome were stratified on the basis of investigator decision to use aspirin only (stratum 1, n=761) or aspirin plus a thienopyridine (stratum 2, n=2730)." | 9.14 | Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. ( Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A, 2009) |
| "The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI." | 9.14 | Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009) |
| "It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy in patients who develop peptic ulcer bleeding while receiving low-dose aspirin." | 9.14 | Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. ( Chan, FK; Ching, JY; Chiu, PW; Lau, JY; Lee, YT; Leung, VK; Sung, JJ; Wong, VW; Wu, JC, 2010) |
| "We randomly assigned a total of 400 patients with ST-segment elevation myocardial infarction referred for primary percutaneous coronary intervention to treatment initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg)." | 9.14 | Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi ( Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA, 2009) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 9.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance." | 9.13 | Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. ( Abdelmoula, MM; Divani, AA; Hussein, HM; Qureshi, AI; Suri, MF, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 9.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 9.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| "Fluctuations in urinary 11-DTB2 after cerebral infarction in blacks do not correlate with changes in aspirin doses, except perhaps when the dose changes by a factor of 4 or more." | 9.11 | Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. ( Bang, NU; Bruno, A; Cohen, SN; Gorelick, PB; McConnell, JP; Tietjen, GE; Wallis, RA, 2004) |
| "To evaluate whether long-term treatment with a fixed low dose of warfarin in combination with aspirin improves the prognosis compared with aspirin treatment alone after an acute myocardial infarction (AMI)." | 9.11 | Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. ( Erhardt, L; Haglid Evander, M; Herlitz, J; Holm, J; Karlson, BW; Peterson, M, 2004) |
| "0 in 52 patients or aspirin alone, 100 mg day(-1) in three patients) to determine whether intensive anticoagulation is superior to standard treatment in preventing symptomatic thromboembolism without increasing the bleeding risk." | 9.11 | A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). ( Barbui, T; Baudo, F; Berrettini, M; Brancaccio, V; D'Angelo, A; Finazzi, G; Marchioli, R; Musial, J; Schinco, P; Testa, S; Tognoni, G; Wisloff, F, 2005) |
| "Colchicine seems to be a good drug for treating recurrences of pericarditis after conventional treatment failure, but no clinical trial has tested the effects of colchicine as first-line drug for the treatment of the first recurrence of pericarditis." | 9.11 | Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. ( Belli, R; Bobbio, M; Cecchi, E; Demarie, D; Ghisio, A; Imazio, M; Moratti, M; Pomari, F; Trinchero, R, 2005) |
| "Overall there were higher thrombolysis in myocardial infarction (TIMI) flows in the infarct related coronary artery in the dalteparin group (p=0." | 9.10 | Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. ( Bergstrand, L; Dellborg, M; Fellenius, C; Granger, CB; Lindahl, B; Lins, LE; Nilsson, T; Pehrsson, K; Siegbahn, A; Swahn, E; Wallentin, L, 2003) |
| "To determine the efficacy and safety of aspirin and ticlopidine to prevent recurrent stroke in black patients." | 9.10 | Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. ( Gorelick, PB; Harris, Y; Hung, E; Kelly, M; Kittner, S; Leurgans, S; Richardson, D; Ruland, S, 2003) |
| "To compare the efficacy and safety of two antiplatelet regimens, ticlopidine alone (200 mg daily) and ticlopidine (100 mg daily) plus aspirin (81 mg daily), in patients with ischemic stroke from the Tokai district of Japan." | 9.10 | Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. ( Ito, E; Kuzuhara, S; Nakajima, M; Takahashi, A; Uchiyama, S; Yamamoto, H, 2003) |
| "The aims of the Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous Unfractionated Heparin and Tirofiban Versus Placebo in the Treatment of Acute ST-Segment Elevation Myocardial Infarction Patients Ineligible for Reperfusion (TETAMI) study were to demonstrate that enoxaparin was superior to unfractionated heparin (UFH) and that tirofiban was better than placebo in patients with acute ST-segment elevation myocardial infarction (STEMI) who do not receive timely reperfusion." | 9.10 | The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial ( Bigonzi, F; Cohen, M; Danchin, N; Gensini, GF; Gurfinkel, EP; Hecquet, C; Huber, K; Krzeminska-Pakula, M; Maritz, F; Santopinto, J; Timerman, A; Vittori, L; White, HD, 2003) |
| "To compare the costs to the Spanish healthcare system of 35 days' treatment with triflusal (600 mg/day) and aspirin (300 mg/day) in patients with confirmed acute myocardial infarction within 24 hours of onset of symptoms." | 9.10 | Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction. ( Darbà, J; Izquierdo, I; Navas, C; Pontes, C; Rovira, J, 2002) |
| "The dose of aspirin for secondary stroke prevention and the clinical meaning of ex vivo platelet abnormalities are debated." | 9.09 | Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study. ( Chamorro, A; Escolar, G; Obach, V; Ordinas, A; Reverter, JC; Revilla, M; Vila, N, 1999) |
| "A longitudinal cohort study was performed comparing 460 participants with intermittent AF with 1,552 with sustained AF treated with aspirin in the Stroke Prevention in Atrial Fibrillation studies and followed for a mean of two years." | 9.09 | Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. ( Asinger, RW; Halperin, JL; Hart, RG; McAnulty, JH; Pearce, LA; Rothbart, RM, 2000) |
| "To compare the efficacy and tolerability of the antiplatelet agent triflusal with aspirin in the prevention of cardiovascular events following acute myocardial infarction." | 9.09 | Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. ( Cabadés, A; Castro-Beiras, A; Cruz-Fernández, JM; García-Dorado, D; López García-Aranda, V; López-Bescós, L; Marfil, F; Martín-Jadraque, L; Navarro, E; Torres, F; Velasco, JA, 2000) |
| "Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation." | 9.09 | Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000) |
| "The aim of the present study was to evaluate the possible interaction between chronic aspirin therapy and angiotensin-converting enzyme inhibitor (ACE-I) on left ventricular ejection fraction (LVEF) in patients surviving an acute myocardial infarction (AMI)." | 9.09 | Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction. ( Arnesen, H; Hole, T; Hurlen, M; Seljeflot, I, 2001) |
| "We sought to compare the efficacy of aspirin and ticlopidine in survivors of acute myocardial infarction (AMI) treated with thrombolysis." | 9.09 | Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. ( Cimminiello, C; Di Biase, M; Marubini, E; Pitzalis, MV; Rizzon, P; Scrutinio, D, 2001) |
| "We sought to compare different antithrombotic secondary treatments (mainly medium-dose aspirin with low-dose low-molecular-weight heparin [LMWH]) in pediatric patients with a first ischemic stroke onset with regard to the risk of stroke recurrence." | 9.09 | Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. ( Heller, C; Kurnik, K; Luigs, P; Nowak-Göttl, U; Schobess, R; Sträter, R, 2001) |
| "To compare aspirin with anticoagulation with regard to risk of cardiac death and reinfarction in patients who received anistreplase thrombolysis for myocardial infarction." | 9.08 | A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. ( Chamberlain, DA; Julian, DG; Pocock, SJ, 1996) |
| "The efficacy of combining antiplatelet agents with low doses of aspirin to prevent cardiac events in patients with myocardial infarction was examined." | 9.08 | Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group. ( Hama, J; Ishikawa, K; Kanamasa, K; Katori, R; Kimura, A; Naito, T; Nakai, S; Ogawa, I; Oyaizu, M; Takenaka, T; Yamamoto, K; Yamamoto, T, 1997) |
| "Healing with bFGF (and cimetidine) was associated with reduced NSAID induced ulcer relapse in this model of gastric ulceration." | 9.08 | Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration. ( Brough, JL; Filipowicz, B; Hawkey, CJ; Hull, MA; Knifton, A; Vautier, G, 1997) |
| "The efficacy of low-dose aspirin in preventing fetal growth retardation was tested in a randomised, placebo-controlled, double-blind trial." | 9.07 | Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. ( Bazin, B; Beaufils, M; Breart, G; Capitant, C; Paris, J; Uzan, S, 1991) |
| "To ascertain whether predischarge arteriography is beneficial in patients with acute myocardial infarction treated with recombinant tissue-type plasminogen activator (rt-PA), heparin and aspirin, the outcome of 197 patients in the Thrombolysis in Myocardial Infarction (TIMI) IIA study assigned to conservative management and routine predischarge coronary arteriography (routine catheterization group) was compared with the outcome of 1,461 patients from the TIMI IIB study assigned to conservative management without routine coronary arteriography unless ischemia recurred spontaneously or on predischarge exercise testing (selective catheterization group)." | 9.07 | Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II Investigators. ( Babb, JD; Baim, DS; Braunwald, E; Chesebro, JH; Frederick, M; Gore, JM; Passamani, ER; Roberts, R; Rogers, WJ; Williams, DO, 1991) |
| "We carried out a pilot study in 15 hemodialysis patients with recurrent vascular access thrombosis to examine whether the combination of low dose aspirin (85 mg once daily) and sulfinpyrazone (200 mg three times daily) is safe and effective in the prevention of vascular access thrombosis." | 9.07 | Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. ( Bauman, JE; Domoto, DT; Joist, JH, 1991) |
| "Recently, it was shown that aspirin given early in acute myocardial infarction (AMI) improves hospital survival, but the mechanisms involved are unclear." | 9.06 | Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. ( Funke-Küpper, AJ; Galema, TW; Roos, JP; Sterkman, LG; van der Laarse, A; Verheugt, FW, 1990) |
| "A randomized, controlled study was conducted in 51 patients to investigate the effect of aspirin administration on traumatic hyphema." | 9.06 | Aspirin and secondary bleeding after traumatic hyphema. ( Biedner, B; Lifshitz, T; Marcus, M; Yassur, Y, 1988) |
| " Low-dose aspirin and dipyridamole direct prostacyclin/thromboxane A2 balance in pregnancy to the dominance of prostacyclin and may thus prevent idiopathic uteroplacental insufficiency and fetal growth retardation in high-risk patients." | 9.06 | Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole. ( Rotmans, N; Wallenburg, HC, 1987) |
| "The MRC Epidemiology Unit in Cardiff, Wales conducted three randomized, controlled trials of aspirin use in patients who had had myocardial infarction." | 9.05 | British studies of aspirin and myocardial infarction. ( Elwood, PC, 1983) |
| "The Aspirin Myocardial Infarction Study (AMIS) was a National Heart, Lung and Blood Institute-sponsored, multicenter, randomized, double-blind, and placebo-controlled trial designed to test whether the regular administration of aspirin to men and women who had experienced at least one documented myocardial infarction (MI) would result in a significant reduction in total mortality over a three-year period." | 9.05 | A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. ( , 1980) |
| " Although a 150 mg dose of aspirin reduced urinary dinor-TxB2 levels by over 75 per cent, it had no effect on the course of the chronic recurrent form of angina pectoris due to vasospasm ("vasotonic angina")." | 9.05 | Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials. ( FitzGerald, GA; Friesinger, GC; Maas, RL; Oates, JA; Roberts, LJ; Robertson, D; Robertson, RM, 1981) |
| "Although neither aspirin nor oral anticoagulants have been conclusively shown to reduce mortality in patients surviving myocardial infarction, both have been widely used for that purpose." | 9.05 | A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. ( , 1982) |
| "The Jenkins Activity Survey (JAS), a questionnaire developed to assess the type A behavior pattern, was administered to 2,314 participants in the Aspirin Myocardial Infarction Study." | 9.05 | Type A score (Jenkins Activity Survey) and risk of recurrent coronary heart disease in the aspirin myocardial infarction study. ( Gale, M; Norusis, M; Shekelle, RB, 1985) |
| "A randomized controlled trial is reported in which a single dose of aspirin (300 mg) was given to patients with myocardial infarction on first contact with a general practitioner." | 9.04 | A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction. ( Elwood, PC; Williams, WO, 1979) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 9.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "The analysis showed lower risks of major adverse cardiovascular or cerebrovascular events, recurrent stroke, and bleeding events for clopidogrel monotherapy compared to aspirin." | 9.01 | Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. ( Del Aguila, M; Girotra, S; Hu, B; Ince, B; Jeng, JS; Kutluk, K; Liu, L; Lou, M; Min Han, J; Paciaroni, M; Paek, D; Parfenov, V; Wong, KSL; Zamani, B, 2019) |
| "To assess the effectiveness and safety of dual agent antiplatelet therapy combining clopidogrel and aspirin to prevent recurrent thrombotic and bleeding events compared with aspirin alone in patients with acute minor ischaemic stroke or transient ischaemic attack (TIA)." | 8.98 | Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. ( Foroutan, F; Guyatt, G; Hao, Q; O'Donnell, M; Siemieniuk, RA; Tampi, M, 2018) |
| "Optimal antiplatelet therapy after an ischemic stroke or transient ischemic attack while on aspirin is uncertain." | 8.95 | Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2017) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for 90 days was recommended as the secondary prevention of minor ischaemic strokes or transient ischaemic attacks (TIAs) in 2014." | 8.93 | Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. ( Chang, T; Ge, F; Guo, R; Li, M; Lin, H; Liu, Y; Ruan, Z, 2016) |
| "Aspirin is recommended for secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke on the basis of trials showing a 13% reduction in long-term risk of recurrent stroke." | 8.93 | Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. ( Algra, A; Chen, Z; Diener, HC; Mehta, Z; Norrving, B; Rothwell, PM, 2016) |
| "Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events." | 8.91 | Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015) |
| "The clinical significance of colchicine in the treatment of acute idiopathic (viral) pericarditis (IP) was only elucidated less than a decade ago." | 8.91 | Pharmacotherapeutic considerations for using colchicine to treat idiopathic pericarditis in the USA. ( Schwier, NC, 2015) |
| "To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack." | 8.91 | [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015) |
| "Dual antiplatelet therapy with aspirin plus clopidogrel is not recommended for secondary stroke prevention because of lack of effectiveness and increased hemorrhagic risk." | 8.90 | Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence. ( Censori, B, 2014) |
| "To review all randomised controlled trials (RCTs) that assess the effects of colchicine alone or combined, compared to any other intervention to prevent further recurrences of pericarditis, in people with acute or recurrent pericarditis." | 8.90 | Colchicine for pericarditis. ( Alabed, S; Burls, A; Cabello, JB; Irving, GJ; Qintar, M, 2014) |
| "The following four studies were evaluated: the Coumadin Aspirin Reinfarction Study (CARS); the Combination Hemotherapy and Mortality Prevention (CHAMP) Study; the Warfarin, Aspirin Reinfarction Study (WARIS)-II; the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT)-2 Study." | 8.82 | [Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?]. ( Landmark, K; Madsen, S; Reikvam, A, 2003) |
| " In patients with arterial or venous thrombosis, there is a high rate of recurrence during the two first years except if high-dose warfarin was used (i." | 8.80 | [Aspirin and antiphospholipid syndrome]. ( Blétry, O; Hachulla, E; Hatron, PY; Piette, AM, 2000) |
| "Both experimental and clinical studies suggest that the prehospital administration of aspirin may be beneficial in patients with unstable angina and acute myocardial infarction." | 8.79 | Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. ( Eisenberg, MJ; Topal, EJ, 1996) |
| "To estimate the risk of myocardial infarction (MI) and death in patients with unstable angina who are treated with aspirin plus heparin compared with patients treated with aspirin alone." | 8.79 | Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. ( Grady, D; Oler, A; Oler, J; Whooley, MA, 1996) |
| " Administration of aspirin and heparin has been shown to improve mortality when combined with thrombolytic therapy in acute myocardial infarction, probably by enhancing lysis and reducing subsequent reocclusion of infarct related artery." | 8.78 | [Aspirin and heparin in the fibrinolytic treatment of acute myocardial infarction]. ( López Bescós, L, 1992) |
| "In October 1985, the Food and Drug Administration approved a new indication of aspirin for the secondary prevention of recurrent myocardial infarction (MI) and death in patients with MI or unstable angina." | 8.77 | Prevention of recurrent myocardial infarction and sudden death with aspirin therapy. ( Goldstein, GS; Rumore, MM, 1987) |
| " A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality." | 8.12 | Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022) |
| "Among the 3456 patients included, a total of 10 patients in the Clopidogrel Discontinuation Group and 11 patients in the non-Clopidogrel Discontinuation Group presented ischemic stroke recurrence during the 90-180-day period." | 8.12 | No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke. ( Jing, J; Johnston, SC; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, D; Wang, Y; Zhang, X; Zhao, X, 2022) |
| "Background Because of a nonresponse to aspirin (aspirin resistance), patients with acute coronary syndrome (ACS) are at increased risk of developing recurrent event." | 8.02 | Low miR-19b-1-5p Expression Is Related to Aspirin Resistance and Major Adverse Cardio- Cerebrovascular Events in Patients With Acute Coronary Syndrome. ( Chan, MY; Creemers, EE; de Ronde, MWJ; Hwee Tan, S; Mark Richards, A; Meijering, R; Pinto-Sietsma, SJ; Singh, S; Tang Chin, C; Troughton, RW; Van der Made, I; Yan, BP; Yean Yip Fong, A, 2021) |
| "To evaluate whether initial treatment with low-dose compared with high-dose aspirin in children with KD is associated with an increase in fever recrudescence." | 7.96 | Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin. ( Belarski, E; Carroll, AE; John, CC; Manaloor, J; Ofner, S; Platt, B; Wood, JB, 2020) |
| "To investigate the association of aspirin resistance (AR) with the plasma 4-hydroxynonenal (4-HNE) level and its impact on recurrent cerebral infarction (CI) in patients with acute cerebral infarction (ACI) who were receiving aspirin therapy." | 7.96 | Association of aspirin resistance with 4-hydroxynonenal and its impact on recurrent cerebral infarction in patients with acute cerebral infarction. ( Feng, J; Guo, J; Guo, Y; Wang, J, 2020) |
| "Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial." | 7.96 | Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC, 2020) |
| "This study compared the effectiveness of dual antiplatelet therapy (DAPT) with clopidogrel-aspirin with that of aspirin monotherapy (AM) in mild-to-moderate acute ischemic stroke considering the risk of recurrent stroke using the Stroke Prognosis Instrument II (SPI-II) score." | 7.96 | Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Mild-to-Moderate Acute Ischemic Stroke According to the Risk of Recurrent Stroke: An Analysis of 15 000 Patients From a Nationwide, Multicent ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, KH; Hong, JH; Hong, KS; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Kwon, JH; Lee, BC; Lee, HL; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Park, HK; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Shin, DI; Sohn, SI; Sun Oh, M; Yu, KH, 2020) |
| "In real-world practice settings, there is insufficient evidence on the efficacy of antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention." | 7.96 | Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan. ( Hsu, YH; Ong, CT; Tsai, CF; Wong, YS, 2020) |
| "All acute coronary syndrome patients from the REgistry of New Antiplatelets in patients with Myocardial Infarction (RENAMI) undergoing percutaneous coronary intervention and treated with aspirin, prasugrel or ticagrelor were stratified according to DAPT duration, that is, shorter than 12 months (D1 group), 12 months (D2 group) and longer than 12 months (D3 group)." | 7.96 | Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. ( Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Bertaina, M; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Fioravanti, F; Gaita, F; Gallo, D; Garay, A; Gili, S; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lüscher, TF; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Taha, S; Templin, C; Valdés, M; Varbella, F; Velicki, L; Xanthopoulou, I, 2020) |
| " Clopidogrel plus aspirin treatment was associated with reduced risk of new stroke in patients with ABCB1 -154 TT and 3435 CC genotype (hazard ratio [HR], 0." | 7.91 | Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial. ( Chen, W; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Simon, T; Wang, D; Wang, Y; Zhao, X, 2019) |
| "In PEGASUS-TIMI 54, ticagrelor significantly reduced the risk of the composite of major adverse cardiovascular (CV) events by 15-16% in stable patients with a prior myocardial infarction (MI) 1-3 years earlier." | 7.91 | Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. ( Ardissino, D; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Dellborg, M; Hamm, C; Himmelmann, A; Im, KA; Johanson, P; Kamensky, G; Kiss, RG; Kontny, F; Lopez-Sendon, J; Montalescot, G; Oude Ophuis, T; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Van de Werf, F, 2019) |
| "The addition of colchicine to prednisone in patients admitted for acute idiopathic pericarditis does not reduce the risk of recurrence." | 7.88 | Does colchicine decrease the rate of recurrence of acute idiopathic pericarditis treated with glucocorticoids? ( Chezar Azzerad, C; Hasdai, D; Iakobishvili, Z; Kornowski, R; Mager, A; Porter, A; Talmor, Y, 2018) |
| "To determine the association between ruptured saccular aneurysms and aspirin use/aspirin dose." | 7.88 | Association between aspirin dose and subarachnoid hemorrhage from saccular aneurysms: A case-control study. ( Cai, T; Can, A; Castro, VM; Dligach, D; Du, R; Finan, S; Gainer, V; Murphy, S; Rudy, RF; Savova, G; Shadick, NA; Weiss, ST; Yu, S, 2018) |
| "WHAT IS THE ROLE OF DUAL ANTIPLATELET THERAPY AFTER HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKE? SPECIFICALLY, DOES DUAL ANTIPLATELET THERAPY WITH A COMBINATION OF ASPIRIN AND CLOPIDOGREL LEAD TO A GREATER REDUCTION IN RECURRENT STROKE AND DEATH OVER THE USE OF ASPIRIN ALONE WHEN GIVEN IN THE FIRST 24 HOURS AFTER A HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR ISCHAEMIC STROKE? AN EXPERT PANEL PRODUCED A STRONG RECOMMENDATION FOR INITIATING DUAL ANTIPLATELET THERAPY WITHIN 24 HOURS OF THE ONSET OF SYMPTOMS, AND FOR CONTINUING IT FOR 10-21 DAYS CURRENT PRACTICE IS TYPICALLY TO USE A SINGLE DRUG." | 7.88 | Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. ( Agoritsas, T; Booth, B; Fisch, L; Fobuzi, AC; Fraiz, A; Gorthi, SP; Guyatt, G; Hao, Q; Heen, AF; Horton, E; Jusufovic, M; Katragunta, N; Lytvyn, L; Muller, J; O'Donnell, M; Prasad, K; Rochwerg, B; Siemieniuk, J; Siemieniuk, R; Vandvik, PO, 2018) |
| "Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS." | 7.85 | Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017) |
| "To investigate the prevalent of aspirin resistance (AR) in stroke and its association with recurrent stroke in 214 patients with ischemic stroke who were receiving aspirin before the stroke onset." | 7.85 | Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke. ( Wang, Z; Zhang, N; Zhou, L, 2017) |
| "Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin." | 7.85 | Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017) |
| "The objective was to compare the efficacy and safety of naproxen (NXN) to acetylsalicylic acid (ASA) in the treatment of acute rheumatic fever (ARF)." | 7.83 | The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen. ( Arı, ME; Azak, E; Çetin, İİ; Çevik, BŞ; Ekici, F; Eminoğlu, S; Kibar, AE; Kocabaş, A; Orgun, A; Sürücü, M, 2016) |
| "To explore the correlation between the recurrence of cerebral infarction and aspirin resistance (AR)/Chinese medical (CM) constitutions." | 7.81 | [Recurrence of Cerebral Infarction Associated Aspirin Resistance or Chinese Medical Constitutions: a Correlation Study]. ( Li, YH; Lu, QA; Wang, DX; Wang, XC; Yu, LH; Zong, SJ, 2015) |
| " We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population." | 7.80 | Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014) |
| "Some patients with a recent ischemic stroke who are being treated with aspirin as an antiaggregant suffer a new ischemic stroke." | 7.80 | Aspirin resistant patients with recent ischemic stroke. ( Castilla-Guerra, L; Fernández-Moreno, MC; Navas-Alcántara, MS, 2014) |
| "Our objective was to investigate the association between recurrent stroke risk and headache induced by extended-release dipyridamole (ER-DP) when administered alone or with low-dose aspirin (ASA+ER-DP)." | 7.80 | Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. ( Bath, PM; Cotton, D; Davidai, G; Diener, HC; Gorelick, P; Lipton, RB; Sacco, R, 2014) |
| "To examine the association between cardioprotective use of low-dose aspirin and the risk of recurrent gout attacks among gout patients." | 7.80 | Low-dose aspirin use and recurrent gout attacks. ( Chaisson, C; Chen, C; Choi, H; Hunter, DJ; Neogi, T; Zhang, Y, 2014) |
| "The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial found no difference between warfarin and aspirin in patients with low ejection fraction in sinus rhythm for the primary outcome: first to occur of 84 incident ischemic strokes (IIS), 7 intracerebral hemorrhages or 531 deaths." | 7.79 | Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. ( Anker, SD; Di Tullio, MR; Diek, M; Freudenberger, RS; Graham, S; Haddad, H; Homma, S; Labovitz, AJ; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2013) |
| "Of the 82 patients with recurrent cerebral ischemia included in this study, 37 (45%) patients were poor compliant with aspirin." | 7.79 | Clinical and biochemical aspirin resistance in patients with recurrent cerebral ischemia. ( Abu-Hegazy, M; Azzam, H; El-Mitwalli, A; Gomaa, M; Wasel, Y, 2013) |
| "The widespread use of aspirin-driven vascular prevention strategies does not impede the occurrence of first and recurrent ischemic strokes in numerous subjects." | 7.78 | Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012) |
| "To examine the effect of proton pump inhibitors on adverse cardiovascular events in aspirin treated patients with first time myocardial infarction." | 7.77 | Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Grove, EL; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Olesen, JB; Selmer, C; Torp-Pedersen, C, 2011) |
| "9 years) with confirmed diagnoses of cerebral infarction and PAS, treated with anticoagulants (n = 54) or aspirin (n = 38) were retrospectively analyzed." | 7.77 | [Aspirin versus anticoagulation in young patients with cerebral infarction secondary to primary antiphospholipid syndrome]. ( Arauz, A; Artigas, C; Barinagarrementeria, F; Cantu-Brito, C; Hernandez, B; Marquez, JM; Merlos, M; Perez, A; Roa, LF, 2011) |
| "The combination of aspirin and clopidogrel is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke." | 7.76 | Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. ( Chandratheva, A; Geraghty, OC; Paul, NL; Rothwell, PM, 2010) |
| "The effect of biochemical aspirin resistance (BAR) on ischemic stroke has not been well established." | 7.76 | Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. ( Jeon, SB; Kang, DW; Kim, BJ; Kim, HJ; Kim, JS; Kwon, SU; Song, HS, 2010) |
| "To assess the prognosis of patients presenting with an acute coronary syndrome (ACS) despite chronic clopidogrel therapy (CCT)." | 7.75 | Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. ( Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R, 2009) |
| "Combinations of aspirin, clopidogrel, and vitamin K antagonists are widely used in patients after myocardial infarction." | 7.75 | Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. ( Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2009) |
| "Gastric ulcers were induced with acetic acid in rats; aspirin was administrated by gavage from day 25 to day 54 after ulcer induction." | 7.74 | Aspirin can elicit the recurrence of gastric ulcer induced with acetic acid in rats. ( Guo, CJ; Huang, GP; Jia, BB; Wang, GZ; Wang, JF; Xie, CG; Yin, GL; Zhou, G, 2007) |
| "Aspirin has been used for secondary prevention of myocardial infarction (MI) in individuals with coronary disease." | 7.74 | Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers. ( Eskola, M; Karhunen, PJ; Mikkelsson, J; Niemela, K; Nikus, K, 2008) |
| "Six patients with a history of recurrent anaphylaxis associated with wheat ingestion were diagnosed as having WDEIA by the provocation test, which included wheat ingestion, exercise, aspirin intake and a combination of these challenges." | 7.73 | Exercise and aspirin increase levels of circulating gliadin peptides in patients with wheat-dependent exercise-induced anaphylaxis. ( Akaki, T; Hide, M; Kaneko, S; Kuroda, T; Kusatake, K; Matsuo, H; Morimoto, K; Morita, E; Niihara, H, 2005) |
| "During the period from January 2000 to May 2002, 70 patients who were prescribed clopidogrel (75 mg/day) for a previous history of non-aspirin-related peptic ulcer disease or a history of aspirin-related gastrointestinal complications (dyspepsia or peptic ulcer) were recruited." | 7.72 | High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. ( Chang, CM; Chen, WH; Kng, C; Lanas, AI; Ng, FH; Wong, BC; Wong, SY, 2003) |
| "Aspirin is a common antiplatelet drug used in the prevention of ischemic stroke due to its inhibitory effect on platelet cyclooxygenase-1 (Cox-1)." | 7.72 | Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. ( Hillarp, A; Lethagen, S; Mattiasson, I; Palmqvist, B; Villoutreix, BO, 2003) |
| "The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes." | 7.72 | Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004) |
| "We studied 30 patients with postsurgical ulcer and aspirin abuse." | 7.70 | Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer. ( Hirschowitz, BI; Lanas, A, 1998) |
| "To investigate the prevalence of aspirin use in older patients with prior myocardial infarction at the time of admission to a nursing home." | 7.70 | Underutilization of aspirin in older patients with prior myocardial infarction at the time of admission to a nursing home. ( Aronow, WS, 1998) |
| "To assess the prevalence of haemostatic abnormalities in patients with an obstetric history of preeclampsia and/or fetal growth restriction and documented thrombophilia, and to evaluate the effects of low-molecular-weight heparin (LMWH) and aspirin on pregnancy outcome." | 7.70 | Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. ( de Vries, JI; Dekker, GA; Huijgens, PC; Leeda, M; Riyazi, N; van Geijn, HP, 1998) |
| "The thienopyridine derivatives, ticlopidine and clopidogrel, provide alternatives to aspirin for use in the prevention of recurrent ischemic events in the post-myocardial infarction patient." | 7.70 | Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient. ( Pepine, CJ, 1998) |
| "For patients who have had a previous myocardial infarction (MI), the use of aspirin, beta-blockers, and lipid-lowering agents reduces the risk of recurrent MI and death." | 7.70 | Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? ( Goldberg, RJ; Gore, JM; Gurwitz, JH; Lessard, D; McCormick, D; Yarzebski, J, 1999) |
| "Aspirin-induced asthma (AIA) is frequently accompanied by nasal polyps." | 7.70 | Detection of activated eosinophils in nasal polyps of an aspirin-induced asthma patient. ( Ogata, Y; Okinaka, Y; Takahashi, M, 1999) |
| "This study confirms the importance of eosinophil infiltration in the pathogenesis of severe or recurrent nasal polyps based on allergy and aspirin intolerance." | 7.70 | [Significance of eosinophilic granulocytes in relation to allergy and aspirin intolerance in patients with sinusitis polyposa]. ( Bittinger, F; Gosepath, J; Kaldenbach, T; Klimek, L; Mann, WJ; Schäfer, D, 1999) |
| "The value of warfarin in preventing stroke in patients with chronic atrial fibrillation is well established." | 7.70 | Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. ( Almoznino-Sarafian, D; Alon, I; Chachashvily, S; Cohen, N; Gorelik, O; Koopfer, M; Litvinjuk, V; Modai, D; Shteinshnaider, M, 2000) |
| "The goal of this health economic analysis was to asses the cost-effectiveness of a fixed combination of aspirin plus extended-release dipyridamole (ASA/ER-DP) or clopidogrel compared with ASA monotherapy for prevention of recurrent ischemic stroke." | 7.70 | Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. ( Gondek, K; Shah, H, 2000) |
| "Adding NTG to a thrombolytic regimen with rt-PA, aspirin and heparin increases the magnitude of restored flow and total patency duration following recanalization in a rabbit model of arterial thrombosis." | 7.69 | Beneficial effect of nitroglycerin on arterial rethrombosis after thrombolysis. Results from a rabbit thrombosis model. ( Battler, A; Chernine, A; Hasdai, D; Kornowski, R; Ovadia, Z, 1995) |
| "To determine how often aspirin was prescribed as a discharge medication to eligible patients 65 years of age and older who were hospitalized with an acute myocardial infarction; to identify patient characteristics associated with the decision to use aspirin; and to evaluate the association between prescription of aspirin at discharge and 6-month survival." | 7.69 | Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. ( Ellerbeck, EF; Hennen, J; Jencks, SF; Krumholz, HM; Meehan, TP; Petrillo, M; Radford, MJ; Wang, Y, 1996) |
| "Asthmatic triad (AT) is a clinical syndrome incorporating bronchial asthma (BA), recurrent nasal and sinus polyps, intolerance of aspirin, derivatives of pirasolone and other nonsteroid antiinflammatory drugs." | 7.69 | [The in-vivo test of the inhibition of leukocyte natural migration with aspirin and analgin in the specific diagnosis of the asthmatic triad]. ( Kanchurina, NA; Poroshina, IuA; Prasolova, NI; Zemskov, VM, 1996) |
| "One hundred thirty-one patients presenting with acute myocardial infarction (AMI) a mean of 3 hours after the onset of symptoms were treated with oral aspirin and intravenous thrombolytic therapy followed by heparin." | 7.68 | Safety of combined intravenous beta-adrenergic blockade (atenolol or metoprolol) and thrombolytic therapy in acute myocardial infarction. ( Commerford, PJ; Gordon, GD; Green, BK; Horak, AR; Millar, RN, 1992) |
| "Fifty-six patients who presented with non-steroidal anti-inflammatory drug-associated duodenal ulcers received maintenance treatment with ranitidine." | 7.67 | Ranitidine maintenance treatment of non-steroidal anti-inflammatory drug-induced duodenal ulceration. ( Penston, JG; Wormsley, KG, 1989) |
| "Aspirin has been reported to induce the adult respiratory distress syndrome (ARDS) in humans." | 7.67 | Bronchoalveolar lavage in recurrent aspirin-induced adult respiratory distress syndrome. ( Krieger, BP; Suarez, M, 1986) |
| "Hydroxyurea has been rarely implicated as a cause of drug fever." | 7.66 | Fever caused by hydroxyurea. ( Bauernfeind, RA; Bauman, JL; Hartsough, N; Hasegawa, GR; Roden, R; Shulruff, S, 1981) |
| "We have studied seventy-five patients with recurrent urticaria and angio-oedema of more than 4 months duration and with positive provocation tests to aspirin, azo dyes, and/or benzoates." | 7.65 | A follow-up study of patients with recurrent urticaria and hypersensitivity to aspirin, benzoates and azo dyes. ( Juhlin, L; Michaëlsson, G; Ros, AM, 1976) |
| "Often used as an oral analgesic in the management of pain associated with traumatic hyphema, aspirin has an inhibitory effect on the blood clotting mechamism by its action on platelets." | 7.65 | The effect of aspirin on rebleeding in traumatic hyphema. ( Chan, W; Crawford, JS; Lewandowski, RL, 1975) |
| "The primary outcome is IS recurrence." | 6.80 | Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015) |
| " The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months." | 6.74 | Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009) |
| "Piracetam was significantly superior to ASA in the secondary endpoint (P=0." | 6.69 | Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. ( Evers, S; Fischer, M; Grotemeyer, KH; Husstedt, IW, 2000) |
| "Acute idiopathic pericarditis is complicated by recurrence in 15 to 30% of cases." | 6.69 | [Efficacy of colchicine in recurrent acute idiopathic pericarditis]. ( Amoura, Z; Cacoub, P; Godeau, P; Piette, JC; Sbaï, A; Wechsler, B, 2000) |
| "Aspirin (ASA) has become a well-documented therapeutic adjunct in patients with coronary heart disease." | 6.68 | Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) ( Aursnes, I; Kjekshus, J; Nguyen, KN, 1997) |
| "Main outcomes were stroke recurrence and major bleeding." | 6.66 | Aspirin or anticoagulation after cryptogenic stroke with patent foramen ovale: systematic review and meta-analysis of randomized controlled trials. ( Calabresi, P; Cupini, LM; Eusebi, P; Giannandrea, D; Ricci, S; Romoli, M, 2020) |
| "Recurrent stroke is common immediately following a transient ischemic attack (TIA) or ischemic stroke." | 6.61 | Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. ( Abdalla, A; Ahmed, S; Al Qasmi, M; Bachuwa, G; Bhatt, DL; Chahine, A; Hassan, M; Haykal, T; Kheiri, B; Osman, M; Swaid, B, 2019) |
| "To assess the balance of benefits and risks of aspirin in particular categories of patient with acute stroke (eg, the elderly, those without a CT scan, or those with atrial fibrillation), a prospectively planned meta-analysis is presented of the data from 40 000 individual patients from both trials on events that occurred in the hospital during the scheduled treatment period (4 weeks in CAST, 2 weeks in IST), with 10 characteristics used to define 28 subgroups." | 6.19 | Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. ( Chen, ZM; Collins, R; Counsell, C; Liu, LS; Pan, HC; Peto, R; Sandercock, P; Warlow, C; Xie, JX, 2000) |
| "In this prospective cohort study, we randomly assigned patients with PFO who had a cryptogenic stroke, in a 1:1 ratio, to dabigatran or aspirin group." | 5.51 | Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study. ( Cai, D; Chen, S; He, J; Huang, P; Lai, Y; Sun, H; Wu, Q; Zhou, L, 2022) |
| "Chest pain recurrence was defined as the first revisit to the emergency room with angina." | 5.48 | Clinical efficacy of aspirin with identification of intimal morphology by optical coherence tomography in preventing event recurrence in patients with vasospasm-induced acute coronary syndrome. ( Lee, Y; Park, HC; Shin, J, 2018) |
| "Stroke recurrence and mortality rates in patients receiving aspirin (N=34 679) were compared with those receiving clopidogrel (N=7611) during a 12-month follow-up period." | 5.48 | Comparison Between Aspirin and Clopidogrel in Secondary Stroke Prevention Based on Real-World Data. ( Chang, WL; Chen, CH; Chi, NF; Hsu, CY; Hu, CJ; Jeng, JS; Li, JY; Lien, LM; Lin, CH; Liu, CH; Sun, Y; Wen, CP, 2018) |
| "The cohort of women with a history of preeclampsia were divided into 2 groups, before and after the release of the US Preventive Services Task Force 2014 recommendations." | 5.46 | Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia. ( Aagaard, KM; Chu, DM; Hollier, LM; Mastrobattista, JM; Racusin, DA; Ramin, SM; Sangi-Haghpeykar, H; Tolcher, MC, 2017) |
| "The primary end point was recurrence of ACS or death >30days after the index event." | 5.46 | Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. ( Geroldinger, A; Heinze, G; Reichardt, B; Sheikh Rezaei, S; Wolzt, M, 2017) |
| "The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage." | 5.43 | [Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016) |
| "Minor stroke and transient ischemic attack are common disorders with high rate of subsequent disabling stroke." | 5.43 | High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. ( Li, J; Lin, J; Liu, L; Meng, X; Wang, A; Wang, C; Wang, Y; Zhao, X, 2016) |
| "Microbleeds mark an increased risk of recurrent stroke, ischemic stroke, intracerebral hemorrhage, and mortality in ESUS but do not appear to influence effects of rivaroxaban on clinical outcomes." | 5.41 | Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial. ( Berkowitz, SD; Connolly, SJ; Field, TS; Hart, RG; Kasner, SE; Liu, YY; Lutsep, H; Martí-Fàbregas, J; Mikulik, R; Muir, KW; Mundl, H; Ntaios, G; O'Donnell, MJ; Olavarria, V; Santo, GC; Sharma, M; Shoamanesh, A; Smith, EE; Uchiyama, S; Veltkamp, R, 2021) |
| " We sought to determine whether the presence of carotid stenosis was associated with increased risk of ischemic stroke and whether the addition of clopidogrel to aspirin was associated with more benefit in patients with versus without carotid stenosis." | 5.41 | Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial. ( de Havenon, A; Easton, JD; Furie, KL; Henninger, N; Johnston, SC; Kim, AS; Kvernland, A; Mac Grory, B; Rostanski, S; Yaghi, S, 2021) |
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 5.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| "Of the 1534 ischemic stroke patients who randomly assigned to aspirin or cilostazol treatment with best medical therapy by the PICASSO (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage) trial, 1240 with baseline mini-mental state examination (MMSE) scores were analysed retrospectively." | 5.34 | Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study. ( Hong, KS; Kang, DW; Kwon, HS; Kwon, SU; Lee, D; Lee, EJ; Lee, JS; Lee, MH; Lim, JS; Oh, MS; Yu, KH; Yu, S, 2020) |
| " Approach and Results: The CHANCE trial (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) randomized patients with acute minor ischemic stroke or high-risk transient ischemic attack to clopidogrel plus aspirin or aspirin alone from October 1, 2009, to July 30, 2012, in China." | 5.34 | Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial. ( Li, H; Li, J; Lin, J; Liu, L; Wang, A; Wang, Y; Zhao, X; Zuo, Z, 2020) |
| "In STEMI patients with HPR, identified by vasodilator stimulated phosphoprotein (VASP)-determined PFT, switching clopidogrel to ticagrelor could significantly improve 1-year clinical outcomes without increasing the risk of bleeding." | 5.34 | Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study. ( Gao, L; Geng, L; Guo, W; Li, H; Li, J; Wan, Q; Wang, X; Wang, Y; You, J; Zhang, Q, 2020) |
| " There were no statistically significant differences between rivaroxaban and aspirin prophylaxis for recurrent ischemic stroke in patients with non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis." | 5.34 | Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. ( Amarenco, P; Ameriso, SF; Bereczki, D; Berkowitz, SD; Connolly, SJ; Ferrari, J; Firstenfeld, A; Hart, RG; Kasner, SE; Lang, W; Lavados, P; Mikulik, R; Mundl, H; Ntaios, G; Pearce, LA; Perera, KS; Povedano, GP; Uchiyama, S; Yoon, BW, 2020) |
| "We performed an exploratory analysis of the interaction of the treatment effects of aspirin plus clopidogrel versus aspirin monotherapy, stratified by presence of ipsilateral nonstenotic carotid disease in patients with minor ischemic stroke in the POINT trial." | 5.34 | Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: an Exploratory Analysis of The POINT Randomized Clinical Trial. ( Brorson, JR; Bulwa, Z; Pinto, CB; Saleh Velez, FG, 2020) |
| "Aspirin users were older on average than nonusers (59 years of age compared with 53 years; p = 0." | 5.32 | Influence of aspirin on outcome following aneurysmal subarachnoid hemorrhage. ( Atkinson, JL; Friedman, JA; McClelland, RL; McIver, JI; Meyer, FB; Nichols, DA; Pichelmann, MA; Piepgras, DG; Toussaint, LG; Wijdicks, EF, 2004) |
| "Triflusal has demonstrated an efficacy similar to aspirin in the prevention of vascular events in patients with acute myocardial infarction (ΜΙ) and ischaemic stroke but with less bleeding events." | 5.30 | Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial. ( Adamopoulos, D; Asimakopoulos, C; Bourdakis, A; Chantzichristos, VG; Darmanis, P; Dimitriadou, A; Gkiokas, S; Goudevenos, JA; Ipeirotis, K; Kalantzi, KI; Kitikidou, K; Klonaris, I; Kostaki, A; Logothetis, D; Mainas, K; Mais, T; Maragiannis, A; Martiadou, K; Mavronasos, K; Michelongonas, I; Mitropoulos, D; Ntalas, IV; Panagiotakos, DB; Papadimitriou, G; Papadopoulos, A; Papaioakeim, M; Sofillas, K; Stabola, S; Stefanakis, E; Stergiou, D; Thoma, M; Tselepis, AD; Tsoumani, ME; Zenetos, A; Zisekas, S, 2019) |
| " In patients with prior coronary artery disease or peripheral arterial disease the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial revealed that compared with acetylsalicylic acid alone, dual pathway inhibition with low-dose rivaroxaban (2." | 5.30 | Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. ( Coppens, M; Eikelboom, JWA; Weitz, JI, 2019) |
| "The NAVIGATE ESUS randomized clinical trial found that 15 mg of rivaroxaban per day does not reduce stroke compared with aspirin in patients with embolic stroke of undetermined source (ESUS); however, it substantially reduces stroke risk in patients with atrial fibrillation (AF)." | 5.30 | Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. ( Arauz, A; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Eckstein, J; Endres, M; Epstein, AE; Gladstone, DJ; Haeusler, KG; Hankey, GJ; Hart, RG; Healey, JS; Karlinski, M; Kasner, SE; Lutsep, H; Mikulik, R; Molina, CA; Mundl, H; Ntaios, G; Pagola, J; Perera, K; Santo, G; Shuaib, A; Swaminathan, B; Toni, D; Uchiyama, S; Yang, X, 2019) |
| " The aim was to assess whether the effect of clopidogrel plus aspirin versus aspirin alone on recurrent stroke would be affected by admission activated partial thromboplastin time (aPTT)." | 5.30 | Effect of dual versus mono antiplatelet therapy on recurrent stroke modulated by activated partial thromboplastin time. ( Laskowitz, DT; Li, H; Liu, L; Meng, X; Miao, Z; Wang, X; Wang, Y; Xie, X; Zhao, X, 2019) |
| "We conducted a multicenter, randomized, double-blind trial of dabigatran at a dose of 150 mg or 110 mg twice daily as compared with aspirin at a dose of 100 mg once daily in patients who had had an embolic stroke of undetermined source." | 5.30 | Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. ( Bernstein, RA; Brueckmann, M; Chernyatina, M; Cotton, D; Cronin, L; Diener, HC; Donnan, G; Easton, JD; Ferro, JM; Granger, CB; Grauer, C; Grond, M; Kallmünzer, B; Kreuzer, J; Krupinski, J; Lee, BC; Lemmens, R; Masjuan, J; Odinak, M; Sacco, RL; Saver, JL; Schellinger, PD; Toni, D; Toyoda, K; Uchiyama, S, 2019) |
| "Exploratory analyses of 7213 participants in the NAVIGATE ESUS international trial who were randomized to aspirin 100 mg/day or rivaroxaban 15 mg/day and followed for a median of 11 months, during which time there were 309 first recurrent ischemic strokes (4." | 5.30 | Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. ( Ameriso, SF; Bangdiwala, SI; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Gagliardi, RJ; Hankey, GJ; Hart, RG; Kasner, SE; Lindgren, A; Mundl, H; Ntaios, G; Perera, KS; Peters, G; Sharma, M; Sheridan, P; Shoamanesh, A; Shuaib, A; Toni, D; Veltkamp, RC, 2019) |
| "Compare efficacy and safety of vonoprazan and lansoprazole for secondary prevention of low-dose aspirin (LDA)-associated peptic ulcers in a 24-week study and long-term extension therapy in separate study." | 5.27 | Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. ( Ashida, K; Funao, N; Kawai, T; Matsumoto, Y; Mizokami, Y; Nishimura, A; Oda, K; Sugano, K, 2018) |
| "These results suggest that patients who have undergone EVT have similar risks for major and life-threatening bleeding events with edoxaban and aspirin compared with clopidogrel and aspirin." | 5.27 | Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial. ( Adams, G; Ansel, G; Baumgartner, I; Grosso, M; Jaff, M; Lin, M; Mercur, MF; Minar, E; Moll, F; Nwachuku, C; Rundback, J; Tangelder, M; Zeller, T, 2018) |
| "For this industry-independent, double-blind, double-dummy, randomised trial done in one academic hospital in Hong Kong, we screened patients with arthritis and cardiothrombotic diseases who were presenting with upper gastrointestinal bleeding, were on NSAIDs, and require concomitant aspirin." | 5.24 | Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. ( Au, KWL; Chan, FKL; Chan, H; Cheong, PK; Ching, JYL; Kee, KM; Kyaw, MH; Lam, K; Lee, V; Lo, A; Ng, SC; Suen, BY; Tse, YK; Wong, GLH; Wong, VWS; Wu, JCY, 2017) |
| "Ticagrelor is an effective antiplatelet therapy among patients with atherosclerotic disease and, therefore, could be more effective than aspirin in preventing recurrent stroke and cardiovascular events among patients with embolic stroke of unknown source (ESUS), which includes patients with ipsilateral stenosis <50% and aortic arch atherosclerosis." | 5.24 | Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL, 2017) |
| "Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is effective in preventing recurrent strokes after minor ischemic stroke or transient ischemic attack (TIA)." | 5.22 | Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis. ( Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Zitikyte, G, 2022) |
| "To examine whether combined treatment with low-molecular-weight heparin (LMWH) and aspirin reduces recurrent hypertensive disorders of pregnancy (HD: pre-eclampsia, eclampsia or HELLP syndrome) in women with antiphospholipid antibodies (aPLA) and a previous delivery for HD and/or small-for-gestational-age (SGA) birthweight before 34 weeks gestation." | 5.22 | Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. ( Bezemer, D; de Vries, JI; Hague, WM; van Hoorn, ME; van Pampus, MG, 2016) |
| "The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours." | 5.22 | Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. ( Jing, J; Johnston, SC; Li, H; Li, Z; Liu, L; Meng, X; Pan, Y; Wang, C; Wang, D; Wang, X; Wang, Y; Xian, Y; Yang, X; Zhang, C; Zhao, X, 2016) |
| " In a previous study, we found that the number of MESs is associated with stroke recurrence and that clopidogrel plus aspirin more effectively reduce the number of MESs than does aspirin alone." | 5.22 | The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial. ( Chen, C; Deng, QQ; Fu, JH; Huang, YN; Markus, H; Ratanakorn, D; Tang, J; Wong, KS; Zhao, H, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 5.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| "The Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events trial randomized minor ischemic stroke or TIA patients to antiplatelet therapy of clopidogrel plus aspirin or aspirin alone." | 5.20 | Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke. ( Li, J; Lin, J; Liu, L; Wang, A; Wang, C; Wang, D; Wang, Y; Zhao, X, 2015) |
| " Treatment with rivaroxaban may prevent more cerebrovascular events with an acceptable risk profile after TIA or minor stroke, compared with aspirin, thus helping to improve the outcome of the disease." | 5.20 | Treatment of Rivaroxaban versus Aspirin for Non-disabling Cerebrovascular Events (TRACE): study protocol for a randomized controlled trial. ( Bai, Y; Han, J; Jiang, W; Liu, X; Yang, F; Zhang, G; Zhao, G, 2015) |
| "In this study, patients taking 100 mg aspirin daily (orally) were examined after admittance to the stroke unit due to a stroke or stroke recurrence." | 5.19 | [Acetylsalicylic acid non-responders after ischemic insult in geriatric patients]. ( Kolb, GF; Nosul, M, 2014) |
| "Altogether 574 patients with acute (≤2 days) large-artery atherosclerosis stroke were randomly assigned to receive either combined clopidogrel and aspirin or aspirin alone." | 5.19 | A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke. ( Chi, W; Lin, J; Wang, C; Yi, X; Zhang, B, 2014) |
| "An individual patient data analysis of these trials was planned, before their results were known, to assess the effect of aspirin versus placebo on recurrent VTE, major vascular events (recurrent VTE, myocardial infarction, stroke, and cardiovascular disease death) and bleeding, overall and within predefined subgroups." | 5.19 | Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. ( Agnelli, G; Becattini, C; Brighton, TA; Eikelboom, JW; Kirby, AC; Mister, R; Prandoni, P; Simes, J, 2014) |
| "We investigated whether CYP2C9 genotype was associated with risk of colorectal adenoma and/or modified associations with aspirin treatment or cigarette smoking in a cohort of 928 participants in a randomized trial of aspirin chemoprevention." | 5.17 | CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment. ( Ahnen, DJ; Baron, JA; Barry, EL; Bresalier, RS; Makar, KW; McKeown-Eyssen, GE; Mott, LA; Poole, EM; Sandler, RS; Ulrich, CM, 2013) |
| "To investigate the prevalent of aspirin resistance (AR) in Chinese stroke patients and its association with recurrent stroke and other vascular events, including cardiovascular disease and death." | 5.17 | Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events. ( Chi, L; Lin, J; Yi, X; Zhou, Q, 2013) |
| "To determine the effect of aspirin on ulcer healing rate in patients with chronic venous insufficiency, and to establish prognostic factors that influence ulcer evolution." | 5.16 | Influence of aspirin therapy in the ulcer associated with chronic venous insufficiency. ( Antonio, J; del Río Solá, ML; Fajardo, G; Vaquero Puerta, C, 2012) |
| "A subset of the TRITON-TIMI 38 study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38), in which patients with acute coronary syndrome were randomized to treatment with aspirin and either clopidogrel or prasugrel, underwent isolated CABG (N = 346)." | 5.16 | Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. ( Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ, 2012) |
| "Among patients with recent lacunar strokes, the addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke and did significantly increase the risk of bleeding and death." | 5.16 | Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. ( Benavente, OR; Coffey, CS; Hart, RG; McClure, LA; Pearce, LA; Szychowski, JM, 2012) |
| "After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 5.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| "We compared baseline features and the rates of stroke or vascular death and stroke in the territory of the symptomatic artery between patients ON (n=299) versus OFF (n=269) antithrombotics at the time of their qualifying event for the Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) trial." | 5.14 | Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis. ( Chimowitz, MI; Cotsonis, G; Levine, SR; Lynn, MJ; Maidan, L; Romano, JG; Turan, TN, 2009) |
| "Patients with thrombolysis in myocardial infarction (TIMI) 3 flow <48 hours after fibrinolysis for ST-elevation myocardial infarction were randomized to aspirin plus coumarin, with prolonged heparinization until the target international normalized ratio (2-3) was reached, or aspirin with standard heparinization." | 5.14 | Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: from early reduction in reocclusion to improved long-term clinical outcome. ( Aengevaeren, WR; Brouwer, MA; Kievit, PC; van den Bergh, PJ; Veen, G; Verheugt, FW, 2009) |
| "We evaluated the location, type (lacunar vs nonlacunar), cause, and severity of stroke in patients who had an ischemic stroke endpoint in the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) trial." | 5.14 | Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis. ( Chimowitz, MI; Famakin, BM; George, MG; Lynn, MJ; Stern, BJ, 2009) |
| "In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries, 3491 patients stabilised after an acute coronary syndrome were stratified on the basis of investigator decision to use aspirin only (stratum 1, n=761) or aspirin plus a thienopyridine (stratum 2, n=2730)." | 5.14 | Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. ( Barnathan, ES; Bordes, P; Braunwald, E; Burton, P; Gibson, CM; Hricak, V; Markov, V; Mega, JL; Misselwitz, F; Mohanavelu, S; Oppenheimer, L; Poulter, R; Witkowski, A, 2009) |
| "The aim of this analysis was to evaluate whether routine pre-hospital administration of high-dose tirofiban in ST-segment elevation myocardial infarction (STEMI) decreases the incidence of early stent thrombosis after primary PCI." | 5.14 | Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. ( De Boer, MJ; Dill, T; Gosselink, AT; Hamm, C; Heestermans, AA; Hoorntje, JC; Koopmans, PC; Ten Berg, JM; Van 't Hof, AW; Van Houwelingen, G; Van Werkum, JW, 2009) |
| "It is uncertain whether aspirin therapy should be continued after endoscopic hemostatic therapy in patients who develop peptic ulcer bleeding while receiving low-dose aspirin." | 5.14 | Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. ( Chan, FK; Ching, JY; Chiu, PW; Lau, JY; Lee, YT; Leung, VK; Sung, JJ; Wong, VW; Wu, JC, 2010) |
| "We randomly assigned a total of 400 patients with ST-segment elevation myocardial infarction referred for primary percutaneous coronary intervention to treatment initiated before cardiac catheterization, with either heparin plus eptifibatide (201 patients) or heparin alone (199 patients), in addition to oral aspirin (160 mg) and high-dose clopidogrel (600 mg)." | 5.14 | Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi ( Froeschl, M; Glover, CA; Jadhav, S; Kass, M; Labinaz, M; Le May, MR; Marquis, JF; O'Brien, ER; So, DY; Thomas, A; Turek, M; Wells, GA, 2009) |
| "In the current era of early revascularization and routine use of dual antiplatelet therapy, the incremental benefit of warfarin to reduce the incidence of left ventricular thrombus (LVT) in patients with impaired left ventricular ejection fraction post anterior ST-elevation myocardial infarction (aSTEMI), remains uncertain." | 5.14 | Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. ( Ahmad, M; Eikelboom, JW; Natarajan, MK; Salehian, O; Schwalm, JD, 2010) |
| "The safety and efficacy of a new surgical method of intravitreal tamponade using silicone oil suspended with aspirin (acetylsalicylic acid) was investigated for the treatment of proliferative vitreoretinopathy." | 5.14 | Safety and feasibility of a novel intravitreal tamponade using a silicone oil/acetyl-salicylic acid suspension for proliferative vitreoretinopathy: first results of the Austrian Clinical Multicenter Study. ( Binder, S; Egger, S; Haas, A; Kieselbach, GF; Kralinger, MT; Parel, JM; Stolba, U; Velikay, M; Wedrich, A, 2010) |
| "The daily dose of aspirin in desensitization in aspirin-sensitive asthmatics with nasal polyps is still a matter of debate." | 5.13 | Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. ( Deutschle, T; Keck, T; Polzehl, D; Riechelmann, H; Rozsasi, A; Smith, E; Wiesmiller, K, 2008) |
| "All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance." | 5.13 | Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. ( Abdelmoula, MM; Divani, AA; Hussein, HM; Qureshi, AI; Suri, MF, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 5.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "To determine the prevalence of platelet nonresponsiveness to aspirin treatment for secondary stroke prophylaxis, the authors studied consecutive patients during a 29-month period." | 5.13 | Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. ( Bates, V; Forrest, A; Gengo, FM; Gengo, MF; Hourihane, M; Rainka, M; Robson, M, 2008) |
| " Randomized clinical trials that compared cilostazol to aspirin and reported the endpoints of ischemic stroke, intracranial hemorrhage and any bleeding were included." | 5.12 | Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis. ( Barrett, KM; Brott, TG; Ertekin-Taner, N; Gopal, N; Lin, MP; Meschia, JF; Ross, OA, 2021) |
| "We examined the outcomes of 627 noncardioembolic stroke patients who were double-blindly assigned to either warfarin or aspirin therapy and assessed VaT using transesophageal echocardiography." | 5.12 | Impact of valvular thickness on stroke recurrence in medically treated patients with stroke. ( Abe, Y; Di Tullio, MR; Homma, S; Jin, Z; Mohr, JP; Okajima, K; Sacco, RL; Salameh, MJ; Suzuki, K, 2007) |
| "Fluctuations in urinary 11-DTB2 after cerebral infarction in blacks do not correlate with changes in aspirin doses, except perhaps when the dose changes by a factor of 4 or more." | 5.11 | Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction. ( Bang, NU; Bruno, A; Cohen, SN; Gorelick, PB; McConnell, JP; Tietjen, GE; Wallis, RA, 2004) |
| "To evaluate whether long-term treatment with a fixed low dose of warfarin in combination with aspirin improves the prognosis compared with aspirin treatment alone after an acute myocardial infarction (AMI)." | 5.11 | Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. ( Erhardt, L; Haglid Evander, M; Herlitz, J; Holm, J; Karlson, BW; Peterson, M, 2004) |
| " Platelet-leukocyte conjugate formation (induced by thrombin receptor activating peptide (TRAP)) and platelet aggregation (induced by ADP and arachidonic acid) were assessed in 30 patients with unstable angina or non-ST elevation myocardial infarction." | 5.11 | Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes. ( Bolton, ED; Braunstein, JB; Chiles, KA; Faraday, N; Gerstenblith, G; Heldman, AW; Schulman, SP, 2004) |
| "We studied 18 558 patients with ischemic stroke, myocardial infarction, or peripheral arterial disease who participated in the trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE), a study that compared the occurrence of ischemic stroke, myocardial infarction, or vascular death under randomized treatment with aspirin or clopidogrel." | 5.11 | Leukocyte count as an independent predictor of recurrent ischemic events. ( Boddy, AW; Brandt, T; Buggle, F; Dukovic, DA; Grau, AJ; Hacke, W; Lichy, C, 2004) |
| " Three subjects with multiple-drug induced urticaria complained of a generalized reaction after challenge (Two due to celecoxib and one due to meloxicam)." | 5.11 | Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. ( Antonicelli, L; Bilò, MB; Bonadonna, P; Crivellaro, MA; Dama, AR; Schiappoli, M; Senna, G, 2004) |
| "We evaluated stroke incidence, subtypes, and outcomes, in addition to demographics and clinical risk characteristics associated with stroke among patients enrolled in the Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes (SYMPHONY) and 2nd SYMPHONY trials." | 5.11 | Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. ( Bhapkar, MV; Califf, RM; Graffagnino, C; Kassem-Moussa, H; Mahaffey, KW; Newby, LK; Sila, CA; Simes, RJ; Tasissa, G; White, HD, 2004) |
| "A total of 335 patients (206 men; mean age 72+/-9 years) with intermittent claudication were randomized according to a 2x2 factorial design to 1 of the 4 groups: probucol, placebo, EVBT, and EVBT+probucol." | 5.11 | Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial. ( Alerci, M; Amann-Vesti, B; Aschwanden, M; Baumgartner, I; Bernier, J; Canevascini, R; Cozzi, L; Do, DD; Gallino, A; Greiner, R; Jacob, AL; Jäger, K; Kann, R; Kellner, F; Mahler, F; Schneider, E; Segatto, JM; Studer, G; Triller, J; Tutta, P, 2004) |
| "Although full platelet inhibition with aspirin and thienopyridines before coronary stenting has significantly reduced the risk of acute stent thrombosis, peri-procedural myonecrosis still occurs frequently and is associated with increased death rate." | 5.11 | Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. ( Bosmans, JM; Claeys, MJ; Michiels, JJ; Van Der Goten, P; Van der Planken, MG; Vertessen, F; Vrints, CJ; Wuyts, FL, 2005) |
| "0 in 52 patients or aspirin alone, 100 mg day(-1) in three patients) to determine whether intensive anticoagulation is superior to standard treatment in preventing symptomatic thromboembolism without increasing the bleeding risk." | 5.11 | A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). ( Barbui, T; Baudo, F; Berrettini, M; Brancaccio, V; D'Angelo, A; Finazzi, G; Marchioli, R; Musial, J; Schinco, P; Testa, S; Tognoni, G; Wisloff, F, 2005) |
| "Evaluate aspirin challenge as a means to distinguish single from multiple NSAID intolerance in patients with a clinical history of acute urticaria induced by a single NSAID." | 5.11 | Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs. ( Asero, R, 2005) |
| "Colchicine seems to be a good drug for treating recurrences of pericarditis after conventional treatment failure, but no clinical trial has tested the effects of colchicine as first-line drug for the treatment of the first recurrence of pericarditis." | 5.11 | Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. ( Belli, R; Bobbio, M; Cecchi, E; Demarie, D; Ghisio, A; Imazio, M; Moratti, M; Pomari, F; Trinchero, R, 2005) |
| "Overall there were higher thrombolysis in myocardial infarction (TIMI) flows in the infarct related coronary artery in the dalteparin group (p=0." | 5.10 | Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. ( Bergstrand, L; Dellborg, M; Fellenius, C; Granger, CB; Lindahl, B; Lins, LE; Nilsson, T; Pehrsson, K; Siegbahn, A; Swahn, E; Wallentin, L, 2003) |
| "To determine the efficacy and safety of aspirin and ticlopidine to prevent recurrent stroke in black patients." | 5.10 | Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. ( Gorelick, PB; Harris, Y; Hung, E; Kelly, M; Kittner, S; Leurgans, S; Richardson, D; Ruland, S, 2003) |
| "Five previously suspected risk factors (valve surgery, prior protamine exposure, history of pulmonary hypertension, fish allergy, and vasectomy), aspirin ingestion within 7 days of surgery, and demographic information were recorded." | 5.10 | Effect of site of venous protamine administration, previously alleged risk factors, and preoperative use of aspirin on acute protamine-induced pulmonary vasoconstriction. ( Comunale, ME; Haering, JM; Lowenstein, E; Mashikian, JS; Maslow, A; Robertson, LK, 2003) |
| "To compare the efficacy and safety of two antiplatelet regimens, ticlopidine alone (200 mg daily) and ticlopidine (100 mg daily) plus aspirin (81 mg daily), in patients with ischemic stroke from the Tokai district of Japan." | 5.10 | Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. ( Ito, E; Kuzuhara, S; Nakajima, M; Takahashi, A; Uchiyama, S; Yamamoto, H, 2003) |
| "The aims of the Safety and Efficacy of Subcutaneous Enoxaparin Versus Intravenous Unfractionated Heparin and Tirofiban Versus Placebo in the Treatment of Acute ST-Segment Elevation Myocardial Infarction Patients Ineligible for Reperfusion (TETAMI) study were to demonstrate that enoxaparin was superior to unfractionated heparin (UFH) and that tirofiban was better than placebo in patients with acute ST-segment elevation myocardial infarction (STEMI) who do not receive timely reperfusion." | 5.10 | The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial ( Bigonzi, F; Cohen, M; Danchin, N; Gensini, GF; Gurfinkel, EP; Hecquet, C; Huber, K; Krzeminska-Pakula, M; Maritz, F; Santopinto, J; Timerman, A; Vittori, L; White, HD, 2003) |
| "To compare the costs to the Spanish healthcare system of 35 days' treatment with triflusal (600 mg/day) and aspirin (300 mg/day) in patients with confirmed acute myocardial infarction within 24 hours of onset of symptoms." | 5.10 | Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction. ( Darbà, J; Izquierdo, I; Navas, C; Pontes, C; Rovira, J, 2002) |
| "Despite use of heparin and aspirin, 5-10% of patients with unstable angina develop myocardial infarction (MI) or refractory angina in the hospital." | 5.09 | Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial. ( Yusuf, S, 1999) |
| "The dose of aspirin for secondary stroke prevention and the clinical meaning of ex vivo platelet abnormalities are debated." | 5.09 | Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study. ( Chamorro, A; Escolar, G; Obach, V; Ordinas, A; Reverter, JC; Revilla, M; Vila, N, 1999) |
| "A longitudinal cohort study was performed comparing 460 participants with intermittent AF with 1,552 with sustained AF treated with aspirin in the Stroke Prevention in Atrial Fibrillation studies and followed for a mean of two years." | 5.09 | Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. ( Asinger, RW; Halperin, JL; Hart, RG; McAnulty, JH; Pearce, LA; Rothbart, RM, 2000) |
| "To compare the efficacy and tolerability of the antiplatelet agent triflusal with aspirin in the prevention of cardiovascular events following acute myocardial infarction." | 5.09 | Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. ( Cabadés, A; Castro-Beiras, A; Cruz-Fernández, JM; García-Dorado, D; López García-Aranda, V; López-Bescós, L; Marfil, F; Martín-Jadraque, L; Navarro, E; Torres, F; Velasco, JA, 2000) |
| "Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation." | 5.09 | Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000) |
| "The aim of the present study was to evaluate the possible interaction between chronic aspirin therapy and angiotensin-converting enzyme inhibitor (ACE-I) on left ventricular ejection fraction (LVEF) in patients surviving an acute myocardial infarction (AMI)." | 5.09 | Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction. ( Arnesen, H; Hole, T; Hurlen, M; Seljeflot, I, 2001) |
| "We sought to compare the efficacy of aspirin and ticlopidine in survivors of acute myocardial infarction (AMI) treated with thrombolysis." | 5.09 | Ticlopidine versus aspirin after myocardial infarction (STAMI) trial. ( Cimminiello, C; Di Biase, M; Marubini, E; Pitzalis, MV; Rizzon, P; Scrutinio, D, 2001) |
| "We sought to compare different antithrombotic secondary treatments (mainly medium-dose aspirin with low-dose low-molecular-weight heparin [LMWH]) in pediatric patients with a first ischemic stroke onset with regard to the risk of stroke recurrence." | 5.09 | Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. ( Heller, C; Kurnik, K; Luigs, P; Nowak-Göttl, U; Schobess, R; Sträter, R, 2001) |
| "This study assessed the effect of the combination of aspirin and dipyridamole on patency of the infarct-related artery between 4 weeks and 1 year after myocardial infarction." | 5.08 | Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy. ( Brown, MA; Cross, DB; French, JK; Hamer, AW; Ormiston, JA; White, HD; Williams, BF, 1995) |
| "1506 patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) took part in a double-blind trial and were randomly assigned subcutaneous dalteparin (Fragmin; 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days then 7500 IU once daily for the next 35-45 days) or placebo injections." | 5.08 | Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group. ( , 1996) |
| "To compare aspirin with anticoagulation with regard to risk of cardiac death and reinfarction in patients who received anistreplase thrombolysis for myocardial infarction." | 5.08 | A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. ( Chamberlain, DA; Julian, DG; Pocock, SJ, 1996) |
| "One hundred twenty-three patients with successful stenting after acute myocardial infarction were randomized to receive aspirin plus ticlopidine (n = 61) or intense anticoagulant therapy (n = 62)." | 5.08 | Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. ( Alt, E; Blasini, R; Dirschinger, J; Hadamitzky, M; Hausleiter, J; Kastrati, A; Neumann, FJ; Schmitt, C; Schömig, A; Schühlen, H; Walter, H; Zitzmann-Roth, EM, 1997) |
| "The efficacy of combining antiplatelet agents with low doses of aspirin to prevent cardiac events in patients with myocardial infarction was examined." | 5.08 | Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group. ( Hama, J; Ishikawa, K; Kanamasa, K; Katori, R; Kimura, A; Naito, T; Nakai, S; Ogawa, I; Oyaizu, M; Takenaka, T; Yamamoto, K; Yamamoto, T, 1997) |
| "Healing with bFGF (and cimetidine) was associated with reduced NSAID induced ulcer relapse in this model of gastric ulceration." | 5.08 | Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration. ( Brough, JL; Filipowicz, B; Hawkey, CJ; Hull, MA; Knifton, A; Vautier, G, 1997) |
| "Antithrombotic therapy with enoxaparin plus aspirin was more effective than unfractionated heparin plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non-Q-wave myocardial infarction in the early phase." | 5.08 | A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. ( Bigonzi, F; Califf, RM; Cohen, M; Demers, C; Fox, KA; Fromell, GJ; Goodman, S; Gurfinkel, EP; Langer, A; Premmereur, J; Turpie, AG, 1997) |
| "In a multicenter trial of antithrombotic therapy in unstable angina or non-Q wave myocardial infarction, 358 patients admitted within 48 h of chest pain were randomized to antithrombotic therapy with either 1) aspirin alone, or 2) aspirin plus heparin followed by aspirin plus warfarin, and were prospectively followed up for 12 weeks." | 5.07 | Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. ( Adams, PC; Chamberlain, D; Chesebro, JH; Cohen, M; Fox, KA; Fuster, V; McBride, R; Parry, G; Wieczorek, I; Xiong, J, 1993) |
| "The purpose of this study was to compare combination antithrombotic therapy with aspirin plus anticoagulation versus aspirin alone, when added to conventional antianginal therapy in patients with unstable rest angina or non-Q-wave myocardial infarction who were nonprior aspirin users." | 5.07 | Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. ( Adams, PC; Chamberlain, D; Chesebro, JH; Cohen, M; Fox, KA; Keller, C; Parry, G; Strain, J; Wieczorek, I; Xiong, J, 1994) |
| "The efficacy of low-dose aspirin in preventing fetal growth retardation was tested in a randomised, placebo-controlled, double-blind trial." | 5.07 | Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial. ( Bazin, B; Beaufils, M; Breart, G; Capitant, C; Paris, J; Uzan, S, 1991) |
| "To ascertain whether predischarge arteriography is beneficial in patients with acute myocardial infarction treated with recombinant tissue-type plasminogen activator (rt-PA), heparin and aspirin, the outcome of 197 patients in the Thrombolysis in Myocardial Infarction (TIMI) IIA study assigned to conservative management and routine predischarge coronary arteriography (routine catheterization group) was compared with the outcome of 1,461 patients from the TIMI IIB study assigned to conservative management without routine coronary arteriography unless ischemia recurred spontaneously or on predischarge exercise testing (selective catheterization group)." | 5.07 | Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II Investigators. ( Babb, JD; Baim, DS; Braunwald, E; Chesebro, JH; Frederick, M; Gore, JM; Passamani, ER; Roberts, R; Rogers, WJ; Williams, DO, 1991) |
| "We carried out a pilot study in 15 hemodialysis patients with recurrent vascular access thrombosis to examine whether the combination of low dose aspirin (85 mg once daily) and sulfinpyrazone (200 mg three times daily) is safe and effective in the prevention of vascular access thrombosis." | 5.07 | Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. ( Bauman, JE; Domoto, DT; Joist, JH, 1991) |
| "Recently, it was shown that aspirin given early in acute myocardial infarction (AMI) improves hospital survival, but the mechanisms involved are unclear." | 5.06 | Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. ( Funke-Küpper, AJ; Galema, TW; Roos, JP; Sterkman, LG; van der Laarse, A; Verheugt, FW, 1990) |
| "We compared the outcomes of 2,500 patients who suffered from previous cerebrovascular disorders (transient ischemic attacks, reversible ischemic neurologic deficits, or completed strokes) treated with acetylsalicylic acid plus dipyridamole or matched placebo and followed for 2 years." | 5.06 | European Stroke Prevention Study. ESPS Group. ( , 1990) |
| "In a randomized pilot study we compared the efficacy of temporary anticoagulation with intravenous heparin sodium to the efficacy of aspirin in preventing cerebral infarction in hospitalized patients with recent (less than 7 days) transient ischemic attacks (TIAs)." | 5.06 | A randomized trial of aspirin or heparin in hospitalized patients with recent transient ischemic attacks. A pilot study. ( Adams, HP; Banwart, KJ; Biller, J; Bruno, A; Godersky, JC; Jones, MP; Loftus, CM; Mitchell, VL, 1989) |
| "In the Persantine-Aspirin Reinfarction Study, Part II (PARIS II), 3,128 persons who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously, were randomized into two groups: dipyridamole (Persantine) plus aspirin (n = 1,563) and placebo (n = 1,565)." | 5.06 | Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. ( Klimt, CR; Knatterud, GL; Meier, P; Stamler, J, 1986) |
| "A randomized, controlled study was conducted in 51 patients to investigate the effect of aspirin administration on traumatic hyphema." | 5.06 | Aspirin and secondary bleeding after traumatic hyphema. ( Biedner, B; Lifshitz, T; Marcus, M; Yassur, Y, 1988) |
| " Low-dose aspirin and dipyridamole direct prostacyclin/thromboxane A2 balance in pregnancy to the dominance of prostacyclin and may thus prevent idiopathic uteroplacental insufficiency and fetal growth retardation in high-risk patients." | 5.06 | Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole. ( Rotmans, N; Wallenburg, HC, 1987) |
| " Dual-antiplatelet therapy is the standard of care for secondary prevention in patients with acute coronary syndrome (ACS), whereas single antiplatelet therapy, generally with aspirin, is the standard of care for secondary prevention in stable patients with coronary artery disease (CAD), peripheral artery disease (PAD), or cerebrovascular disease." | 5.05 | Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence. ( Angiolillo, DJ; Geisler, T; Heitmeier, S; Weitz, JI, 2020) |
| "The MRC Epidemiology Unit in Cardiff, Wales conducted three randomized, controlled trials of aspirin use in patients who had had myocardial infarction." | 5.05 | British studies of aspirin and myocardial infarction. ( Elwood, PC, 1983) |
| "The Aspirin Myocardial Infarction Study (AMIS) was a National Heart, Lung and Blood Institute-sponsored, multicenter, randomized, double-blind, and placebo-controlled trial designed to test whether the regular administration of aspirin to men and women who had experienced at least one documented myocardial infarction (MI) would result in a significant reduction in total mortality over a three-year period." | 5.05 | A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. ( , 1980) |
| " Although a 150 mg dose of aspirin reduced urinary dinor-TxB2 levels by over 75 per cent, it had no effect on the course of the chronic recurrent form of angina pectoris due to vasospasm ("vasotonic angina")." | 5.05 | Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials. ( FitzGerald, GA; Friesinger, GC; Maas, RL; Oates, JA; Roberts, LJ; Robertson, D; Robertson, RM, 1981) |
| " These trials were prompted by earlier observations that aspirin takers seemed to fare better after acute myocardial infarction and were further stimulated by the recent growth of knowledge about the role of vascular and platelet prostaglandins." | 5.05 | Anti platelet agents for strokes and myocardial infarction: a critical appraisal of recent clinical trials. ( Castaldi, PA, 1981) |
| "Although neither aspirin nor oral anticoagulants have been conclusively shown to reduce mortality in patients surviving myocardial infarction, both have been widely used for that purpose." | 5.05 | A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. ( , 1982) |
| "The Jenkins Activity Survey (JAS), a questionnaire developed to assess the type A behavior pattern, was administered to 2,314 participants in the Aspirin Myocardial Infarction Study." | 5.05 | Type A score (Jenkins Activity Survey) and risk of recurrent coronary heart disease in the aspirin myocardial infarction study. ( Gale, M; Norusis, M; Shekelle, RB, 1985) |
| "A randomized controlled trial is reported in which a single dose of aspirin (300 mg) was given to patients with myocardial infarction on first contact with a general practitioner." | 5.04 | A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction. ( Elwood, PC; Williams, WO, 1979) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 5.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "The analysis showed lower risks of major adverse cardiovascular or cerebrovascular events, recurrent stroke, and bleeding events for clopidogrel monotherapy compared to aspirin." | 5.01 | Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. ( Del Aguila, M; Girotra, S; Hu, B; Ince, B; Jeng, JS; Kutluk, K; Liu, L; Lou, M; Min Han, J; Paciaroni, M; Paek, D; Parfenov, V; Wong, KSL; Zamani, B, 2019) |
| " Data from one randomised controlled trial showed no significant difference in benefit with aspirin versus placebo in asymptomatic carotid stenosis, but it is still reasonable to recommend aspirin (81-325 mg daily) for prevention of vascular events in these patients." | 5.01 | Optimal Antiplatelet Therapy in Moderate to Severe Asymptomatic and Symptomatic Carotid Stenosis: A Comprehensive Review of the Literature. ( de Borst, GJ; Halliday, A; Hamilton, G; Kakkos, S; McCabe, DJH; Murphy, SJX; Naylor, AR; Ricco, JB; Sillesen, H; Vega de Ceniga, M, 2019) |
| "To assess the effectiveness and safety of dual agent antiplatelet therapy combining clopidogrel and aspirin to prevent recurrent thrombotic and bleeding events compared with aspirin alone in patients with acute minor ischaemic stroke or transient ischaemic attack (TIA)." | 4.98 | Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. ( Foroutan, F; Guyatt, G; Hao, Q; O'Donnell, M; Siemieniuk, RA; Tampi, M, 2018) |
| "Optimal antiplatelet therapy after an ischemic stroke or transient ischemic attack while on aspirin is uncertain." | 4.95 | Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2017) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for 90 days was recommended as the secondary prevention of minor ischaemic strokes or transient ischaemic attacks (TIAs) in 2014." | 4.93 | Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis. ( Chang, T; Ge, F; Guo, R; Li, M; Lin, H; Liu, Y; Ruan, Z, 2016) |
| "Aspirin is recommended for secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke on the basis of trials showing a 13% reduction in long-term risk of recurrent stroke." | 4.93 | Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. ( Algra, A; Chen, Z; Diener, HC; Mehta, Z; Norrving, B; Rothwell, PM, 2016) |
| "Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events." | 4.91 | Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis. ( Li, J; Li, Y; Shang, X; Wang, C; Yan, C; Zhang, L; Zhang, Q; Zheng, M, 2015) |
| "The clinical significance of colchicine in the treatment of acute idiopathic (viral) pericarditis (IP) was only elucidated less than a decade ago." | 4.91 | Pharmacotherapeutic considerations for using colchicine to treat idiopathic pericarditis in the USA. ( Schwier, NC, 2015) |
| "A systematic review and meta-analysis to determine the risks (major bleeding) and benefits (recurrent VTE and mortality) of extended anticoagulation with vitamin k antagonists (VKA), DOACs and aspirin in patients with an unprovoked VTE and in those patients with clinical equipoise regarding continuation or cessation of anticoagulant therapy." | 4.91 | Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis. ( Cavallazzi, R; Marik, PE, 2015) |
| "To present the systematic assessment on the efficacy and bleeding adverse events of dual-antiplatelet therapy with aspirin and clopidogrel versus aspirin-mono-antiplatelet therapy in patients with ischemic stroke or transient ischemic attack." | 4.91 | [Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack]. ( Gao, P; Hu, Y; Qian, J; Tang, X; Yang, C, 2015) |
| "Dual antiplatelet therapy with aspirin plus clopidogrel is not recommended for secondary stroke prevention because of lack of effectiveness and increased hemorrhagic risk." | 4.90 | Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence. ( Censori, B, 2014) |
| "To review all randomised controlled trials (RCTs) that assess the effects of colchicine alone or combined, compared to any other intervention to prevent further recurrences of pericarditis, in people with acute or recurrent pericarditis." | 4.90 | Colchicine for pericarditis. ( Alabed, S; Burls, A; Cabello, JB; Irving, GJ; Qintar, M, 2014) |
| "To summarise and compare the efficacy and safety of various oral anticoagulants (dabigatran, rivaroxaban, apixaban, and vitamin K antagonists) and antiplatelet agents (acetylsalicylic acid) for the secondary prevention of venous thromboembolism." | 4.89 | Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. ( Cameron, C; Carrier, M; Castellucci, LA; Clifford, T; Coyle, D; Gandara, E; Le Gal, G; Rodger, MA; Wells, G; Wells, PS, 2013) |
| " In comparison with mono antiplatelet therapy, dual therapy (aspirin+dipyridamole and aspirin+clopidogrel) significantly reduced stroke recurrence, dual 58 (3." | 4.88 | Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. ( Algra, A; Bath, MW; Bath, PM; Chen, C; Dengler, R; Diener, HC; Geeganage, CM; Markus, HS; Topol, EJ, 2012) |
| "The following four studies were evaluated: the Coumadin Aspirin Reinfarction Study (CARS); the Combination Hemotherapy and Mortality Prevention (CHAMP) Study; the Warfarin, Aspirin Reinfarction Study (WARIS)-II; the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT)-2 Study." | 4.82 | [Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?]. ( Landmark, K; Madsen, S; Reikvam, A, 2003) |
| "Based on current references four clinical scenarios were discussed and different management strategies were compared for secondary and primary prophylaxis of ulcer or peptic ulcer bleeding under continuous therapy with non-steroidal antiinflammatory drugs (NSAID) or low-dose-aspirin, for H." | 4.82 | [Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios]. ( Ittel, TH; Limmer, S; Wietholtz, H, 2003) |
| "Although intra-uterine fetal death is considered at high risk of recurrence in case of antiphospholipid syndrome (APS), a uniform management protocol including aspirin and heparin and close obstetrical follow-up led to a favorable outcome in most cases." | 4.82 | Antiphospholipid syndrome and second- or third-trimester fetal death: follow-up in the next pregnancy. ( Bats, AS; Carbonne, B; Cynober, E; Gonzales, M; Lejeune, V; Milliez, J; Safar, E, 2004) |
| " Pooled data from trials comparing antithrombotic treatment with placebo show that warfarin reduces the risk of stroke by 62% and that aspirin alone reduces the risk by 22%." | 4.82 | [Preventing cerebrovascular accidents during atrial fibrillation]. ( Boccara, F; Cohen, A; Ederhy, S; Hammoudi, N; Janower, S; Meuleman, C, 2005) |
| "Combination therapy with aspirin and heparin may reduce pregnancy loss in women with antiphospholipid antibodies by 54%." | 4.81 | Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. ( Craig, JC; Empson, M; Lassere, M; Scott, JR, 2002) |
| " In the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events) Trial, clopidogrel (clopidogrel bisulphate) was superior to acetylsalicylic acid (ASA) in reducing the combined risk of ischaemic stroke (IS), myocardial infarction (MI) or vascular death in patients with symptomatic atherosclerosis." | 4.81 | From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. ( Hacke, W, 2002) |
| " The gastrointestinal bleeding risk was significantly lower with ticlopidine and clopidogrel, which were both somewhat more effective than aspirin in the prevention of vascular events." | 4.80 | Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis. ( Boysen, G, 1999) |
| "At the acute phase of cerebral infarction, two recent large studies found that the use of aspirin reduces both mortality and the risk of the recurrence of stroke." | 4.80 | [Aspirin and cerebral ischemic accidents]. ( Bousser, MG; Crassard, I; Niclot, P, 2000) |
| " In patients with arterial or venous thrombosis, there is a high rate of recurrence during the two first years except if high-dose warfarin was used (i." | 4.80 | [Aspirin and antiphospholipid syndrome]. ( Blétry, O; Hachulla, E; Hatron, PY; Piette, AM, 2000) |
| "Randomized trials of aspirin have been conducted in three main populations: patients with evolving acute myocardial infarction (MI), patients with a history of cardiovascular disease and apparently healthy subjects." | 4.80 | Aspirin in the treatment and prevention of cardiovascular disease. ( Buring, JE; Gaziano, JM; Skerrett, PJ, 2000) |
| " Smoking cessation, increased physical activity and lipid lowering are key lifestyle objectives, while beta blockade and aspirin should be routinely prescribed for all patients following acute myocardial infarction, unless there are specific contraindications." | 4.79 | What do we really know about secondary prevention after myocardial infarction? ( Wielgosz, AT, 1995) |
| "English-language articles published after 1977 and indexed in MEDLINE under the following Medical Subject Heading terms: anticoagulants, aspirin, dipyridamole, ticlopidine, or sulfinpyrazone, combined with cerebrovascular disorders." | 4.79 | Medical treatment for stroke prevention. ( Barnett, HJ; Feussner, JR; Matchar, DB; McCrory, DC, 1994) |
| "Both experimental and clinical studies suggest that the prehospital administration of aspirin may be beneficial in patients with unstable angina and acute myocardial infarction." | 4.79 | Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction. ( Eisenberg, MJ; Topal, EJ, 1996) |
| "To estimate the risk of myocardial infarction (MI) and death in patients with unstable angina who are treated with aspirin plus heparin compared with patients treated with aspirin alone." | 4.79 | Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. ( Grady, D; Oler, A; Oler, J; Whooley, MA, 1996) |
| "Most randomised trials of anticoagulant therapy for suspected acute myocardial infarction have been small and, in some, aspirin and fibrinolytic therapy were not used routinely." | 4.79 | Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. ( Appleby, P; Baigent, C; Collins, R; Flather, M; Godwin, J; MacMahon, S; Mortensen, S; Peto, R; Remvig, L; Yusuf, S, 1996) |
| " Administration of aspirin and heparin has been shown to improve mortality when combined with thrombolytic therapy in acute myocardial infarction, probably by enhancing lysis and reducing subsequent reocclusion of infarct related artery." | 4.78 | [Aspirin and heparin in the fibrinolytic treatment of acute myocardial infarction]. ( López Bescós, L, 1992) |
| " Secondary prevention strategies include smoking cessation; the control of hyperlipidemia, obesity and diabetes; the management of hypertension and stress; exercise; the use of drugs such as beta blockers and aspirin, and increased attention to general health." | 4.77 | Secondary prevention in elderly survivors of heart attacks. ( Davenport, J; Whittaker, K, 1988) |
| "In October 1985, the Food and Drug Administration approved a new indication of aspirin for the secondary prevention of recurrent myocardial infarction (MI) and death in patients with MI or unstable angina." | 4.77 | Prevention of recurrent myocardial infarction and sudden death with aspirin therapy. ( Goldstein, GS; Rumore, MM, 1987) |
| "Tartrazine, a common additive in foods and drugs, often causes adverse reactions such as recurrent urticaria, angioedema, and asthma and is frequently implicated in hyperkinesis." | 4.77 | Clinical spectrum of adverse reactions to tartrazine. ( Collins-Williams, C, 1985) |
| "Among Chinese minor stroke/transient ischemic attack population, the efficacy of clopidogrel-aspirin therapy was decreased in patients with higher ABCD-GENE score." | 4.12 | Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial. ( Chen, Z; Dai, L; Li, H; Meng, X; Pan, Y; Wang, Y; Xu, J; Yan, H, 2022) |
| " A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality." | 4.12 | Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022) |
| "Among the 3456 patients included, a total of 10 patients in the Clopidogrel Discontinuation Group and 11 patients in the non-Clopidogrel Discontinuation Group presented ischemic stroke recurrence during the 90-180-day period." | 4.12 | No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke. ( Jing, J; Johnston, SC; Liu, L; Meng, X; Pan, Y; Wang, A; Wang, D; Wang, Y; Zhang, X; Zhao, X, 2022) |
| "Our previous trial acute dual study (ADS) reported that dual antiplatelet therapy (DAPT) using cilostazol and aspirin did not reduce the rate of short-term neurological worsening in non-cardioembolic stroke patients." | 4.02 | Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis. ( Abe, K; Aoki, J; Fujimoto, S; Idomari, K; Iguchi, Y; Inoue, T; Iwanaga, T; Kaneko, N; Kimura, K; Matsuoka, H; Nomura, K; Okada, Y; Tanaka, R; Terasaki, T; Todo, K; Tsujino, A; Uno, M; Urabe, T; Yagita, Y; Yamagami, H; Yamagata, S; Yamamoto, N; Yamamoto, Y; Yonehara, T, 2021) |
| "Background Because of a nonresponse to aspirin (aspirin resistance), patients with acute coronary syndrome (ACS) are at increased risk of developing recurrent event." | 4.02 | Low miR-19b-1-5p Expression Is Related to Aspirin Resistance and Major Adverse Cardio- Cerebrovascular Events in Patients With Acute Coronary Syndrome. ( Chan, MY; Creemers, EE; de Ronde, MWJ; Hwee Tan, S; Mark Richards, A; Meijering, R; Pinto-Sietsma, SJ; Singh, S; Tang Chin, C; Troughton, RW; Van der Made, I; Yan, BP; Yean Yip Fong, A, 2021) |
| " Anticipated bleeding event rates (including both minor and major bleeds) with aspirin, dabigatran 150 mg, and rivaroxaban 20 mg were sourced from published meta-analyses, whilst a 30% ischaemic stroke reduction for both DOACs was assumed." | 4.02 | Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation. ( de Brouwer, B; Egea, M; Eggington, S; Franco, N; Huynh, M; Ismyrloglou, E; Joglekar, R; Liu, S; Lyon, J; Reynolds, MR; Rosemas, SC; Thijs, V; Tsintzos, SI; Tsivgoulis, G; Witte, KK; Ziegler, PD, 2021) |
| "We pooled individual patient data from 6 randomized clinical trials (CAPRIE [Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events], ESPS-2 [European Stroke Prevention Study-2], MATCH [Management of Atherothrombosis With Clopidogrel in High-Risk Patients], CHARISMA [Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance], ESPRIT [European/Australasian Stroke Prevention in Reversible Ischemia Trial], and PRoFESS [Prevention Regimen for Effectively Avoiding Second Strokes]) investigating antiplatelet therapy in the subacute or chronic phase after noncardioembolic transient ischemic attack or stroke." | 4.02 | Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. ( Algra, A; Bath, PM; Csiba, L; Diener, HC; Greving, JP; Hacke, W; Hilkens, NA; Kappelle, LJ; Koudstaal, PJ; Leys, D; Mas, JL; Sacco, RL, 2021) |
| "To evaluate whether initial treatment with low-dose compared with high-dose aspirin in children with KD is associated with an increase in fever recrudescence." | 3.96 | Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin. ( Belarski, E; Carroll, AE; John, CC; Manaloor, J; Ofner, S; Platt, B; Wood, JB, 2020) |
| "To investigate the association of aspirin resistance (AR) with the plasma 4-hydroxynonenal (4-HNE) level and its impact on recurrent cerebral infarction (CI) in patients with acute cerebral infarction (ACI) who were receiving aspirin therapy." | 3.96 | Association of aspirin resistance with 4-hydroxynonenal and its impact on recurrent cerebral infarction in patients with acute cerebral infarction. ( Feng, J; Guo, J; Guo, Y; Wang, J, 2020) |
| "In AUGUSTUS (Open-Label, 2×2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention), patients with atrial fibrillation and a recent acute coronary syndrome and those undergoing percutaneous coronary intervention had less bleeding with apixaban than vitamin K antagonist (VKA) and with placebo than aspirin." | 3.96 | Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. ( Alexander, JH; Aronson, R; Goodman, SG; Granger, CB; Lopes, RD; Mehran, R; Thomas, L; Vora, AN; Windecker, S; Wojdyla, D, 2020) |
| "Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial." | 3.96 | Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC, 2020) |
| "This study compared the effectiveness of dual antiplatelet therapy (DAPT) with clopidogrel-aspirin with that of aspirin monotherapy (AM) in mild-to-moderate acute ischemic stroke considering the risk of recurrent stroke using the Stroke Prognosis Instrument II (SPI-II) score." | 3.96 | Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Mild-to-Moderate Acute Ischemic Stroke According to the Risk of Recurrent Stroke: An Analysis of 15 000 Patients From a Nationwide, Multicent ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, KH; Hong, JH; Hong, KS; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Kwon, JH; Lee, BC; Lee, HL; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Park, HK; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Shin, DI; Sohn, SI; Sun Oh, M; Yu, KH, 2020) |
| "In real-world practice settings, there is insufficient evidence on the efficacy of antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention." | 3.96 | Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan. ( Hsu, YH; Ong, CT; Tsai, CF; Wong, YS, 2020) |
| "All acute coronary syndrome patients from the REgistry of New Antiplatelets in patients with Myocardial Infarction (RENAMI) undergoing percutaneous coronary intervention and treated with aspirin, prasugrel or ticagrelor were stratified according to DAPT duration, that is, shorter than 12 months (D1 group), 12 months (D2 group) and longer than 12 months (D3 group)." | 3.96 | Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. ( Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Bertaina, M; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Fioravanti, F; Gaita, F; Gallo, D; Garay, A; Gili, S; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lüscher, TF; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Taha, S; Templin, C; Valdés, M; Varbella, F; Velicki, L; Xanthopoulou, I, 2020) |
| " Clopidogrel plus aspirin treatment was associated with reduced risk of new stroke in patients with ABCB1 -154 TT and 3435 CC genotype (hazard ratio [HR], 0." | 3.91 | Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial. ( Chen, W; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Simon, T; Wang, D; Wang, Y; Zhao, X, 2019) |
| "In PEGASUS-TIMI 54, ticagrelor significantly reduced the risk of the composite of major adverse cardiovascular (CV) events by 15-16% in stable patients with a prior myocardial infarction (MI) 1-3 years earlier." | 3.91 | Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54. ( Ardissino, D; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Dellborg, M; Hamm, C; Himmelmann, A; Im, KA; Johanson, P; Kamensky, G; Kiss, RG; Kontny, F; Lopez-Sendon, J; Montalescot, G; Oude Ophuis, T; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Van de Werf, F, 2019) |
| "The addition of colchicine to prednisone in patients admitted for acute idiopathic pericarditis does not reduce the risk of recurrence." | 3.88 | Does colchicine decrease the rate of recurrence of acute idiopathic pericarditis treated with glucocorticoids? ( Chezar Azzerad, C; Hasdai, D; Iakobishvili, Z; Kornowski, R; Mager, A; Porter, A; Talmor, Y, 2018) |
| "To compare ticagrelor and prasugrel with clopidogrel for recurrent fatal and non-fatal myocardial infarction (reMI) in real-life conditions." | 3.88 | Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction. ( Abenhaim, L; Benichou, J; Bonello, L; Cottin, Y; Dallongeville, J; Danchin, N; Delarche, N; Falissard, B; Furber, A; Ghanem, F; Grimaldi-Bensouda, L; Leclercq, F; Morel, O; Puymirat, E, 2018) |
| "To determine the association between ruptured saccular aneurysms and aspirin use/aspirin dose." | 3.88 | Association between aspirin dose and subarachnoid hemorrhage from saccular aneurysms: A case-control study. ( Cai, T; Can, A; Castro, VM; Dligach, D; Du, R; Finan, S; Gainer, V; Murphy, S; Rudy, RF; Savova, G; Shadick, NA; Weiss, ST; Yu, S, 2018) |
| "WHAT IS THE ROLE OF DUAL ANTIPLATELET THERAPY AFTER HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKE? SPECIFICALLY, DOES DUAL ANTIPLATELET THERAPY WITH A COMBINATION OF ASPIRIN AND CLOPIDOGREL LEAD TO A GREATER REDUCTION IN RECURRENT STROKE AND DEATH OVER THE USE OF ASPIRIN ALONE WHEN GIVEN IN THE FIRST 24 HOURS AFTER A HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR ISCHAEMIC STROKE? AN EXPERT PANEL PRODUCED A STRONG RECOMMENDATION FOR INITIATING DUAL ANTIPLATELET THERAPY WITHIN 24 HOURS OF THE ONSET OF SYMPTOMS, AND FOR CONTINUING IT FOR 10-21 DAYS CURRENT PRACTICE IS TYPICALLY TO USE A SINGLE DRUG." | 3.88 | Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. ( Agoritsas, T; Booth, B; Fisch, L; Fobuzi, AC; Fraiz, A; Gorthi, SP; Guyatt, G; Hao, Q; Heen, AF; Horton, E; Jusufovic, M; Katragunta, N; Lytvyn, L; Muller, J; O'Donnell, M; Prasad, K; Rochwerg, B; Siemieniuk, J; Siemieniuk, R; Vandvik, PO, 2018) |
| "From January 2014 to September 2014, a single center continuously enrolled patients with minor ischemic stroke or high-risk TIA and gave them antiplatelet therapy consisting of aspirin with clopidogrel." | 3.85 | The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA. ( Cao, Y; Dong, K; Liu, L; Rao, Z; Wang, A; Wang, F; Wang, Y; Zhao, X; Zheng, H, 2017) |
| " Conservative treatment included: (a) weight-adjusted bemiparin plus six hours/day intravenous iloprost for 28 days, (b) aspirin (100 mg/day) plus cilostazol (100 mg twice/day) after discharge, and (c) strict recommendations/monitoring for smoking cessation." | 3.85 | Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia. ( Anastasiadou, C; Galyfos, G; Geropapas, G; Giannakakis, S; Kastrisios, G; Kerasidis, S; Maltezos, C; Papacharalampous, G; Papapetrou, A; Sachmpazidis, I, 2017) |
| "Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS." | 3.85 | Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017) |
| "To investigate the prevalent of aspirin resistance (AR) in stroke and its association with recurrent stroke in 214 patients with ischemic stroke who were receiving aspirin before the stroke onset." | 3.85 | Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke. ( Wang, Z; Zhang, N; Zhou, L, 2017) |
| "Acute coronary syndrome patients infected with HIV (n = 80) were matched to ACS patients without HIV (n = 160) on age, sex, diabetes, and DAPT (aspirin 100%, clopidogrel 68%, prasugrel 31%, ticagrelor 1%)." | 3.85 | Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study. ( Boccara, F; Boyd, A; Brugier, D; Cohen, A; Collet, JP; Curjol, A; Galier, S; Hauguel-Moreau, M; Hulot, JS; Kerneis, M; Montalescot, G; Salem, JE; Silvain, J, 2017) |
| "Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin." | 3.85 | Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017) |
| "The objective was to compare the efficacy and safety of naproxen (NXN) to acetylsalicylic acid (ASA) in the treatment of acute rheumatic fever (ARF)." | 3.83 | The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen. ( Arı, ME; Azak, E; Çetin, İİ; Çevik, BŞ; Ekici, F; Eminoğlu, S; Kibar, AE; Kocabaş, A; Orgun, A; Sürücü, M, 2016) |
| " Prevention with aspirin or heparin was administered in ten cases during pregnancy, and in all the cases with heparin in postpartum." | 3.81 | [Thrombosis risk during pregnancy after history of cerebral venous thrombosis]. ( Neau, JP; Pierre, F; Pouget-Abadie, JF; Pourrat, O, 2015) |
| "In patients with ischemic stroke of non-cardioembolic origin, acetylsalicylic acid, clopidogrel, or a combination of acetylsalicylic acid and dipyridamole are recommended for the prevention of a recurrent stroke." | 3.81 | Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study. ( Carlson, N; Christiansen, CB; Gerds, TA; Gislason, G; Jørgensen, ME; Kristensen, SL; Numé, AK; Olesen, JB; Pallisgaard, J; Torp-Pedersen, C, 2015) |
| "To explore the correlation between the recurrence of cerebral infarction and aspirin resistance (AR)/Chinese medical (CM) constitutions." | 3.81 | [Recurrence of Cerebral Infarction Associated Aspirin Resistance or Chinese Medical Constitutions: a Correlation Study]. ( Li, YH; Lu, QA; Wang, DX; Wang, XC; Yu, LH; Zong, SJ, 2015) |
| " We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population." | 3.80 | Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014) |
| "Some patients with a recent ischemic stroke who are being treated with aspirin as an antiaggregant suffer a new ischemic stroke." | 3.80 | Aspirin resistant patients with recent ischemic stroke. ( Castilla-Guerra, L; Fernández-Moreno, MC; Navas-Alcántara, MS, 2014) |
| "We estimated the effectiveness and safety of antiplatelet drugs (aspirin and clopidogrel) for the prevention of recurrent ischemic stroke in end-stage renal disease patients undergoing dialysis during long-term follow-up after first-time ischemic stroke." | 3.80 | Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis. ( Chen, CY; Huang, YB; Lai, WT; Lee, CT; Lee, KT, 2014) |
| "Our objective was to investigate the association between recurrent stroke risk and headache induced by extended-release dipyridamole (ER-DP) when administered alone or with low-dose aspirin (ASA+ER-DP)." | 3.80 | Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. ( Bath, PM; Cotton, D; Davidai, G; Diener, HC; Gorelick, P; Lipton, RB; Sacco, R, 2014) |
| "To examine the association between cardioprotective use of low-dose aspirin and the risk of recurrent gout attacks among gout patients." | 3.80 | Low-dose aspirin use and recurrent gout attacks. ( Chaisson, C; Chen, C; Choi, H; Hunter, DJ; Neogi, T; Zhang, Y, 2014) |
| "The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial found no difference between warfarin and aspirin in patients with low ejection fraction in sinus rhythm for the primary outcome: first to occur of 84 incident ischemic strokes (IIS), 7 intracerebral hemorrhages or 531 deaths." | 3.79 | Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. ( Anker, SD; Di Tullio, MR; Diek, M; Freudenberger, RS; Graham, S; Haddad, H; Homma, S; Labovitz, AJ; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2013) |
| "Of the 82 patients with recurrent cerebral ischemia included in this study, 37 (45%) patients were poor compliant with aspirin." | 3.79 | Clinical and biochemical aspirin resistance in patients with recurrent cerebral ischemia. ( Abu-Hegazy, M; Azzam, H; El-Mitwalli, A; Gomaa, M; Wasel, Y, 2013) |
| "The widespread use of aspirin-driven vascular prevention strategies does not impede the occurrence of first and recurrent ischemic strokes in numerous subjects." | 3.78 | Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012) |
| "To examine the effect of proton pump inhibitors on adverse cardiovascular events in aspirin treated patients with first time myocardial infarction." | 3.77 | Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. ( Ahlehoff, O; Charlot, M; Gislason, GH; Grove, EL; Hansen, PR; Køber, L; Lindhardsen, J; Madsen, JK; Olesen, JB; Selmer, C; Torp-Pedersen, C, 2011) |
| "We conducted a retrospective cohort study to assess CV outcomes of 9753 patients taking dual antiplatelet therapy of aspirin plus clopidogrel with or without a PPI after hospitalization for acute coronary syndrome (ACS)." | 3.77 | Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. ( Chen, PF; Hsiao, FY; Huang, WF; Mullins, CD; Tsai, YW; Wen, YW, 2011) |
| "9 years) with confirmed diagnoses of cerebral infarction and PAS, treated with anticoagulants (n = 54) or aspirin (n = 38) were retrospectively analyzed." | 3.77 | [Aspirin versus anticoagulation in young patients with cerebral infarction secondary to primary antiphospholipid syndrome]. ( Arauz, A; Artigas, C; Barinagarrementeria, F; Cantu-Brito, C; Hernandez, B; Marquez, JM; Merlos, M; Perez, A; Roa, LF, 2011) |
| "We present a 19-month-old boy with a history of asthma who presented to the pediatric emergency department with noisy breathing and tachypnea partially responsive to albuterol." | 3.76 | A 19-month-old boy with recurrent respiratory distress. ( Cross, KP; Herr, SM; Randell, KA, 2010) |
| "Administrative claims from a large, geographically diverse US health plan were used to evaluate acetylsalicylic acid / extended-release dipyridamole (ASA/ERDP) treated and clopidogrel treated patients from November 1, 2002 - December 31, 2005 who had an ischemic stroke requiring hospitalization." | 3.76 | Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. ( Burke, JP; Henk, H; Sander, S; Shah, H; Zarotsky, V, 2010) |
| " Thrombolysis in myocardial infarction (TIMI) 3 flow predicted a good outcome, whereas recurrent ischemia in hospital, prior aspirin therapy and discharge creatinine predicted a poor outcome; age alone was not an adverse prognostic factor." | 3.76 | Influence of age on long-term outcome after emergent percutaneous coronary intervention for ST-elevation myocardial infarction. ( Attia, J; Baker, F; Collins, N; Hatton, R; Hiew, C; McElduff, P; Narasimhan, S; O'Connor, S; Williams, T, 2010) |
| "The combination of aspirin and clopidogrel is indicated after acute coronary events and possibly for a short period after TIA or minor ischemic stroke." | 3.76 | Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. ( Chandratheva, A; Geraghty, OC; Paul, NL; Rothwell, PM, 2010) |
| "The effect of biochemical aspirin resistance (BAR) on ischemic stroke has not been well established." | 3.76 | Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. ( Jeon, SB; Kang, DW; Kim, BJ; Kim, HJ; Kim, JS; Kwon, SU; Song, HS, 2010) |
| "Platelet deposition and thrombus formation caused by angioplasty appear to be important in the development of 2 complications: acute thrombotic occlusion and restenosis." | 3.76 | Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. ( Harker, LA, 1987) |
| "To assess the prognosis of patients presenting with an acute coronary syndrome (ACS) despite chronic clopidogrel therapy (CCT)." | 3.75 | Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. ( Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R, 2009) |
| "Aspirin remains the most commonly used antithrombotic agent for the prevention of recurrent stroke among antithrombotic naive patients with a first-ever ischemic stroke in our institution." | 3.75 | The prescribing patterns of antithrombotic agents for prevention of recurrent ischemic stroke. ( Hseuh, IH; Lin, YJ; Po, HL, 2009) |
| "(1) For patients with acute coronary syndromes who have undergone percutaneous angioplasty and stenting, the best-assessed treatment for preventing relapses is a combination of aspirin and clopidogrel; (2) Prasugrel, an antiplatelet drug belonging the same chemical class as clopidogrel, is authorized in the EU for use in this indication; (3) Clinical evaluation is based on a randomized double-blind trial comparing prasugrel + aspirin versus clopidogrel + aspirin in 13 608 patients with acute coronary syndromes, half of whom were treated for at least 15 months." | 3.75 | Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. ( , 2009) |
| "In primary prevention, aspirin reduces the risk of stroke but not of myocardial infarction in women while in men only the risk of myocardial infarction but not stroke could be significantly reduced." | 3.75 | Antiplatelet agents in stroke prevention: acute and long-term treatment strategies. ( Diener, HC; Weber, R; Weimar, C, 2009) |
| "Combinations of aspirin, clopidogrel, and vitamin K antagonists are widely used in patients after myocardial infarction." | 3.75 | Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. ( Abildstrom, SZ; Andersson, C; Gislason, GH; Hansen, ML; Hansen, PR; Hvelplund, A; Jørgensen, C; Køber, L; Madsen, JK; Sørensen, R; Torp-Pedersen, C, 2009) |
| "The rate of clopidogrel use within 30 days after hospital discharge following myocardial infarction increased from 35% in the prior-authorization period to 88% in the limited-use period." | 3.74 | Cardiovascular outcomes after a change in prescription policy for clopidogrel. ( Behlouli, H; Cox, J; Demers, V; Jackevicius, CA; Johansen, H; Kalavrouziotis, D; Melo, M; Newman, A; Pilote, L; Rinfret, S; Tu, JV, 2008) |
| "Gastric ulcers were induced with acetic acid in rats; aspirin was administrated by gavage from day 25 to day 54 after ulcer induction." | 3.74 | Aspirin can elicit the recurrence of gastric ulcer induced with acetic acid in rats. ( Guo, CJ; Huang, GP; Jia, BB; Wang, GZ; Wang, JF; Xie, CG; Yin, GL; Zhou, G, 2007) |
| " With a treatment that included aspirin, heparin, and a nitric oxide donor, her third pregnancy ended with a healthy neonate at term." | 3.74 | Successful pregnancy with the use of nitric oxide donors and heparin after recurrent severe preeclampsia in a woman with scleroderma. ( Cabane, J; Carbonne, B; Cynober, E; Macé, G; Milliez, J, 2007) |
| "We conducted a retrospective study to determine the prevalence of Samter's triad (nasal polyps, asthma, and aspirin sensitivity) in 208 consecutively presenting patients who had undergone functional endoscopic sinus surgery (FESS) for chronic rhinosinusitis from September 2001 through August 2003." | 3.74 | The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery. ( Kim, JE; Kountakis, SE, 2007) |
| "Aspirin resistance is a well-documented laboratory finding, but the effects of clinical aspirin (ASA) failure on patients with acute coronary syndrome (ACS) have been debated." | 3.74 | Dual antiplatelet agent failure: a new syndrome or clinical nonentity? ( Armstrong, DF; Barnes, GD; Eagle, KA; Froehlich, JB; Gurm, HS; Kline-Rogers, E; Li, J; Vedre, A, 2007) |
| "In acute ischemic stroke and transient ischemic attack (TIA), aspirin is recommended to all patients (except immediately following thrombolysis)." | 3.74 | [Antithrombotic therapy in ischemic stroke and transient ischemic attack]. ( Husted, SE; Overgaard, K; Poulsen, TS, 2007) |
| " Hypertension, diabetes mellitus, transient ischemic attack (TIA), hyperlipemia and mural thrombus in left atrium were significantly correlated with the recurrence rate by univariate Cox proportional hazards regression analysis; but aspirin therapy, warfarin therapy and hypertension control were protective factors for the recurrence of ischemic stroke in patients with NVAF." | 3.74 | [A study on the recurrence of ischemic stroke in nonvalvular atrial fibrillation]. ( Cai, YY; Hu, Y; Luo, M; Quan, HB; Xie, RM, 2007) |
| "Aspirin is the standard therapy applied after coronary intervention, and statins are also prescribed to prevent secondary coronary heart disease." | 3.74 | Therapy with statins and aspirin enhances long-term outcome of percutaneous coronary intervention. ( Akimoto, Y; Hiroyuki, D; Kajimoto, K; Kasai, T; Ken, Y; Kojima, T; Kubota, N; Miyauchi, K; Njaman, W; Takeshi, K, 2008) |
| "A literature search was conducted using EMBASE (1980-January 2008), PubMed (1966-January 2008), Google, and a manual search of the reference lists using the search terms gastrointestinal bleed, gastrointestinal hemorrhage, peptic ulcer hemorrhage, ASA, aspirin, Plavix, clopidogrel, and PPI." | 3.74 | Single antiplatelet therapy for patients with previous gastrointestinal bleeds. ( Ackman, ML; Gellatly, RM, 2008) |
| "Aspirin has been used for secondary prevention of myocardial infarction (MI) in individuals with coronary disease." | 3.74 | Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers. ( Eskola, M; Karhunen, PJ; Mikkelsson, J; Niemela, K; Nikus, K, 2008) |
| "At a similar level of efficacy in inhibiting secondary thrombosis, triflusal seems to better preserve Cox-2 expression than aspirin and its metabolite HTB was able to protect endothelial prostacyclin production." | 3.74 | Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2. ( Badimon, L; Duran, X; Sánchez, S; Vilahur, G, 2008) |
| " The cost-effectiveness of longer combination therapy depends critically on the balance of thrombotic event rates, durable efficacy, and the increased bleeding rate in patients taking clopidogrel." | 3.73 | A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. ( Heidenreich, PA; Schleinitz, MD, 2005) |
| "Six patients with a history of recurrent anaphylaxis associated with wheat ingestion were diagnosed as having WDEIA by the provocation test, which included wheat ingestion, exercise, aspirin intake and a combination of these challenges." | 3.73 | Exercise and aspirin increase levels of circulating gliadin peptides in patients with wheat-dependent exercise-induced anaphylaxis. ( Akaki, T; Hide, M; Kaneko, S; Kuroda, T; Kusatake, K; Matsuo, H; Morimoto, K; Morita, E; Niihara, H, 2005) |
| "Thrombotic events still occur in aspirin-treated patients with coronary artery disease." | 3.73 | Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. ( Barnard, MR; Fox, ML; Frelinger, AL; Furman, MI; Li, Y; Linden, MD; Michelson, AD, 2006) |
| "Aspirin is the drug of choice in most patients with acute stroke, if thrombolysis is contraindicated." | 3.72 | [Anticoagulation and antiaggregation in neurological patients]. ( Arnold, M; Mattle, HP; Nedeltchev, K, 2003) |
| "Despite evidence-based guidelines, aspirin prescribing for the secondary prevention of stroke is sub-optimal." | 3.72 | Why are eligible patients not prescribed aspirin in primary care? A qualitative study indicating measures for improvement. ( Ashcroft, D; Bashford, J; Frischer, M; Short, D, 2003) |
| "During the period from January 2000 to May 2002, 70 patients who were prescribed clopidogrel (75 mg/day) for a previous history of non-aspirin-related peptic ulcer disease or a history of aspirin-related gastrointestinal complications (dyspepsia or peptic ulcer) were recruited." | 3.72 | High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. ( Chang, CM; Chen, WH; Kng, C; Lanas, AI; Ng, FH; Wong, BC; Wong, SY, 2003) |
| "Aspirin is a common antiplatelet drug used in the prevention of ischemic stroke due to its inhibitory effect on platelet cyclooxygenase-1 (Cox-1)." | 3.72 | Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. ( Hillarp, A; Lethagen, S; Mattiasson, I; Palmqvist, B; Villoutreix, BO, 2003) |
| "The antiplatelet effect of clopidogrel was studied prospectively in 60 consecutive patients who underwent primary angioplasty (percutaneous coronary intervention [PCI]) with stenting for acute ST-segment-elevation myocardial infarction (STEMI) to determine whether variability in response to clopidogrel affects clinical outcomes." | 3.72 | Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. ( Beinart, R; Bienart, R; Goldenberg, I; Guetta, V; Hod, H; Matetzky, S; Novikov, I; Pres, H; Savion, N; Shechter, M; Shenkman, B; Varon, D, 2004) |
| "The possible additive antiplatelet effects of aspirin and clopidogrel have been explored in the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) and Management of Atherothrombosis with Clopidogrel in High Risk Patients (MATCH) studies." | 3.72 | Long-term combination therapy with aspirin and clopidogrel. ( Cheung, BM; Cheung, G; Kumana, CR; Lauder, IJ, 2004) |
| "Patients with both patent foramen ovale and atrial septal aneurysm who have had a stroke constitute a subgroup at substantial risk for recurrent stroke, and preventive strategies other than aspirin should be considered." | 3.71 | Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. ( Arquizan, C; Cabanes, L; Coste, J; Derumeaux, G; Lamy, C; Mas, JL; Zuber, M, 2001) |
| " Fever always occurred before their admission and aspirin (n = 12) or acetaminophen (n = 7) was prescribed." | 3.71 | [Severe Reye syndrome: report of 14 cases managed in a pediatric intensive care unit over 11 years]. ( Brivet, M; Chevret, L; Debray, D; Devictor, D; Durand, P; Fabre, M; Thabet, F, 2002) |
| "We studied 30 patients with postsurgical ulcer and aspirin abuse." | 3.70 | Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer. ( Hirschowitz, BI; Lanas, A, 1998) |
| "To investigate the prevalence of aspirin use in older patients with prior myocardial infarction at the time of admission to a nursing home." | 3.70 | Underutilization of aspirin in older patients with prior myocardial infarction at the time of admission to a nursing home. ( Aronow, WS, 1998) |
| "To assess the prevalence of haemostatic abnormalities in patients with an obstetric history of preeclampsia and/or fetal growth restriction and documented thrombophilia, and to evaluate the effects of low-molecular-weight heparin (LMWH) and aspirin on pregnancy outcome." | 3.70 | Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. ( de Vries, JI; Dekker, GA; Huijgens, PC; Leeda, M; Riyazi, N; van Geijn, HP, 1998) |
| "The thienopyridine derivatives, ticlopidine and clopidogrel, provide alternatives to aspirin for use in the prevention of recurrent ischemic events in the post-myocardial infarction patient." | 3.70 | Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient. ( Pepine, CJ, 1998) |
| " All patients were contacted for ultrasonography and were interviewed for additional information on daily intake of aspirin, NSAIDs, cholesterol lowering medication, estrogen therapy, and biliary pain during follow-up." | 3.70 | Gallstone recurrence after successful shock wave therapy: the magnitude of the problem and the predictive factors. ( Afschrift, M; Cesmeli, E; De Buyzere, M; Elewaut, A; Elewaut, AE; Kerre, T, 1999) |
| "For patients who have had a previous myocardial infarction (MI), the use of aspirin, beta-blockers, and lipid-lowering agents reduces the risk of recurrent MI and death." | 3.70 | Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? ( Goldberg, RJ; Gore, JM; Gurwitz, JH; Lessard, D; McCormick, D; Yarzebski, J, 1999) |
| "Aspirin-induced asthma (AIA) is frequently accompanied by nasal polyps." | 3.70 | Detection of activated eosinophils in nasal polyps of an aspirin-induced asthma patient. ( Ogata, Y; Okinaka, Y; Takahashi, M, 1999) |
| "The clinical characteristics of idiopathic nasal polyposis in children (11 males and nine females; median: 12 years; range: 8-15 years) were very similar to those observed in adults (median: 50 years), in particular the relation to asthma (ten of 20 cases) and aspirin intolerance (two Fernand-Widal syndromes of 20 cases)." | 3.70 | [Does idiopathic naso-sinusal polyposis exist in children?]. ( Coffinet, L; Derelle, J; Jankowski, R; Pialoux, R, 1999) |
| "This study confirms the importance of eosinophil infiltration in the pathogenesis of severe or recurrent nasal polyps based on allergy and aspirin intolerance." | 3.70 | [Significance of eosinophilic granulocytes in relation to allergy and aspirin intolerance in patients with sinusitis polyposa]. ( Bittinger, F; Gosepath, J; Kaldenbach, T; Klimek, L; Mann, WJ; Schäfer, D, 1999) |
| "Ischemic event rates were estimated for 12,931 aspirin users drawn from the Saskatchewan Health population between 1990 and 1995 who had an index diagnosis of myocardial infarction, ischemic stroke, or peripheral arterial disease." | 3.70 | Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi ( Caro, JJ; Migliaccio-Walle, K, 1999) |
| "The value of warfarin in preventing stroke in patients with chronic atrial fibrillation is well established." | 3.70 | Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. ( Almoznino-Sarafian, D; Alon, I; Chachashvily, S; Cohen, N; Gorelik, O; Koopfer, M; Litvinjuk, V; Modai, D; Shteinshnaider, M, 2000) |
| "The goal of this health economic analysis was to asses the cost-effectiveness of a fixed combination of aspirin plus extended-release dipyridamole (ASA/ER-DP) or clopidogrel compared with ASA monotherapy for prevention of recurrent ischemic stroke." | 3.70 | Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis. ( Gondek, K; Shah, H, 2000) |
| "Compared with aspirin alone, use of the new antiplatelet regimens, including aspirin combined with dipyridamole and clopidogrel bisulfate, has been found to further reduce the risk of stroke and other vascular events in patients who have experienced stroke or transient ischemic attack." | 3.70 | Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack. ( Bounameaux, H; Gaspoz, JM; Sarasin, FP, 2000) |
| "Adding NTG to a thrombolytic regimen with rt-PA, aspirin and heparin increases the magnitude of restored flow and total patency duration following recanalization in a rabbit model of arterial thrombosis." | 3.69 | Beneficial effect of nitroglycerin on arterial rethrombosis after thrombolysis. Results from a rabbit thrombosis model. ( Battler, A; Chernine, A; Hasdai, D; Kornowski, R; Ovadia, Z, 1995) |
| "To determine how often aspirin was prescribed as a discharge medication to eligible patients 65 years of age and older who were hospitalized with an acute myocardial infarction; to identify patient characteristics associated with the decision to use aspirin; and to evaluate the association between prescription of aspirin at discharge and 6-month survival." | 3.69 | Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes. ( Ellerbeck, EF; Hennen, J; Jencks, SF; Krumholz, HM; Meehan, TP; Petrillo, M; Radford, MJ; Wang, Y, 1996) |
| " Those with acute myocardial infarction, radiolucent defects in coronary arteries suggestive of thrombus, and results that were not optimal after stent implantation were anticoagulated with warfarin and not Included in the study." | 3.69 | Elective implantation of intracoronary stents without intravascular ultrasound guidance or subsequent warfarin. ( Aroney, CN; Bett, JH; McEniery, PT; Sankardas, MA, 1996) |
| "Weight-adjusted duteplase infusion, together with oral aspirin and intravenous heparin, in acute myocardial infarction resulted in patency of the infarct-related coronary artery and a safety profile comparable to those reported for the other form of tissue-type plasminogen activator, alteplase." | 3.69 | ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction. ( Keltai, M; Malcolm, AD; Walsh, MJ, 1996) |
| "Asthmatic triad (AT) is a clinical syndrome incorporating bronchial asthma (BA), recurrent nasal and sinus polyps, intolerance of aspirin, derivatives of pirasolone and other nonsteroid antiinflammatory drugs." | 3.69 | [The in-vivo test of the inhibition of leukocyte natural migration with aspirin and analgin in the specific diagnosis of the asthmatic triad]. ( Kanchurina, NA; Poroshina, IuA; Prasolova, NI; Zemskov, VM, 1996) |
| "Treatment with warfarin was most effective in preventing recurrent arterial and venous thrombosis." | 3.69 | A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. ( Harris, EN; Krnic-Barrie, S; Looney, SW; O'Connor, CR; Pierangeli, SS, 1997) |
| " In 1982, it was suggested for the first time low doses of aspirin and prednisone for treatment of recurrent fetal death associated to this syndrome, heparin therapy was reported in 1984, recommended a doses of 15,000 U/day during first pregnancy trimester and 20,000 U/day posteriorly." | 3.69 | [Recurrent fetal death and antiphospholipid antibody syndrome. A case report]. ( Bustos López, HH; Hernández Andrade, E; Ramírez Peredo, J; Rojas-Poceros, G, 1997) |
| " Studies concerning the sensitivity, specificity and tolerance of the new intranasal provocation procedure using lysine-ASA were based primarily on cases of bronchial asthma and yielded differing results." | 3.68 | [Intranasal provocation with lysine acetylsalicylic acid]. ( Brasch, J; Cornelius, M; Mertens, J; Wellbrock, M, 1993) |
| "Recurrent chest pain with new ST-segment elevation was observed in 26 of 652 patients (4%) with myocardial infarction in a clinical trial of alteplase (recombinant tissue-type plasminogen activator; 100 mg) and aspirin with or without heparin." | 3.68 | Retreatment with alteplase for early signs of reocclusion after thrombolysis. The European Cooperative Study Group. ( Arnout, J; Nÿssen, K; Simoons, ML; van den Brand, M; Verstraete, M, 1993) |
| "Low-dose aspirin is widely used in patients operated on for coronary disease as secondary prevention of coronary artery occlusion." | 3.68 | Gastric changes in coronary-operated patients with low-dose aspirin. ( Kivilaakso, E; Leivonen, M; Sipponen, P, 1992) |
| "One hundred thirty-one patients presenting with acute myocardial infarction (AMI) a mean of 3 hours after the onset of symptoms were treated with oral aspirin and intravenous thrombolytic therapy followed by heparin." | 3.68 | Safety of combined intravenous beta-adrenergic blockade (atenolol or metoprolol) and thrombolytic therapy in acute myocardial infarction. ( Commerford, PJ; Gordon, GD; Green, BK; Horak, AR; Millar, RN, 1992) |
| "Patients with acute myocardial infarction (AMI) admitted between 1986 and 1989 were divided into aspirin (ASA) group (216 cases) and control group (211 cases)." | 3.68 | [A clinical trial of the secondary prevention of reinfarction with low dose aspirin]. ( Chen, Z, 1991) |
| "In conscious dogs with coronary thrombosis induced by electrical current, we assessed the impact on the rapidity of thrombolysis and the incidence of reocclusion of two types of adjunctive treatment given concomitantly with intravenous tissue-type plasminogen activator (t-PA): 1) inhibition of platelet function with a peptide mimetic antagonist of platelet glycoprotein IIb/IIIa receptors or with lysine acetylsalicylic acid (ASA) and 2) inhibition of thrombin activity with recombinant hirudin or with heparin." | 3.68 | Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. ( Abendschein, DR; Haskel, EJ; Prager, NA; Sobel, BE, 1991) |
| "Fifty-six patients who presented with non-steroidal anti-inflammatory drug-associated duodenal ulcers received maintenance treatment with ranitidine." | 3.67 | Ranitidine maintenance treatment of non-steroidal anti-inflammatory drug-induced duodenal ulceration. ( Penston, JG; Wormsley, KG, 1989) |
| "Aspirin has been reported to induce the adult respiratory distress syndrome (ARDS) in humans." | 3.67 | Bronchoalveolar lavage in recurrent aspirin-induced adult respiratory distress syndrome. ( Krieger, BP; Suarez, M, 1986) |
| "Baseline white blood cell count (WCC) and haematocrit were examined in relation to recurrent coronary events and to all-cause mortality in 2026 persons enrolled in the first Persantin-Aspirin Reinfarction Study (PARIS-1) 2-60 months after myocardial infarction." | 3.67 | White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction. ( Barton, BA; Forbes, CD; Krol, WF; Lowe, GD; Machado, SG, 1985) |
| " Seven recently completed clinical trials, the Coronary Drug Project, the Aspirin Myocardial Infarction Study, the Anturane Reinfarction Trial, the Hypertension Detection and Follow-Up Program and three drug trials of betablockers, are reviewed from the perspective of both their clinical and methodological significance." | 3.66 | Overview of recent clinical and methodological advances from clinical trials of cardiovascular disease. ( Friedewald, WT; Schoenberger, JA, 1982) |
| "Hydroxyurea has been rarely implicated as a cause of drug fever." | 3.66 | Fever caused by hydroxyurea. ( Bauernfeind, RA; Bauman, JL; Hartsough, N; Hasegawa, GR; Roden, R; Shulruff, S, 1981) |
| "We have studied seventy-five patients with recurrent urticaria and angio-oedema of more than 4 months duration and with positive provocation tests to aspirin, azo dyes, and/or benzoates." | 3.65 | A follow-up study of patients with recurrent urticaria and hypersensitivity to aspirin, benzoates and azo dyes. ( Juhlin, L; Michaëlsson, G; Ros, AM, 1976) |
| " There were five chronic alcoholics, one aspirin abuser, one severely burned patient, and one patient with sepsis." | 3.65 | Gastric devascularization: an alternate approach to the surgical treatment of massive, diffuse hemorrhage from gastritis. ( Aust, JB; McFee, AS; Rittenhouse, M, 1976) |
| "Often used as an oral analgesic in the management of pain associated with traumatic hyphema, aspirin has an inhibitory effect on the blood clotting mechamism by its action on platelets." | 3.65 | The effect of aspirin on rebleeding in traumatic hyphema. ( Chan, W; Crawford, JS; Lewandowski, RL, 1975) |
| "A proportion of patients with embolic stroke of undetermined source have silent atrial fibrillation (AF) or develop AF after the initial evaluation." | 3.01 | Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial. ( Bahit, MC; Brainin, M; Brueckmann, M; Cronin, L; Diener, HC; Easton, JD; Granger, CB; Grauer, C; Kleine, E; Lopes, RD; Lyrer, P; Meyerhoff, J; Sacco, RL; Segura, T; Wachter, R, 2021) |
| "Patients with a recent embolic stroke of undetermined source were randomized to dabigatran (150 or 110 mg BID) or aspirin (100 mg QD)." | 3.01 | Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis. ( Brueckmann, M; Easton, JD; Grauer, C; Lee, BC; Liou, CW; Taniguchi, A; Toyoda, K; Uchiyama, S; Urano, Y; Wong, LKS, 2021) |
| "Patients with watershed infarction had higher risk of stroke recurrence than those without (17." | 2.94 | Higher early recurrence risk and potential benefit of dual antiplatelet therapy for minor stroke with watershed infarction: subgroup analysis of CHANCE. ( Atchaneeyasakul, K; Jing, J; Johnston, SC; Liebeskind, DS; Liu, L; Liu, X; Meng, X; Pan, Y; Pu, Y; Wang, A; Wang, Y; Zhao, X; Zou, X, 2020) |
| "The concept of embolic stroke of undetermined source (ESUS) unifies a subgroup of cryptogenic strokes based on neuroimaging, a defined minimum set of diagnostic tests, and exclusion of certain causes." | 2.94 | Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial. ( Ameriso, SF; Arauz, A; Berkowitz, SD; Chamorro, Á; Connolly, SJ; Hankey, GJ; Hart, RG; Kasner, SE; Korompoki, E; Lindgren, A; Muir, KW; Mundl, H; Ozturk, S; Pearce, LA; Perera, K; Rudilosso, S; Sharma, M; Shoamanesh, A; Shuaib, A; Tatlisumak, T; Toni, D; Veltkamp, R, 2020) |
| "Major bleeding was the primary safety end point." | 2.90 | Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial. ( Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Knutsson, M; Ladenvall, P; Minematsu, K; Molina, CA; Röther, J; Wang, Y; Wong, KSL, 2019) |
| "Acute minor ischemic stroke (AMIS) or transient ischemic attack (TIA) is a common cerebrovascular event with a considerable high recurrence." | 2.87 | Rationale and Study Design for a Single-Arm Phase IIa Study Investigating Feasibility of Preventing Ischemic Cerebrovascular Events in High-Risk Patients with Acute Non-disabling Ischemic Cerebrovascular Events Using Remote Ischemic Conditioning. ( Feng, WW; Ji, XM; Li, SJ; Liu, SM; Meng, R; Ovbiagele, B; Ren, CH; Song, HQ; Zhao, WL, 2018) |
| "With unprovoked VTE, rates of recurrence in the 1173 patients given rivaroxaban, the 468 given aspirin, and the 243 given placebo were 2." | 2.87 | Risk of recurrent venous thromboembolism according to baseline risk factor profiles. ( Bauersachs, R; Beyer-Westendorf, J; Bounameaux, H; Brighton, TA; Cohen, AT; Davidson, BL; Decousus, H; Homering, M; Kakkar, AK; Lensing, AWA; Pap, AF; Prandoni, P; Prins, MH; Tamm, M; van Bellen, B; Verhamme, P; Weitz, JI; Wells, PS, 2018) |
| "Patients with lacunar stroke and CMBs likely harbor a more advanced form of cerebral small vessel disease in need of efficacious therapeutic strategies." | 2.84 | Microbleeds in the Secondary Prevention of Small Subcortical Strokes Trial: Stroke, mortality, and treatment interactions. ( Anderson, DC; Bazan, C; Benavente, OR; Catanese, L; Hart, RG; Kase, CS; Marti-Fabregas, J; McClure, LA; Pearce, LA; Sharma, M; Shoamanesh, A, 2017) |
| " Secondary outcomes include target lesion revascularization, major bleeding, ipsilateral major amputation, all-cause mortality, and all adverse events that take place in those six months." | 2.84 | SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial. ( Ahn, S; Cho, MJ; Cho, S; Ha, J; Kim, SY; Lee, J; Min, SI; Min, SK, 2017) |
| "Aspirin) was effective." | 2.82 | [Idiopathic recurrent pericarditis: review of the literature and the Geneva experience]. ( Dominati, A; Meyer, P; Seebach, JD, 2022) |
| "Secondary outcomes are ulcer recurrence, wound pain, quality of life and wellbeing, adherence to study medication, adherence to compression therapy, serum inflammatory markers, hospitalisations, and adverse events at 24 weeks." | 2.82 | Aspirin in venous leg ulcer study (ASPiVLU): study protocol for a randomised controlled trial. ( Aldons, P; Barker, A; Dapiran, E; Darby, I; Haines, T; Loveland, P; Madan, JJ; McNeil, J; Sinha, S; Underwood, M; Vicaretti, M; Ward, S; Weller, CD; Wolfe, R; Woodward, M, 2016) |
| "The primary outcome is IS recurrence." | 2.80 | Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015) |
| "Triflusal was more effective and demonstrated a more consistent impact on the improvement of symptoms and blood flow in patients with PVD than aspirin." | 2.80 | Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A Double-Blind, Randomized, Crossover Trial. ( Chang, HJ; Cho, IJ; Chung, N; Hong, GR; Jang, Y; Kim, KJ; Rah, YM; Shin, S, 2015) |
| "60." | 2.79 | Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up. ( Alvarez-Sabín, J; Maisterra, O; Quintana, M; Santamarina, E, 2014) |
| "Among 1244 patients with lacunar stroke (mean age, 63." | 2.79 | C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study. ( Benavente, OR; Coffey, CS; Del Brutto, OH; Elkind, MS; Luna, JM; McClure, LA; Meyer, BC; Pettigrew, LC; Pretell, EJ; Roldan, A; Tapia, J; White, C; Zhang, Y, 2014) |
| "Rabeprazole was well tolerated at both doses." | 2.79 | Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. ( Arakawa, T; Fujimoto, K; Fujishiro, M; Higuchi, K; Iwakiri, R; Kato, M; Kinoshita, Y; Nakagawa, H; Ogawa, H; Okada, Y; Sanomura, M; Sugisaki, N; Takeuchi, T; Watanabe, T; Yamauchi, M, 2014) |
| "Secondary end points were the restenosis rate on duplex ultrasound, the rate of major adverse cardiac events, and target lesion event-free survival." | 2.78 | Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study. ( Hamasaki, T; Hirano, K; Iida, O; Inoue, N; Isshiki, T; Kawasaki, D; Miyamoto, A; Miyashita, Y; Nakamura, M; Nanto, S; Shinozaki, N; Shintani, Y; Soga, Y; Suzuki, K; Tsuchiya, T; Urasawa, K; Yokoi, H; Yokoi, Y; Zen, K, 2013) |
| "Background stroke care was limited and none of the patients received thrombolytic therapy." | 2.76 | The International Stroke Trial database. ( Członkowska, A; Niewada, M; Sandercock, PA, 2011) |
| "Aspirin (ASA) is an effective antiplatelet drug that reduces the risk of myocardial infarction, stroke, or death by approximately 25% in patients who are at increased risk of cardiovascular events." | 2.75 | Factors responsible for "aspirin resistance" - can we identify them? ( Filipiak, KJ; Huczek, Z; Kosior, D; Opolski, G; Postuła, M; Serafin, A; Tarchalska-Kryńska, B, 2010) |
| " The primary end point was major adverse cardiac events (death, MI, and ischemia-driven target vessel revascularization) at 12 months." | 2.74 | Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. ( Cheong, SS; Cho, YH; Hong, MK; Hong, TJ; Jeong, MH; Kim, JJ; Kim, KS; Kim, YH; Lee, CW; Lee, JH; Lee, NH; Lee, SG; Lee, SH; Lim, DS; Park, DW; Park, SJ; Park, SW; Seong, IW; Seung, KB; Yang, JY; Yoon, J; Yun, SC, 2009) |
| "Myocardial infarction was more frequent in the early invasive strategy group (106 [18." | 2.73 | Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. ( Cornel, JH; de Winter, RJ; Hirsch, A; Tijssen, JG; Verheugt, FW; Windhausen, F, 2007) |
| "Documented VTE (including deep vein thrombosis or pulmonary embolism) and unprovoked VTE (no recent surgery, trauma, or cancer diagnosis) were prospectively evaluated, secondary end points of the trial." | 2.73 | Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. ( Buring, JE; Glynn, RJ; Goldhaber, SZ; Ridker, PM; Zee, RY, 2007) |
| "Women with a prior pregnancy affected by FGR have a 20% to 30% risk of recurrence, but effective preventive strategies are lacking." | 2.72 | Recurrence Risk of Fetal Growth Restriction: Management of Subsequent Pregnancies. ( Blue, NR; Page, JM; Silver, RM, 2021) |
| ""Pericarditis Acute pericarditis is a common disease, most often idiopathic or viral." | 2.72 | [Pericarditis]. ( Cacoub, P; Marques, C, 2021) |
| " There is no study that assessed the effect of age on adverse event rates in cryptogenic stroke patients with PFO." | 2.71 | Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. ( DiTullio, MR; Homma, S; Mohr, JP; Sacco, RL; Sciacca, RR, 2004) |
| "Odds ratios (ORs) for adenoma recurrence were calculated using the lowest quartile of fiber intake as the reference." | 2.70 | Baseline dietary fiber intake and colorectal adenoma recurrence in the wheat bran fiber randomized trial. ( Alberts, DS; Giuliano, AR; Guillén-Rodríguez, JM; Jacobs, ET; Martínez, ME; Roe, DJ, 2002) |
| "We analyzed the incidence and recurrence rate of early and late primary VF in 9,720 patients with a first acute MI, treated with thrombolytics, enrolled in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-2 trial." | 2.69 | Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction--results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) database. ( Cavalli, A; Negri, E; Santoro, L; Volpi, A, 1998) |
| "Dipyridamole was associated with a slight increase in headache, which resolved in most patients if therapy was continued." | 2.69 | Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study. ( Forbes, CD, 1998) |
| "Eptifibatide was not associated with an increase in intracranial hemorrhage, and no significant effect on nonhemorrhagic stroke was observed." | 2.69 | Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. ( Alberts, MJ; Berdan, LG; Califf, RM; Deckers, J; Graffagnino, C; Granger, CB; Harrington, RA; Laskowitz, DT; Lincoff, AM; MacAulay, CM; Mahaffey, KW; Miller, JM; Simoons, ML; Sloan, MA; Topol, EJ, 1999) |
| "Danaparoid sodium appears to be an efficient and safe treatment in critically ill patients with HIT." | 2.69 | Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. ( Guyotat, D; Mahul, P; Mazet, E; Mismetti, P; Reynaud, J; Tardy, B; Tardy-Poncet, B, 1999) |
| " Sumatriptan is more effective, but resulted in more adverse events." | 2.69 | Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG St ( Diener, HC, 1999) |
| "Cilostazol is a potent antiplatelet agent with less serious side effects." | 2.69 | Comparison of cilostazol versus ticlopidine therapy after stent implantation. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, HJ; Park, HK; Park, SJ; Park, SW, 1999) |
| "Fifty-two patients had symptomatic intracranial atherosclerosis and fulfilled entry criteria." | 2.69 | Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy. ( Albers, GW; Thijs, VN, 2000) |
| "Cilostazol is a potent antiplatelet agent with antiproliferative properties." | 2.69 | Effects of cilostazol on angiographic restenosis after coronary stent placement. ( Hong, MK; Kim, HS; Kim, JJ; Lee, CW; Lee, NH; Nah, DY; Park, SJ; Park, SW, 2000) |
| "Piracetam was significantly superior to ASA in the secondary endpoint (P=0." | 2.69 | Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study. ( Evers, S; Fischer, M; Grotemeyer, KH; Husstedt, IW, 2000) |
| "Acute idiopathic pericarditis is complicated by recurrence in 15 to 30% of cases." | 2.69 | [Efficacy of colchicine in recurrent acute idiopathic pericarditis]. ( Amoura, Z; Cacoub, P; Godeau, P; Piette, JC; Sbaï, A; Wechsler, B, 2000) |
| "Nonfatal myocardial infarction was present in seven patients in group A, four in group B and none in group C (group B vs." | 2.68 | Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. ( Cerdá, MA; Daroca, AM; Duronto, EA; García, CN; Gurfinkel, EP; Manos, EJ; Mautner, B; Mejaíl, RI, 1995) |
| "Aspirin was the most widely prescribed drug (79." | 2.68 | [Drug prescription in the postinfarction period; results of the EPPI II (Study of Postinfarct Prescription). A French cooperative study]. ( Boissel, JP; Gillet, J; Leizorovicz, A; Némoz, C, 1995) |
| "In the remainder symptomatic polyp recurrence was delayed compared with the previous experience while on intranasal steroids, with eight patients remaining symptom free at 15 months compared with an expected number of three (P = < 0." | 2.68 | Intranasal lysine aspirin in recurrent nasal polyposis. ( Darby, YC; Freedman, A; Hassab, M; Lund, VJ; Scadding, GK, 1995) |
| "Taprostene was administered to 19 patients as a continuous intravenous infusion from 2 hours before until 8 (n = 6) or 24 (n = 6) hours after angioplasty; 7 control patients were given a combination of 330 mg aspirin and 75 mg dipyridamole." | 2.68 | [The effect of Taprostene on platelet activation and clinical course after percutaneous transluminal angioplasty]. ( Heinz, M; Söhngen, M; Theiss, W; van de Flierdt, E, 1996) |
| "Aspirin was associated with a significant excess of 5 (SD 1) transfused or fatal extracranial bleeds per 1000; in the absence of heparin the excess was 2 (SD 1) and was not significant." | 2.68 | The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. ( , 1997) |
| "Aspirin (ASA) has become a well-documented therapeutic adjunct in patients with coronary heart disease." | 2.68 | Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) ( Aursnes, I; Kjekshus, J; Nguyen, KN, 1997) |
| "Restenosis was assessed by repeat angiography at 3 months and clinical symptoms up to 12 months." | 2.68 | The effects of platelet inhibitors on platelet uptake and restenosis after femoral angioplasty. ( Fligelstone, LJ; Horrocks, EH; Horrocks, M; Lane, IF; Murphy, P; Ruttley, MS; Watson, HR, 1997) |
| "Dipyridamole was applied in 550 interventions (455 interventions in men, 95 interventions in women, age = 59." | 2.68 | [Intracoronary dipyridamole reduces the incidence of acute coronary vessel occlusion in percutaneous transluminal coronary angioplasty--a prospective randomized study]. ( Heidland, UE; Heintzen, MP; Kelm, M; Klimek, WJ; Leschke, M; Michel, CJ; Schwartzkopff, B; Strauer, BE; Vester, EG, 1997) |
| "Aspirin is a safe, though less effective, alternative when anticoagulation is contraindicated; it prevents 40 vascular events each year for every 1000 treated patients." | 2.67 | Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. ( , 1993) |
| "In the aspirin group the recurrence rate was 18." | 2.67 | Can aspirin prevent gallstone recurrence after successful extracorporeal shockwave lithotripsy? ( Adamek, HE; Buttmann, A; Riemann, JF; Weber, J, 1994) |
| "Aspirin was effective only in complex and less severe lesions (< 90% stenosis)." | 2.67 | Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: angiographic results of the APRICOT study. Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis. ( de Swart, H; Lie, KI; Meyer, A; Michels, HR; van der Pol, JM; van Eenige, MJ; Veen, G; Verheugt, FW; Werter, CJ, 1993) |
| " Unfortunately, dosing strategies and monitoring have not kept pace with the rest of the field." | 2.67 | The challenge of maintaining coronary arterial patency with intravenous heparin following tissue plasminogen activator administration. ( Becker, RC; Gore, JM, 1993) |
| "Ticlopidine has not been formally compared with aspirin in patients with a completed stroke." | 2.67 | Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study. ( Harbison, JW, 1992) |
| "Heparin is an effective, widely used treatment for unstable angina." | 2.67 | Reactivation of unstable angina after the discontinuation of heparin. ( Juneau, M; Lam, J; McCans, J; Théroux, P; Waters, D, 1992) |
| "Aspirin-treated lesions (n = 163) had lost 16 +/- 22% (mean +/- standard deviation) of lumen and placebo-treated lesions 22 +/- 25% of lumen (n = 134) at angiography (p less than 0." | 2.67 | Effects of low-dose aspirin on restenosis after coronary angioplasty. ( Cope, GD; Cumpston, GN; Gibbons, FA; Luke, P; Mews, GC; Taylor, RR, 1991) |
| "Restenosis was assessed by percent area stenosis as determined by quantitative angiographic techniques before, immediately and 1 year after angioplasty." | 2.67 | Effects of diltiazem on complications and restenosis after coronary angioplasty. ( Giorgi, LV; Good, TH; Hartzler, GO; Ligon, RW; McCallister, BD; O'Keefe, JH; Webb, DL, 1991) |
| " These results demonstrate that high aspirin dosage does not reduce the restenosis rate more than low dosage." | 2.67 | [Effects of high and low doses of acetylsalicylic acid on the restenosis rate after initially successful coronary angioplasty]. ( Grimme, M; Kochsiek, K; Schanzenbächer, P; Walter, U, 1991) |
| " It cannot, however, be concluded from this study that 75 mg dipyridamole in combination with 100 mg ASA tid is more effective in preventing reocclusion after PTA than in combination with 330 mg ASA tid." | 2.67 | Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA. ( Deichsel, G; Heiss, HW; Just, H; Middleton, D, 1990) |
| "These data indicate that migraine is mediated, at least in part, by the effects of platelets and suggest that low-dose aspirin should be considered for prophylaxis among those with a history of established migraine." | 2.67 | Low-dose aspirin for migraine prophylaxis. ( Buring, JE; Hennekens, CH; Peto, R, 1990) |
| "Pericarditis is the most common form of pericardial disease and may be associated with significant morbidity and mortality." | 2.66 | Managing acute and recurrent idiopathic pericarditis. ( Cornelio, CK; Epperson, TM; Schwier, NC, 2020) |
| "Main outcomes were stroke recurrence and major bleeding." | 2.66 | Aspirin or anticoagulation after cryptogenic stroke with patent foramen ovale: systematic review and meta-analysis of randomized controlled trials. ( Calabresi, P; Cupini, LM; Eusebi, P; Giannandrea, D; Ricci, S; Romoli, M, 2020) |
| "BACKGROUND Priapism is rarely reported as a complication in patients with essential thrombocythemia at presentation." | 2.66 | Essential Thrombocythemia Presenting with Recurrent Priapism: A Case Report and Review of Literature. ( Jain, M; Kumar, N; Tripathi, AK; Verma, SP, 2020) |
| "Dabigatran was shown to be safer than vitamin K antagonists and similarly effective for the prevention of recurrent VTE." | 2.66 | Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study. ( Imberti, D; Mastroiacovo, D; Pomero, F, 2020) |
| " Eight hours before PTCA, the oral dipyridamole was replaced with intravenous dipyridamole at a dosage of 10 mg per hour for 24 hours, and oral aspirin was continued." | 2.66 | Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. ( Aldridge, HE; Bonan, R; Bourassa, MG; David, PR; Henderson, M; Kazim, F; Lespérance, J; Salvatori, VA; Schwartz, L, 1988) |
| " A statistically significant superiority of the 30 mg aspirin dosage compared with the 1000 mg dosage was found in patients aged over 50 years, in male patients, in patients with angina pectoris in their anamnesis, in patients with ST-depression of greater than 0." | 2.66 | Superior prevention of reinfarction by 30 mg/d aspirin compared with 1000 mg/d: results of a two years follow-up study in Cottbus. ( Förster, W; Hoffmann, W, 1988) |
| "Of the 5 cerebral infarcts, 4 occurred in the control group, 3 patients died." | 2.65 | [The treatment of transitory ischemic attacks with acetylsalicylic acid: results of a double-blind-study (author's transl)]. ( Dorndorf, W; Loew, D; Reuther, R, 1980) |
| "However, considering that most stroke recurrences occur i n the short term, a time limited double antiplatelet scheme could result in significant benefits to patients with acute ischemic stroke." | 2.61 | [Dual antiplatelet therapy for secondary stroke prevention in patients with acute ischemic stroke. CIERTO group recommendation]. ( Bottaro, F; Caruso, D; Catalano, HN; Izcovich, A; Pollán, J; Saavedra, E; Tisi Baña, M, 2019) |
| "Recurrent stroke is common immediately following a transient ischemic attack (TIA) or ischemic stroke." | 2.61 | Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. ( Abdalla, A; Ahmed, S; Al Qasmi, M; Bachuwa, G; Bhatt, DL; Chahine, A; Hassan, M; Haykal, T; Kheiri, B; Osman, M; Swaid, B, 2019) |
| "Recurrent pericarditis is one of the most frequent pericardial diseases, affecting up to 30% of the patients who have experienced acute pericarditis." | 2.58 | Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism. ( Brucato, A; Cantarini, L; Di Lenarda, A; Emmi, G; Gattorno, M; Imazio, M; Lopalco, G; Marcolongo, R; Martini, A; Prisco, D, 2018) |
| "All drug classes were found to favour migraine chronification." | 2.58 | Is Medication Overuse Drug Specific or Not? Data from a Review of Published Literature and from an Original Study on Italian MOH Patients. ( D'Amico, D; Grazzi, L; Grignani, E; Raggi, A; Sansone, E, 2018) |
| "Stillbirth affects at least 2." | 2.58 | Care prior to and during subsequent pregnancies following stillbirth for improving outcomes. ( Ellwood, DA; Flenady, V; Heazell, AE; Lassi, ZS; Middleton, P; Murphy, MM; Shepherd, E; Silver, RM; Wilson, T; Wojcieszek, AM, 2018) |
| "Acute and recurrent pericarditis is the most common pericardial syndrome encountered in clinical practice either as an isolated process or as part of a systemic disease." | 2.55 | Acute and Recurrent Pericarditis. ( Gaita, F; Imazio, M, 2017) |
| " The combination of clopidogrel and aspirin is not recommended for long-term use (more than two to three years) because of increased bleeding risk." | 2.55 | Recurrent Ischemic Stroke: Strategies for Prevention. ( Garcellano, M; Oza, R; Rundell, K, 2017) |
| "Recurrent pericarditis is the most troublesome complication of pericarditis occurring in 15 to 30% of cases." | 2.55 | Recurrent pericarditis. ( Battaglia, A; Gaido, L; Gaita, F; Imazio, M, 2017) |
| "Recurrent pericarditis is one of the most common and troublesome complications after an episode of pericarditis, and affects 20-50% of patients treated for pericarditis." | 2.53 | Recurrent pericarditis: new and emerging therapeutic options. ( Brucato, A; Gaita, F; Imazio, M; Lazaros, G, 2016) |
| "Recurrent pericarditis is one of the most troublesome complications of pericarditis occurring in about one third of patients with a previous attack of pericarditis." | 2.53 | Recurrent Pericarditis: Modern Approach in 2016. ( Adler, Y; Charron, P; Imazio, M, 2016) |
| "Idiopathic (viral) pericarditis is the most common form of pericardial disease in the Western world." | 2.52 | Pharmacotherapy update of acute idiopathic pericarditis. ( Coons, JC; Rao, SK; Schwier, NC, 2015) |
| "Treatment of celecoxib with a proton pump inhibitor is safer than treatment with nonselective NSAID and a proton pump inhibitor in high risk gastrointestinal and cardiovascular patients who mostly also take acetylsalicylic acid." | 2.52 | [Gastrointestinal bleeding]. ( Lanas, Á, 2015) |
| "Recurrence is rare and occurs most commonly in children." | 2.50 | Recurrent Kawasaki disease in a child with retropharyngeal involvement: a case report and literature review. ( Aldemir-Kocabaş, B; Çiftçi, E; Fitöz, S; İnce, E; Kcal, MM; Ramoğlu, MG; Tutar, E, 2014) |
| "Recurrent pericarditis are common and their management remains a matter of debate." | 2.47 | [What's new in recurrent pericarditis in 2011?]. ( Cacoub, P; Geri, G, 2011) |
| "Bleeding is potentially the most significant antiplatelet-associated side effect." | 2.47 | Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events. ( Guthrie, R, 2011) |
| "Aspirin was given as well as percutaneous endovascular PFO closure was performed with no immediate complication." | 2.47 | Patent foramen ovale and recurrent transient neurological symptoms: a case report and review of literature. ( Anamnart, C; Poungvarin, N, 2011) |
| " If both Clopidogrel and PPI need to be prescribed, a split dosage regimen of PPI in the morning and clopidogrel in the evening can be recommended." | 2.46 | [Dilemma between gastroprotection and cardiovascular prevention]. ( Kandulski, A; Malfertheiner, P; Venerito, M, 2010) |
| "Chronic rhinosinusitis is often associated with bronchial asthma." | 2.45 | [Chronic rhinosinusitis in morbus widal: clinical aspects and therapeutic options]. ( Jung, H, 2009) |
| "Women with a history of previous preeclampsia are at increased risk of preeclampsia and other adverse pregnancy outcomes in subsequent pregnancies." | 2.44 | Prediction and prevention of recurrent preeclampsia. ( Barton, JR; Sibai, BM, 2008) |
| "Ten patients with aneurysms and/or pseudoaneurysms and six patients with occlusive lesions have undergone surgical treatment." | 2.44 | Major arterial involvement and review of Behcet's disease. ( Alpagut, U; Dayioglu, E; Ugurlucan, M, 2007) |
| "Atherothrombosis is a progressive and generalized pathologic process that affects the vascular system." | 2.44 | Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician. ( Brown, MT; Kikano, GE, 2007) |
| "The antiphospholipid syndrome is an antibody mediated hypercoagulable state characterized by recurrent venous and arterial thromboembolic events." | 2.44 | [The antiphospholipid syndrome, an update]. ( Alonso Santor, JE; Inglada Galiana, L; Pérez Paredes, G, 2007) |
| "Preventive treatment of preeclampsia consists essentially of low dose aspirin." | 2.44 | [Latest developments: management and treatment of preeclampsia]. ( Tsasaris, V; Winer, N, 2008) |
| "Aspirin non-response was more frequently associated with the use of "home-established" cut-offs or when closure time was only assessed after aspirin (rather than both before and after)." | 2.44 | Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. ( Cerletti, C; Crescente, M; de Gaetano, G; Di Castelnuovo, A; Iacoviello, L; Vermylen, J, 2008) |
| "The short-term risk of stroke after transient ischemic attack (TIA) is about 10% to 20% in the first 3 months, with much of the risk front-loaded in the first week." | 2.43 | Stroke prevention. MATCHing therapy to the patient with TIA. ( Buchan, AM; Demchuk, AM; Hill, MD; Weir, NU, 2005) |
| "Twenty-three children had varicella at age 1." | 2.43 | Post-varicella arteriopathy of childhood: natural history of vascular stenosis. ( Armstrong, D; deVeber, G; Domi, T; Lanthier, S, 2005) |
| "The antiphospholipid syndrome is currently best treated with anticoagulation." | 2.43 | Anticoagulation therapy in the antiphospholipid syndrome: recent advances. ( Crowther, MA; Ng, HJ, 2005) |
| "About 80% of strokes have ischemic origin." | 2.43 | [Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke]. ( Szapáry, L, 2005) |
| "The risk of TIA or stroke recurrence reaches 30-45%." | 2.42 | [Stenosis of the carotid arteries]. ( Kaźmierski, MK, 2003) |
| "The diagnosis of carotid stenosis is made after occurrence of a cerebral ischemic event or during an angiologic examination, mainly using Doppler/Duplex-sonography." | 2.42 | [Carotid stenosis: diagnosis, patient selection, therapy]. ( Barth, A, 2003) |
| "Nasal polyps are as common as adult onset asthma and unilateral polyps require histological examination." | 2.42 | Nasal polyps. ( Drake-Lee, AB, 2004) |
| "The treatment of migraine takes into consideration the intensity of the headache and the accompanying symptoms." | 2.42 | [Treatment and prophylaxis of an acute migraine attack]. ( Diener, HC; Gendolla, A, 2004) |
| "Since 1987 the antiphospholipid syndrome has been recognized as a major cause of acquired thrombophilia, whether it is associated with systemic lupus erythematosus or occurs as a free-standing syndrome (primary form)." | 2.41 | [Antiphospholipid syndrome]. ( Arvieux, J; Hachulla, E, 2002) |
| "The standard therapy in Crohn's disease and ulcerative colitis is based on corticosteroids and aminosalicylates." | 2.41 | [Therapy of chronic inflammatory bowel diseases]. ( Stange, EF, 2002) |
| "Arterial and venous thrombosis are the most common and clinically relevant events of the so-called antiphospholipid syndrome; they are reported in approximately one third of patients with the antiphospholipid (aPL) antibodies." | 2.41 | The epidemiology of the antiphospholipid syndrome: who is at risk? ( Finazzi, G, 2001) |
| "Colchicine treatment seems to be efficacious and can be used to stop steroid therapy." | 2.41 | [Is chronic or recurrent idiopathic pericarditis an autonomous inflammatory disease?]. ( Disdier, P; Ene, N; Granel, B; Habib, G; Mesana, T; Pache, X; Rey, J; Serratrice, J; Swiader, L; Weiller, PJ, 2001) |
| "Prevention of recurrence with antiarrhythmic drugs is somewhat problematic because of incomplete efficacy (30% recurrence at 1 year) and the potential for inducing other, life-threatening arrhythmias." | 2.40 | Management of atrial fibrillation: out-of-hospital approach. ( Folland, ED, 1999) |
| "6 studies with a placebo-controlled, double blind, randomized protocol on the effect of acetylsalicylic acid (ASA) in a dosage of higher than 100 mg/day have been published." | 2.39 | [High dosage acetylsalicylic acid administration for prevention of acute cerebral ischemia]. ( Hartmann, A, 1995) |
| " There is disagreement over the optimal dosage to prevent a stroke: earlier studies considered > or = 975 mg ASS per day, sometimes in combination with other substances, while more recently, lower dosages of about 300 mg per day or even as low as < or = 100 mg per day have been proposed." | 2.39 | [Aspirin dosage for prevention of cerebral infarct: arguments for low dosage]. ( Hennerici, MG; Meairs, S, 1995) |
| "Over 80% of recurrences are infrequent and can be treated when they occur n 20% of ulcer patients have 3 recurrences/yr, ulcer complications, or such poor health that recurrence might prove fatal." | 2.38 | Maintenance therapy for peptic ulcer--who needs it? ( McCarthy, DM, 1993) |
| "Aspirin has many uses in cardiovascular disease." | 2.38 | The use of aspirin in cardiovascular disease. ( Byers, JF, 1993) |
| "The role of Kawasaki disease (KD) as a contributor to early childhood cardiac morbidity in Adelaide was investigated by a review of hospital admission and case-note data from January 1979 to June 1990." | 2.38 | Kawasaki disease in Adelaide: a review. ( Goldwater, PN; Smith, PK, 1993) |
| "The risk of early recurrence of embolism in the first 30 days ranges from 8 to 15%." | 2.38 | [Embolic complications of chronic atrial fibrillation]. ( Brechenmacher, C; Chauvin, M; Koenig, A; Théolade, R, 1992) |
| " Some of the newer NSAIDs seem at normal dosage to be far less damaging than traditional ASA or indomethacin." | 2.37 | Gastroduodenal damage due to drugs, alcohol and smoking. ( Domschke, S; Domschke, W, 1984) |
| "Epistaxis is the most common otolaryngological emergency and one-third of epistaxis patients regularly take low-dose acetylsalicylic acid (ASA) for the prevention of cardiovascular disease (CVD)." | 1.91 | The pattern of epistaxis recurrence in patients taking prophylactic acetylsalicylic acid (ASA) from a 10 year cohort. ( Hoch, S; Rudhart, S; Stanković, P; Stojković, S; Wilhelm, T, 2023) |
| "Acute pericarditis has a wide spectrum of clinical presentations largely depending on underlying aetiologies." | 1.62 | Age- and sex-based differences in patients with acute pericarditis. ( Antonopoulos, AS; Lazaros, G; Lazarou, E; Tousoulis, D; Vassilopoulos, D; Vlachopoulos, C; Vogiatzi, G, 2021) |
| "Following an acute ischemic stroke or transient ischemic attack, 2 rates of stroke recurrence are suggested by data from trials of acute secondary prevention treatments: a transient rapid rate followed by a persisting slower rate of stroke." | 1.62 | Two-State Kinetic Model of Rates of Stroke Recurrence in the POINT Study Population. ( Brorson, JR; Bulwa, ZB, 2021) |
| "The score was predictive of recurrence among most patient subgroups." | 1.62 | A risk score for pericarditis recurrence. ( Antonopoulos, AS; Imazio, M; Karavidas, A; Lazaros, G; Lazarou, E; Tousoulis, D; Toutouzas, K; Tsioufis, C; Vasileiou, P; Vassilopoulos, D; Vlachopoulos, C, 2021) |
| "Aspirin and warfarin were resumed at a median (IQR) of 5." | 1.56 | The Dilemma of Resuming Antithrombotic Therapy After Intracranial Hemorrhage in Patients With Left Ventricular Assist Devices. ( Asleh, R; Dawit, S; Freeman, WD; Li, Z; Matos, NL; O'Carroll, CB; Rabinstein, AA; Santos, CD, 2020) |
| "The majority presented with recurrent transient ischemic attacks/minor strokes within a single vascular territory over days to weeks." | 1.56 | Focal Cerebral Arteriopathy in Young Adult Patients With Stroke. ( Cronin, S; Fanning, N; McKenna, MC, 2020) |
| "No recurrences were registered in the polypill group, compared to 1 recurrence in the conventional treatment group." | 1.56 | Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients. ( Alonso-Canovas, A; Chico-García, JL; Cruz-Culebras, A; de Felipe Mimbrera, A; García-Madrona, S; Gómez-López, A; Masjuan, J; Matute-Lozano, C; Natera-Villalba, E; Ros-Castelló, V; Sánchez-Sánchez, A; Vera-Lechuga, R, 2020) |
| "The PLA recurrence rate in patients taking aspirin daily for 30 or more days, from 90 days before to 90 days after the first PLA episode (aspirin users), and aspirin non-users was 42." | 1.51 | Aspirin use is associated with reduced risk for recurrence of pyogenic liver abscess: a propensity score analysis. ( Chang, CC; Chen, FJ; Chuah, SK; Lee, CH; Liu, JS; Tai, WC, 2019) |
| "Peripheral artery disease affects 1." | 1.51 | Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective. ( Ademi, Z; Hird, TR; Liew, D; Owen, AJ; Reid, CM; Si, S; Tonkin, A; Zomer, E, 2019) |
| "Default of therapy for polycythemia is associated with a profound risk of recurrent strokes requiring patient education and support to prevent the devastating consequence of this modifiable but rare cause of stroke." | 1.51 | Recurrent Stroke in a Ghanaian Patient With Polycythemia. ( Berchie, PO; Opare-Sem, OK; Ovbiagele, B; Sarfo, FS, 2019) |
| "2." | 1.51 | Management of idiopathic recurrent pericarditis during pregnancy. ( Adler, Y; Brucato, A; Imazio, M; Lucianetti, M; Maestroni, S; Pluymaekers, N; Rampello, S; Tombetti, E; Valenti, A, 2019) |
| "A part of familial Hirschsprung disease has genetic factors in common with cerebrovascular disease." | 1.51 | A Unique Recurrent Stroke Case due to Bilateral Vertebral Artery Dissection with Familial Hirschsprung Disease. ( Abe, K; Hishikawa, N; Ohta, Y; Sasaki, R; Sato, K; Takemoto, M; Yamashita, T, 2019) |
| " Direct oral anticoagulants (DOACs): For long-term secondary prevention, a reduced dosing regimen of DOACs was found to be effective with a low bleeding risk." | 1.48 | [Prolonged Secondary Prevention After Venous Thromboembolism]. ( Bauersachs, R, 2018) |
| "We report a patient who had recurrent deep vein thrombosis (DVT) as the presenting symptom of Behcet's Disease." | 1.48 | Recurrent Iliofemoral Venous Thrombosis in the Setting of May-Thurner Syndrome as the Presenting Symptom of Behcet's Disease. ( Chun, K; Lakha, S; Png, CYM; Ting, W, 2018) |
| "Chest pain recurrence was defined as the first revisit to the emergency room with angina." | 1.48 | Clinical efficacy of aspirin with identification of intimal morphology by optical coherence tomography in preventing event recurrence in patients with vasospasm-induced acute coronary syndrome. ( Lee, Y; Park, HC; Shin, J, 2018) |
| " Major adverse cardiac and cerebrovascular events (MACCE) [death, myocardial infarction (MI), stroke, and unplanned reintervention] and thrombolysis in myocardial infarction (TIMI) bleeding (major/minor) were registered during hospitalization and follow-up." | 1.48 | Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction. ( Dannenberg, L; Dimitroulis, D; Golabkesh, M; Helten, C; Jung, C; Kelm, M; Knoop, B; Naguib, D; Pöhl, M; Polzin, A; Zeus, T, 2018) |
| "Stroke recurrence and mortality rates in patients receiving aspirin (N=34 679) were compared with those receiving clopidogrel (N=7611) during a 12-month follow-up period." | 1.48 | Comparison Between Aspirin and Clopidogrel in Secondary Stroke Prevention Based on Real-World Data. ( Chang, WL; Chen, CH; Chi, NF; Hsu, CY; Hu, CJ; Jeng, JS; Li, JY; Lien, LM; Lin, CH; Liu, CH; Sun, Y; Wen, CP, 2018) |
| "The cohort of women with a history of preeclampsia were divided into 2 groups, before and after the release of the US Preventive Services Task Force 2014 recommendations." | 1.46 | Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia. ( Aagaard, KM; Chu, DM; Hollier, LM; Mastrobattista, JM; Racusin, DA; Ramin, SM; Sangi-Haghpeykar, H; Tolcher, MC, 2017) |
| "Aspirin use was updated at each clinic visit and considered as a time-varying covariate." | 1.46 | Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events. ( Bavry, AA; Bhatt, DL; Elbez, Y; Elgendy, IY; Mahmoud, AN; Sorbets, E; Steg, PG, 2017) |
| "The cumulative recurrence rate at 1 year was 15%." | 1.46 | Analysis of risk factors for colonic diverticular bleeding and recurrence. ( Fukui, H; Miwa, H; Ohda, Y; Oshima, T; Taki, M; Taniguchi, Y; Tomita, T; Tozawa, K; Watari, J, 2017) |
| "Given the high risk of stroke recurrence, antiplatelets followed by anticoagulation for secondary prevention were initiated." | 1.46 | Isolated left ventricular non-compaction (LVNC) and recurrent strokes: to anticoagulate or not to anticoagulate, that is the question. ( Abubakar, H; Hassan, AAI; Ibrahim, W; Subahi, A, 2017) |
| "The primary end point was recurrence of ACS or death >30days after the index event." | 1.46 | Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. ( Geroldinger, A; Heinze, G; Reichardt, B; Sheikh Rezaei, S; Wolzt, M, 2017) |
| "Age above 55 years was associated with recurrence of ACS in C2238/ANP-minor allele carriers (hazard ratio 1." | 1.43 | T2238C ANP gene variant and risk of recurrent acute coronary syndromes in an Italian cohort of ischemic heart disease patients. ( Abbolito, S; Battistoni, A; Bianchi, F; Burocchi, S; Cangianiello, S; Caprinozzi, M; Comito, F; Cotugno, M; De Giusti, M; Di Castro, S; Dito, E; Farcomeni, A; Greco, ES; Marchitti, S; Pagliaro, B; Pierelli, G; Rubattu, S; Sciarretta, S; Stanzione, R; Volpe, M, 2016) |
| "The early recurrence of neurological symptoms (NR) after urgent aggressive best medical therapy (BMT) in symptomatic carotid stenosis is not well documented." | 1.43 | Risk of early recurrent stroke in symptomatic carotid stenosis after best medical therapy and before endarterectomy. ( Ellemann, K; Gottschalksen, B; Owen-Falkenberg, A; Shahidi, S, 2016) |
| "In conclusion, recurrence of CVEs occurred independently of HTPR and residual COX-1 activity." | 1.43 | Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients. ( Abumiya, T; Furui, E; Hattori, A; Hosomi, N; Isshiki, T; Kada, A; Kaikita, K; Kario, K; Katayama, Y; Kawamura, A; Kimura, K; Kitagawa, K; Minematsu, K; Miyata, S; Miyata, T; Nagao, T; Nagatsuka, K; Nakagawara, J; Nakane, H; Nishikawa, M; Ogawa, H; Okada, H; Saito, K; Takiuchi, S; Tanaka, K; Taomoto, K; Uchiyama, S; Wada, H; Yamawaki, T; Yonemoto, N, 2016) |
| "Only one patient had a late recurrence almost 11 years after shunt implantation." | 1.43 | Subdural haematoma complicating shunting for normal pressure hydrocephalus in the setting of concomitant antiplatelet medication - a report of 11 cases. ( Birkeland, P; Lauritsen, J; Poulsen, FR, 2016) |
| "Six cases (6." | 1.43 | Complication of Stenting in Intracranial Arterial Stenosis. ( Liu, L; Zhang, F, 2016) |
| "Nineteen patients presented vascular recurrence after stroke, and 19 matched patients did not present vascular recurrence during the first year of follow-up." | 1.43 | PPM1A Methylation Is Associated With Vascular Recurrence in Aspirin-Treated Patients. ( Bin Dukhyil, AA; Carrera, C; Cullell, N; Fernandez-Cadenas, I; Fontana, P; Gallego-Fabrega, C; Krupinski, J; Martí-Fàbregas, J; Montaner, J; Muiño, E; Pera, J; Pezzini, A; Reny, JL; Segura, T; Serrano-Heras, G; Slowik, A, 2016) |
| "The major result events, included: (1) recurrence of ischemic stroke; (2) hemorrhagic transformation of ischemic stroke; (3) myocardial infarction; (4) the digestive hemorrhage." | 1.43 | [Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy]. ( Gao, P; Hu, YH; Tang, X; Wei, CL; Yang, C; Zhang, YQ, 2016) |
| "Minor stroke and transient ischemic attack are common disorders with high rate of subsequent disabling stroke." | 1.43 | High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial. ( Li, J; Lin, J; Liu, L; Meng, X; Wang, A; Wang, C; Wang, Y; Zhao, X, 2016) |
| "Antiplatelet therapy in patients with chronic subdural hematoma (cSDH) presents significant neurosurgical challenges." | 1.43 | Does Early Resumption of Low-Dose Aspirin After Evacuation of Chronic Subdural Hematoma With Burr-Hole Drainage Lead to Higher Recurrence Rates? ( Fandino, J; Kamenova, M; Lutz, K; Mariani, L; Schaedelin, S; Soleman, J, 2016) |
| "The long-term recurrence of lower gastrointestinal bleeding (LGIB) and associated mortality have not been studied extensively." | 1.42 | Recurrence and mortality among patients hospitalized for acute lower gastrointestinal bleeding. ( Akiyama, J; Aoki, T; Kishida, Y; Mizokami, M; Nagata, N; Niikura, R; Sakurai, T; Sekine, K; Shimbo, T; Tanaka, S; Uemura, N; Watanabe, K; Yanase, M; Yokoi, C, 2015) |
| "An autoimmune disease was present in seven (29%) cases." | 1.42 | Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study. ( Botta, A; Bucourt, M; Carbillon, L; Chollet-Martin, S; Chudzinski, A; Cornelis, F; Costedoat-Chalumeau, N; De Carolis, S; Emmanuelli, V; Fain, O; Hachulla, E; Masseau, A; Mekinian, A; Montestruc, F; Nicaise, P; Revaux, A; Subtil, D; Theulin, A, 2015) |
| "These results suggest that the recurrence of NSAID-induced small bowel injury was not frequent in the presence of conservative treatment." | 1.42 | Long-Term Outcomes of NSAID-Induced Small Intestinal Injury Assessed by Capsule Endoscopy in Korea: A Nationwide Multicenter Retrospective Study. ( Chang, DK; Cheon, JH; Choi, MG; Chun, HJ; Jang, BI; Jeen, YT; Jeon, SR; Jeon, SW; Kim, JH; Kim, JO; Kim, JS; Lee, KJ; Lim, YJ; Moon, JS; Park, CH; Shim, KN; Song, EM; Song, HJ; Ye, BD, 2015) |
| "Antiphospholipid syndrome is an autoimmune disorder characterized by the occurrence of venous and arterial thrombosis, as well as morbidity in pregnancy, in the presence of anti-phospholipid antibodies." | 1.42 | Elevated levels of antibodies against phosphatidylserine/prothrombin complex and/or cardiolipin associated with infection and recurrent purpura in a child: a forme fruste of antiphospholipid syndrome? ( Igarashi, T; Inaba, M; Katagiri, I; Kawana, S; Kinoshita, Y; Mayumi, N, 2015) |
| "Prior cases of APS associated with cardiac tamponade despite low volumes of effusion have been reported, albeit without good demonstration of hemodynamic findings." | 1.40 | Cardiac tamponade due to low-volume effusive constrictive pericarditis in a patient with uncontrolled type II autoimmune polyglandular syndrome. ( Blackshear, JL; Kurklinsky, A; Lane, G; Palmer, WC; Ussavarungsi, K, 2014) |
| "Twenty-two cases of childhood bacterial meningitis complicated by stroke were identified." | 1.40 | Antithrombotic therapy for secondary stroke prevention in bacterial meningitis in children. ( Askalan, R; Bjornson, B; Boelman, C; deVeber, G; MacGregor, D; Moharir, M; Richrdson, S; Shroff, M; Yau, I, 2014) |
| "Liver fibrosis was assessed by histological evaluation." | 1.40 | Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation. ( Boëlle, PY; Chazouillères, O; Conti, F; Corpechot, C; Durand, F; Duvoux, C; Mackiewicz, V; Paradis, V; Poujol-Robert, A; Poupon, R; Wendum, D, 2014) |
| "Rebleeding was diagnosed when the previously treated lesion bled again within 30 days of the initial episode." | 1.40 | Rebleeding after initial endoscopic hemostasis in peptic ulcer disease. ( Hong, MJ; Jin, CJ; Kim, JH; Lee, SY; Park, HS; Shim, CS; Sung, IK, 2014) |
| "We describe a case of recurrent Kawasaki disease (KD) in a non-Asian 6-year-old boy who had been diagnosed with typical KD without cardiac involvement at age 3 years." | 1.40 | Kawasaki shock syndrome complicating a recurrence of Kawasaki disease. ( Bœuf, B; Dauphin, C; Lang, M; Lusson, JR; Merlin, E; Tissandier, C, 2014) |
| "Routine follow-up has revealed no recurrence of symptoms." | 1.40 | The mystery of recurrent idiopathic cerebrovascular and coronary arterial thrombosis. ( BinBrek, AS; Mahmoud, WE; Murugesan, V; Rajani, AR, 2014) |
| "Recurrent epistaxis is a rare presentation of internal carotid artery C4/C5 segment pseudo-aneurysm rupture." | 1.40 | Endovascular treatment of internal carotid artery pseudo-aneurysm presenting with epistaxis. A case report. ( Bazina, A; Hucika, Z; Mišmaš, A; Pavliša, G; Poljaković, Z, 2014) |
| "In selected low TE risk patients undergoing ablation for AF, a short period of periprocedural therapeutic anticoagulation with LMWH together with aspirin is an effective and safe strategy to prevent TE events." | 1.39 | Catheter ablation of atrial fibrillation in patients at low thrombo-embolic risk: efficacy and safety of a simplified periprocedural anticoagulation strategy. ( Acena, M; Berte, B; Bun, SS; De Meyer, G; Duytschaever, M; Tavernier, R; Van Heuverswyn, F; Vandekerckhove, Y, 2013) |
| "Recurrent Takotsubo cardiomyopathy is a relatively uncommon condition seen in patients with severe physical or emotional stress." | 1.39 | An unusual cause of recurrent chest pain in an adult woman: a case of recurrent stress-induced (Takotsubo) cardiomyopathy. ( Aryal, MR; Hope, EJ; Mainali, NR; Pradhan, R, 2013) |
| "Atorvastatin 80 mg was found to be independent predictor of survival, and major amputation was found to be independent predictor of mortality." | 1.39 | Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry). ( Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL, 2013) |
| "Within a regional STEMI system of care, half-dose fibrinolysis combined with immediate transfer for PCI may be a safe and effective option for STEMI patients with expected delays due to long-distance transfer." | 1.38 | Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. ( Dirks, TG; Duval, S; Garberich, RF; Harris, JL; Henry, TD; Larson, DM; Madison, JD; Sharkey, SW; Stokman, PJ; Westin, RK, 2012) |
| "Cardiogenic shock was present in 12 (11%) patients and in-hospital mortality was 6." | 1.38 | The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI. ( Buffon, A; Burzotta, F; Crea, F; De Caterina, AR; Leone, AM; Mazzari, MA; Mongiardo, R; Niccoli, G; Porto, I; Rebuzzi, AG; Sgueglia, GA; Trani, C, 2012) |
| "The risk for preeclampsia increased in patients who were positive for multiple antiphospholipid antibodies (aPL) (odds ratio (OR) 3." | 1.38 | Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. ( Brinks, R; Fischer-Betz, R; Schneider, M; Specker, C, 2012) |
| "An acute spontaneous spinal epidural hematoma (SSEH) is a rare spinal pathology." | 1.37 | Relapsed spontaneous spinal epidural hematoma associated with aspirin and clopidogrel. ( Cho, YR; Hong, BY; Kim, HS; Kim, HW; Ko, YJ; Lee, JI; Lim, SH, 2011) |
| "The diagnosis of Kawasaki disease must be raised when predisposing factors are present in this group." | 1.37 | [Kawasaki disease in older children and young adults: 10 years of experience in Marseille, France]. ( Bonello, B; Bosdure, E; Bresson, V; Chabrol, B; Dubus, JC; Rousset-Rouvière, C; Serratrice, J, 2011) |
| "The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes." | 1.37 | Level of systolic blood pressure within the normal range and risk of recurrent stroke. ( Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S, 2011) |
| "Freedom from repeat intervention for re-recurrence was 89% in the CEA group and 95% in the CAS group (p=0." | 1.36 | Redo surgery or carotid stenting for restenosis after carotid endarterectomy: results of two different treatment strategies. ( Attigah, N; Böckler, D; Deyle, C; Geisbüsch, P; Hartmann, M; Külkens, S; Ringleb, P, 2010) |
| "Over all, he had 15 times of transient ischemic attack with no lasting deficit." | 1.36 | [Case of branch atheromatous disease presenting capsular warning syndrome]. ( Dougu, N; Nukui, T; Taguchi, Y; Takashima, S; Tanaka, K; Toyoda, S, 2010) |
| "These findings were compatible with systemic lupus erythematosus (SLE)." | 1.36 | [Sporadic hemiplegic migraine-like headache in a patient with systemic lupus erythematosus]. ( Doi, H; Isobe, N; Kira, J; Ohyagi, Y; Tateishi, T; Yamasaki, R, 2010) |
| " Moreover, dosage and duration of postoperative low-molecular-weight heparin (LMWH) administration were associated with a higher risk of reoperation (Mann-Whitney U-test, p<0." | 1.36 | The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma. ( Forster, MT; Gerlach, R; Mathé, AK; Scharrer, I; Seifert, V; Senft, C, 2010) |
| "There were early recurrences (while in hospital) in 20 previously unaffected arteries (26." | 1.36 | Neurosonographic monitoring of 105 spontaneous cervical artery dissections: a prospective study. ( Ballotta, E; Baracchini, C; Meneghetti, G; Tonello, S, 2010) |
| "Tirofiban was administered for 24 h and the IABP was withdrawn after 60 h." | 1.35 | Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis? ( Braun-Dullaeus, RC; Hass, N; Ibrahim, K; Kolschmann, S; Strasser, RH, 2008) |
| "The lack of reported recurrences may lead to less cautious administration of antithrombotic therapy." | 1.35 | Recurrent perimesencephalic subarachnoid hemorrhage during antithrombotic therapy. ( Fonville, S; Ramos, LM; Rinkel, GJ; van der Worp, HB, 2009) |
| "Aspirin resistance was determined by platelet aggregation (>20%) to one or more of the four agonists, namely arachidonic acid (1." | 1.35 | Aspirin resistance in South African Caucasian patients with thrombotic cerebrovascular events. ( Becker, PJ; Bernstein, PL; Connor, MD; Jacobson, BF, 2009) |
| "He was diagnosed as idiopathic cerebral infarction." | 1.35 | [Recurrent idiopathic cerebral infarction in a 5-year-old boy, with emphasis on the importance of platelet aggregation analysis for appropriate selection of anti-platelet drugs]. ( Ikegami, M; Matsuda, S; Miyashita, Y; Obara, S; Shimizu, M; Sugiyama, N; Takagi, S; Takizawa, S; Yokoyama, J, 2009) |
| "Histology showed typical wedge-shaped infarction in the affected organs with endothelial proliferation and occlusion by thrombus." | 1.35 | Degos' disease: a rare condition simulating rheumatic diseases. ( Chung, HY; Mok, MY; Trendell-Smith, NJ; Yeung, CK, 2009) |
| "In addition, the recurrence of atrial fibrillation increased 2." | 1.35 | [Factors influencing development of atrial fibrillation after implantation of cardiac pacemaker for sinus node dysfunction]. ( Aganauskiene, J; Aidietiene, S; Aidietis, A; Bagdonas, K; Barysiene, J; Jezovas, V; Jurkuvenas, P; Kaireviciūte, D; Laucevicius, A; Marinskis, G, 2009) |
| "We describe an infant who had recurrence of Kawasaki disease and responded to therapy with Intravenous Immune globulin (IVIG) and highlight the need for recognition of this vasculitis, which is being increasingly recognised in the Indian subcontinent." | 1.35 | Recurrent Kawasaki disease. ( Balasubramanian, S; Ganesh, R, 2009) |
| "Myopericarditis is relatively common and shows a benign evolution also in spontaneous cases not related to vaccination." | 1.35 | Myopericarditis versus viral or idiopathic acute pericarditis. ( Belli, R; Cecchi, E; Chinaglia, A; Demarie, D; Demichelis, B; Ghisio, A; Ierna, S; Imazio, M; Pomari, F; Trinchero, R, 2008) |
| "Patients with transient ischemic attack (TIA) or ischemic stroke carry a risk of recurrent stroke of between 5% and 20% per year." | 1.33 | Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling? ( Diener, HC, 2006) |
| "The cumulative 10 year mortality and recurrence rate were 92." | 1.33 | Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study. ( Manios, E; Peppes, V; Spengos, K; Tsivgoulis, G; Vemmos, K; Zakopoulos, N, 2005) |
| "Arteriosclerosis is the main cause of lacunar CVA and IOMP." | 1.33 | Clinical characteristics of patients with ischemic ocular nerve palsies and lacunar brain infarcts: a retrospective comparative study. ( Goldhammer, Y; Hartmann, B; Kessler, A; Pollak, L; Rabey, MJ, 2005) |
| "Aspirin treatment had no significant effect on the neointimal smooth muscle component, but partially inhibited macrophage infiltration, without inhibiting ICAM-1 expression." | 1.33 | S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. ( Berry, CL; Campbell, JH; Thomas, AC; Worth, NF, 2005) |
| "Symptom recurrence (angina and congestive heart failure), adverse cardiac events (myocardial infarction, coronary reintervention, and sudden cardiac death), and overall mortality were prospectively recorded." | 1.33 | Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. ( Aytac, A; Cui, H; Gurbuz, AT; Vuran, AC; Zia, AA, 2006) |
| "First, patients with quiescent Crohn's disease and ulcerative colitis received the non-NSAID analgesic acetaminophen (n = 26) and the conventional NSAIDs naproxen (n = 32), diclofenac (n = 29), and indomethacin (n = 22) for 4 weeks." | 1.33 | Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. ( Bjarnason, I; Bjornsson, E; Maiden, L; Premchand, P; Sherwood, R; Smale, S; Takeuchi, K; Thjodleifsson, B, 2006) |
| "The sequence and timing of taking migraine medications, whether prescription or over-the-counter, and the patient's response to their treatment, is unknown." | 1.33 | Acute migraine treatment: patterns of use and satisfaction in a clinical population. ( Hopkins, M; Malik, SN; Silberstein, SD; Young, WB, 2006) |
| "Cryptogenic stroke is part of the disease of stress-induced cerebrovascular disease." | 1.33 | A new theory of cryptogenic stroke and its relationship to patent foramen ovale; or, the puzzle of the missing extra risk. ( Eggers, AE, 2006) |
| "Their mitral regurgitation (MR) is a result of left ventricular (LV) geometrical distortion." | 1.33 | Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair. ( Bolling, SF; Geltz, A; Spoor, MT, 2006) |
| "Stroke is a major health problem worldwide." | 1.33 | Effects of policosanol on patients with ischemic stroke: a pilot open study. ( Alvarez, E; Fernández, JC; Fernández, L; Gámez, R; Illnait, J; Más, R; Mendoza, S; Ortega, LL; Sánchez, J, 2006) |
| "Poststroke recurrence rate was low (7." | 1.32 | Ischaemic stroke in young people: a prospective and long-term follow-up study. ( Carerj, S; Di Perri, R; Epifanio, A; Gallitto, G; Gangemi, S; Granata, A; La Spina, P; Leggiadro, N; Manganaro, A; Musolino, R; Tripodi, F, 2003) |
| "Two of the intracerebral hemorrhages occurred in the site where asymptomatic MBs were found at baseline." | 1.32 | Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. ( Fan, YH; Lam, WW; Mok, VC; Wong, KS; Zhang, L, 2003) |
| "During follow-up 56 recurrences occurred, making a total of 110 episodes of vitreous haemorrhage in 79 eyes of 54 patients." | 1.32 | Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease? ( Banerjee, S; Denniston, AK; Dodson, PM; Gibson, JM, 2004) |
| "Acute pericarditis has generally a brief and benign course after empiric treatment by non-steroidal anti-inflammatory drugs, and routine hospitalization of most patients may be unnecessary." | 1.32 | Day-hospital treatment of acute pericarditis: a management program for outpatient therapy. ( Cecchi, E; Demarie, D; Demichelis, B; Gaschino, G; Ghisio, A; Giuggia, M; Imazio, M; Parrini, I; Trinchero, R, 2004) |
| "Strokes were subtyped according to inferred mechanism." | 1.32 | Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study. ( Barzegar, S; Bauer, K; Costigan, T; Furie, KL; Kistler, JP; Mohr, JP; Rosenberg, R; Rosner, B; Sciacca, R; Thompson, JL; Thornell, B, 2004) |
| "Aspirin users were older on average than nonusers (59 years of age compared with 53 years; p = 0." | 1.32 | Influence of aspirin on outcome following aneurysmal subarachnoid hemorrhage. ( Atkinson, JL; Friedman, JA; McClelland, RL; McIver, JI; Meyer, FB; Nichols, DA; Pichelmann, MA; Piepgras, DG; Toussaint, LG; Wijdicks, EF, 2004) |
| "During restenosis, an impairment of nitric oxide (NO)-dependent pathways may occur." | 1.31 | Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. ( Cirino, G; Condorelli, M; Del Soldato, P; Ignarro, LJ; Napoli, C; Pinto, A; Sica, V; Sorrentino, R, 2001) |
| "Severe bleeding was defined by the need for admission to hospital." | 1.31 | Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment. ( Castellino, G; Cuadrado, MJ; Godfrey, T; Hughes, GR; Khamashta, MA, 2001) |
| " We present several illustrative cases in which platelet monitoring with the Rapid Platelet Function Assay (RPFA, Accumetrics) was used to guide dosing of a glycoprotein (GP) IIb/IIIa inhibitor for coronary and peripheral intervention among patients at increased bleeding risk." | 1.31 | Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. ( Chew, DP; Moliterno, DJ; Mukherjee, D; Raymond, RE; Robbins, M; Yadav, JS, 2001) |
| " After a transient response to pulse corticosteroids, his disease ultimately subsided with combination therapy with pulse and high dosage corticosteroids and cyclosporin A." | 1.31 | Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. ( Chatila, T; Kim, J; Raman, V; Sharkey, A, 2001) |
| "Patients with antiphospholipid syndrome are at high risk of pregnancy loss as well as maternal morbidity, especially thrombo-embolic disease." | 1.30 | Obstetric outcome in antiphospholipid syndrome. ( Farquharson, RG; Granger, KA, 1997) |
| "History of untreated hypertension prior to the initial stroke (RR = 1." | 1.30 | Stroke recurrence among 30 days survivors of ischemic stroke in a prospective community-based study. ( Baranska-Gieruszczak, M; Czlonkowska, A; Hier, DB; Lechowicz, W; Ryglewicz, D, 1997) |
| "A therapy-resistant angle closure glaucoma following displacement of the lens-iris diaphragm due to massive choroidal and subretinal hemorrhages has rarely been reported." | 1.30 | [Acute glaucoma caused by massive subretinal hemorrhage in age-related macular degeneration and disordered thrombocyte function]. ( Hesse, L; Poller, S, 1997) |
| "In 52 patients who presented with NAION between 1984 and 1997 adequate information was available regarding use of aspirin, presence of risk factors and second eye involvement." | 1.30 | Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy. ( Huna-Baron, R; Kurtz, S; Salomon, O; Seligsohn, U; Steinberg, DM, 1999) |
| "We examined 159 patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in Japan." | 1.30 | Outcome of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in Japan. ( Ihara, T; Kakisita, E; Minami, N; Mori, Y; Omine, M; Shiku, H; Tamaki, S; Wada, H, 1999) |
| "Six cases of acute myocardial infarction are reported with early disease reactivation following the abrupt discontinuation of heparin infusion three days after alteplase thrombolysis and concomitant aspirin therapy." | 1.29 | Early reactivation of ischaemia after abrupt discontinuation of heparin in acute myocardial infarction. ( Di Tano, G; Mazzù, A, 1995) |
| "The rate of recurrence of thrombosis was highest (1." | 1.29 | The management of thrombosis in the antiphospholipid-antibody syndrome. ( Cuadrado, MJ; Hughes, GR; Hunt, BJ; Khamashta, MA; Mujic, F; Taub, NA, 1995) |
| "Women with acute myocardial infarction have a worse prognosis than men but the excess risk is confined to the first 30 days and is only partly explained by age and other baseline variables." | 1.29 | Acute myocardial infarction in women: survival analysis in first six months. ( Laji, K; Parsons, L; Ranjadayalan, K; Timmis, AD; Wilkinson, P, 1994) |
| "The embolic risk and changes of thrombus location and size were investigated in 29 consecutive patients with echocardiographically proven thrombi in the left atrium." | 1.29 | [Transthoracic and transesophageal follow-up in patients with left atrial thrombosis]. ( Erbel, R; Genth, S; Meyer, J; Pinnau, U; Zotz, R, 1994) |
| " Of the 52 with partial inhibition at initial testing, 35 achieved complete inhibition either by ASA dosage escalation (in 325 mg/d increments) or fluctuation of response at the same dosage, but 8 of those 35 (22." | 1.29 | Development of aspirin resistance in persons with previous ischemic stroke. ( Bolin, KM; Brace, LD; Helgason, CM; Hoff, JA; Mangat, A; Tortorice, KL; Winkler, SR, 1994) |
| "Acute myocardial infarctions were registered in group 1 in 25% (11." | 1.29 | [Emergency intracoronary stent implantation: complications and experiences with 124 patients]. ( Arens, R; Heuer, H; Krakau, I; Müller, T; Rissel, U; Schulze-Waltrup, N; Willgeroth, W, 1994) |
| "Aspirin was usually chosen after initial brain ischemia." | 1.29 | Patent foramen ovale and brain infarct. Echocardiographic predictors, recurrence, and prevention. ( Furlan, AJ; Hanna, JP; Sila, CA; Stewart, WJ; Sun, JP; Tan, M, 1994) |
| "Blood clots were produced in a femoral artery segment with endothelial damage and distal stenosis." | 1.29 | Does external ultrasound accelerate thrombolysis? Results from a rabbit model. ( Battler, A; Chernine, A; Kornowski, R; Meltzer, RS; Vered, Z, 1994) |
| "In patients with migraine, ECT may be expected to trigger a migraine attack, probably in the same way as spontaneous seizures." | 1.29 | Migraine after electroconvulsive therapy. ( Folkerts, H, 1995) |
| "Prevention of recurrence of fibrillation is unnecessary for many after a first episode, especially when idiopathic." | 1.28 | [Drug treatments of atrial fibrillation]. ( Brechenmacher, C; Chauvin, M; Koenig, A, 1992) |
| "Chronic subdural hematoma appears to be a suitable model for the evaluation of risk factors in the development of hemorrhage." | 1.28 | Aspirin as a risk factor for hemorrhage in patients with head injuries. ( Gratzl, O; Marbet, G; Radü, EW; Reymond, MA, 1992) |
| "Five warfarin-treated patients had five significant bleeding events (0." | 1.28 | Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. ( Brewer, PM; Rosove, MH, 1992) |
| " No effect on APTT was detectable in this dosage after 3 h infusion." | 1.28 | Reocclusion after thrombolysis: a problem solved by hirudin? ( Eschenfelder, V; Rübsamen, K, 1991) |
| "Fibrin monomers were threefold positive and D-dimer concentration was increased to 4 mg/l (elevated clotting activation)." | 1.28 | [Recurrent thromboembolism due to increased acetylsalicylic acid-resistant platelet aggregation]. ( Himmelreich, G; Riess, H, 1991) |
| " While steroid dosage was gradually decreased, administration of acetylsalicylic acid (for three months 100 mg daily, then three times daily 100 mg) brought about complete disappearance of the visual signs." | 1.28 | [The antiphospholipid syndrome. The neurological complications and the therapeutic possibilities]. ( Berg, PA; Leo-Kottler, B; Weller, M; Wiethölter, H, 1991) |
| "Treatment with aspirin and a residual stenosis of 25-49% immediately after successful PTCA were the only variables associated with restenosis (P less than 0." | 1.28 | Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty. ( Emanuelsson, H; Hjalmarson, A; Johansson, SR; Karlsson, T; Wiklund, O, 1991) |
| " Whereas the death rate was nearly the same in all three former dosage groups the total reinfarction rate was higher (22." | 1.28 | Reevaluation of the Cottbus Reinfarction Study with 30 mg aspirin per day 4 years after the end of the study. ( Förster, W; Handreg, W; Hoffmann, W; Kampe, W; Muche, J; Nitschke, M, 1991) |
| "The overall restenosis rate was 40%." | 1.28 | Patient-related variables and restenosis after percutaneous transluminal coronary angioplasty--a report from the M-HEART Group. ( Bass, T; Cowley, M; Goldberg, SH; Henderson, MA; Hirshfeld, JW; Macdonald, RG; Margolis, JR; Taussig, A; Vetrovec, G; Whitworth, H, 1990) |
| " The risk of therapy with acetyl salicylic acid (ASS) in low dosage is significantly smaller." | 1.28 | [Experiences from general practice: use of acetylsalicylic acid and anticoagulants in patients following acute myocardial infarct]. ( Dahn, G; Kothe, K, 1990) |
| "The composition of an evolving arterial thrombus may be a determinant of how effectively pharmacologic agents prevent reocclusion after initially successful thrombolysis." | 1.28 | Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors. ( Abendschein, DR; Adams, SP; Feigen, LP; Gorczynski, RJ; Haskel, EJ; Saffitz, JE; Sobel, BE, 1989) |
| " Platelet accumulation at the PTA site occurred with both doses of aspirin, with no differences between the two dosage groups." | 1.28 | Platelet deposition at angioplasty sites and its relation to restenosis in human iliac and femoropopliteal arteries. ( Ahmadi, R; Dudczak, R; Ehringer, H; Jung, M; Koppensteiner, R; Leitha, T; Minar, E; Stümpflen, A, 1989) |
| "Thrombotic thrombocytopenic purpura is a severe multisystemic disorder of unknown origin." | 1.28 | Successful pregnancies of two patients with relapsing thrombotic thrombocytopenic purpura. ( Eldor, A; Ezra, Y; Mordel, N; Sadovsky, E; Schenker, JG, 1989) |
| "The frequency of a high-grade restenosis in patients with diabetes mellitus and coronary heart disease was not significantly increased, but supports the view that these are risk factors in the development of atherosclerotic changes in an operated carotid artery." | 1.28 | Late carotid restenosis: aetiologic factors for recurrent carotid artery stenosis during long-term follow-up. ( Haapanen, A; Harju, E; Jokela, H; Riekkinen, H; Salenius, JP, 1989) |
| "The reported recurrence rate is lower than comparable figures in published reports." | 1.27 | [Incidence of recurrence after successful transluminal coronary angioplasty]. ( Kaltenbach, M; Kober, G; Scherer, D; Schmidt-Moritz, A, 1983) |
| "The mean degree of stenosis was reduced from 77 +/- 12% to 29 +/- 15% and the mean systolic pressure gradient from 78 +/- 18 to 25 +/- 9 mmHg." | 1.27 | Role of percutaneous transluminal coronary angioplasty in patients with variant angina and coexistent coronary stenosis refractory to maximal medical therapy. ( Brücke, P; Herbinger, W; Leisch, F, 1984) |
| "A clinical diagnosis of systemic lupus erythematosus (SLE) was made in four women." | 1.27 | Lupus anticoagulant in pregnancy. ( Butler, WS; Liggins, GC; Lubbe, WF; Palmer, SJ, 1984) |
| " Dose-response platelet aggregometry detected no differences between groups in the sensitivity of platelets to adenosine diphosphate (ADP), collagen, and epinephrine." | 1.27 | Etiologic factors for recurrent carotid artery stenosis. ( Clagett, GP; Hutton, JE; McDonald, PT; Olson, DW; Rich, NM; Salander, JM; Youkey, JR, 1983) |
| "01)." | 1.27 | Analgesic ingestion and other factors preceding relapse in ulcerative colitis. ( McNeil, NI; Rampton, DS; Sarner, M, 1983) |
| "A higher recurrence rate after angioplasty is seen in the presence of a wall thrombus." | 1.27 | [Prevention of thrombosis in the after-care of coronary dilatation and thrombolysis]. ( Lorenz, RL; Schramm, W; Theisen, K; Weber, MA, 1986) |
| "Therapy that will reduce acute platelet-thrombus deposition appears to be an important factor for reduction of restenosis." | 1.27 | Restenosis after arterial angioplasty: a hemorrheologic response to injury. ( Badimon, L; Chesebro, JH; Fuster, V; Lam, JY, 1987) |
| "This is a reangiography rate of 94%." | 1.27 | The Frankfurt experience in restenosis after coronary angioplasty. ( Bussmann, WD; Kaltenbach, M; Kober, G; Vallbracht, C, 1987) |
| "The observed restenosis rate is less than 50% of that reported by the PTCA registry of the NHLBI." | 1.27 | Recurrence rate after successful coronary angioplasty. ( Kaltenbach, M; Kober, G; Scherer, D; Vallbracht, C, 1985) |
| "An 18-month-old child with Kawasaki syndrome twice developed severe recurrence of symptoms when the acetylsalicylic acid (Aspirin) dosage was decreased from 80 mg/kg/day." | 1.27 | Relapsing Kawasaki's disease. ( Brady, S; Feild, C; Lowe, B, 1987) |
| "The hypotension was found to be refractory to intravenous fluids, dopamine, and antihistamines, but was immediately reversed by intravenous epinephrine." | 1.26 | Shock syndrome associated with mastocytosis: pharmacologic reversal of the acute episode and therapeutic prevention of recurrent attacks. ( Oates, JA; Roberts, LJ; Turk, JW, 1982) |
| "Eight patients with transient ischemic attacks, and three with partial nonprogressive strokes associated with mitral valve prolapse, are reported." | 1.26 | TIA, stroke, and mitral valve prolapse. ( Watson, RT, 1979) |
| "Growing pains are recurrent limb pains peculiar to children." | 1.26 | Growing pains: fact or fiction? ( Calabro, JJ; Holgerson, WB; Repice, MM; Wachtel, AE, 1976) |
| "The factors that determine the recurrence rate of chronic gastric ulcer were studied in 105 patients." | 1.25 | Factors relevant to the prognosis of chronic gastric ulcer. ( Coupland, GA; Greig, M; Hobbin, E; Piper, DW; Shinners, J, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 204 (16.49) | 18.7374 |
| 1990's | 336 (27.16) | 18.2507 |
| 2000's | 313 (25.30) | 29.6817 |
| 2010's | 308 (24.90) | 24.3611 |
| 2020's | 76 (6.14) | 2.80 |
| Authors | Studies |
|---|---|
| Bahit, MC | 1 |
| Sacco, RL | 9 |
| Easton, JD | 9 |
| Meyerhoff, J | 2 |
| Cronin, L | 3 |
| Kleine, E | 2 |
| Grauer, C | 4 |
| Brueckmann, M | 4 |
| Diener, HC | 15 |
| Lopes, RD | 2 |
| Brainin, M | 2 |
| Lyrer, P | 2 |
| Wachter, R | 1 |
| Segura, T | 2 |
| Granger, CB | 8 |
| Dai, L | 2 |
| Xu, J | 3 |
| Yan, H | 1 |
| Chen, Z | 4 |
| Pan, Y | 7 |
| Meng, X | 12 |
| Li, H | 9 |
| Wang, Y | 38 |
| Merkler, AE | 1 |
| Pearce, LA | 8 |
| Kasner, SE | 8 |
| Shoamanesh, A | 6 |
| Birnbaum, LA | 1 |
| Kamel, H | 2 |
| Sheth, KN | 2 |
| Sharma, R | 2 |
| Lun, R | 1 |
| Dhaliwal, S | 1 |
| Zitikyte, G | 1 |
| Roy, DC | 1 |
| Hutton, B | 1 |
| Dowlatshahi, D | 1 |
| Santana-Mateos, M | 1 |
| Medina-Gil, JM | 2 |
| Saavedra-Santana, P | 1 |
| Martínez-Quintana, E | 2 |
| Rodríguez-González, F | 2 |
| Tugores, A | 2 |
| Mac Grory, B | 2 |
| Piccini, JP | 1 |
| Yaghi, S | 3 |
| Poli, S | 2 |
| De Havenon, A | 3 |
| Rostanski, SK | 1 |
| Weiss, M | 1 |
| Xian, Y | 3 |
| Johnston, SC | 14 |
| Feng, W | 2 |
| Chen, S | 1 |
| Cai, D | 1 |
| Lai, Y | 1 |
| He, J | 1 |
| Wu, Q | 1 |
| Huang, P | 1 |
| Zhou, L | 2 |
| Sun, H | 2 |
| Dominati, A | 1 |
| Meyer, P | 1 |
| Seebach, JD | 1 |
| Ezquer, F | 2 |
| Quintanilla, ME | 2 |
| Morales, P | 2 |
| Santapau, D | 2 |
| Munita, JM | 1 |
| Moya-Flores, F | 1 |
| Ezquer, M | 2 |
| Herrera-Marschitz, M | 2 |
| Israel, Y | 2 |
| Zhang, X | 1 |
| Jing, J | 6 |
| Zhao, X | 15 |
| Liu, L | 17 |
| Wang, A | 11 |
| Wang, D | 7 |
| Stanković, P | 1 |
| Hoch, S | 1 |
| Rudhart, S | 1 |
| Stojković, S | 1 |
| Wilhelm, T | 1 |
| Akao, K | 1 |
| Izumida, T | 1 |
| Imamura, T | 1 |
| Liu, JS | 2 |
| Lee, CH | 1 |
| Chuah, SK | 2 |
| Tai, WC | 2 |
| Chang, CC | 2 |
| Chen, FJ | 1 |
| Hankey, GJ | 8 |
| Izcovich, A | 1 |
| Caruso, D | 1 |
| Tisi Baña, M | 1 |
| Bottaro, F | 1 |
| Pollán, J | 1 |
| Saavedra, E | 1 |
| Catalano, HN | 1 |
| Santos, CD | 1 |
| Matos, NL | 1 |
| Asleh, R | 1 |
| Dawit, S | 1 |
| Rabinstein, AA | 1 |
| O'Carroll, CB | 1 |
| Li, Z | 3 |
| Freeman, WD | 1 |
| Kim, SM | 1 |
| Jung, JM | 1 |
| Kim, BJ | 3 |
| Lee, JS | 4 |
| Kwon, SU | 3 |
| Vanassche, T | 1 |
| Verhamme, P | 3 |
| Anand, SS | 2 |
| Shestakovska, O | 1 |
| Fox, KA | 7 |
| Bhatt, DL | 12 |
| Avezum, A | 1 |
| Alings, M | 1 |
| Aboyans, V | 1 |
| Maggioni, AP | 2 |
| Widimsky, P | 3 |
| Berkowitz, SD | 6 |
| Yusuf, S | 5 |
| Connolly, SJ | 6 |
| Eikelboom, JW | 5 |
| Bosch, J | 1 |
| Wang, IK | 1 |
| Yen, TH | 1 |
| Guo, YC | 1 |
| Sun, Y | 2 |
| Lien, LM | 2 |
| Chang, WL | 2 |
| Chen, PL | 1 |
| Yang, YC | 1 |
| Sung, FC | 1 |
| Hsu, CY | 2 |
| Kwon, HS | 1 |
| Lee, D | 1 |
| Lee, MH | 1 |
| Yu, S | 2 |
| Lim, JS | 1 |
| Yu, KH | 2 |
| Oh, MS | 1 |
| Hong, KS | 3 |
| Lee, EJ | 1 |
| Kang, DW | 2 |
| Berríos-Cárcamo, P | 1 |
| Olivares, B | 1 |
| Yang, M | 1 |
| Li, J | 8 |
| Zhang, N | 3 |
| Garg, S | 1 |
| Chichareon, P | 1 |
| Kogame, N | 1 |
| Takahashi, K | 1 |
| Modolo, R | 1 |
| Tomaniak, M | 1 |
| Fath-Ordoubadi, F | 1 |
| Anderson, R | 1 |
| Oldroyd, KG | 1 |
| Stables, RH | 1 |
| Kukreja, N | 1 |
| Chowdhary, S | 1 |
| Galasko, G | 1 |
| Hoole, S | 1 |
| Zaman, A | 1 |
| Hamm, CW | 2 |
| Steg, PG | 9 |
| Jüni, P | 1 |
| Valgimigli, M | 2 |
| Windecker, S | 4 |
| Onuma, Y | 1 |
| Serruys, PW | 2 |
| D'Ascenzo, F | 2 |
| Gili, S | 2 |
| Bertaina, M | 2 |
| Iannaccone, M | 1 |
| Cammann, VL | 1 |
| Di Vece, D | 1 |
| Kato, K | 1 |
| Saglietto, A | 1 |
| Szawan, KA | 1 |
| Frangieh, AH | 1 |
| Boffini, B | 1 |
| Annaratone, M | 1 |
| Sarcon, A | 1 |
| Levinson, RA | 1 |
| Franke, J | 1 |
| Napp, LC | 1 |
| Jaguszewski, M | 1 |
| Noutsias, M | 1 |
| Münzel, T | 1 |
| Knorr, M | 1 |
| Heiner, S | 1 |
| Katus, HA | 2 |
| Burgdorf, C | 1 |
| Schunkert, H | 1 |
| Thiele, H | 2 |
| Bauersachs, J | 1 |
| Tschöpe, C | 1 |
| Pieske, BM | 1 |
| Rajan, L | 1 |
| Michels, G | 1 |
| Pfister, R | 1 |
| Cuneo, A | 1 |
| Jacobshagen, C | 1 |
| Hasenfuß, G | 1 |
| Karakas, M | 1 |
| Koenig, W | 1 |
| Rottbauer, W | 1 |
| Said, SM | 1 |
| Braun-Dullaeus, RC | 2 |
| Banning, A | 1 |
| Cuculi, F | 1 |
| Kobza, R | 1 |
| Fischer, TA | 1 |
| Vasankari, T | 1 |
| Airaksinen, KEJ | 1 |
| Opolski, G | 3 |
| Dworakowski, R | 1 |
| MacCarthy, P | 1 |
| Kaiser, C | 1 |
| Osswald, S | 1 |
| Galiuto, L | 1 |
| Crea, F | 3 |
| Dichtl, W | 1 |
| Franz, WM | 1 |
| Empen, K | 1 |
| Felix, SB | 1 |
| Delmas, C | 1 |
| Lairez, O | 1 |
| El-Battrawy, I | 1 |
| Akin, I | 1 |
| Borggrefe, M | 2 |
| Horowitz, JD | 1 |
| Kozel, M | 1 |
| Tousek, P | 1 |
| Gilyarova, E | 1 |
| Shilova, A | 1 |
| Gilyarov, M | 1 |
| Biondi-Zoccai, G | 1 |
| Winchester, DE | 1 |
| Ukena, C | 1 |
| Neuhaus, M | 1 |
| Bax, JJ | 1 |
| Prasad, A | 1 |
| Di Mario, C | 2 |
| Böhm, M | 1 |
| Gasparini, M | 1 |
| Ruschitzka, F | 1 |
| Bossone, E | 1 |
| Citro, R | 1 |
| Rinaldi, M | 2 |
| De Ferrari, GM | 1 |
| Lüscher, T | 1 |
| Ghadri, JR | 1 |
| Templin, C | 3 |
| Paciaroni, M | 1 |
| Ince, B | 1 |
| Hu, B | 1 |
| Jeng, JS | 2 |
| Kutluk, K | 1 |
| Lou, M | 1 |
| Parfenov, V | 1 |
| Wong, KSL | 3 |
| Zamani, B | 1 |
| Paek, D | 1 |
| Min Han, J | 1 |
| Del Aguila, M | 1 |
| Girotra, S | 1 |
| Liu, X | 4 |
| Qiu, Y | 1 |
| Yu, ED | 1 |
| Xiang, S | 1 |
| Meng, R | 2 |
| Niu, KF | 1 |
| Zhu, H | 1 |
| Cacoub, P | 4 |
| Schwier, NC | 3 |
| Cornelio, CK | 1 |
| Epperson, TM | 1 |
| Schneider, DJ | 1 |
| McMahon, SR | 1 |
| Ehle, GL | 1 |
| Chava, S | 1 |
| Taatjes-Sommer, HS | 1 |
| Meagher, S | 1 |
| Platt, B | 1 |
| Belarski, E | 1 |
| Manaloor, J | 1 |
| Ofner, S | 1 |
| Carroll, AE | 1 |
| John, CC | 1 |
| Wood, JB | 1 |
| García-Ropero, Á | 1 |
| Vargas-Delgado, AP | 1 |
| Santos-Gallego, CG | 1 |
| Badimon, JJ | 1 |
| Faggioni, M | 1 |
| Redfors, B | 1 |
| Crowley, A | 1 |
| Claessen, BE | 1 |
| Farhan, S | 1 |
| Mastoris, I | 1 |
| Witzenbichler, B | 1 |
| Maehara, A | 1 |
| Weisz, G | 1 |
| Généreux, P | 1 |
| Ben-Yehuda, O | 1 |
| Mehran, R | 3 |
| Kirtane, AJ | 1 |
| Stone, GW | 3 |
| Kwon, S | 1 |
| Chan, AT | 1 |
| Zuo, Z | 1 |
| Lin, J | 7 |
| You, J | 1 |
| Guo, W | 1 |
| Gao, L | 1 |
| Geng, L | 1 |
| Wang, X | 5 |
| Wan, Q | 1 |
| Zhang, Q | 3 |
| Pu, Y | 2 |
| Zou, X | 2 |
| Atchaneeyasakul, K | 1 |
| Liebeskind, DS | 1 |
| Guo, J | 1 |
| Wang, J | 2 |
| Guo, Y | 2 |
| Feng, J | 1 |
| Randall, B | 1 |
| Andersen, G | 1 |
| Iversen, HK | 1 |
| Roine, RO | 1 |
| Sjostrand, C | 1 |
| Rhodes, JF | 1 |
| Søndergaard, L | 1 |
| Cucchiara, B | 1 |
| Elm, J | 1 |
| Coutts, SB | 3 |
| Willey, JZ | 1 |
| Biros, MH | 1 |
| Ross, MA | 1 |
| Zhang, C | 3 |
| Kleindorfer, DO | 1 |
| Levitan, EB | 1 |
| Howard, VJ | 1 |
| Howard, G | 1 |
| Soliman, EZ | 1 |
| Richards, A | 1 |
| Jackson, NJ | 1 |
| Cheng, EM | 1 |
| Bryg, RJ | 1 |
| Brown, A | 1 |
| Towfighi, A | 1 |
| Sanossian, N | 1 |
| Barry, F | 1 |
| Li, N | 1 |
| Vickrey, BG | 1 |
| Egan, RA | 1 |
| Arnold, AC | 1 |
| Lee, AG | 1 |
| Van Stavern, GP | 1 |
| McKenna, MC | 1 |
| Fanning, N | 1 |
| Cronin, S | 1 |
| Alexander, JH | 1 |
| Wojdyla, D | 1 |
| Vora, AN | 1 |
| Thomas, L | 1 |
| Goodman, SG | 2 |
| Aronson, R | 1 |
| Romoli, M | 1 |
| Giannandrea, D | 1 |
| Eusebi, P | 1 |
| Cupini, LM | 1 |
| Ricci, S | 2 |
| Calabresi, P | 1 |
| Gencer, B | 1 |
| Li, XS | 1 |
| Gurmu, Y | 2 |
| Bonaca, MP | 3 |
| Morrow, DA | 2 |
| Cohen, M | 10 |
| Storey, RF | 4 |
| Johanson, P | 3 |
| Wang, Z | 3 |
| Hazen, SL | 1 |
| Sabatine, MS | 3 |
| Bar, M | 1 |
| Bernstein, RA | 2 |
| Donnan, G | 2 |
| Gdovinová, Z | 1 |
| Kleinig, TJ | 1 |
| Martins, S | 1 |
| Milling, T | 1 |
| Pfeilschifter, W | 1 |
| Reif, M | 1 |
| Rose, DZ | 1 |
| Šaňák, D | 1 |
| Schäbitz, WR | 1 |
| Mill, J | 1 |
| Olivares, AL | 1 |
| Arzamendi, D | 1 |
| Agudelo, V | 1 |
| Regueiro, A | 1 |
| Camara, O | 1 |
| Freixa, X | 1 |
| Furtado, RHM | 1 |
| Venkateswaran, RV | 1 |
| Nicolau, JC | 1 |
| Magnani, G | 2 |
| Goto, S | 1 |
| Dellborg, M | 3 |
| Kamensky, G | 2 |
| Isaza, D | 1 |
| Aylward, P | 1 |
| Weitz, JI | 5 |
| Angiolillo, DJ | 2 |
| Geisler, T | 1 |
| Heitmeier, S | 1 |
| Veltkamp, R | 3 |
| Korompoki, E | 1 |
| Sharma, M | 4 |
| Toni, D | 5 |
| Ameriso, SF | 4 |
| Mundl, H | 5 |
| Tatlisumak, T | 1 |
| Lindgren, A | 2 |
| Arauz, A | 4 |
| Ozturk, S | 1 |
| Muir, KW | 2 |
| Chamorro, Á | 2 |
| Perera, K | 2 |
| Shuaib, A | 3 |
| Rudilosso, S | 1 |
| Hart, RG | 10 |
| Verdoia, M | 1 |
| Nardin, M | 1 |
| Gioscia, R | 1 |
| Negro, F | 1 |
| Marcolongo, M | 1 |
| Suryapranata, H | 1 |
| Kedhi, E | 1 |
| De Luca, G | 1 |
| Amarenco, P | 3 |
| Perera, KS | 2 |
| Ntaios, G | 5 |
| Lang, W | 1 |
| Bereczki, D | 1 |
| Uchiyama, S | 10 |
| Yoon, BW | 1 |
| Lavados, P | 1 |
| Firstenfeld, A | 1 |
| Mikulik, R | 3 |
| Povedano, GP | 2 |
| Ferrari, J | 1 |
| Verma, SP | 1 |
| Kumar, N | 1 |
| Jain, M | 1 |
| Tripathi, AK | 1 |
| Lazaros, G | 3 |
| Antonopoulos, AS | 2 |
| Lazarou, E | 2 |
| Vlachopoulos, C | 2 |
| Vogiatzi, G | 1 |
| Vassilopoulos, D | 2 |
| Tousoulis, D | 2 |
| Conway, J | 1 |
| Friedman, BW | 1 |
| Cameli, P | 1 |
| D'Alessandro, M | 1 |
| Bergantini, L | 1 |
| Silvestri, E | 1 |
| Romaldi, A | 1 |
| Emmi, G | 2 |
| Parronchi, P | 1 |
| Bargagli, E | 1 |
| Bulwa, Z | 1 |
| Saleh Velez, FG | 1 |
| Brorson, JR | 2 |
| Pinto, CB | 1 |
| Smith, EE | 1 |
| Martí-Fàbregas, J | 4 |
| Liu, YY | 1 |
| O'Donnell, MJ | 1 |
| Field, TS | 4 |
| Santo, GC | 1 |
| Olavarria, V | 1 |
| Lutsep, H | 2 |
| You, SC | 1 |
| Rho, Y | 1 |
| Bikdeli, B | 1 |
| Kim, J | 2 |
| Siapos, A | 1 |
| Weaver, J | 1 |
| Londhe, A | 1 |
| Cho, J | 1 |
| Park, J | 1 |
| Schuemie, M | 1 |
| Suchard, MA | 1 |
| Madigan, D | 1 |
| Hripcsak, G | 1 |
| Gupta, A | 1 |
| Reich, CG | 1 |
| Ryan, PB | 1 |
| Park, RW | 1 |
| Krumholz, HM | 2 |
| Ros-Castelló, V | 1 |
| Natera-Villalba, E | 1 |
| Gómez-López, A | 1 |
| Sánchez-Sánchez, A | 1 |
| Chico-García, JL | 1 |
| García-Madrona, S | 1 |
| Vera-Lechuga, R | 1 |
| Matute-Lozano, C | 1 |
| de Felipe Mimbrera, A | 1 |
| Cruz-Culebras, A | 2 |
| Alonso-Canovas, A | 1 |
| Masjuan, J | 3 |
| Lee, HL | 2 |
| Kim, JT | 1 |
| Park, MS | 1 |
| Choi, KH | 1 |
| Cho, KH | 2 |
| Park, JM | 1 |
| Kang, K | 1 |
| Lee, SJ | 1 |
| Kim, JG | 1 |
| Cha, JK | 1 |
| Kim, DH | 1 |
| Park, TH | 1 |
| Park, SS | 1 |
| Lee, KB | 1 |
| Lee, J | 3 |
| Cho, YJ | 1 |
| Park, HK | 2 |
| Lee, BC | 3 |
| Sun Oh, M | 1 |
| Kim, DE | 1 |
| Ryu, WS | 1 |
| Choi, JC | 1 |
| Kwon, JH | 2 |
| Kim, WJ | 1 |
| Shin, DI | 1 |
| Sohn, SI | 1 |
| Hong, JH | 1 |
| Bae, HJ | 1 |
| Aoki, J | 1 |
| Iguchi, Y | 1 |
| Urabe, T | 1 |
| Yamagami, H | 1 |
| Todo, K | 1 |
| Fujimoto, S | 1 |
| Idomari, K | 1 |
| Kaneko, N | 1 |
| Iwanaga, T | 1 |
| Terasaki, T | 1 |
| Tanaka, R | 1 |
| Yamamoto, N | 1 |
| Tsujino, A | 1 |
| Nomura, K | 1 |
| Abe, K | 2 |
| Uno, M | 1 |
| Okada, Y | 3 |
| Matsuoka, H | 1 |
| Yamagata, S | 1 |
| Yamamoto, Y | 2 |
| Yonehara, T | 1 |
| Inoue, T | 1 |
| Yagita, Y | 1 |
| Kimura, K | 4 |
| Espersen, J | 1 |
| Weber, U | 1 |
| Römer-Franz, A | 1 |
| Lenarz, T | 1 |
| Stolle, SRO | 1 |
| Warnecke, A | 1 |
| Wong, YS | 1 |
| Tsai, CF | 1 |
| Hsu, YH | 1 |
| Ong, CT | 1 |
| Lin, MP | 1 |
| Meschia, JF | 1 |
| Gopal, N | 1 |
| Barrett, KM | 1 |
| Ross, OA | 1 |
| Ertekin-Taner, N | 1 |
| Brott, TG | 1 |
| Singh, S | 1 |
| de Ronde, MWJ | 1 |
| Creemers, EE | 1 |
| Van der Made, I | 1 |
| Meijering, R | 1 |
| Chan, MY | 1 |
| Hwee Tan, S | 1 |
| Tang Chin, C | 1 |
| Mark Richards, A | 1 |
| Troughton, RW | 1 |
| Yean Yip Fong, A | 1 |
| Yan, BP | 1 |
| Pinto-Sietsma, SJ | 1 |
| Song, CG | 1 |
| Bi, LJ | 1 |
| Zhao, JJ | 1 |
| Li, W | 2 |
| Yang, F | 2 |
| Jiang, W | 2 |
| Toyoda, K | 3 |
| Liou, CW | 2 |
| Wong, LKS | 1 |
| Taniguchi, A | 1 |
| Urano, Y | 1 |
| Bulwa, ZB | 1 |
| Witte, KK | 1 |
| Tsivgoulis, G | 2 |
| Reynolds, MR | 1 |
| Tsintzos, SI | 1 |
| Eggington, S | 1 |
| Ismyrloglou, E | 1 |
| Lyon, J | 1 |
| Huynh, M | 1 |
| Egea, M | 1 |
| de Brouwer, B | 1 |
| Ziegler, PD | 1 |
| Franco, N | 1 |
| Joglekar, R | 1 |
| Rosemas, SC | 1 |
| Liu, S | 1 |
| Thijs, V | 1 |
| Sheriff, F | 1 |
| Inam, ME | 1 |
| Thanh Truong, VT | 1 |
| Lopez-Rivera, V | 1 |
| Lekka, E | 1 |
| Kermali, K | 1 |
| Sheth, S | 1 |
| Maud, A | 1 |
| Gupta, V | 1 |
| Rodriguez, G | 1 |
| Pedroza, C | 1 |
| Chen, PR | 1 |
| Rostanski, S | 1 |
| Kvernland, A | 1 |
| Furie, KL | 2 |
| Kim, AS | 2 |
| Henninger, N | 1 |
| Blue, NR | 1 |
| Page, JM | 1 |
| Silver, RM | 2 |
| Imazio, M | 11 |
| Vasileiou, P | 1 |
| Karavidas, A | 1 |
| Toutouzas, K | 1 |
| Tsioufis, C | 1 |
| Lansberg, M | 1 |
| Tirschwell, D | 1 |
| Mistry, E | 1 |
| Marques, C | 1 |
| Hilkens, NA | 1 |
| Algra, A | 7 |
| Bath, PM | 5 |
| Csiba, L | 1 |
| Hacke, W | 3 |
| Kappelle, LJ | 3 |
| Koudstaal, PJ | 5 |
| Leys, D | 2 |
| Mas, JL | 4 |
| Greving, JP | 1 |
| Huynh, K | 1 |
| Rao, Z | 2 |
| Zheng, H | 2 |
| Wang, F | 2 |
| Dong, K | 3 |
| Cao, Y | 3 |
| Chan, FKL | 1 |
| Ching, JYL | 1 |
| Tse, YK | 3 |
| Lam, K | 2 |
| Wong, GLH | 1 |
| Ng, SC | 3 |
| Lee, V | 2 |
| Au, KWL | 1 |
| Cheong, PK | 2 |
| Suen, BY | 1 |
| Chan, H | 2 |
| Kee, KM | 1 |
| Lo, A | 2 |
| Wong, VWS | 1 |
| Wu, JCY | 1 |
| Kyaw, MH | 1 |
| Tolcher, MC | 1 |
| Chu, DM | 1 |
| Hollier, LM | 1 |
| Mastrobattista, JM | 1 |
| Racusin, DA | 1 |
| Ramin, SM | 1 |
| Sangi-Haghpeykar, H | 1 |
| Aagaard, KM | 1 |
| Majidi, S | 1 |
| Leon Guerrero, CR | 1 |
| Gandhy, S | 1 |
| Burger, KM | 1 |
| Sigounas, D | 1 |
| Pareek, M | 1 |
| Ten Berg, JM | 2 |
| Kristensen, SD | 1 |
| Grove, EL | 2 |
| Bavry, AA | 1 |
| Elgendy, IY | 1 |
| Elbez, Y | 1 |
| Mahmoud, AN | 1 |
| Sorbets, E | 1 |
| Shavadia, J | 1 |
| Welsh, R | 1 |
| Gershlick, A | 1 |
| Zheng, Y | 1 |
| Huber, K | 2 |
| Halvorsen, S | 1 |
| Van de Werf, F | 3 |
| Armstrong, PW | 1 |
| Kern, A | 1 |
| Gil, RJ | 1 |
| Bojko, K | 1 |
| Sienkiewicz, E | 1 |
| Januszko-Giergielewicz, B | 1 |
| Górny, J | 1 |
| Bil, J | 1 |
| Çetin, İİ | 1 |
| Ekici, F | 1 |
| Kocabaş, A | 1 |
| Çevik, BŞ | 1 |
| Eminoğlu, S | 1 |
| Azak, E | 1 |
| Kibar, AE | 1 |
| Arı, ME | 1 |
| Sürücü, M | 1 |
| Orgun, A | 1 |
| Dunn, A | 1 |
| Bazan, C | 2 |
| Catanese, L | 1 |
| McClure, LA | 4 |
| Anderson, DC | 2 |
| Kase, CS | 1 |
| Benavente, OR | 7 |
| Lee, M | 2 |
| Saver, JL | 3 |
| Rao, NM | 2 |
| Wu, YL | 2 |
| Ovbiagele, B | 6 |
| Visser, L | 1 |
| de Boer, MA | 1 |
| de Groot, CJM | 1 |
| Nijman, TAJ | 1 |
| Hemels, MAC | 1 |
| Bloemenkamp, KWM | 1 |
| Bosmans, JE | 1 |
| Kok, M | 1 |
| van Laar, JO | 1 |
| Sueters, M | 1 |
| Scheepers, H | 1 |
| van Drongelen, J | 1 |
| Franssen, MTM | 1 |
| Sikkema, JM | 1 |
| Duvekot, HJJ | 1 |
| Bekker, MN | 1 |
| van der Post, JAM | 1 |
| Naaktgeboren, C | 1 |
| Mol, BWJ | 1 |
| Oudijk, MA | 1 |
| Ramotowski, B | 1 |
| Żuk, A | 1 |
| Budaj, A | 3 |
| Albers, GW | 4 |
| Denison, H | 2 |
| Evans, SR | 2 |
| Held, P | 2 |
| Hill, MD | 2 |
| Jonasson, J | 1 |
| Ladenvall, P | 2 |
| Minematsu, K | 5 |
| Molina, CA | 3 |
| Yelnik, CM | 1 |
| Urbanski, G | 1 |
| Drumez, E | 1 |
| Caron, C | 1 |
| Maillard, H | 1 |
| Morell-Dubois, S | 1 |
| Dubucquoi, S | 1 |
| Launay, D | 1 |
| Hachulla, E | 4 |
| Hatron, PY | 2 |
| Duhamel, A | 1 |
| Lambert, M | 1 |
| Galyfos, G | 1 |
| Kerasidis, S | 1 |
| Kastrisios, G | 1 |
| Giannakakis, S | 1 |
| Sachmpazidis, I | 1 |
| Anastasiadou, C | 1 |
| Geropapas, G | 1 |
| Papapetrou, A | 1 |
| Papacharalampous, G | 1 |
| Maltezos, C | 1 |
| Milionis, H | 1 |
| Papavasileiou, V | 1 |
| Spengos, K | 2 |
| Manios, E | 2 |
| Elisaf, M | 1 |
| Vemmos, K | 2 |
| Zhang, J | 3 |
| Ming, T | 1 |
| Cong, Y | 1 |
| Li, F | 1 |
| Taki, M | 1 |
| Oshima, T | 1 |
| Tozawa, K | 1 |
| Taniguchi, Y | 1 |
| Tomita, T | 1 |
| Ohda, Y | 1 |
| Fukui, H | 1 |
| Watari, J | 1 |
| Miwa, H | 1 |
| Ielasi, A | 1 |
| Campo, G | 1 |
| Rapetto, C | 1 |
| Varricchio, A | 1 |
| Cortese, B | 1 |
| Brugaletta, S | 1 |
| Geraci, S | 1 |
| Vicinelli, P | 1 |
| Scotto di Uccio, F | 1 |
| Secco, GG | 1 |
| Poli, A | 1 |
| Nicolini, E | 1 |
| Ishida, K | 1 |
| Latib, A | 1 |
| Tespili, M | 1 |
| Ahn, S | 1 |
| Min, SK | 1 |
| Ha, J | 1 |
| Min, SI | 1 |
| Kim, SY | 1 |
| Cho, MJ | 1 |
| Cho, S | 1 |
| Gaita, F | 4 |
| Subahi, A | 1 |
| Hassan, AAI | 1 |
| Abubakar, H | 1 |
| Ibrahim, W | 1 |
| Oza, R | 1 |
| Rundell, K | 1 |
| Garcellano, M | 1 |
| Ahmadi, M | 1 |
| Abdolmohammadi-Vahid, S | 1 |
| Ghaebi, M | 1 |
| Aghebati-Maleki, L | 1 |
| Dolati, S | 1 |
| Farzadi, L | 1 |
| Ghasemzadeh, A | 1 |
| Hamdi, K | 1 |
| Younesi, V | 1 |
| Nouri, M | 1 |
| Yousefi, M | 1 |
| Kim, JB | 1 |
| Choi, BG | 1 |
| Rha, SW | 1 |
| Seo, HS | 1 |
| Choi, SY | 1 |
| Byun, JK | 1 |
| Na, JO | 1 |
| Choi, CU | 1 |
| Kim, EJ | 1 |
| Park, CG | 1 |
| Oh, DJ | 1 |
| Kawai, T | 1 |
| Oda, K | 1 |
| Funao, N | 1 |
| Nishimura, A | 1 |
| Matsumoto, Y | 1 |
| Mizokami, Y | 1 |
| Ashida, K | 1 |
| Sugano, K | 1 |
| Mager, A | 1 |
| Talmor, Y | 1 |
| Chezar Azzerad, C | 1 |
| Iakobishvili, Z | 1 |
| Porter, A | 1 |
| Kornowski, R | 4 |
| Hasdai, D | 2 |
| Aoki, T | 2 |
| Yamada, A | 1 |
| Hirata, Y | 1 |
| Suzuki, H | 2 |
| Nakada, A | 1 |
| Niikura, R | 2 |
| Seto, M | 1 |
| Okamoto, M | 1 |
| Koike, K | 1 |
| Robertson, L | 1 |
| Yeoh, SE | 1 |
| Ramli, A | 1 |
| Woodhouse, LJ | 1 |
| Appleton, JP | 1 |
| Beridze, M | 1 |
| Christensen, H | 1 |
| Dineen, RA | 1 |
| Duley, L | 1 |
| England, TJ | 1 |
| Flaherty, K | 1 |
| Havard, D | 1 |
| Heptinstall, S | 1 |
| James, M | 1 |
| Krishnan, K | 1 |
| Markus, HS | 3 |
| Montgomery, AA | 1 |
| Pocock, SJ | 2 |
| Randall, M | 1 |
| Ranta, A | 1 |
| Robinson, TG | 1 |
| Scutt, P | 1 |
| Venables, GS | 2 |
| Sprigg, N | 1 |
| Antigüedad-Muñoz, J | 1 |
| de la Riva, P | 1 |
| Arenaza Choperena, G | 1 |
| Muñoz Lopetegi, A | 1 |
| Andrés Marín, N | 1 |
| Fernández-Eulate, G | 1 |
| Moreno Valladares, M | 1 |
| Martínez Zabaleta, M | 1 |
| Liu, SM | 1 |
| Zhao, WL | 1 |
| Song, HQ | 1 |
| Li, SJ | 1 |
| Ren, CH | 1 |
| Ji, XM | 1 |
| Feng, WW | 1 |
| Bauersachs, R | 3 |
| Lakha, S | 1 |
| Png, CYM | 1 |
| Chun, K | 1 |
| Ting, W | 1 |
| Tanaskovic, S | 1 |
| Radak, D | 1 |
| Aleksic, N | 1 |
| Calija, B | 1 |
| Maravic-Stojkovic, V | 1 |
| Nenezic, D | 1 |
| Ilijevski, N | 1 |
| Popov, P | 1 |
| Vucurevic, G | 1 |
| Babic, S | 1 |
| Matic, P | 1 |
| Gajin, P | 1 |
| Vasic, D | 1 |
| Rancic, Z | 1 |
| Wangqin, R | 1 |
| Grimaldi-Bensouda, L | 1 |
| Danchin, N | 4 |
| Dallongeville, J | 1 |
| Falissard, B | 1 |
| Furber, A | 1 |
| Cottin, Y | 1 |
| Bonello, L | 2 |
| Morel, O | 1 |
| Leclercq, F | 1 |
| Puymirat, E | 1 |
| Ghanem, F | 1 |
| Delarche, N | 1 |
| Benichou, J | 1 |
| Abenhaim, L | 1 |
| Moll, F | 1 |
| Baumgartner, I | 2 |
| Jaff, M | 1 |
| Nwachuku, C | 1 |
| Tangelder, M | 1 |
| Ansel, G | 1 |
| Adams, G | 1 |
| Zeller, T | 3 |
| Rundback, J | 1 |
| Grosso, M | 1 |
| Lin, M | 1 |
| Mercur, MF | 1 |
| Minar, E | 5 |
| Prins, MH | 1 |
| Lensing, AWA | 1 |
| Prandoni, P | 4 |
| Wells, PS | 3 |
| Beyer-Westendorf, J | 2 |
| Bounameaux, H | 4 |
| Brighton, TA | 3 |
| Cohen, AT | 2 |
| Davidson, BL | 2 |
| Decousus, H | 1 |
| Kakkar, AK | 1 |
| van Bellen, B | 2 |
| Pap, AF | 1 |
| Homering, M | 1 |
| Tamm, M | 1 |
| Brucato, A | 3 |
| Cantarini, L | 1 |
| Di Lenarda, A | 1 |
| Gattorno, M | 1 |
| Lopalco, G | 1 |
| Marcolongo, R | 2 |
| Martini, A | 1 |
| Prisco, D | 1 |
| Belcaro, G | 3 |
| Dugall, M | 3 |
| Hu, S | 3 |
| Feragalli, B | 3 |
| Cotellese, R | 2 |
| Ledda, A | 2 |
| Corsi, M | 2 |
| Ricci, A | 2 |
| Ippolito, E | 2 |
| Errichi, BM | 1 |
| Cornelli, U | 2 |
| Cesarone, MR | 2 |
| Hosoi, M | 3 |
| Kalantzi, KI | 1 |
| Ntalas, IV | 1 |
| Chantzichristos, VG | 1 |
| Tsoumani, ME | 1 |
| Adamopoulos, D | 1 |
| Asimakopoulos, C | 1 |
| Bourdakis, A | 1 |
| Darmanis, P | 1 |
| Dimitriadou, A | 1 |
| Gkiokas, S | 1 |
| Ipeirotis, K | 1 |
| Kitikidou, K | 1 |
| Klonaris, I | 1 |
| Kostaki, A | 1 |
| Logothetis, D | 1 |
| Mainas, K | 1 |
| Mais, T | 1 |
| Maragiannis, A | 1 |
| Martiadou, K | 1 |
| Mavronasos, K | 1 |
| Michelongonas, I | 1 |
| Mitropoulos, D | 1 |
| Papadimitriou, G | 1 |
| Papadopoulos, A | 1 |
| Papaioakeim, M | 1 |
| Sofillas, K | 1 |
| Stabola, S | 1 |
| Stefanakis, E | 1 |
| Stergiou, D | 1 |
| Thoma, M | 1 |
| Zenetos, A | 1 |
| Zisekas, S | 1 |
| Goudevenos, JA | 1 |
| Panagiotakos, DB | 1 |
| Tselepis, AD | 1 |
| Lee, Y | 1 |
| Park, HC | 1 |
| Shin, J | 1 |
| De Stefano, V | 1 |
| Finazzi, G | 3 |
| Barbui, T | 2 |
| Dimitroulis, D | 1 |
| Golabkesh, M | 1 |
| Naguib, D | 1 |
| Knoop, B | 1 |
| Dannenberg, L | 1 |
| Helten, C | 1 |
| Pöhl, M | 1 |
| Jung, C | 1 |
| Kelm, M | 2 |
| Zeus, T | 1 |
| Polzin, A | 1 |
| Khan, SU | 1 |
| Talluri, S | 1 |
| Rahman, H | 1 |
| Lekkala, M | 1 |
| Khan, MS | 1 |
| Riaz, H | 1 |
| Shah, H | 3 |
| Kaluski, E | 1 |
| Sattur, S | 1 |
| Chen, G | 1 |
| Ma, C | 1 |
| Li, X | 1 |
| Wang, Q | 1 |
| Xu, Q | 1 |
| Lv, Q | 1 |
| Can, A | 1 |
| Rudy, RF | 1 |
| Castro, VM | 1 |
| Dligach, D | 1 |
| Finan, S | 1 |
| Gainer, V | 1 |
| Shadick, NA | 1 |
| Savova, G | 1 |
| Murphy, S | 1 |
| Cai, T | 1 |
| Weiss, ST | 1 |
| Du, R | 1 |
| Grazzi, L | 1 |
| Grignani, E | 1 |
| D'Amico, D | 1 |
| Sansone, E | 1 |
| Raggi, A | 1 |
| Palareti, G | 1 |
| Poli, D | 1 |
| Malinova, LI | 1 |
| Furman, NV | 1 |
| Dolotovskaya, PV | 1 |
| Chernousova, LA | 1 |
| Denisova, TP | 1 |
| Chi, NF | 1 |
| Wen, CP | 1 |
| Liu, CH | 1 |
| Li, JY | 1 |
| Chen, CH | 1 |
| Lin, CH | 1 |
| Hu, CJ | 1 |
| Murphy, SJX | 1 |
| Naylor, AR | 2 |
| Ricco, JB | 1 |
| Sillesen, H | 1 |
| Kakkos, S | 1 |
| Halliday, A | 1 |
| de Borst, GJ | 1 |
| Vega de Ceniga, M | 1 |
| Hamilton, G | 1 |
| McCabe, DJH | 1 |
| Kheiri, B | 1 |
| Osman, M | 1 |
| Abdalla, A | 1 |
| Haykal, T | 1 |
| Swaid, B | 1 |
| Ahmed, S | 1 |
| Chahine, A | 1 |
| Hassan, M | 1 |
| Bachuwa, G | 1 |
| Al Qasmi, M | 1 |
| Zomer, E | 1 |
| Si, S | 1 |
| Hird, TR | 1 |
| Liew, D | 1 |
| Owen, AJ | 1 |
| Tonkin, A | 1 |
| Reid, CM | 1 |
| Ademi, Z | 1 |
| Wojcieszek, AM | 1 |
| Shepherd, E | 1 |
| Middleton, P | 1 |
| Lassi, ZS | 1 |
| Wilson, T | 1 |
| Murphy, MM | 1 |
| Heazell, AE | 1 |
| Ellwood, DA | 1 |
| Flenady, V | 1 |
| Hao, Q | 2 |
| Tampi, M | 1 |
| O'Donnell, M | 2 |
| Foroutan, F | 1 |
| Siemieniuk, RA | 1 |
| Guyatt, G | 2 |
| Prasad, K | 1 |
| Siemieniuk, R | 1 |
| Lytvyn, L | 1 |
| Heen, AF | 1 |
| Agoritsas, T | 1 |
| Vandvik, PO | 1 |
| Gorthi, SP | 1 |
| Fisch, L | 1 |
| Jusufovic, M | 1 |
| Muller, J | 1 |
| Booth, B | 1 |
| Horton, E | 1 |
| Fraiz, A | 1 |
| Siemieniuk, J | 1 |
| Fobuzi, AC | 1 |
| Katragunta, N | 1 |
| Rochwerg, B | 1 |
| Salido, L | 1 |
| DeFelipe, A | 1 |
| Hernández-Antolín, R | 1 |
| Fernández-Golfín, C | 1 |
| Matute, C | 1 |
| Vera, R | 1 |
| Pérez-Torre, P | 1 |
| Zamorano, JL | 1 |
| Berchie, PO | 1 |
| Sarfo, FS | 1 |
| Opare-Sem, OK | 1 |
| Kamenova, M | 3 |
| Mueller, C | 1 |
| Coslovsky, M | 1 |
| Guzman, R | 1 |
| Mariani, L | 3 |
| Soleman, J | 3 |
| Coppens, M | 1 |
| Eikelboom, JWA | 1 |
| Chen, W | 2 |
| Simon, T | 1 |
| Wutzler, A | 1 |
| Krogias, C | 1 |
| Grau, A | 1 |
| Heuschmann, PU | 1 |
| Haeusler, KG | 2 |
| Pluymaekers, N | 1 |
| Tombetti, E | 1 |
| Rampello, S | 1 |
| Maestroni, S | 1 |
| Lucianetti, M | 1 |
| Valenti, A | 1 |
| Adler, Y | 2 |
| Knutsson, M | 1 |
| Röther, J | 1 |
| Melis, M | 1 |
| Levi, C | 1 |
| King, A | 1 |
| Madigan, J | 1 |
| Norris, J | 1 |
| Chan, NC | 1 |
| Fioravanti, F | 1 |
| Bongiovanni, F | 1 |
| Raposeiras-Roubin, S | 1 |
| Abu-Assi, E | 1 |
| Kinnaird, T | 1 |
| Ariza-Solé, A | 1 |
| Manzano-Fernández, S | 1 |
| Velicki, L | 1 |
| Xanthopoulou, I | 1 |
| Cerrato, E | 1 |
| Rognoni, A | 1 |
| Boccuzzi, G | 1 |
| Omedè, P | 1 |
| Montabone, A | 1 |
| Taha, S | 1 |
| Durante, A | 1 |
| Autelli, M | 1 |
| Grosso, A | 1 |
| Blanco, PF | 1 |
| Garay, A | 1 |
| Quadri, G | 1 |
| Varbella, F | 1 |
| Queija, BC | 1 |
| Paz, RC | 1 |
| Fernández, MC | 1 |
| Pousa, IM | 1 |
| Gallo, D | 1 |
| Morbiducci, U | 1 |
| Dominguez-Rodriguez, A | 1 |
| Valdés, M | 1 |
| Cequier, A | 1 |
| Alexopoulos, D | 1 |
| Iñiguez-Romo, A | 1 |
| Lüscher, TF | 1 |
| Ma, Y | 1 |
| Liu, Y | 3 |
| Du, F | 1 |
| Healey, JS | 1 |
| Gladstone, DJ | 1 |
| Swaminathan, B | 1 |
| Eckstein, J | 1 |
| Epstein, AE | 1 |
| Pagola, J | 1 |
| Yang, X | 3 |
| Endres, M | 1 |
| Karlinski, M | 1 |
| Czlonkowska, A | 3 |
| Santo, G | 1 |
| Bradford, HD | 1 |
| Gizzi, C | 2 |
| Rodriguez, P | 2 |
| Xie, X | 1 |
| Laskowitz, DT | 2 |
| Miao, Z | 1 |
| Kong, T | 1 |
| Chen, J | 2 |
| Sun, K | 1 |
| Zhang, W | 2 |
| Song, L | 1 |
| Hui, R | 1 |
| Kreuzer, J | 1 |
| Cotton, D | 3 |
| Chernyatina, M | 1 |
| Ferro, JM | 1 |
| Grond, M | 1 |
| Kallmünzer, B | 1 |
| Krupinski, J | 2 |
| Lemmens, R | 1 |
| Odinak, M | 1 |
| Schellinger, PD | 1 |
| Sato, K | 1 |
| Sasaki, R | 1 |
| Ohta, Y | 1 |
| Takemoto, M | 1 |
| Hishikawa, N | 1 |
| Yamashita, T | 1 |
| Veltkamp, RC | 1 |
| Sheridan, P | 1 |
| Bangdiwala, SI | 1 |
| Gagliardi, RJ | 1 |
| Peters, G | 1 |
| Imberti, D | 1 |
| Pomero, F | 1 |
| Mastroiacovo, D | 1 |
| Im, KA | 1 |
| Oude Ophuis, T | 1 |
| Hamm, C | 2 |
| Spinar, J | 1 |
| Kiss, RG | 1 |
| Lopez-Sendon, J | 1 |
| Ardissino, D | 1 |
| Kontny, F | 1 |
| Montalescot, G | 2 |
| Bengtsson, O | 1 |
| Himmelmann, A | 1 |
| Braunwald, E | 4 |
| Wester, A | 1 |
| Attar, R | 1 |
| Mohammad, MA | 1 |
| Andell, P | 1 |
| Hofmann, R | 1 |
| Jensen, J | 1 |
| Szummer, K | 1 |
| Erlinge, D | 1 |
| Koul, S | 1 |
| Ringelstein, A | 1 |
| Schlamann, M | 1 |
| Goericke, SL | 1 |
| Mönninghoff, C | 1 |
| Sandalcioglu, IE | 1 |
| El Hindy, N | 1 |
| Forsting, M | 2 |
| Wanke, I | 1 |
| Fruth, K | 1 |
| Pogorzelski, B | 1 |
| Schmidtmann, I | 1 |
| Springer, J | 1 |
| Fennan, N | 1 |
| Fraessdorf, N | 1 |
| Boessert, A | 1 |
| Schaefer, D | 1 |
| Gosepath, J | 2 |
| Mann, WJ | 2 |
| Duytschaever, M | 1 |
| Berte, B | 1 |
| Acena, M | 1 |
| De Meyer, G | 1 |
| Bun, SS | 1 |
| Van Heuverswyn, F | 1 |
| Vandekerckhove, Y | 1 |
| Tavernier, R | 1 |
| Lilly, LS | 1 |
| Kim, SJ | 1 |
| Bang, OY | 1 |
| Iida, O | 1 |
| Yokoi, H | 1 |
| Soga, Y | 1 |
| Inoue, N | 1 |
| Suzuki, K | 3 |
| Yokoi, Y | 1 |
| Kawasaki, D | 1 |
| Zen, K | 2 |
| Urasawa, K | 1 |
| Shintani, Y | 1 |
| Miyamoto, A | 1 |
| Hirano, K | 1 |
| Miyashita, Y | 2 |
| Tsuchiya, T | 1 |
| Shinozaki, N | 1 |
| Nakamura, M | 1 |
| Isshiki, T | 2 |
| Hamasaki, T | 1 |
| Nanto, S | 1 |
| Mainali, NR | 1 |
| Aryal, MR | 1 |
| Pradhan, R | 1 |
| Hope, EJ | 1 |
| Pullicino, PM | 2 |
| Thompson, JL | 3 |
| Sanford, AR | 1 |
| Qian, M | 2 |
| Teerlink, JR | 2 |
| Haddad, H | 1 |
| Diek, M | 1 |
| Freudenberger, RS | 1 |
| Labovitz, AJ | 2 |
| Di Tullio, MR | 4 |
| Lok, DJ | 2 |
| Ponikowski, P | 2 |
| Anker, SD | 2 |
| Graham, S | 2 |
| Mann, DL | 1 |
| Mohr, JP | 6 |
| Homma, S | 5 |
| Castellucci, LA | 1 |
| Cameron, C | 1 |
| Le Gal, G | 1 |
| Rodger, MA | 1 |
| Coyle, D | 1 |
| Clifford, T | 1 |
| Gandara, E | 1 |
| Wells, G | 1 |
| Carrier, M | 1 |
| Pourrat, O | 1 |
| Neau, JP | 1 |
| Pouget-Abadie, JF | 1 |
| Pierre, F | 1 |
| Strobl, FF | 1 |
| Brechtel, K | 1 |
| Schmehl, J | 1 |
| Reiser, MF | 1 |
| Claussen, CD | 1 |
| Tepe, G | 1 |
| Varenhorst, C | 1 |
| Jensevik, K | 1 |
| Jernberg, T | 1 |
| Sundström, A | 1 |
| Hasvold, P | 1 |
| Held, C | 1 |
| Lagerqvist, B | 1 |
| James, S | 1 |
| Castilla-Guerra, L | 1 |
| Navas-Alcántara, MS | 1 |
| Fernández-Moreno, MC | 1 |
| Nosul, M | 1 |
| Kolb, GF | 1 |
| Pergolini, A | 1 |
| Pino, PG | 1 |
| Zampi, G | 1 |
| Polizzi, V | 1 |
| Musumeci, F | 1 |
| Butterfield, JH | 1 |
| Weiler, CR | 1 |
| Arruti, M | 1 |
| Aldazabal, M | 1 |
| Blanco, A | 1 |
| Piñeiro, L | 1 |
| Zapico, MS | 1 |
| González, F | 1 |
| López de Munain, A | 1 |
| Diez-Ewald, M | 1 |
| Rotondano, G | 1 |
| Cipolletta, L | 1 |
| Koch, M | 2 |
| Bianco, MA | 1 |
| Grossi, E | 1 |
| Marmo, R | 1 |
| Pumar, JM | 1 |
| Banguero, A | 1 |
| Arias-Rivas, S | 1 |
| Blanco, M | 2 |
| Rodríguez-Yáñez, M | 1 |
| Sucasas, P | 1 |
| Castiñeira-Mourenza, JA | 1 |
| Vázquez-Herrero, F | 1 |
| Tai, WA | 1 |
| Alvarez-Sabín, J | 1 |
| Quintana, M | 1 |
| Santamarina, E | 1 |
| Maisterra, O | 1 |
| Garay-Sánchez, P | 1 |
| Limiñana, JM | 1 |
| Saavedra, P | 1 |
| Elkind, MS | 1 |
| Luna, JM | 1 |
| Zhang, Y | 2 |
| Coffey, CS | 2 |
| Roldan, A | 1 |
| Del Brutto, OH | 1 |
| Pretell, EJ | 1 |
| Pettigrew, LC | 1 |
| Meyer, BC | 1 |
| Tapia, J | 2 |
| White, C | 1 |
| Palmer, WC | 1 |
| Kurklinsky, A | 1 |
| Lane, G | 1 |
| Ussavarungsi, K | 1 |
| Blackshear, JL | 1 |
| Abu Daya, H | 1 |
| Eloubeidi, M | 1 |
| Tamim, H | 1 |
| Halawi, H | 1 |
| Malli, AH | 1 |
| Rockey, DC | 1 |
| Barada, K | 1 |
| Chen, CY | 1 |
| Lee, KT | 1 |
| Lee, CT | 1 |
| Lai, WT | 1 |
| Huang, YB | 1 |
| Yi, X | 2 |
| Wang, C | 7 |
| Zhang, B | 1 |
| Chi, W | 1 |
| Vranckx, P | 1 |
| Leonardi, S | 2 |
| Tebaldi, M | 1 |
| Biscaglia, S | 1 |
| Parrinello, G | 1 |
| Rao, SV | 1 |
| Lai, YS | 1 |
| Yang, LT | 1 |
| Kao Yang, YH | 1 |
| Liu, PY | 1 |
| Censori, B | 1 |
| Nagata, N | 1 |
| Shimbo, T | 1 |
| Tanaka, S | 2 |
| Sekine, K | 1 |
| Kishida, Y | 1 |
| Watanabe, K | 1 |
| Sakurai, T | 1 |
| Yokoi, C | 1 |
| Akiyama, J | 1 |
| Yanase, M | 1 |
| Mizokami, M | 1 |
| Uemura, N | 1 |
| Blake, DM | 1 |
| Vazquez, A | 2 |
| Tomovic, S | 1 |
| Jyung, RW | 1 |
| Mekinian, A | 1 |
| Costedoat-Chalumeau, N | 1 |
| Masseau, A | 1 |
| Botta, A | 1 |
| Chudzinski, A | 1 |
| Theulin, A | 1 |
| Emmanuelli, V | 1 |
| De Carolis, S | 1 |
| Revaux, A | 1 |
| Nicaise, P | 1 |
| Cornelis, F | 1 |
| Subtil, D | 1 |
| Montestruc, F | 1 |
| Bucourt, M | 1 |
| Chollet-Martin, S | 1 |
| Carbillon, L | 1 |
| Fain, O | 1 |
| Davidai, G | 1 |
| Gorelick, P | 1 |
| Lipton, RB | 1 |
| Sacco, R | 1 |
| Boelman, C | 1 |
| Shroff, M | 1 |
| Yau, I | 1 |
| Bjornson, B | 1 |
| Richrdson, S | 1 |
| deVeber, G | 2 |
| MacGregor, D | 1 |
| Moharir, M | 1 |
| Askalan, R | 1 |
| Iwakiri, R | 1 |
| Higuchi, K | 2 |
| Kato, M | 1 |
| Fujishiro, M | 1 |
| Kinoshita, Y | 3 |
| Watanabe, T | 2 |
| Takeuchi, T | 2 |
| Yamauchi, M | 1 |
| Sanomura, M | 1 |
| Nakagawa, H | 1 |
| Sugisaki, N | 1 |
| Ogawa, H | 2 |
| Arakawa, T | 2 |
| Fujimoto, K | 2 |
| Poujol-Robert, A | 1 |
| Boëlle, PY | 1 |
| Conti, F | 1 |
| Durand, F | 1 |
| Duvoux, C | 1 |
| Wendum, D | 1 |
| Paradis, V | 1 |
| Mackiewicz, V | 1 |
| Chazouillères, O | 1 |
| Corpechot, C | 1 |
| Poupon, R | 1 |
| Simes, J | 1 |
| Becattini, C | 1 |
| Agnelli, G | 1 |
| Kirby, AC | 1 |
| Mister, R | 1 |
| Alabed, S | 1 |
| Cabello, JB | 1 |
| Irving, GJ | 1 |
| Qintar, M | 1 |
| Burls, A | 1 |
| Undas, A | 1 |
| Brummel-Ziedins, K | 1 |
| Mann, KG | 1 |
| Rubattu, S | 1 |
| De Giusti, M | 1 |
| Farcomeni, A | 1 |
| Abbolito, S | 1 |
| Comito, F | 1 |
| Cangianiello, S | 1 |
| Greco, ES | 1 |
| Dito, E | 1 |
| Pagliaro, B | 1 |
| Cotugno, M | 1 |
| Stanzione, R | 1 |
| Marchitti, S | 1 |
| Bianchi, F | 1 |
| Di Castro, S | 1 |
| Battistoni, A | 1 |
| Burocchi, S | 1 |
| Caprinozzi, M | 1 |
| Pierelli, G | 1 |
| Sciarretta, S | 1 |
| Volpe, M | 1 |
| Mutlu, I | 1 |
| Mutlu, MF | 1 |
| Biri, A | 1 |
| Bulut, B | 1 |
| Erdem, M | 1 |
| Erdem, A | 1 |
| Freudenberger, R | 1 |
| Mann, D | 1 |
| Lip, GY | 2 |
| Estol, CJ | 1 |
| Levin, B | 1 |
| Hong, MJ | 1 |
| Lee, SY | 1 |
| Kim, JH | 4 |
| Sung, IK | 1 |
| Park, HS | 1 |
| Shim, CS | 1 |
| Jin, CJ | 1 |
| Tissandier, C | 1 |
| Lang, M | 1 |
| Lusson, JR | 1 |
| Bœuf, B | 1 |
| Merlin, E | 1 |
| Dauphin, C | 1 |
| Rajani, AR | 1 |
| Mahmoud, WE | 1 |
| Murugesan, V | 1 |
| BinBrek, AS | 1 |
| Lee, HC | 1 |
| Lee, JD | 1 |
| Chang, KC | 1 |
| Wu, CY | 1 |
| Lee, TH | 1 |
| Wang, HH | 1 |
| Shim, KN | 1 |
| Song, EM | 1 |
| Jeen, YT | 1 |
| Kim, JO | 1 |
| Jeon, SR | 1 |
| Chang, DK | 1 |
| Song, HJ | 1 |
| Lim, YJ | 1 |
| Kim, JS | 2 |
| Ye, BD | 1 |
| Park, CH | 1 |
| Jeon, SW | 2 |
| Cheon, JH | 1 |
| Lee, KJ | 1 |
| Jang, BI | 1 |
| Moon, JS | 1 |
| Chun, HJ | 1 |
| Choi, MG | 1 |
| Hoshino, H | 1 |
| Origasa, H | 1 |
| Naritomi, H | 1 |
| Yamaguchi, T | 1 |
| Wu, C | 2 |
| Alotaibi, GS | 1 |
| Alsaleh, K | 1 |
| Linkins, LA | 1 |
| McMurtry, MS | 1 |
| Bazina, A | 1 |
| Mišmaš, A | 1 |
| Hucika, Z | 1 |
| Pavliša, G | 1 |
| Poljaković, Z | 1 |
| Zheng, YM | 1 |
| Xie, CH | 1 |
| Gong, FQ | 1 |
| Aldemir-Kocabaş, B | 1 |
| Kcal, MM | 1 |
| Ramoğlu, MG | 1 |
| Tutar, E | 1 |
| Fitöz, S | 1 |
| Çiftçi, E | 1 |
| İnce, E | 1 |
| Zheng, M | 1 |
| Li, Y | 2 |
| Zhang, L | 2 |
| Shang, X | 1 |
| Yan, C | 1 |
| Coons, JC | 1 |
| Rao, SK | 1 |
| Kwok, CS | 1 |
| Copley, HC | 1 |
| Myint, PK | 1 |
| Loke, YK | 1 |
| Boonyawat, K | 1 |
| Crowther, MA | 2 |
| Abdel-Rahman, I | 1 |
| Murphy, C | 1 |
| Shore, S | 1 |
| Jones, PG | 1 |
| Maddox, TM | 1 |
| Bradley, SM | 1 |
| Stolker, JM | 1 |
| Arnold, SV | 1 |
| Parashar, S | 1 |
| Peterson, P | 1 |
| Spertus, J | 1 |
| Ho, PM | 1 |
| Chen, T | 1 |
| Xu, G | 1 |
| Tan, D | 1 |
| Asinger, RW | 2 |
| Smyth, NG | 1 |
| De, SK | 1 |
| Lefaucheur, R | 1 |
| Bourre, B | 1 |
| Ozkul-Wermester, O | 1 |
| Maltête, D | 1 |
| Wallon, D | 1 |
| Telaku, S | 1 |
| Kraja, B | 1 |
| Qirjako, G | 1 |
| Prifti, S | 1 |
| Fejza, H | 1 |
| Valenzuela, A | 1 |
| Aizman, A | 1 |
| Luzzi, R | 1 |
| Holberg, G | 1 |
| Kakkar, A | 1 |
| Lensing, AW | 1 |
| Prins, M | 1 |
| Haskell, L | 1 |
| Wei, YQ | 1 |
| Wang, DG | 1 |
| Yang, H | 1 |
| Cao, H | 1 |
| Gary, T | 1 |
| Prüller, F | 1 |
| Raggam, R | 1 |
| Mahla, E | 1 |
| Eller, P | 1 |
| Hafner, F | 1 |
| Brodmann, M | 1 |
| Satoh, K | 1 |
| Tanabe, H | 1 |
| Ichiishi, E | 1 |
| Ando, K | 1 |
| Chung, WC | 1 |
| Jeon, EJ | 1 |
| Kim, DB | 1 |
| Sung, HJ | 1 |
| Kim, YJ | 1 |
| Lim, ES | 1 |
| Kim, MA | 1 |
| Oh, JH | 1 |
| Alnæs, MS | 1 |
| Mardal, KA | 1 |
| Bakke, S | 1 |
| Sorteberg, A | 1 |
| Shin, S | 1 |
| Kim, KJ | 1 |
| Cho, IJ | 1 |
| Hong, GR | 1 |
| Jang, Y | 2 |
| Chung, N | 1 |
| Rah, YM | 1 |
| Chang, HJ | 2 |
| Batchelder, A | 1 |
| Hunter, J | 1 |
| Cairns, V | 1 |
| Sandford, R | 1 |
| Munshi, A | 1 |
| Kim, SH | 1 |
| Jung, JT | 1 |
| Kwon, JG | 1 |
| Kim, EY | 1 |
| Lee, DW | 1 |
| Park, KS | 1 |
| Lee, SH | 4 |
| Park, JB | 1 |
| Ha, CY | 1 |
| Park, YS | 2 |
| Wong, KS | 3 |
| Leng, X | 1 |
| Soo, Y | 1 |
| Li-Sha, G | 1 |
| Peng, C | 1 |
| Yue-Chun, L | 1 |
| Vergallo, R | 1 |
| Aguirre, AD | 1 |
| Abtahian, F | 1 |
| Minami, Y | 1 |
| Soeda, T | 1 |
| Chatzizisis, YS | 1 |
| Croce, K | 1 |
| Jang, IK | 2 |
| Mayumi, N | 1 |
| Inaba, M | 1 |
| Igarashi, T | 1 |
| Katagiri, I | 1 |
| Kawana, S | 1 |
| Bai, Y | 1 |
| Han, J | 1 |
| Zhang, G | 1 |
| Zhao, G | 1 |
| Kim, YS | 1 |
| Lee, SR | 1 |
| Lanas, Á | 2 |
| Christiansen, CB | 1 |
| Pallisgaard, J | 1 |
| Gerds, TA | 1 |
| Olesen, JB | 2 |
| Jørgensen, ME | 1 |
| Numé, AK | 1 |
| Carlson, N | 1 |
| Kristensen, SL | 1 |
| Gislason, G | 1 |
| Torp-Pedersen, C | 3 |
| Odden, MC | 1 |
| Sawaya, BP | 1 |
| White, CL | 1 |
| Peralta, CA | 1 |
| Pergola, PE | 1 |
| Marik, PE | 1 |
| Cavallazzi, R | 1 |
| Yu, LH | 1 |
| Wang, DX | 1 |
| Li, YH | 1 |
| Lu, QA | 1 |
| Zong, SJ | 1 |
| Wang, XC | 1 |
| Lee, JY | 1 |
| Moon, IT | 1 |
| Lee, HY | 1 |
| Han, DS | 1 |
| Park, TK | 1 |
| Song, YB | 1 |
| Ahn, J | 1 |
| Carriere, KC | 1 |
| Hahn, JY | 1 |
| Yang, JH | 1 |
| Choi, SH | 1 |
| Choi, JH | 1 |
| Gwon, HC | 1 |
| Shahidi, S | 1 |
| Owen-Falkenberg, A | 1 |
| Gottschalksen, B | 1 |
| Ellemann, K | 1 |
| van Hoorn, ME | 1 |
| Hague, WM | 1 |
| van Pampus, MG | 1 |
| Bezemer, D | 1 |
| de Vries, JI | 2 |
| Radovanovic, D | 1 |
| Maurer, L | 1 |
| Bertel, O | 1 |
| Witassek, F | 1 |
| Urban, P | 2 |
| Stauffer, JC | 1 |
| Pedrazzini, G | 1 |
| Erne, P | 1 |
| Murphy, SJ | 1 |
| Coughlan, CA | 1 |
| Tobin, O | 1 |
| Kinsella, J | 1 |
| Lonergan, R | 1 |
| Gutkin, M | 1 |
| McCabe, DJ | 1 |
| Yang, C | 2 |
| Qian, J | 1 |
| Tang, X | 2 |
| Gao, P | 2 |
| Hu, Y | 2 |
| Parker, WA | 1 |
| Beato, J | 1 |
| Fígueira, L | 1 |
| Penas, S | 1 |
| Santos-Silva, R | 1 |
| Falcão, M | 1 |
| Carneiro, Â | 1 |
| Reis, FF | 1 |
| Wilson, LK | 1 |
| Dake, MD | 1 |
| Ansel, GM | 1 |
| Jaff, MR | 1 |
| Ohki, T | 1 |
| Saxon, RR | 1 |
| Smouse, HB | 1 |
| Machan, LS | 1 |
| Snyder, SA | 1 |
| O'Leary, EE | 1 |
| Ragheb, AO | 1 |
| Ge, F | 1 |
| Lin, H | 1 |
| Li, M | 1 |
| Guo, R | 1 |
| Ruan, Z | 1 |
| Chang, T | 1 |
| Ayub, A | 1 |
| Parkash, O | 1 |
| Naeem, B | 1 |
| Murtaza, D | 1 |
| Khan, AH | 1 |
| Jafri, W | 1 |
| Hamid, S | 1 |
| Bernlochner, I | 1 |
| Jaitner, J | 1 |
| Fries, V | 1 |
| Dommasch, M | 1 |
| Mayer, K | 1 |
| Ott, I | 1 |
| Langwieser, N | 1 |
| Fusaro, M | 1 |
| Laugwitz, KL | 1 |
| Kastrati, A | 3 |
| Ibrahim, T | 1 |
| Weller, CD | 1 |
| Barker, A | 1 |
| Darby, I | 1 |
| Haines, T | 1 |
| Underwood, M | 1 |
| Ward, S | 1 |
| Aldons, P | 1 |
| Dapiran, E | 1 |
| Madan, JJ | 1 |
| Loveland, P | 1 |
| Sinha, S | 1 |
| Vicaretti, M | 1 |
| Wolfe, R | 1 |
| Woodward, M | 1 |
| McNeil, J | 1 |
| Nagatsuka, K | 1 |
| Miyata, S | 1 |
| Kada, A | 1 |
| Kawamura, A | 1 |
| Nakagawara, J | 1 |
| Furui, E | 1 |
| Takiuchi, S | 1 |
| Taomoto, K | 1 |
| Kario, K | 1 |
| Saito, K | 2 |
| Nagao, T | 1 |
| Kitagawa, K | 1 |
| Hosomi, N | 1 |
| Tanaka, K | 2 |
| Kaikita, K | 1 |
| Katayama, Y | 1 |
| Abumiya, T | 1 |
| Nakane, H | 1 |
| Wada, H | 2 |
| Hattori, A | 2 |
| Nishikawa, M | 1 |
| Yamawaki, T | 1 |
| Yonemoto, N | 1 |
| Okada, H | 1 |
| Miyata, T | 1 |
| Birkeland, P | 1 |
| Lauritsen, J | 1 |
| Poulsen, FR | 1 |
| Charron, P | 1 |
| Holzgreve, H | 1 |
| Chan, FK | 3 |
| Leung Ki, EL | 1 |
| Wong, GL | 1 |
| Ching, JY | 3 |
| Au, KW | 1 |
| Wu, JC | 3 |
| Zhang, F | 1 |
| Rothwell, PM | 3 |
| Norrving, B | 2 |
| Mehta, Z | 1 |
| Kamal, S | 1 |
| Khan, MA | 1 |
| Altorok, N | 1 |
| Gallego-Fabrega, C | 1 |
| Carrera, C | 1 |
| Reny, JL | 3 |
| Fontana, P | 3 |
| Slowik, A | 1 |
| Pera, J | 1 |
| Pezzini, A | 1 |
| Serrano-Heras, G | 1 |
| Bin Dukhyil, AA | 1 |
| Muiño, E | 1 |
| Cullell, N | 1 |
| Montaner, J | 1 |
| Fernandez-Cadenas, I | 1 |
| Zhang, YQ | 1 |
| Wei, CL | 1 |
| Hu, YH | 1 |
| Kraszewska-Głomba, B | 1 |
| Kuchar, E | 1 |
| Szenborn, L | 1 |
| Savino, K | 1 |
| Maiello, M | 1 |
| Pelliccia, F | 1 |
| Ambrosio, G | 1 |
| Palmiero, P | 1 |
| Deng, QQ | 1 |
| Tang, J | 1 |
| Chen, C | 3 |
| Markus, H | 1 |
| Huang, YN | 1 |
| Zhao, H | 1 |
| Ratanakorn, D | 1 |
| Fu, JH | 1 |
| Packard, KA | 1 |
| Hilleman, DE | 1 |
| Lutz, K | 2 |
| Schaedelin, S | 1 |
| Fandino, J | 2 |
| Godley, RW | 1 |
| Hernandez-Vila, E | 1 |
| Liang, CM | 1 |
| Hsu, CN | 1 |
| Yang, SC | 1 |
| Wu, CK | 1 |
| Shih, CW | 1 |
| Ku, MK | 1 |
| Yuan, LT | 1 |
| Wang, JW | 1 |
| Tseng, KL | 1 |
| Sun, WC | 1 |
| Hung, TH | 1 |
| Nguang, SH | 1 |
| Hsu, PI | 1 |
| Wu, DC | 1 |
| He, Y | 1 |
| Kyaw, M | 1 |
| Tanigawa, T | 1 |
| Naito, Y | 1 |
| Lui, R | 1 |
| Tang, RS | 1 |
| Sakata, Y | 1 |
| Handa, O | 1 |
| Nebiki, H | 1 |
| Abe, T | 1 |
| Mishiro, T | 1 |
| Cosmi, B | 1 |
| Rosenberg, K | 1 |
| Ferri, LA | 1 |
| Morici, N | 1 |
| Grosseto, D | 1 |
| Tortorella, G | 1 |
| Bossi, I | 1 |
| Sganzerla, P | 1 |
| Cacucci, M | 1 |
| Sibilio, G | 1 |
| Tondi, S | 1 |
| Toso, A | 1 |
| Ferrario, M | 1 |
| Gandolfo, N | 1 |
| Ravera, A | 1 |
| Mariani, M | 1 |
| Corrada, E | 1 |
| Di Ascenzo, L | 1 |
| Petronio, AS | 2 |
| Cavallini, C | 1 |
| Moffa, N | 1 |
| De Servi, S | 1 |
| Savonitto, S | 1 |
| Kang, X | 1 |
| Wang, T | 1 |
| He, L | 1 |
| Xu, H | 1 |
| Liu, Z | 1 |
| Zhao, A | 1 |
| Bank, S | 1 |
| Maiti, S | 1 |
| Guha, S | 1 |
| Sinha, AK | 1 |
| Zhang, T | 1 |
| Jin, SS | 1 |
| Yang, RL | 1 |
| Wang, XD | 1 |
| Jiang, N | 1 |
| Gan, YH | 1 |
| Kou, XX | 1 |
| Zhou, YH | 1 |
| Hauguel-Moreau, M | 1 |
| Boccara, F | 2 |
| Boyd, A | 1 |
| Salem, JE | 1 |
| Brugier, D | 1 |
| Curjol, A | 1 |
| Hulot, JS | 1 |
| Kerneis, M | 1 |
| Galier, S | 1 |
| Cohen, A | 2 |
| Collet, JP | 1 |
| Silvain, J | 1 |
| Song, H | 1 |
| Hou, C | 1 |
| Cao, Q | 1 |
| Huang, X | 1 |
| Wang, M | 1 |
| Ji, X | 1 |
| Nevzati, E | 1 |
| Dolp, A | 1 |
| Battaglia, A | 1 |
| Gaido, L | 1 |
| Skeith, L | 1 |
| Rodger, M | 1 |
| Sheikh Rezaei, S | 1 |
| Geroldinger, A | 1 |
| Heinze, G | 1 |
| Reichardt, B | 1 |
| Wolzt, M | 1 |
| Li, XG | 1 |
| Ma, N | 1 |
| Sun, SS | 1 |
| Xu, Z | 1 |
| Wang, YJ | 1 |
| Miao, ZR | 1 |
| Zhao, ZG | 1 |
| Lin, Y | 1 |
| Ou, L | 1 |
| Crescente, M | 2 |
| Di Castelnuovo, A | 2 |
| Iacoviello, L | 2 |
| de Gaetano, G | 2 |
| Cerletti, C | 2 |
| Stern, S | 1 |
| Cohen, MJ | 1 |
| Gilon, D | 2 |
| Leshno, M | 1 |
| Brezis, M | 1 |
| Diener, C | 1 |
| Kauffman, AB | 1 |
| Delate, T | 1 |
| Olson, KL | 1 |
| Cymbala, AA | 1 |
| Hutka, KA | 1 |
| Kasten, SL | 1 |
| Rasmussen, JR | 1 |
| Ibrahim, K | 1 |
| Hass, N | 1 |
| Kolschmann, S | 1 |
| Strasser, RH | 1 |
| Barton, JR | 1 |
| Sibai, BM | 1 |
| Mateen, FJ | 1 |
| Mohr, DN | 1 |
| Hoover, PL | 1 |
| Mold, JW | 1 |
| Rozsasi, A | 1 |
| Polzehl, D | 1 |
| Deutschle, T | 1 |
| Smith, E | 1 |
| Wiesmiller, K | 1 |
| Riechelmann, H | 1 |
| Keck, T | 1 |
| Suri, MF | 1 |
| Hussein, HM | 1 |
| Abdelmoula, MM | 1 |
| Divani, AA | 1 |
| Qureshi, AI | 1 |
| Stammler, F | 1 |
| Grau, C | 1 |
| Eckstein, HH | 1 |
| Jackevicius, CA | 1 |
| Tu, JV | 1 |
| Demers, V | 1 |
| Melo, M | 1 |
| Cox, J | 1 |
| Rinfret, S | 1 |
| Kalavrouziotis, D | 1 |
| Johansen, H | 1 |
| Behlouli, H | 1 |
| Newman, A | 1 |
| Pilote, L | 1 |
| van der Worp, HB | 1 |
| Fonville, S | 1 |
| Ramos, LM | 1 |
| Rinkel, GJ | 1 |
| Bernstein, PL | 1 |
| Jacobson, BF | 1 |
| Connor, MD | 1 |
| Becker, PJ | 1 |
| Mehta, SR | 1 |
| Bassand, JP | 1 |
| Chrolavicius, S | 1 |
| Diaz, R | 1 |
| Jolly, S | 1 |
| Rupprecht, HJ | 2 |
| Suryadevara, S | 1 |
| Capranzano, P | 1 |
| Zenni, MZ | 1 |
| Guzman, LA | 1 |
| Bass, TA | 3 |
| Turan, TN | 1 |
| Maidan, L | 1 |
| Cotsonis, G | 1 |
| Lynn, MJ | 2 |
| Romano, JG | 1 |
| Levine, SR | 1 |
| Chimowitz, MI | 2 |
| Hanhart, J | 1 |
| Koskas, P | 1 |
| Obadia, M | 1 |
| Le Mer, Y | 1 |
| Sahel, JA | 1 |
| Paques, M | 1 |
| Cartwright, MS | 1 |
| White, DL | 1 |
| Miller, LM | 1 |
| Roach, ES | 1 |
| Bevilacqua, S | 1 |
| Alkodami, AA | 1 |
| Volpi, E | 1 |
| Cerillo, AG | 1 |
| Berti, S | 1 |
| Glauber, M | 1 |
| Gianetti, J | 2 |
| Sugiyama, N | 1 |
| Matsuda, S | 1 |
| Shimizu, M | 1 |
| Obara, S | 1 |
| Ikegami, M | 1 |
| Yokoyama, J | 1 |
| Takizawa, S | 1 |
| Takagi, S | 1 |
| De Labriolle, A | 1 |
| Lemesle, G | 2 |
| Steinberg, DH | 1 |
| Roy, P | 1 |
| Torguson, R | 1 |
| Suddath, WO | 1 |
| Satler, LF | 2 |
| Kent, KM | 5 |
| Pichard, AD | 2 |
| Waksman, R | 2 |
| van den Bergh, PJ | 1 |
| Kievit, PC | 2 |
| Brouwer, MA | 2 |
| Aengevaeren, WR | 1 |
| Veen, G | 3 |
| Verheugt, FW | 8 |
| Butera, G | 1 |
| Gaio, G | 1 |
| Carminati, M | 1 |
| Chung, HY | 1 |
| Trendell-Smith, NJ | 1 |
| Yeung, CK | 1 |
| Mok, MY | 1 |
| Georgiadis, D | 2 |
| Arnold, M | 3 |
| von Buedingen, HC | 1 |
| Valko, P | 1 |
| Sarikaya, H | 1 |
| Rousson, V | 1 |
| Mattle, HP | 3 |
| Bousser, MG | 2 |
| Baumgartner, RW | 3 |
| Laalou, FZ | 1 |
| Kuntzmann, H | 1 |
| Mahoudeau, G | 1 |
| Kremer, S | 1 |
| Pain, L | 1 |
| Aidietis, A | 1 |
| Barysiene, J | 1 |
| Marinskis, G | 1 |
| Aidietiene, S | 1 |
| Kaireviciūte, D | 1 |
| Jurkuvenas, P | 1 |
| Aganauskiene, J | 1 |
| Bagdonas, K | 1 |
| Jezovas, V | 1 |
| Laucevicius, A | 1 |
| Famakin, BM | 1 |
| Stern, BJ | 1 |
| George, MG | 1 |
| Rocher, F | 1 |
| Brunschwig, C | 1 |
| Lebrun, C | 1 |
| Bischoff, A | 1 |
| Chiu, PW | 2 |
| Ng, EK | 1 |
| Beales, IL | 1 |
| Yamasaki, H | 1 |
| Matsubara, S | 2 |
| Sasaki, I | 1 |
| Nagahiro, S | 1 |
| Balasubramanian, S | 1 |
| Ganesh, R | 1 |
| Szczeklik, A | 1 |
| Shetty, S | 1 |
| Ghosh, K | 1 |
| Mega, JL | 1 |
| Mohanavelu, S | 1 |
| Burton, P | 1 |
| Poulter, R | 1 |
| Misselwitz, F | 1 |
| Hricak, V | 1 |
| Barnathan, ES | 1 |
| Bordes, P | 1 |
| Witkowski, A | 2 |
| Markov, V | 1 |
| Oppenheimer, L | 1 |
| Gibson, CM | 1 |
| Bonvini, RF | 1 |
| Barazer, I | 1 |
| Berdagué, P | 1 |
| de Moerloose, P | 1 |
| Schved, JF | 1 |
| Gris, JC | 1 |
| Najafi, L | 1 |
| Noohi, AH | 1 |
| Renard, E | 1 |
| Chiquet, C | 1 |
| Bouillet, L | 1 |
| Romanet, JP | 1 |
| Po, HL | 2 |
| Lin, YJ | 1 |
| Hseuh, IH | 1 |
| Heestermans, AA | 1 |
| Van Werkum, JW | 1 |
| Dill, T | 1 |
| Gosselink, AT | 1 |
| De Boer, MJ | 2 |
| Van Houwelingen, G | 1 |
| Hoorntje, JC | 1 |
| Koopmans, PC | 1 |
| Van 't Hof, AW | 1 |
| Kurosawa, H | 1 |
| Okuya, M | 1 |
| Matsushita, T | 1 |
| Kubota, T | 1 |
| Endoh, K | 1 |
| Kuwashima, S | 1 |
| Hagisawa, S | 1 |
| Sato, Y | 1 |
| Fukushima, K | 1 |
| Sugita, K | 1 |
| Park, MJ | 1 |
| Hayashi, Y | 1 |
| Arisaka, O | 1 |
| Attigah, N | 1 |
| Külkens, S | 1 |
| Deyle, C | 1 |
| Ringleb, P | 1 |
| Hartmann, M | 1 |
| Geisbüsch, P | 1 |
| Böckler, D | 1 |
| Cheung, J | 1 |
| Rajala, J | 1 |
| Moroz, D | 1 |
| Zhu, Q | 1 |
| Stamm, M | 1 |
| Sandha, GS | 1 |
| Weber, R | 2 |
| Weimar, C | 1 |
| Lee, CW | 3 |
| Park, DW | 1 |
| Kim, YH | 1 |
| Hong, MK | 4 |
| Kim, JJ | 4 |
| Park, SW | 3 |
| Yun, SC | 1 |
| Seong, IW | 1 |
| Lee, JH | 1 |
| Lee, NH | 2 |
| Cho, YH | 1 |
| Cheong, SS | 1 |
| Lim, DS | 1 |
| Yang, JY | 1 |
| Lee, SG | 1 |
| Kim, KS | 1 |
| Yoon, J | 1 |
| Jeong, MH | 3 |
| Seung, KB | 1 |
| Hong, TJ | 1 |
| Park, SJ | 3 |
| Jung, H | 1 |
| Papi, C | 1 |
| Aratari, A | 1 |
| Moretti, A | 1 |
| Mangone, M | 1 |
| Margagnoni, G | 1 |
| Capurso, L | 1 |
| Barkun, AN | 2 |
| Bardou, M | 1 |
| Sung, JJ | 1 |
| Lau, JY | 1 |
| Lee, YT | 1 |
| Leung, VK | 1 |
| Wong, VW | 1 |
| Sharma, RK | 1 |
| Reddy, HK | 1 |
| Singh, VN | 2 |
| Voelker, DJ | 1 |
| Bhatt, G | 1 |
| Sørensen, R | 1 |
| Hansen, ML | 1 |
| Abildstrom, SZ | 1 |
| Hvelplund, A | 1 |
| Andersson, C | 1 |
| Jørgensen, C | 1 |
| Madsen, JK | 2 |
| Hansen, PR | 2 |
| Køber, L | 2 |
| Gislason, GH | 2 |
| Juhász, M | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Le May, MR | 1 |
| Wells, GA | 1 |
| Glover, CA | 1 |
| So, DY | 1 |
| Froeschl, M | 1 |
| Marquis, JF | 1 |
| O'Brien, ER | 1 |
| Turek, M | 1 |
| Thomas, A | 1 |
| Kass, M | 1 |
| Jadhav, S | 1 |
| Labinaz, M | 1 |
| Kim, SS | 1 |
| Kim, HK | 1 |
| Kim, MC | 1 |
| Lee, MG | 2 |
| Ko, JS | 2 |
| Park, KH | 2 |
| Sim, DS | 2 |
| Yoon, NS | 2 |
| Yoon, HJ | 2 |
| Park, HW | 2 |
| Hong, YJ | 2 |
| Ahn, YK | 1 |
| Cho, JG | 2 |
| Park, JC | 2 |
| Kang, JC | 2 |
| Cross, KP | 1 |
| Randell, KA | 1 |
| Herr, SM | 1 |
| Schwalm, JD | 1 |
| Ahmad, M | 1 |
| Salehian, O | 1 |
| Natarajan, MK | 1 |
| Sallustio, F | 1 |
| Di Legge, S | 1 |
| Rossi, C | 1 |
| Stanzione, P | 1 |
| Burke, JP | 1 |
| Sander, S | 1 |
| Zarotsky, V | 1 |
| Henk, H | 1 |
| Nannucci, S | 1 |
| Pescini, F | 1 |
| Valenti, R | 1 |
| Ciolli, L | 1 |
| Bianchi, S | 1 |
| Dotti, MT | 1 |
| Inzitari, D | 1 |
| Pantoni, L | 1 |
| Kralinger, MT | 1 |
| Stolba, U | 1 |
| Velikay, M | 1 |
| Egger, S | 1 |
| Binder, S | 1 |
| Wedrich, A | 1 |
| Haas, A | 1 |
| Parel, JM | 1 |
| Kieselbach, GF | 1 |
| Postuła, M | 1 |
| Tarchalska-Kryńska, B | 1 |
| Filipiak, KJ | 2 |
| Kosior, D | 1 |
| Serafin, A | 1 |
| Huczek, Z | 2 |
| Dato, I | 1 |
| Niccoli, G | 2 |
| Bacà, M | 1 |
| Pontecorvo, ML | 1 |
| Hiew, C | 1 |
| Williams, T | 1 |
| Hatton, R | 1 |
| Narasimhan, S | 1 |
| O'Connor, S | 1 |
| Baker, F | 1 |
| McElduff, P | 1 |
| Attia, J | 1 |
| Collins, N | 1 |
| Geraghty, OC | 1 |
| Paul, NL | 1 |
| Chandratheva, A | 1 |
| Taguchi, Y | 1 |
| Takashima, S | 1 |
| Nukui, T | 1 |
| Dougu, N | 1 |
| Toyoda, S | 1 |
| Doi, H | 1 |
| Tateishi, T | 1 |
| Isobe, N | 1 |
| Yamasaki, R | 1 |
| Ohyagi, Y | 1 |
| Kira, J | 1 |
| Forster, MT | 1 |
| Mathé, AK | 1 |
| Senft, C | 1 |
| Scharrer, I | 1 |
| Seifert, V | 1 |
| Gerlach, R | 1 |
| Jeon, SB | 1 |
| Song, HS | 1 |
| Kim, HJ | 1 |
| Alberts, MJ | 2 |
| Emery, J | 1 |
| Oliveira, DC | 1 |
| Silva, RF | 1 |
| Silva, DJ | 1 |
| Lima, VC | 1 |
| Baracchini, C | 1 |
| Tonello, S | 1 |
| Meneghetti, G | 1 |
| Ballotta, E | 1 |
| Kim, N | 1 |
| Lee, BH | 1 |
| Kang, JM | 1 |
| Seo, P | 1 |
| Lim, MK | 2 |
| Song, BJ | 1 |
| Lee, JW | 1 |
| Hwang, JH | 1 |
| Kim, JW | 1 |
| Jeong, SH | 1 |
| Lee, DH | 2 |
| Jung, HC | 1 |
| Song, IS | 1 |
| Gizewski, ER | 1 |
| Venerito, M | 1 |
| Kandulski, A | 1 |
| Malfertheiner, P | 1 |
| Kim, KH | 1 |
| Ahn, Y | 1 |
| Barison, A | 1 |
| de Carlo, M | 1 |
| Bellini, F | 1 |
| Capozza, PF | 1 |
| Lunardini, A | 1 |
| Lim, SH | 1 |
| Hong, BY | 1 |
| Cho, YR | 1 |
| Kim, HS | 4 |
| Lee, JI | 1 |
| Kim, HW | 1 |
| Ko, YJ | 1 |
| Farina, A | 1 |
| Spinazzola, A | 1 |
| Abbiati, G | 1 |
| Arpini, MT | 1 |
| Bergamaschi, L | 1 |
| Riva, A | 1 |
| Berticelli, P | 1 |
| Geri, G | 1 |
| Sandercock, PA | 2 |
| Niewada, M | 1 |
| Członkowska, A | 1 |
| Guthrie, R | 1 |
| Oldgren, J | 1 |
| Khder, Y | 1 |
| Roberts, J | 1 |
| Siegbahn, A | 2 |
| Tijssen, JG | 2 |
| Wallentin, L | 3 |
| Charlot, M | 1 |
| Ahlehoff, O | 1 |
| Selmer, C | 1 |
| Lindhardsen, J | 1 |
| Bresson, V | 1 |
| Bonello, B | 1 |
| Rousset-Rouvière, C | 1 |
| Serratrice, J | 2 |
| Chabrol, B | 1 |
| Dubus, JC | 1 |
| Bosdure, E | 1 |
| Tchan, M | 1 |
| Sillence, D | 1 |
| McEvoy, JW | 1 |
| Blaha, MJ | 1 |
| Nasir, K | 1 |
| Yoon, YE | 1 |
| Choi, EK | 1 |
| Cho, IS | 1 |
| Chun, EJ | 1 |
| Choi, SI | 1 |
| Rivera, JJ | 1 |
| Blumenthal, RS | 2 |
| Vidal-Jordana, A | 1 |
| Barroeta-Espar, I | 1 |
| Sáinz Pelayo, MP | 1 |
| Mateo, J | 1 |
| Delgado-Mederos, R | 1 |
| Pujol Lereis, VA | 1 |
| Ameriso, S | 1 |
| Anamnart, C | 1 |
| Poungvarin, N | 1 |
| Mono, ML | 2 |
| Geister, L | 1 |
| Galimanis, A | 1 |
| Jung, S | 1 |
| Praz, F | 1 |
| Fischer, U | 1 |
| Wolff, S | 1 |
| Findling, O | 1 |
| Wahl, A | 2 |
| Meier, B | 7 |
| Nedeltchev, K | 4 |
| Hsiao, FY | 1 |
| Mullins, CD | 1 |
| Wen, YW | 1 |
| Huang, WF | 1 |
| Chen, PF | 1 |
| Tsai, YW | 1 |
| Cuisset, T | 1 |
| Quilici, J | 1 |
| Grosdidier, C | 1 |
| Fourcade, L | 1 |
| Gaborit, B | 1 |
| Pankert, M | 1 |
| Molines, L | 1 |
| Morange, PE | 1 |
| Bonnet, JL | 1 |
| Alessi, MC | 1 |
| Larson, DM | 1 |
| Duval, S | 1 |
| Sharkey, SW | 1 |
| Garberich, RF | 1 |
| Madison, JD | 1 |
| Stokman, PJ | 1 |
| Dirks, TG | 1 |
| Westin, RK | 1 |
| Harris, JL | 1 |
| Henry, TD | 1 |
| Leone, AM | 1 |
| Sgueglia, GA | 1 |
| Porto, I | 1 |
| Burzotta, F | 1 |
| Trani, C | 1 |
| De Caterina, AR | 1 |
| Buffon, A | 1 |
| Mazzari, MA | 1 |
| Mongiardo, R | 1 |
| Rebuzzi, AG | 1 |
| Roa, LF | 1 |
| Hernandez, B | 1 |
| Merlos, M | 1 |
| Marquez, JM | 1 |
| Artigas, C | 1 |
| Perez, A | 1 |
| Cantu-Brito, C | 1 |
| Barinagarrementeria, F | 1 |
| Delhaye, C | 1 |
| Martin, RH | 1 |
| Vinisko, R | 1 |
| Donnan, GA | 1 |
| Tricoci, P | 1 |
| Mahaffey, KW | 3 |
| Chong, BH | 1 |
| Chan, KH | 1 |
| Pong, V | 1 |
| Lau, KK | 1 |
| Chan, YH | 1 |
| Zuo, ML | 1 |
| Lui, WM | 1 |
| Leung, GK | 1 |
| Lau, CP | 1 |
| Tse, HF | 1 |
| Pu, JK | 1 |
| Siu, CW | 1 |
| Geeganage, CM | 1 |
| Topol, EJ | 5 |
| Dengler, R | 1 |
| Bath, MW | 1 |
| Elgin, U | 1 |
| Sen, E | 1 |
| Teke, MY | 1 |
| Tirhis, H | 1 |
| Ozturk, F | 1 |
| Renard, D | 1 |
| Larue, A | 1 |
| Taieb, G | 1 |
| Jeanjean, L | 1 |
| Labauge, P | 1 |
| del Río Solá, ML | 1 |
| Antonio, J | 1 |
| Fajardo, G | 1 |
| Vaquero Puerta, C | 1 |
| Havel, M | 1 |
| Ertl, L | 1 |
| Braunschweig, F | 1 |
| Markmann, S | 1 |
| Leunig, A | 1 |
| Gamarra, F | 1 |
| Kramer, MF | 1 |
| Gokce, M | 1 |
| Altan, I | 1 |
| Unal, S | 1 |
| Kuskonmaz, B | 1 |
| Aytac, S | 1 |
| Cetin, M | 1 |
| Tuncer, M | 1 |
| Gumruk, F | 1 |
| Gurgey, A | 1 |
| Smith, PK | 2 |
| Goodnough, LT | 1 |
| Levy, JH | 1 |
| Poston, RS | 1 |
| Short, MA | 1 |
| Weerakkody, GJ | 1 |
| Lenarz, LA | 1 |
| Fischer-Betz, R | 1 |
| Specker, C | 1 |
| Brinks, R | 1 |
| Schneider, M | 1 |
| Barraclough, K | 1 |
| Mallen, CD | 1 |
| Helliwell, T | 1 |
| Hider, SL | 1 |
| Dasgupta, B | 1 |
| Milan, M | 1 |
| Noventa, F | 2 |
| Ghirarduzzi, A | 1 |
| Pengo, V | 1 |
| Vedovetto, V | 1 |
| Filippi, L | 1 |
| Campello, E | 1 |
| Szychowski, JM | 1 |
| Zhang, Z | 1 |
| Jian, X | 1 |
| Liu, H | 1 |
| Zhou, Q | 2 |
| Fang, YB | 1 |
| Li, Q | 1 |
| Yang, PF | 1 |
| Huang, QH | 1 |
| Zhao, WY | 1 |
| Xu, Y | 2 |
| Hong, B | 1 |
| Liu, JM | 1 |
| El-Mitwalli, A | 1 |
| Azzam, H | 1 |
| Abu-Hegazy, M | 1 |
| Gomaa, M | 1 |
| Wasel, Y | 1 |
| Barry, EL | 1 |
| Poole, EM | 1 |
| Baron, JA | 2 |
| Makar, KW | 1 |
| Mott, LA | 2 |
| Sandler, RS | 2 |
| Ahnen, DJ | 1 |
| Bresalier, RS | 1 |
| McKeown-Eyssen, GE | 2 |
| Ulrich, CM | 1 |
| Burrows, AM | 1 |
| Zipfel, G | 1 |
| Lanzino, G | 1 |
| Kiesz, RS | 1 |
| Wiernek, SL | 1 |
| Wiernek, BK | 1 |
| Radvany, MG | 1 |
| Buszman, PP | 1 |
| Szymanski, R | 1 |
| Konkolewska, MD | 1 |
| Martin, JL | 1 |
| Buszman, PE | 1 |
| Mulukutla, SR | 1 |
| Marroquin, OC | 1 |
| Vlachos, HA | 1 |
| Selzer, F | 1 |
| Toma, C | 1 |
| Kip, KE | 1 |
| Abbott, JD | 1 |
| Holper, E | 1 |
| Khandhar, S | 1 |
| Kutcher, M | 1 |
| Kelsey, S | 1 |
| Smith, C | 1 |
| Faxon, D | 1 |
| Williams, DO | 2 |
| Chi, L | 1 |
| Li, L | 1 |
| Han, JL | 1 |
| Li, HY | 1 |
| Qiao, R | 1 |
| Yu, HY | 1 |
| Zeng, H | 1 |
| Gao, W | 1 |
| Neogi, T | 1 |
| Chaisson, C | 1 |
| Hunter, DJ | 1 |
| Choi, H | 1 |
| Kahn, JE | 1 |
| Veyssier-Belot, C | 1 |
| Renier, JL | 1 |
| de Mazancourt, P | 1 |
| Peltier, JY | 1 |
| de Raucourt, E | 1 |
| Lopez-Yunez, AM | 1 |
| Cuadrado, MJ | 3 |
| Shah, PB | 1 |
| Lilly, CM | 1 |
| Turpie, AG | 3 |
| Hiller, E | 2 |
| Kao, A | 1 |
| Dlugos, D | 1 |
| Hunter, JV | 1 |
| Mamula, P | 1 |
| Thorarensen, O | 1 |
| Fliri, M | 1 |
| Jacobs, ET | 1 |
| Giuliano, AR | 1 |
| Roe, DJ | 1 |
| Guillén-Rodríguez, JM | 1 |
| Alberts, DS | 2 |
| Martínez, ME | 2 |
| Kübler, W | 2 |
| Arvieux, J | 1 |
| Hoppe, UC | 1 |
| Musolino, R | 1 |
| La Spina, P | 1 |
| Granata, A | 1 |
| Gallitto, G | 1 |
| Leggiadro, N | 1 |
| Carerj, S | 1 |
| Manganaro, A | 1 |
| Tripodi, F | 1 |
| Epifanio, A | 1 |
| Gangemi, S | 1 |
| Di Perri, R | 1 |
| Schölmerich, J | 1 |
| Stange, EF | 1 |
| Ornato, JP | 1 |
| Maillard, L | 1 |
| Michiels, JJ | 2 |
| Berneman, Z | 1 |
| Schroyens, W | 1 |
| van Urk, H | 1 |
| Gerschutz, GP | 1 |
| Bergstrand, L | 1 |
| Fellenius, C | 2 |
| Lindahl, B | 1 |
| Lins, LE | 1 |
| Nilsson, T | 1 |
| Pehrsson, K | 1 |
| Swahn, E | 1 |
| Trespalacios, FC | 1 |
| Taylor, AJ | 1 |
| Agodoa, LY | 1 |
| Bakris, GL | 1 |
| Abbott, KC | 1 |
| Gorelick, PB | 2 |
| Richardson, D | 1 |
| Kelly, M | 1 |
| Ruland, S | 1 |
| Hung, E | 1 |
| Harris, Y | 1 |
| Kittner, S | 1 |
| Leurgans, S | 1 |
| O'Brien, TG | 1 |
| Fultz, KE | 1 |
| Babbar, N | 1 |
| Yerushalmi, H | 1 |
| Qu, N | 1 |
| Boorman, D | 1 |
| Einspahr, J | 1 |
| Gerner, EW | 1 |
| Comunale, ME | 1 |
| Maslow, A | 1 |
| Robertson, LK | 1 |
| Haering, JM | 1 |
| Mashikian, JS | 1 |
| Lowenstein, E | 1 |
| Reikvam, A | 1 |
| Madsen, S | 1 |
| Landmark, K | 1 |
| Short, D | 1 |
| Frischer, M | 1 |
| Bashford, J | 1 |
| Ashcroft, D | 1 |
| James, MW | 1 |
| Hawkey, CJ | 2 |
| Limmer, S | 1 |
| Ittel, TH | 1 |
| Wietholtz, H | 1 |
| Ng, FH | 1 |
| Wong, SY | 1 |
| Chang, CM | 1 |
| Chen, WH | 1 |
| Kng, C | 1 |
| Lanas, AI | 1 |
| Wong, BC | 2 |
| Nanda, S | 1 |
| Agarwal, U | 1 |
| Sangwan, K | 1 |
| Fan, YH | 1 |
| Lam, WW | 1 |
| Mok, VC | 1 |
| Petri, M | 1 |
| Mahé, I | 1 |
| Grenard, AS | 1 |
| Caulin, C | 1 |
| Bergmann, JF | 1 |
| Ito, E | 2 |
| Takahashi, A | 1 |
| Yamamoto, H | 1 |
| Kuzuhara, S | 1 |
| Nakajima, M | 2 |
| Kaźmierski, MK | 1 |
| Leschke, M | 2 |
| Klimek, W | 1 |
| Gensini, GF | 3 |
| Maritz, F | 1 |
| Gurfinkel, EP | 5 |
| Timerman, A | 1 |
| Krzeminska-Pakula, M | 1 |
| White, HD | 5 |
| Santopinto, J | 1 |
| Bigonzi, F | 3 |
| Hecquet, C | 1 |
| Vittori, L | 1 |
| Haberl, R | 1 |
| Barth, A | 1 |
| Bonnefoy, E | 1 |
| Chabaud, S | 1 |
| Lapostolle, F | 1 |
| Dubien, PY | 1 |
| Cristofini, P | 1 |
| Leizorovicz, A | 4 |
| Touboul, P | 1 |
| Werner, GS | 1 |
| Emig, U | 1 |
| Mutschke, O | 1 |
| Schwarz, G | 1 |
| Bahrmann, P | 1 |
| Figulla, HR | 1 |
| Füessl, HS | 1 |
| Takada, T | 1 |
| Tanaka, M | 1 |
| Hunt, RH | 2 |
| Bazzoli, F | 1 |
| Giugliano, RP | 1 |
| Murphy, SA | 1 |
| Demopoulos, LA | 1 |
| DiBattiste, PM | 1 |
| Weintraub, WS | 1 |
| McCabe, CH | 1 |
| Antman, EM | 1 |
| Cannon, CP | 1 |
| Bruno, A | 3 |
| McConnell, JP | 1 |
| Cohen, SN | 1 |
| Tietjen, GE | 1 |
| Wallis, RA | 1 |
| Bang, NU | 2 |
| Bellelli, G | 1 |
| Trabucchi, M | 1 |
| Herlitz, J | 1 |
| Holm, J | 2 |
| Peterson, M | 1 |
| Karlson, BW | 1 |
| Haglid Evander, M | 1 |
| Erhardt, L | 2 |
| Banerjee, S | 1 |
| Denniston, AK | 1 |
| Gibson, JM | 1 |
| Dodson, PM | 1 |
| Faraday, N | 1 |
| Braunstein, JB | 1 |
| Heldman, AW | 1 |
| Bolton, ED | 1 |
| Chiles, KA | 1 |
| Gerstenblith, G | 1 |
| Schulman, SP | 1 |
| Grau, AJ | 1 |
| Boddy, AW | 1 |
| Dukovic, DA | 1 |
| Buggle, F | 1 |
| Lichy, C | 1 |
| Brandt, T | 1 |
| Demichelis, B | 2 |
| Parrini, I | 1 |
| Giuggia, M | 1 |
| Cecchi, E | 3 |
| Gaschino, G | 1 |
| Demarie, D | 3 |
| Ghisio, A | 3 |
| Trinchero, R | 3 |
| Hillarp, A | 2 |
| Palmqvist, B | 1 |
| Lethagen, S | 1 |
| Villoutreix, BO | 1 |
| Mattiasson, I | 1 |
| McKevitt, FM | 1 |
| Macdonald, S | 1 |
| Cleveland, TJ | 1 |
| Gaines, PA | 1 |
| Sciacca, RR | 2 |
| Schuepbach, RA | 1 |
| Meili, EO | 1 |
| Schneider, E | 2 |
| Peter, U | 1 |
| Bachli, EB | 1 |
| Freeman, AF | 1 |
| Shulman, ST | 1 |
| Bats, AS | 1 |
| Lejeune, V | 1 |
| Cynober, E | 2 |
| Safar, E | 1 |
| Gonzales, M | 1 |
| Milliez, J | 2 |
| Carbonne, B | 2 |
| Drake-Lee, AB | 1 |
| Santa-Cruz, RA | 1 |
| Steinhubl, SR | 1 |
| Matetzky, S | 1 |
| Shenkman, B | 1 |
| Guetta, V | 1 |
| Shechter, M | 1 |
| Beinart, R | 1 |
| Bienart, R | 1 |
| Goldenberg, I | 1 |
| Novikov, I | 1 |
| Pres, H | 1 |
| Savion, N | 1 |
| Varon, D | 1 |
| Hod, H | 2 |
| Wienbergen, H | 1 |
| Gitt, AK | 1 |
| Schiele, R | 1 |
| Juenger, C | 1 |
| Heer, T | 1 |
| Vogel, C | 1 |
| Gottwik, M | 1 |
| Senges, J | 1 |
| DiTullio, MR | 1 |
| Locker, C | 1 |
| Mohr, R | 1 |
| Lev-Ran, O | 1 |
| Uretzky, G | 1 |
| Frimerman, A | 1 |
| Shaham, Y | 1 |
| Shapira, I | 1 |
| Matsui, M | 1 |
| Tomimoto, H | 1 |
| Sano, K | 1 |
| Hashikawa, K | 1 |
| Fukuyama, H | 1 |
| Shibasaki, H | 1 |
| Senna, G | 1 |
| Bilò, MB | 1 |
| Antonicelli, L | 1 |
| Schiappoli, M | 1 |
| Crivellaro, MA | 1 |
| Bonadonna, P | 1 |
| Dama, AR | 1 |
| Rosenberg, R | 1 |
| Bauer, K | 1 |
| Rosner, B | 1 |
| Sciacca, R | 1 |
| Barzegar, S | 1 |
| Thornell, B | 1 |
| Costigan, T | 1 |
| Kistler, JP | 1 |
| Kassem-Moussa, H | 1 |
| Graffagnino, C | 2 |
| Tasissa, G | 1 |
| Sila, CA | 2 |
| Simes, RJ | 1 |
| Califf, RM | 7 |
| Bhapkar, MV | 1 |
| Newby, LK | 1 |
| Reissmann, A | 1 |
| Bischoff, SC | 1 |
| Fleig, W | 1 |
| Bogousslavsky, J | 1 |
| Hirsh, J | 1 |
| Stejskal, D | 1 |
| Prosková, J | 1 |
| Lacnák, B | 1 |
| Horalík, D | 1 |
| Hamplová, A | 1 |
| Oral, I | 1 |
| Hrabovská, I | 1 |
| Ochmanová, R | 1 |
| Adamovská, S | 1 |
| Juráková, R | 1 |
| Ozanová, G | 1 |
| Juchelka, J | 1 |
| Kulísková, O | 1 |
| Pĕnkavová, H | 1 |
| Karreman, AJ | 1 |
| Gendolla, A | 1 |
| Zakopoulos, N | 1 |
| Peppes, V | 1 |
| Toussaint, LG | 1 |
| Friedman, JA | 1 |
| Wijdicks, EF | 1 |
| Piepgras, DG | 1 |
| Pichelmann, MA | 1 |
| McIver, JI | 1 |
| McClelland, RL | 1 |
| Nichols, DA | 1 |
| Meyer, FB | 1 |
| Atkinson, JL | 1 |
| Gallino, A | 1 |
| Do, DD | 1 |
| Alerci, M | 1 |
| Cozzi, L | 1 |
| Segatto, JM | 1 |
| Bernier, J | 1 |
| Tutta, P | 1 |
| Kellner, F | 1 |
| Triller, J | 1 |
| Amann-Vesti, B | 1 |
| Studer, G | 1 |
| Jäger, K | 1 |
| Aschwanden, M | 1 |
| Canevascini, R | 1 |
| Jacob, AL | 1 |
| Kann, R | 1 |
| Greiner, R | 1 |
| Mahler, F | 1 |
| Claeys, MJ | 1 |
| Van der Planken, MG | 1 |
| Bosmans, JM | 1 |
| Vertessen, F | 1 |
| Van Der Goten, P | 1 |
| Wuyts, FL | 1 |
| Vrints, CJ | 1 |
| Arkkila, PE | 1 |
| Seppälä, K | 1 |
| Kosunen, TU | 1 |
| Sipponen, P | 2 |
| Mäkinen, J | 1 |
| Rautelin, H | 1 |
| Färkkilä, M | 1 |
| Weir, NU | 1 |
| Demchuk, AM | 1 |
| Buchan, AM | 1 |
| Kumana, CR | 1 |
| Cheung, G | 1 |
| Lauder, IJ | 1 |
| Cheung, BM | 1 |
| Kiechl, S | 1 |
| Schleinitz, MD | 1 |
| Heidenreich, PA | 1 |
| Lanthier, S | 1 |
| Armstrong, D | 1 |
| Domi, T | 1 |
| Gassaye, D | 1 |
| Atipo Ibara, BI | 1 |
| Ndolo-Mpika, AB | 1 |
| Ibara, JR | 1 |
| Okouo, M | 1 |
| Ossendza, RA | 1 |
| Ngoma-Mambouana, P | 1 |
| Itoua-Ngaporo, A | 1 |
| Pollak, L | 1 |
| Kessler, A | 1 |
| Rabey, MJ | 1 |
| Hartmann, B | 1 |
| Goldhammer, Y | 1 |
| Matsuo, H | 1 |
| Morimoto, K | 1 |
| Akaki, T | 1 |
| Kaneko, S | 1 |
| Kusatake, K | 1 |
| Kuroda, T | 1 |
| Niihara, H | 1 |
| Hide, M | 1 |
| Morita, E | 1 |
| Khamashta, MA | 4 |
| Hunt, BJ | 2 |
| Marchioli, R | 2 |
| Brancaccio, V | 1 |
| Schinco, P | 1 |
| Wisloff, F | 1 |
| Musial, J | 1 |
| Baudo, F | 1 |
| Berrettini, M | 1 |
| Testa, S | 1 |
| D'Angelo, A | 1 |
| Tognoni, G | 2 |
| Nakashima, S | 1 |
| Arai, S | 1 |
| Mizuno, Y | 1 |
| Yoshino, K | 1 |
| Ando, S | 1 |
| Nakamura, Y | 1 |
| Sugawara, K | 1 |
| Koike, M | 1 |
| Saito, E | 1 |
| Naito, M | 1 |
| Nakao, M | 1 |
| Ito, H | 1 |
| Hamaoka, K | 1 |
| Rai, F | 1 |
| Asakura, Y | 1 |
| Akamatu, M | 1 |
| Fujimori, K | 1 |
| Inao, M | 1 |
| Imai, Y | 1 |
| Ota, S | 1 |
| Fujiwara, K | 1 |
| Shiibashi, M | 1 |
| Worth, NF | 1 |
| Berry, CL | 1 |
| Thomas, AC | 1 |
| Campbell, JH | 1 |
| Asero, R | 1 |
| Sick, PB | 1 |
| Brosteanu, O | 1 |
| Ulrich, M | 1 |
| Niebauer, J | 2 |
| Busch, I | 1 |
| Schuler, G | 2 |
| Koga, T | 1 |
| Oshita, Y | 1 |
| Kamimura, T | 1 |
| Koga, H | 1 |
| Aizawa, H | 1 |
| Yip, HK | 1 |
| Chang, HW | 1 |
| Lan, MY | 1 |
| Chen, MC | 1 |
| Meier, JM | 1 |
| Delabays, A | 1 |
| Girod, G | 1 |
| Eeckhout, E | 1 |
| Ng, HJ | 1 |
| Bobbio, M | 1 |
| Pomari, F | 2 |
| Moratti, M | 1 |
| Belli, R | 2 |
| Jamieson, DG | 1 |
| Parekh, A | 1 |
| Ezekowitz, MD | 1 |
| Woodside, DB | 1 |
| Colton, P | 1 |
| Staab, R | 1 |
| Schreiber, M | 1 |
| Sutandar-Pinnock, K | 1 |
| Poynter, B | 1 |
| Sacevich, T | 1 |
| Ederhy, S | 1 |
| Meuleman, C | 1 |
| Hammoudi, N | 1 |
| Janower, S | 1 |
| Szapáry, L | 1 |
| Brogan, GX | 1 |
| Peterson, ED | 1 |
| Mulgund, J | 1 |
| Ohman, EM | 2 |
| Gibler, WB | 1 |
| Pollack, CV | 1 |
| Farkouh, ME | 1 |
| Roe, MT | 1 |
| Gurbuz, AT | 1 |
| Zia, AA | 1 |
| Vuran, AC | 1 |
| Cui, H | 1 |
| Aytac, A | 1 |
| Takeuchi, K | 3 |
| Smale, S | 1 |
| Premchand, P | 1 |
| Maiden, L | 1 |
| Sherwood, R | 1 |
| Thjodleifsson, B | 1 |
| Bjornsson, E | 1 |
| Bjarnason, I | 1 |
| Schneider, CA | 1 |
| Schaefer, A | 1 |
| Stumme, B | 1 |
| Drexler, H | 1 |
| von Depka, M | 1 |
| Malik, SN | 1 |
| Hopkins, M | 1 |
| Young, WB | 1 |
| Silberstein, SD | 1 |
| Halkes, PH | 1 |
| van Gijn, J | 3 |
| van Wijk, I | 1 |
| Casella, G | 1 |
| Greco, C | 1 |
| Perugini, E | 1 |
| Pallotti, MG | 1 |
| Pavesi, PC | 1 |
| Di Pasquale, G | 1 |
| Frelinger, AL | 1 |
| Furman, MI | 1 |
| Linden, MD | 1 |
| Fox, ML | 1 |
| Barnard, MR | 1 |
| Michelson, AD | 1 |
| Freedman, JE | 1 |
| Eggers, AE | 1 |
| Spoor, MT | 1 |
| Geltz, A | 1 |
| Bolling, SF | 1 |
| Stiefelhagen, P | 1 |
| Palumbo, A | 1 |
| Rus, C | 1 |
| Zeldis, JB | 1 |
| Rodeghiero, F | 1 |
| Boccadoro, M | 1 |
| Onizuka, M | 1 |
| Kazekawa, K | 1 |
| Nagata, S | 1 |
| Tsutsumi, M | 1 |
| Aikawa, H | 1 |
| Tomokiyo, M | 1 |
| Iko, M | 1 |
| Kodama, T | 1 |
| Nii, K | 1 |
| Tanaka, A | 1 |
| Albucher, JF | 1 |
| Martel, P | 1 |
| Cordonnier, C | 1 |
| Fuchs, I | 1 |
| Frossard, M | 1 |
| Spiel, A | 1 |
| Riedmüller, E | 1 |
| Laggner, AN | 1 |
| Jilma, B | 1 |
| Ortega, LL | 1 |
| Sánchez, J | 1 |
| Más, R | 1 |
| Fernández, L | 1 |
| Mendoza, S | 1 |
| Gámez, R | 1 |
| Fernández, JC | 1 |
| Illnait, J | 1 |
| Alvarez, E | 1 |
| Boos, CJ | 1 |
| Harrison, P | 1 |
| Keeling, D | 1 |
| Johansen, M | 1 |
| Derendorf, H | 1 |
| Kim, S | 1 |
| Burke, CA | 1 |
| Church, TR | 1 |
| Cole, BF | 1 |
| Haile, RW | 1 |
| Sharifkazemi, MB | 1 |
| Zamirian, M | 1 |
| Aslani, A | 1 |
| O'Donoghue, M | 1 |
| Wiviott, SD | 1 |
| Yilmaz, S | 1 |
| Bayan, K | 1 |
| Dursun, M | 1 |
| Canoruç, F | 1 |
| Kilinç, N | 1 |
| Tüzün, Y | 1 |
| Daniş, R | 1 |
| Ertem, M | 1 |
| Spencer, FA | 1 |
| Lessard, D | 2 |
| Doubeni, C | 1 |
| Yarzebski, J | 2 |
| Gore, JM | 4 |
| Goldberg, RJ | 2 |
| Kozieradzka, A | 1 |
| Kamiński, KA | 1 |
| Pepiński, W | 1 |
| Janica, J | 1 |
| Korecki, J | 1 |
| Skolimowski, K | 1 |
| Frankowska, E | 1 |
| Kralisz, P | 1 |
| Bonda, TA | 1 |
| Dobrzycki, S | 1 |
| Musiał, WJ | 1 |
| Małek, ŁA | 1 |
| Spiewak, M | 1 |
| Grabowski, M | 1 |
| Szpotańska, M | 1 |
| Rosiak, M | 1 |
| Główczyńska, R | 1 |
| Imiela, T | 1 |
| Alpagut, U | 1 |
| Ugurlucan, M | 1 |
| Dayioglu, E | 1 |
| Hirsch, A | 1 |
| Windhausen, F | 1 |
| Cornel, JH | 1 |
| de Winter, RJ | 1 |
| Liao, JK | 1 |
| Kikano, GE | 1 |
| Brown, MT | 1 |
| Luxembourg, B | 1 |
| Mani, H | 1 |
| Toennes, SW | 1 |
| Strubel, G | 1 |
| Klaeffling, C | 1 |
| Daemgen-von Brevern, G | 1 |
| Geisen, C | 1 |
| Lindhoff-Last, E | 1 |
| Chinaglia, A | 1 |
| Ierna, S | 1 |
| Wang, GZ | 1 |
| Huang, GP | 1 |
| Yin, GL | 1 |
| Zhou, G | 1 |
| Guo, CJ | 1 |
| Xie, CG | 1 |
| Jia, BB | 1 |
| Wang, JF | 1 |
| Macé, G | 1 |
| Cabane, J | 1 |
| Kim, JE | 1 |
| Kountakis, SE | 1 |
| Okajima, K | 1 |
| Abe, Y | 1 |
| Salameh, MJ | 1 |
| Jin, Z | 1 |
| Glynn, RJ | 1 |
| Ridker, PM | 1 |
| Goldhaber, SZ | 1 |
| Zee, RY | 1 |
| Buring, JE | 4 |
| Barnes, GD | 1 |
| Kline-Rogers, E | 1 |
| Vedre, A | 1 |
| Armstrong, DF | 1 |
| Froehlich, JB | 1 |
| Eagle, KA | 1 |
| Gurm, HS | 1 |
| Alonso Santor, JE | 1 |
| Inglada Galiana, L | 1 |
| Pérez Paredes, G | 1 |
| Hsia, J | 2 |
| Domenig, CM | 1 |
| Aspalter, M | 1 |
| Umathum, M | 1 |
| Holzenbein, TJ | 1 |
| Overgaard, K | 1 |
| Poulsen, TS | 1 |
| Husted, SE | 1 |
| Lorenzen, ND | 1 |
| Eldrup, N | 1 |
| Laustsen, J | 1 |
| Sztriha, LK | 1 |
| Sas, K | 1 |
| Seres, E | 1 |
| Boda, K | 1 |
| Lenti, L | 1 |
| Csifcsak, G | 1 |
| Kovacs, N | 1 |
| Vecsei, L | 1 |
| Luo, M | 1 |
| Xie, RM | 1 |
| Quan, HB | 1 |
| Cai, YY | 1 |
| Winer, N | 1 |
| Tsasaris, V | 1 |
| Vermylen, J | 1 |
| Smout, J | 1 |
| Cleanthis, M | 1 |
| Stansby, G | 1 |
| Gengo, FM | 1 |
| Rainka, M | 1 |
| Robson, M | 1 |
| Gengo, MF | 1 |
| Forrest, A | 1 |
| Hourihane, M | 1 |
| Bates, V | 1 |
| Sofi, F | 1 |
| Marcucci, R | 1 |
| Gori, AM | 1 |
| Abbate, R | 1 |
| Kubota, N | 1 |
| Kasai, T | 1 |
| Miyauchi, K | 1 |
| Njaman, W | 1 |
| Kajimoto, K | 1 |
| Akimoto, Y | 1 |
| Kojima, T | 1 |
| Ken, Y | 1 |
| Takeshi, K | 1 |
| Hiroyuki, D | 1 |
| Dalen, JE | 1 |
| Levi, M | 1 |
| Nagarakanti, R | 1 |
| Sodhi, S | 1 |
| Lee, R | 1 |
| Ezekowitz, M | 1 |
| Gellatly, RM | 1 |
| Ackman, ML | 1 |
| Mikkelsson, J | 1 |
| Eskola, M | 1 |
| Nikus, K | 1 |
| Karhunen, PJ | 1 |
| Niemela, K | 1 |
| Tseng, GY | 1 |
| Lin, HJ | 1 |
| Duran, X | 1 |
| Sánchez, S | 1 |
| Vilahur, G | 1 |
| Badimon, L | 2 |
| Schubert, TT | 2 |
| Boissel, JP | 3 |
| Faucomprez, C | 1 |
| McNicol, GP | 1 |
| Schröder, R | 1 |
| Kallio, V | 1 |
| Mitchell, JR | 2 |
| Friedewald, WT | 1 |
| Schoenberger, JA | 1 |
| Toshima, H | 1 |
| Adachi, K | 1 |
| Chabali, R | 1 |
| Haynes, RE | 1 |
| Spann, JF | 1 |
| Offerhaus, L | 1 |
| Burkart, F | 2 |
| Gorlin, R | 1 |
| Fuster, V | 4 |
| Kornitzer, M | 1 |
| Il'in, VN | 1 |
| Stepanov, NV | 1 |
| Ikhaev, ZA | 1 |
| Sharonin, GV | 1 |
| Bogdanets, LI | 1 |
| Buckler, P | 1 |
| Douglas, AS | 1 |
| Kirchhof, B | 1 |
| Haustein, UF | 1 |
| Rytter, M | 1 |
| Kaltenbach, M | 3 |
| Kober, G | 3 |
| Schmidt-Moritz, A | 1 |
| Scherer, D | 2 |
| Thornton, MA | 1 |
| Gruentzig, AR | 1 |
| Hollman, J | 2 |
| King, SB | 4 |
| Douglas, JS | 2 |
| Faxon, DP | 3 |
| Sanborn, TA | 2 |
| Haudenschild, CC | 1 |
| Ryan, TJ | 2 |
| Hillis, LD | 1 |
| Leisch, F | 1 |
| Herbinger, W | 1 |
| Brücke, P | 1 |
| Elwood, PC | 4 |
| Wüthrich, B | 1 |
| Ramirez-Lassepas, M | 1 |
| Domschke, S | 1 |
| Domschke, W | 1 |
| Weber, M | 1 |
| von Schacky, C | 1 |
| Lorenz, R | 1 |
| Meister, W | 1 |
| Kotzur, J | 1 |
| Reichart, B | 1 |
| Theisen, K | 2 |
| Weber, PC | 1 |
| Breddin, K | 5 |
| Markiewicz, M | 1 |
| Rymar, B | 1 |
| Florkiewicz, H | 1 |
| Wysokiński, A | 1 |
| Volger, E | 1 |
| Theiss, W | 2 |
| Lubbe, WF | 1 |
| Butler, WS | 1 |
| Palmer, SJ | 1 |
| Liggins, GC | 1 |
| Lucas, MA | 1 |
| Ganley, JP | 1 |
| Geiger, JM | 1 |
| Clement, JR | 1 |
| Rigby, PG | 1 |
| Levy, GJ | 1 |
| Mannucci, PM | 1 |
| Romano, P | 1 |
| Van Aken, WG | 1 |
| Verdecchia, P | 1 |
| Reuther, R | 1 |
| Dorndorf, W | 1 |
| Loew, D | 4 |
| Lechner, K | 2 |
| Oberla, K | 1 |
| Walter, E | 4 |
| Rentrop, P | 1 |
| Blanke, H | 1 |
| Karsch, KR | 1 |
| Guiraud-Chaumeil, B | 1 |
| Rascol, A | 1 |
| David, J | 1 |
| Boneu, B | 2 |
| Clanet, M | 1 |
| Bierme, R | 2 |
| Clagett, GP | 1 |
| Rich, NM | 1 |
| McDonald, PT | 1 |
| Salander, JM | 1 |
| Youkey, JR | 1 |
| Olson, DW | 1 |
| Hutton, JE | 1 |
| Rampton, DS | 1 |
| McNeil, NI | 1 |
| Sarner, M | 1 |
| Jones, RJ | 1 |
| Lundh, B | 1 |
| Fagher, B | 1 |
| Weber, E | 2 |
| Loeliger, EA | 1 |
| Robertson, RM | 1 |
| Robertson, D | 1 |
| Roberts, LJ | 2 |
| Maas, RL | 1 |
| FitzGerald, GA | 1 |
| Friesinger, GC | 1 |
| Oates, JA | 2 |
| Straub, PW | 1 |
| Kraska, T | 1 |
| Malanowicz, W | 1 |
| Skarzyńska, M | 1 |
| Tymińska, K | 1 |
| Kent, S | 1 |
| van de Loo, J | 1 |
| Castaldi, PA | 1 |
| Schbath, J | 1 |
| Destors, JM | 1 |
| Gillet, J | 2 |
| Halawa, B | 1 |
| Mazurek, W | 1 |
| Sherry, DD | 1 |
| Patterson, MW | 1 |
| Petty, RE | 1 |
| Turk, JW | 1 |
| Horwitz, DL | 1 |
| Settipane, RA | 1 |
| Constantine, HP | 1 |
| Settipane, GA | 1 |
| Klimt, CR | 2 |
| Faergeman, O | 1 |
| Bauman, JL | 1 |
| Shulruff, S | 1 |
| Hasegawa, GR | 1 |
| Roden, R | 1 |
| Hartsough, N | 1 |
| Bauernfeind, RA | 1 |
| Maruyama, S | 1 |
| Tohgi, H | 2 |
| Hirai, S | 1 |
| Ikeda, Y | 1 |
| Shinohara, Y | 1 |
| Matsuda, T | 1 |
| Fujishima, M | 1 |
| Kameyama, M | 1 |
| Larsson, H | 1 |
| Areskog, M | 1 |
| Areskog, NH | 1 |
| Jonasson, T | 1 |
| Ringqvist, I | 1 |
| Poole-Wilson, PA | 1 |
| Langford, EJ | 1 |
| Brown, AS | 1 |
| Wainwright, RJ | 1 |
| de Belder, AJ | 1 |
| Thomas, MR | 1 |
| Smith, RE | 1 |
| Radomski, MW | 1 |
| Martin, JF | 1 |
| Moncada, S | 1 |
| Di Tano, G | 1 |
| Mazzù, A | 1 |
| Isogaya, M | 1 |
| Yamada, N | 1 |
| Koike, H | 1 |
| Ueno, Y | 1 |
| Kumagai, H | 1 |
| Ochi, Y | 1 |
| Okazaki, S | 1 |
| Nishio, S | 1 |
| Savage, MP | 2 |
| Goldberg, S | 3 |
| Bove, AA | 2 |
| Deutsch, E | 2 |
| Vetrovec, G | 3 |
| Macdonald, RG | 3 |
| Bass, T | 2 |
| Margolis, JR | 3 |
| Whitworth, HB | 2 |
| Taussig, A | 2 |
| Schmitt, C | 2 |
| Karch, M | 1 |
| Plewan, A | 1 |
| Montero, M | 1 |
| Schömig, A | 5 |
| Russo, R | 1 |
| Laveder, F | 1 |
| Agostini, C | 1 |
| Manos, EJ | 1 |
| Mejaíl, RI | 1 |
| Cerdá, MA | 1 |
| Duronto, EA | 1 |
| García, CN | 1 |
| Daroca, AM | 1 |
| Mautner, B | 1 |
| Förster, W | 7 |
| Frölich, JC | 2 |
| van Latum, JC | 1 |
| van Swieten, JC | 1 |
| Channer, KS | 1 |
| Lasry, JL | 1 |
| Boyer, JC | 1 |
| Bories, H | 1 |
| Kadouch, R | 1 |
| Lagneau, P | 1 |
| Schrör, K | 2 |
| Ahmadi, A | 1 |
| Koppensteiner, R | 4 |
| Maca, T | 1 |
| Stümpflen, A | 3 |
| Ugurluoglu, A | 1 |
| Ehringer, H | 4 |
| Chernine, A | 2 |
| Ovadia, Z | 1 |
| Battler, A | 2 |
| Moulin, C | 1 |
| Bosson, JL | 1 |
| Rolachon, A | 1 |
| Li, V | 1 |
| Cohard, M | 1 |
| Girard, M | 1 |
| Hostein, J | 1 |
| Mehan, VK | 2 |
| Salzmann, C | 1 |
| Kaufmann, U | 1 |
| French, JK | 2 |
| Hamer, AW | 1 |
| Brown, MA | 2 |
| Williams, BF | 2 |
| Ormiston, JA | 1 |
| Cross, DB | 1 |
| Pickard, JD | 1 |
| Walker, V | 1 |
| Brandt, L | 1 |
| Zygmunt, S | 1 |
| Smythe, J | 1 |
| Wielgosz, AT | 1 |
| Valentín Segura, V | 1 |
| Valls Grima, F | 1 |
| Broch Porcar, MJ | 1 |
| Miralles Serrano, L | 1 |
| Olivares Toledo, D | 1 |
| Alvarez Cebrián, F | 1 |
| Matchar, DB | 1 |
| McCrory, DC | 1 |
| Barnett, HJ | 1 |
| Feussner, JR | 1 |
| Mujic, F | 1 |
| Taub, NA | 1 |
| Hughes, GR | 2 |
| Eriksson, SE | 1 |
| Whitford, DL | 1 |
| Southern, AJ | 1 |
| Fitch, LL | 1 |
| Buchwald, H | 1 |
| Matts, JP | 1 |
| Johnson, JW | 1 |
| Campos, CT | 1 |
| Long, JM | 1 |
| Xiong, J | 2 |
| Parry, G | 2 |
| Adams, PC | 3 |
| Chamberlain, D | 2 |
| Wieczorek, I | 2 |
| McBride, R | 1 |
| Chesebro, JH | 4 |
| Laupacis, A | 1 |
| Flaker, GC | 1 |
| Singer, DE | 1 |
| Pfeffer, MA | 1 |
| Braunvald, Iu | 1 |
| Moĭe, LA | 1 |
| Basta, L | 1 |
| Kaddi, TE | 1 |
| Dévis, BR | 1 |
| Geltman, EM | 1 |
| Goldman, S | 1 |
| Fleĭker, GS | 1 |
| Bonnier, JJ | 1 |
| Post, D | 1 |
| Wilkinson, P | 2 |
| Laji, K | 1 |
| Ranjadayalan, K | 2 |
| Parsons, L | 1 |
| Timmis, AD | 2 |
| Vlachoyiannopoulos, PG | 1 |
| Tsiakou, E | 1 |
| Chalevelakis, G | 1 |
| Raptis, SA | 1 |
| Moutsopoulos, HM | 1 |
| Zotz, R | 1 |
| Pinnau, U | 1 |
| Genth, S | 1 |
| Erbel, R | 3 |
| Meyer, J | 3 |
| Averkov, OV | 1 |
| Zateĭshchikov, DA | 1 |
| Gratsianskiĭ, NA | 1 |
| Logutov, IuA | 1 |
| Iavelov, IS | 1 |
| Ianus, Vm | 1 |
| Helgason, CM | 1 |
| Bolin, KM | 1 |
| Hoff, JA | 1 |
| Winkler, SR | 1 |
| Mangat, A | 1 |
| Tortorice, KL | 1 |
| Brace, LD | 1 |
| Anaya Ordóñez, S | 1 |
| Matas Hoces, A | 1 |
| Britton, M | 1 |
| Michel, PL | 1 |
| Chiba, K | 1 |
| Takahashi, H | 1 |
| Tamura, K | 1 |
| Sasaki, K | 1 |
| Yao, SK | 2 |
| Ober, JC | 2 |
| Ferguson, JJ | 2 |
| Maffrand, JP | 2 |
| Anderson, HV | 2 |
| Buja, LM | 2 |
| Willerson, JT | 3 |
| Shahar, E | 1 |
| McGovern, PG | 1 |
| Sprafka, JM | 1 |
| Adamek, HE | 1 |
| Buttmann, A | 1 |
| Weber, J | 1 |
| Riemann, JF | 1 |
| Rissel, U | 1 |
| Müller, T | 1 |
| Schulze-Waltrup, N | 1 |
| Krakau, I | 1 |
| Arens, R | 1 |
| Willgeroth, W | 1 |
| Heuer, H | 1 |
| Theilmann, L | 1 |
| Sauer, P | 1 |
| Roeren, T | 1 |
| Otto, G | 1 |
| Arnold, JC | 1 |
| Noeldge, G | 1 |
| Richter, G | 1 |
| Stiehl, A | 1 |
| McCarthy, DM | 1 |
| Heller, RF | 2 |
| Knapp, JC | 1 |
| Valenti, LA | 1 |
| Dobson, AJ | 2 |
| Byers, JF | 1 |
| Juillière, Y | 1 |
| Kettani, C | 1 |
| Buffet, P | 1 |
| Anconina, J | 1 |
| Cuillière, M | 1 |
| Cherrier, F | 1 |
| Wellbrock, M | 1 |
| Mertens, J | 1 |
| Cornelius, M | 1 |
| Brasch, J | 1 |
| Hoberg, E | 1 |
| Dietz, R | 1 |
| Frees, U | 1 |
| Rauch, B | 1 |
| Schwarz, F | 1 |
| Tillmanns, H | 1 |
| Weichert, W | 1 |
| Meents, H | 1 |
| Abt, K | 1 |
| Lieb, H | 1 |
| Hach, W | 1 |
| Krzywanek, HJ | 1 |
| Breddin, HK | 2 |
| Hanna, JP | 1 |
| Sun, JP | 1 |
| Furlan, AJ | 1 |
| Stewart, WJ | 1 |
| Tan, M | 1 |
| Chaturvedi, S | 1 |
| Ansell, J | 1 |
| Recht, L | 1 |
| Heigl, F | 1 |
| Heigl, B | 1 |
| Kampfhammer, HP | 1 |
| Steinbeck, G | 1 |
| Grotemeyer, KH | 3 |
| Scharafinski, HW | 2 |
| Husstedt, IW | 3 |
| Meyer, A | 1 |
| Werter, CJ | 2 |
| de Swart, H | 1 |
| Lie, KI | 2 |
| van der Pol, JM | 2 |
| Michels, HR | 1 |
| van Eenige, MJ | 2 |
| Becker, RC | 1 |
| Meltzer, RS | 1 |
| Vered, Z | 1 |
| Desmet, W | 1 |
| Vrolix, M | 1 |
| De Scheerder, I | 1 |
| Van Lierde, J | 1 |
| Willems, JL | 1 |
| Piessens, J | 1 |
| Strain, J | 1 |
| Keller, C | 1 |
| Gull, S | 1 |
| Prentice, A | 1 |
| Wehmeier, A | 1 |
| Bischof, G | 1 |
| Pratschner, T | 1 |
| Kail, M | 1 |
| Mittlböck, M | 1 |
| Turkof, E | 1 |
| Puig, S | 1 |
| Polterauer, P | 1 |
| Kretschmer, G | 2 |
| Hansen, F | 1 |
| Lindblad, B | 1 |
| Persson, NH | 1 |
| Bergqvist, D | 1 |
| Zeitler, E | 1 |
| Beyer-Enke, S | 1 |
| Rompel, O | 1 |
| Stevenson, R | 1 |
| Roberts, R | 4 |
| Kaaja, R | 1 |
| Julkunen, H | 1 |
| Ammälä, P | 1 |
| Palosuo, T | 1 |
| Kurki, P | 1 |
| Langer, A | 3 |
| Green, D | 1 |
| Miller, V | 1 |
| Simoons, ML | 5 |
| Arnout, J | 1 |
| van den Brand, M | 1 |
| Nÿssen, K | 1 |
| Verstraete, M | 2 |
| Sivenius, J | 1 |
| Riekkinen, PJ | 1 |
| Laakso, M | 1 |
| Smets, P | 1 |
| Lowenthal, A | 2 |
| Sarin, S | 1 |
| Shami, SK | 1 |
| Cheatle, TR | 1 |
| Bearn, P | 1 |
| Scurr, JH | 1 |
| Coleridge Smith, PD | 1 |
| Saito, T | 1 |
| Saitoh, S | 1 |
| Asakura, T | 1 |
| Kanke, M | 1 |
| Owada, K | 1 |
| Maruyama, Y | 1 |
| Bologna, SD | 1 |
| Nensey, Y | 1 |
| Schubert, AB | 1 |
| Mascha, EJ | 1 |
| Ma, CK | 1 |
| Goldwater, PN | 1 |
| Meijer, A | 1 |
| Prager, NA | 2 |
| Torr-Brown, SR | 1 |
| Sobel, BE | 3 |
| Abendschein, DR | 3 |
| Lodder, J | 1 |
| Boiten, J | 1 |
| Fernández-Avilés, F | 1 |
| Alonso, JJ | 1 |
| Durán, JM | 1 |
| Gimeno, F | 1 |
| Muñoz, JC | 1 |
| de la Fuente, L | 1 |
| San Román, JA | 1 |
| Némoz, C | 1 |
| Folkerts, H | 1 |
| Caruzzo, E | 1 |
| Caruzzo, C | 1 |
| Graf, WD | 1 |
| Riback, PS | 1 |
| Radford, MJ | 1 |
| Ellerbeck, EF | 1 |
| Hennen, J | 1 |
| Meehan, TP | 1 |
| Petrillo, M | 1 |
| Jencks, SF | 1 |
| Andersson, R | 1 |
| Ezra, Y | 2 |
| Rose, M | 1 |
| Eldor, A | 2 |
| Altman, R | 1 |
| Rouvier, J | 1 |
| Gurfinkel, E | 1 |
| Haddad, B | 1 |
| Uzan, M | 1 |
| Bréart, G | 2 |
| Uzan, S | 3 |
| Hartmann, A | 1 |
| Hennerici, MG | 1 |
| Meairs, S | 1 |
| Scadding, GK | 1 |
| Hassab, M | 1 |
| Darby, YC | 1 |
| Lund, VJ | 1 |
| Freedman, A | 1 |
| Cottier, C | 1 |
| Elikowski, W | 1 |
| Psuja, P | 1 |
| Lewandowski, K | 1 |
| Przybył, M | 1 |
| Wendland, M | 1 |
| Wróblewski, D | 1 |
| Jazienicki, B | 1 |
| Przybył, L | 1 |
| Zawilska, K | 1 |
| Eisenberg, MJ | 1 |
| Topal, EJ | 1 |
| Rodgers, A | 1 |
| MacMahon, S | 2 |
| Gamble, G | 1 |
| Slattery, J | 1 |
| Sandercock, P | 5 |
| Warlow, C | 3 |
| Bowker, TJ | 1 |
| Clayton, TC | 1 |
| Ingham, J | 1 |
| McLennan, NR | 1 |
| Hobson, HL | 1 |
| Pyke, SD | 1 |
| Schofield, B | 1 |
| Wood, DA | 1 |
| Sankardas, MA | 1 |
| McEniery, PT | 1 |
| Aroney, CN | 1 |
| Bett, JH | 1 |
| Chen, LY | 1 |
| Nichols, WW | 1 |
| Mattsson, C | 1 |
| Teger-Nilson, AC | 1 |
| Wallin, R | 1 |
| Saldeen, TG | 1 |
| Mehta, JL | 1 |
| Stroobandt, G | 1 |
| Fransen, P | 1 |
| Thauvoy, C | 1 |
| Menard, E | 1 |
| Saito, S | 1 |
| Hosokawa, FG | 1 |
| Kim, K | 1 |
| Miyake, S | 1 |
| Norris, RM | 1 |
| Hart, HH | 1 |
| Oler, A | 1 |
| Whooley, MA | 1 |
| Oler, J | 1 |
| Grady, D | 1 |
| Mark, DB | 1 |
| Talley, JD | 1 |
| Bowman, L | 1 |
| Lam, LC | 1 |
| Anderson, KM | 2 |
| Jollis, JG | 1 |
| Cleman, MW | 2 |
| Lee, KL | 1 |
| Aversano, T | 1 |
| Untereker, WJ | 1 |
| Davidson-Ray, L | 1 |
| Diethrich, EB | 1 |
| Ndiaye, M | 1 |
| Reid, DB | 1 |
| Collins, R | 4 |
| Flather, M | 1 |
| Baigent, C | 1 |
| Remvig, L | 1 |
| Mortensen, S | 1 |
| Appleby, P | 1 |
| Godwin, J | 1 |
| Peto, R | 5 |
| Heinz, M | 1 |
| van de Flierdt, E | 1 |
| Söhngen, M | 1 |
| van den Brand, MJ | 1 |
| van Miltenburg, A | 1 |
| van der Wieken, LR | 1 |
| de Feyter, PJ | 1 |
| Rapaport, E | 1 |
| Gheorghiade, M | 1 |
| Malcolm, AD | 1 |
| Keltai, M | 1 |
| Walsh, MJ | 1 |
| Umemura, K | 1 |
| Nishiyama, H | 1 |
| Kikuchi, S | 1 |
| Kondo, K | 1 |
| Nakashima, M | 1 |
| Julian, DG | 1 |
| Chamberlain, DA | 1 |
| Enserink, M | 1 |
| Neumann, FJ | 1 |
| Walter, H | 2 |
| Schühlen, H | 3 |
| Hadamitzky, M | 2 |
| Zitzmann-Roth, EM | 1 |
| Dirschinger, J | 2 |
| Hausleiter, J | 1 |
| Blasini, R | 1 |
| Alt, E | 1 |
| Santiago, T | 1 |
| Chasuk, R | 1 |
| Lenkovsky, F | 1 |
| Neirinck, LG | 1 |
| Glezer, SV | 1 |
| Klein, LW | 1 |
| Wahid, F | 1 |
| VandenBerg, BJ | 1 |
| Parrillo, JE | 1 |
| Calvin, JE | 1 |
| Gregorini, L | 1 |
| Marco, J | 1 |
| de Lorgeril, M | 1 |
| Salen, P | 1 |
| Caillat-Vallet, E | 1 |
| Hanauer, MT | 1 |
| Barthelemy, JC | 1 |
| Mamelle, N | 1 |
| Kanchurina, NA | 1 |
| Poroshina, IuA | 1 |
| Prasolova, NI | 1 |
| Zemskov, VM | 1 |
| Baim, DS | 3 |
| Carrozza, JP | 1 |
| Galassi, AR | 1 |
| Tamburino, C | 1 |
| Grassi, R | 1 |
| Monaco, A | 1 |
| Russo, G | 1 |
| Ierna, SM | 1 |
| Calvi, V | 1 |
| Giuffrida, G | 1 |
| Ishikawa, K | 2 |
| Kanamasa, K | 1 |
| Hama, J | 1 |
| Ogawa, I | 1 |
| Takenaka, T | 1 |
| Naito, T | 1 |
| Yamamoto, T | 1 |
| Nakai, S | 1 |
| Oyaizu, M | 1 |
| Kimura, A | 1 |
| Yamamoto, K | 1 |
| Katori, R | 1 |
| Seaton, TL | 1 |
| Hull, MA | 1 |
| Knifton, A | 1 |
| Filipowicz, B | 1 |
| Brough, JL | 1 |
| Vautier, G | 1 |
| Kher, A | 1 |
| Samama, MM | 1 |
| Barragan, P | 1 |
| Pietri, P | 1 |
| Villain, P | 1 |
| Silvestri, M | 1 |
| Roquebert, PO | 1 |
| Dippel, DW | 2 |
| Nichols, FT | 1 |
| Ulm, K | 1 |
| Hennekens, CH | 3 |
| Wilber, DJ | 1 |
| Gunnar, RM | 1 |
| Nguyen, KN | 1 |
| Aursnes, I | 1 |
| Kjekshus, J | 1 |
| Stiegler, H | 1 |
| Schädlich, PK | 1 |
| Brecht, JG | 1 |
| Moussa, I | 1 |
| Moses, J | 1 |
| Reimers, B | 1 |
| Di Francesco, L | 1 |
| Martini, G | 1 |
| Tobis, J | 1 |
| Colombo, A | 2 |
| Laperche, T | 1 |
| Laurian, C | 1 |
| Roudaut, R | 1 |
| Demers, C | 2 |
| Fromell, GJ | 3 |
| Goodman, S | 2 |
| Premmereur, J | 2 |
| Granger, KA | 1 |
| Farquharson, RG | 1 |
| Horrocks, M | 1 |
| Horrocks, EH | 1 |
| Murphy, P | 1 |
| Lane, IF | 2 |
| Ruttley, MS | 1 |
| Fligelstone, LJ | 1 |
| Watson, HR | 1 |
| Lee, TK | 2 |
| Chan, KW | 1 |
| Huang, ZS | 1 |
| Ng, SK | 1 |
| Lin, RT | 1 |
| Yuan, RY | 1 |
| Lai, ML | 1 |
| Chang, TW | 1 |
| Yan, SH | 1 |
| Deng, JC | 1 |
| Liu, LH | 1 |
| Lee, KY | 2 |
| Lie, SK | 1 |
| Sung, SM | 1 |
| Hu, HH | 2 |
| Ryglewicz, D | 1 |
| Baranska-Gieruszczak, M | 1 |
| Lechowicz, W | 1 |
| Hier, DB | 1 |
| Robinson, J | 1 |
| Poller, S | 1 |
| Hesse, L | 1 |
| Aylward, PE | 1 |
| Frey, MJ | 1 |
| Adgey, AA | 1 |
| Nair, R | 1 |
| Hillis, WS | 1 |
| Shalev, Y | 1 |
| Maraganore, J | 1 |
| Adelman, B | 1 |
| Leadley, RJ | 1 |
| Kasiewski, CJ | 1 |
| Bostwick, JS | 1 |
| Bentley, R | 1 |
| McVey, MJ | 1 |
| White, FJ | 1 |
| Perrone, MH | 1 |
| Dunwiddie, CT | 1 |
| Anzuini, A | 2 |
| Rosanio, S | 2 |
| Legrand, V | 2 |
| Tocchi, M | 2 |
| Coppi, R | 2 |
| Marazzi, G | 1 |
| Vicedomini, G | 1 |
| Pagnotta, P | 1 |
| Montorfano, M | 1 |
| Bonnier, H | 2 |
| Sheiban, I | 2 |
| Kulbertus, HE | 2 |
| Chierchia, SL | 2 |
| Krnic-Barrie, S | 1 |
| O'Connor, CR | 1 |
| Looney, SW | 1 |
| Pierangeli, SS | 1 |
| Harris, EN | 2 |
| Rojas-Poceros, G | 1 |
| Ramírez Peredo, J | 1 |
| Hernández Andrade, E | 1 |
| Bustos López, HH | 1 |
| Bruna, C | 1 |
| Rossetti, G | 1 |
| Vado, A | 1 |
| Racca, E | 1 |
| Steffenino, G | 2 |
| Dellavalle, A | 1 |
| Ribichini, F | 1 |
| Ferrero, V | 1 |
| Menardi, E | 1 |
| Uslenghi, E | 1 |
| Heintzen, MP | 1 |
| Heidland, UE | 1 |
| Klimek, WJ | 1 |
| Michel, CJ | 1 |
| Schwartzkopff, B | 1 |
| Vester, EG | 1 |
| Strauer, BE | 1 |
| Rossi, G | 1 |
| Karádi, I | 1 |
| Kárpáti, S | 1 |
| Romics, L | 1 |
| Venketasubramanian, N | 1 |
| Singh, J | 1 |
| Hui, F | 1 |
| Stoupel, E | 1 |
| Hirschowitz, BI | 1 |
| Sullivan, MH | 1 |
| Clark, NA | 1 |
| de Swiet, M | 1 |
| Nelson-Piercy, C | 1 |
| Elder, MG | 1 |
| Calvey, TA | 1 |
| Gough, MJ | 1 |
| Aronow, WS | 1 |
| Oemrawsingh, PV | 2 |
| Tuinenburg, JC | 1 |
| Schalij, MJ | 2 |
| Jukema, JW | 1 |
| Reiber, JH | 1 |
| Bruschke, AV | 2 |
| Pizzulli, L | 1 |
| Lüderitz, B | 1 |
| Kleiman, NS | 1 |
| Lincoff, AM | 3 |
| Kereiakes, DJ | 1 |
| Miller, DP | 1 |
| Aguirre, FV | 1 |
| Weisman, HF | 1 |
| Raza, K | 1 |
| Karokis, D | 1 |
| Kitas, GD | 1 |
| Udayachalerm, W | 1 |
| van der Wall, EE | 1 |
| Martínez Elbal, L | 1 |
| López Mínguez, JR | 1 |
| Alonso, M | 1 |
| Calvo, I | 1 |
| Insa, L | 1 |
| Lezaun, R | 1 |
| Colman, T | 1 |
| Esplugas, E | 1 |
| Vázquez, N | 1 |
| Picó, F | 1 |
| Amaro, A | 1 |
| Kurz, X | 1 |
| Annemans, L | 1 |
| Dresse, A | 1 |
| Volpi, A | 1 |
| Cavalli, A | 1 |
| Santoro, L | 1 |
| Negri, E | 1 |
| Riyazi, N | 1 |
| Leeda, M | 1 |
| Huijgens, PC | 1 |
| van Geijn, HP | 1 |
| Dekker, GA | 1 |
| Klootwijk, P | 1 |
| Meij, S | 1 |
| Melkert, R | 1 |
| Lenderink, T | 1 |
| Pepine, CJ | 1 |
| Bystedt, J | 1 |
| Asplund, K | 1 |
| Higgins, RM | 1 |
| Connolly, JO | 1 |
| Hendry, BM | 1 |
| Forbes, CD | 2 |
| Popma, JJ | 2 |
| Weitz, J | 1 |
| Bittl, JA | 1 |
| Kuntz, RE | 1 |
| Lansky, AJ | 1 |
| Saucedo, J | 1 |
| Greenberg, A | 1 |
| Leon, MB | 1 |
| Maizels, M | 1 |
| Nordt, TK | 1 |
| Moser, M | 1 |
| Kohler, B | 1 |
| Ruef, J | 1 |
| Peter, K | 1 |
| Bode, C | 1 |
| Gensini, G | 1 |
| De Caterina, R | 1 |
| Calver, AL | 1 |
| Dawkins, KD | 1 |
| Gray, HH | 1 |
| Haywood, GA | 1 |
| Morgan, JM | 1 |
| Simpson, IA | 1 |
| Cesmeli, E | 1 |
| Elewaut, AE | 1 |
| Kerre, T | 1 |
| De Buyzere, M | 1 |
| Afschrift, M | 1 |
| Elewaut, A | 1 |
| McCormick, D | 1 |
| Gurwitz, JH | 1 |
| Maresta, A | 1 |
| Balducelli, M | 1 |
| Cantini, L | 1 |
| Casari, A | 1 |
| Chioin, R | 1 |
| Fontanelli, A | 1 |
| Monici Preti, PA | 1 |
| Repetto, S | 1 |
| Raffaghello, S | 1 |
| Morice, MC | 1 |
| García-Dorado, D | 2 |
| Permanyer-Miralda, G | 1 |
| Brotons, C | 1 |
| Calvo, F | 1 |
| Campreciós, M | 1 |
| Oliveras, J | 1 |
| Santos, MT | 1 |
| Moral, I | 1 |
| Soler-Soler, J | 1 |
| Catherwood, E | 1 |
| Fitzpatrick, WD | 1 |
| Greenberg, ML | 1 |
| Holzberger, PT | 1 |
| Malenka, DJ | 1 |
| Gerling, BR | 1 |
| Birkmeyer, JD | 1 |
| Ogata, Y | 1 |
| Okinaka, Y | 1 |
| Takahashi, M | 1 |
| Pialoux, R | 1 |
| Coffinet, L | 1 |
| Derelle, J | 1 |
| Jankowski, R | 1 |
| Harrington, RA | 1 |
| Miller, JM | 1 |
| Sloan, MA | 1 |
| Berdan, LG | 1 |
| MacAulay, CM | 1 |
| Deckers, J | 1 |
| Gorter, JW | 1 |
| De Schryver, EL | 1 |
| Folland, ED | 1 |
| Tardy-Poncet, B | 1 |
| Tardy, B | 1 |
| Reynaud, J | 1 |
| Mahul, P | 1 |
| Mismetti, P | 1 |
| Mazet, E | 1 |
| Guyotat, D | 1 |
| Tsuchikane, E | 1 |
| Fukuhara, A | 1 |
| Kobayashi, T | 2 |
| Kirino, M | 1 |
| Yamasaki, K | 1 |
| Izumi, M | 1 |
| Otsuji, S | 1 |
| Tateyama, H | 1 |
| Sakurai, M | 1 |
| Awata, N | 1 |
| Atamuradov, MA | 1 |
| Garaev, TA | 1 |
| Boysen, G | 1 |
| Lee, HJ | 1 |
| Kaldenbach, T | 1 |
| Schäfer, D | 1 |
| Bittinger, F | 1 |
| Klimek, L | 1 |
| Jauhar, R | 1 |
| Bergman, G | 1 |
| Savino, S | 1 |
| Shaknovich, A | 1 |
| Parikh, M | 1 |
| Danenberg, HD | 1 |
| Hasin, Y | 1 |
| Gavaghan, BJ | 1 |
| Kittleson, MD | 1 |
| McAloose, D | 1 |
| Steiner, M | 1 |
| Escolar, G | 2 |
| Revilla, M | 1 |
| Obach, V | 1 |
| Vila, N | 1 |
| Reverter, JC | 1 |
| Ordinas, A | 1 |
| Berntorp, E | 1 |
| Yoon, Y | 1 |
| Shim, WH | 1 |
| Pyun, WB | 1 |
| Kim, IJ | 1 |
| Cho, SY | 1 |
| Robbins, MA | 1 |
| Marso, SP | 1 |
| Wolski, K | 1 |
| Peterson, J | 1 |
| Brener, S | 1 |
| Salomon, O | 1 |
| Huna-Baron, R | 1 |
| Steinberg, DM | 1 |
| Kurtz, S | 1 |
| Seligsohn, U | 1 |
| Caro, JJ | 1 |
| Migliaccio-Walle, K | 1 |
| Le Roux, A | 1 |
| Rothbart, RM | 1 |
| McAnulty, JH | 1 |
| Halperin, JL | 1 |
| Cruz-Fernández, JM | 1 |
| López-Bescós, L | 1 |
| López García-Aranda, V | 1 |
| Cabadés, A | 1 |
| Martín-Jadraque, L | 1 |
| Velasco, JA | 1 |
| Castro-Beiras, A | 1 |
| Torres, F | 1 |
| Marfil, F | 1 |
| Navarro, E | 1 |
| Nakai, K | 1 |
| Tajima, K | 1 |
| Kishimoto, Y | 1 |
| Katsura, K | 1 |
| Kawamura, M | 1 |
| Hanada, M | 1 |
| Amakawa, R | 1 |
| Fujimoto, M | 1 |
| Fukuhara, S | 1 |
| Mori, Y | 1 |
| Tamaki, S | 1 |
| Minami, N | 1 |
| Shiku, H | 1 |
| Ihara, T | 1 |
| Omine, M | 1 |
| Kakisita, E | 1 |
| Hemphill, JC | 1 |
| Crassard, I | 1 |
| Niclot, P | 1 |
| Piette, AM | 1 |
| Blétry, O | 1 |
| Berge, E | 2 |
| Abdelnoor, M | 1 |
| Nakstad, PH | 1 |
| Sandset, PM | 2 |
| Van Langenhove, G | 1 |
| Vermeersch, P | 1 |
| Serrano, P | 1 |
| Kutryk, MJ | 1 |
| Stockman, D | 1 |
| Convens, C | 1 |
| Van den Branden, F | 1 |
| Vanagt, E | 1 |
| Albertal, M | 1 |
| Van den Heuvel, P | 1 |
| Zeymer, U | 1 |
| Neuhaus, KL | 1 |
| Franke, A | 1 |
| Stinnett, SS | 1 |
| Weatherley, BD | 1 |
| Cohen, N | 1 |
| Almoznino-Sarafian, D | 1 |
| Alon, I | 1 |
| Gorelik, O | 1 |
| Koopfer, M | 1 |
| Chachashvily, S | 1 |
| Shteinshnaider, M | 1 |
| Litvinjuk, V | 1 |
| Modai, D | 1 |
| Chen, ZM | 1 |
| Pan, HC | 1 |
| Counsell, C | 1 |
| Liu, LS | 1 |
| Xie, JX | 1 |
| Ruzyłło, W | 1 |
| Gil, R | 1 |
| Górecka, B | 1 |
| Purzycki, Z | 1 |
| Kośmider, M | 1 |
| Poloński, L | 1 |
| Lekston, A | 1 |
| Gasior, M | 1 |
| Zmudka, K | 1 |
| Pieniazek, P | 1 |
| Buszman, P | 1 |
| Drzewiecki, J | 1 |
| Ciećwierz, D | 1 |
| Sadowski, Z | 1 |
| Thijs, VN | 1 |
| Gondek, K | 1 |
| Nucera, E | 2 |
| Schiavino, D | 2 |
| Milani, A | 1 |
| Del Ninno, M | 1 |
| Misuraca, C | 1 |
| Buonomo, A | 1 |
| D'Ambrosio, C | 1 |
| Paludetti, G | 1 |
| Patriarca, G | 2 |
| Nah, DY | 1 |
| Sarasin, FP | 2 |
| Gaspoz, JM | 1 |
| Qasim, A | 1 |
| Chauhan, A | 1 |
| More, RS | 1 |
| Silber, S | 1 |
| Krischke, I | 1 |
| Prohaska, M | 1 |
| Evers, S | 1 |
| Fischer, M | 2 |
| Siegel, AM | 1 |
| Sandor, P | 1 |
| Kollias, SS | 1 |
| Borja, J | 1 |
| Olivella, P | 1 |
| Modrzyński, M | 1 |
| Wróbel, B | 1 |
| Zawisza, E | 1 |
| Grochowski, P | 1 |
| Pache, J | 1 |
| Gaziano, JM | 1 |
| Skerrett, PJ | 1 |
| Backues, KA | 1 |
| Hoover, JP | 1 |
| Bahr, RJ | 1 |
| Confer, AW | 1 |
| Chalman, JA | 1 |
| Larry, ML | 1 |
| Schütt, M | 1 |
| Klüter, H | 1 |
| Wiedemann, GJ | 1 |
| Richardt, G | 1 |
| Sbaï, A | 1 |
| Wechsler, B | 1 |
| Amoura, Z | 1 |
| Godeau, P | 1 |
| Piette, JC | 1 |
| Napoli, C | 1 |
| Cirino, G | 1 |
| Del Soldato, P | 1 |
| Sorrentino, R | 1 |
| Sica, V | 1 |
| Condorelli, M | 1 |
| Pinto, A | 1 |
| Ignarro, LJ | 1 |
| Farquhar, D | 1 |
| Hurlen, M | 1 |
| Hole, T | 1 |
| Seljeflot, I | 1 |
| Arnesen, H | 1 |
| Naber, CK | 1 |
| Kaiser, CA | 1 |
| Rahman, YA | 1 |
| Haude, M | 1 |
| Baumgart, D | 1 |
| Chorzempa, A | 1 |
| Tabloski, P | 1 |
| Scrutinio, D | 1 |
| Cimminiello, C | 1 |
| Marubini, E | 1 |
| Pitzalis, MV | 1 |
| Di Biase, M | 1 |
| Rizzon, P | 1 |
| Castellino, G | 1 |
| Godfrey, T | 1 |
| Branch, DW | 1 |
| Porter, TF | 1 |
| Rittenhouse, L | 1 |
| Caritis, S | 1 |
| Sibai, B | 1 |
| Hogg, B | 1 |
| Lindheimer, MD | 1 |
| Klebanoff, M | 1 |
| MacPherson, C | 1 |
| VanDorsten, JP | 1 |
| Landon, M | 1 |
| Paul, R | 1 |
| Miodovnik, M | 1 |
| Meis, P | 1 |
| Thurnau, G | 1 |
| Kuroda, Y | 1 |
| Hara, K | 1 |
| Nakajima, H | 1 |
| Ikari, Y | 1 |
| Deva, R | 1 |
| Ciccoli, R | 1 |
| Kock, L | 1 |
| Nigam, S | 1 |
| Kollum, M | 1 |
| Bhargava, B | 1 |
| Mintz, GS | 1 |
| Kolodgie, FD | 1 |
| Virmani, R | 1 |
| Kipp, A | 1 |
| Allen, JK | 1 |
| Margolis, S | 1 |
| Young, DR | 1 |
| Tanabe, Y | 1 |
| Nakagawa, I | 1 |
| Walenga, JM | 1 |
| Hoppensteadt, D | 1 |
| Pifarré, R | 1 |
| Fox, NL | 1 |
| Forman, S | 1 |
| Hunninghake, DB | 1 |
| Campeau, L | 1 |
| Herd, JA | 1 |
| Hoogwerf, BJ | 1 |
| Hickey, A | 1 |
| Probstfield, JL | 1 |
| Terrin, ML | 1 |
| Mukherjee, D | 1 |
| Chew, DP | 1 |
| Robbins, M | 1 |
| Yadav, JS | 1 |
| Raymond, RE | 1 |
| Moliterno, DJ | 1 |
| Raman, V | 1 |
| Sharkey, A | 1 |
| Chatila, T | 1 |
| Walters, MR | 1 |
| Lees, KR | 1 |
| Ogasawara, MS | 1 |
| Iinuma, Y | 1 |
| Aoki, K | 1 |
| Katano, K | 1 |
| Ozaki, Y | 1 |
| Suzumori, K | 1 |
| Darius, H | 2 |
| Bertrand-Hardy, JM | 1 |
| Humphreys, M | 1 |
| Yagi, K | 1 |
| Nakamura, A | 1 |
| Sekine, A | 1 |
| Watanabe, H | 1 |
| Liistro, F | 1 |
| Grundmann, T | 1 |
| Töpfner, M | 1 |
| Sträter, R | 1 |
| Kurnik, K | 1 |
| Heller, C | 1 |
| Schobess, R | 1 |
| Luigs, P | 1 |
| Nowak-Göttl, U | 1 |
| Gottlieb, S | 1 |
| Arquizan, C | 1 |
| Lamy, C | 1 |
| Zuber, M | 3 |
| Cabanes, L | 1 |
| Derumeaux, G | 1 |
| Coste, J | 1 |
| Rollins, G | 1 |
| Empson, M | 1 |
| Lassere, M | 1 |
| Craig, JC | 1 |
| Scott, JR | 1 |
| Granel, B | 1 |
| Rey, J | 1 |
| Pache, X | 1 |
| Swiader, L | 1 |
| Habib, G | 1 |
| Mesana, T | 1 |
| Ene, N | 1 |
| Disdier, P | 1 |
| Weiller, PJ | 1 |
| Morais, J | 1 |
| Du, ZD | 1 |
| Cao, QL | 1 |
| Joseph, A | 1 |
| Koenig, P | 1 |
| Heischmidt, M | 1 |
| Waight, DJ | 1 |
| Rhodes, J | 1 |
| Brorson, J | 1 |
| Hijazi, ZM | 1 |
| Schweiger, C | 1 |
| Tavazzi, L | 1 |
| Valagussa, F | 1 |
| Goertler, M | 1 |
| Blaser, T | 1 |
| Krueger, S | 1 |
| Hofmann, K | 1 |
| Baeumer, M | 1 |
| Wallesch, CW | 1 |
| Poerner, TC | 1 |
| Kralev, S | 1 |
| Voelker, W | 1 |
| Sueselbeck, T | 1 |
| Latsch, A | 1 |
| Pfleger, S | 1 |
| Schumacher, B | 1 |
| Haase, KK | 1 |
| Darbà, J | 1 |
| Izquierdo, I | 1 |
| Pontes, C | 1 |
| Navas, C | 1 |
| Rovira, J | 1 |
| Proia, A | 1 |
| Paesano, R | 1 |
| Torcia, F | 1 |
| Annino, L | 1 |
| Capria, S | 1 |
| Ferrari, A | 1 |
| Ferrazza, G | 1 |
| Pacifici, E | 1 |
| Pantalissi, A | 1 |
| Meloni, G | 1 |
| Baron, D | 1 |
| Bombardier, C | 1 |
| Bursey, FR | 1 |
| Marshall, JR | 1 |
| Morgan, DG | 1 |
| Paré, P | 1 |
| Thomson, AB | 1 |
| Whittaker, JS | 1 |
| Lai, KC | 1 |
| Lam, SK | 1 |
| Chu, KM | 1 |
| Hui, WM | 1 |
| Hu, WH | 1 |
| Lau, GK | 1 |
| Wong, WM | 1 |
| Yuen, MF | 1 |
| Chan, AO | 1 |
| Lai, CL | 1 |
| Wong, J | 1 |
| Rote, NS | 1 |
| Thabet, F | 1 |
| Durand, P | 1 |
| Chevret, L | 1 |
| Fabre, M | 1 |
| Debray, D | 1 |
| Brivet, M | 1 |
| Devictor, D | 1 |
| de Jong, MC | 1 |
| Monnens, LA | 1 |
| Goodlin, RC | 1 |
| Haesslein, HO | 1 |
| Fleming, J | 1 |
| Vogel, G | 1 |
| Fischer, C | 1 |
| Huyke, R | 1 |
| Williams, WO | 1 |
| Gorn, RA | 1 |
| Elliott, J | 1 |
| Uberla, K | 2 |
| McDowell, FH | 1 |
| Wayoff, M | 1 |
| Simon, C | 1 |
| Gazel, P | 1 |
| Watson, RT | 1 |
| Fisherman, EW | 2 |
| Cohen, GN | 2 |
| Okabe, S | 2 |
| Takagi, K | 2 |
| Umeda, N | 1 |
| Mit'kin, AF | 1 |
| Hess, H | 1 |
| Müller-Fassbender, H | 1 |
| Ingrisch, H | 1 |
| Mietaschk, A | 1 |
| Bucher, HJ | 1 |
| Jacobs, JC | 1 |
| Hui, RM | 1 |
| Illig, L | 1 |
| Crawford, JS | 2 |
| Ros, AM | 1 |
| Juhlin, L | 1 |
| Michaëlsson, G | 1 |
| Honda, K | 1 |
| Shaper, AG | 1 |
| Rittenhouse, M | 1 |
| McFee, AS | 1 |
| Aust, JB | 1 |
| Heuchel, G | 1 |
| Hässler, W | 1 |
| Kalendovsky, Z | 1 |
| Austin, J | 1 |
| Steele, P | 1 |
| Lewandowski, RL | 1 |
| Chan, W | 1 |
| Piper, DW | 1 |
| Greig, M | 1 |
| Coupland, GA | 1 |
| Hobbin, E | 1 |
| Shinners, J | 1 |
| Colin, P | 1 |
| Noir, A | 1 |
| Menget, A | 1 |
| Schirrer, J | 1 |
| Estavoyer, JM | 1 |
| Raffi, A | 1 |
| Calabro, JJ | 1 |
| Wachtel, AE | 1 |
| Holgerson, WB | 1 |
| Repice, MM | 1 |
| Wu, KK | 1 |
| Barnes, RW | 1 |
| Hoak, JC | 1 |
| Dabrowski, M | 1 |
| Sleight, P | 1 |
| Rubowitz, AH | 1 |
| Porath, A | 1 |
| Chauvin, M | 2 |
| Koenig, A | 2 |
| Brechenmacher, C | 2 |
| Terres, W | 1 |
| Ruchelka, A | 1 |
| Weilepp, A | 1 |
| Kupper, W | 1 |
| Hatzis, J | 1 |
| Noutsis, K | 1 |
| Hatzidakis, E | 1 |
| Bassioukas, K | 1 |
| Perissios, A | 1 |
| Fouchard, J | 1 |
| Le, F | 1 |
| Py, A | 1 |
| Guérin, F | 1 |
| Balelli, LA | 1 |
| Sandborn, T | 1 |
| Haudenschild, C | 1 |
| Valeri, R | 1 |
| Kimata, S | 1 |
| Harbison, JW | 1 |
| Arslan, Z | 1 |
| Tezic, T | 1 |
| Akinci, A | 1 |
| Gur, I | 1 |
| Haspolat, E | 1 |
| Karademir, S | 1 |
| Leivonen, M | 1 |
| Kivilaakso, E | 1 |
| López Bescós, L | 1 |
| Ranke, C | 2 |
| Creutzig, A | 2 |
| Hecker, H | 2 |
| Alexander, K | 3 |
| Luska, G | 1 |
| Wagner, HH | 1 |
| Galanski, M | 1 |
| Avenarius, HJ | 1 |
| Sankarkumar, T | 1 |
| Panda, A | 1 |
| Angra, SK | 1 |
| Roux, S | 1 |
| Christeller, S | 1 |
| Lüdin, E | 1 |
| Juliard, JM | 1 |
| Himbert, D | 1 |
| Sherry, S | 1 |
| Marder, VJ | 1 |
| Cherng, WJ | 1 |
| Chiang, CW | 1 |
| Kuo, CT | 1 |
| Lee, CP | 1 |
| Lee, YS | 1 |
| Harker, LA | 2 |
| Bernstein, EF | 1 |
| Dilley, RB | 1 |
| Scala, TE | 1 |
| Sise, MJ | 1 |
| Hye, RJ | 1 |
| Otis, SM | 1 |
| Roberts, RS | 1 |
| Gent, M | 1 |
| Théolade, R | 1 |
| Reymond, MA | 1 |
| Marbet, G | 1 |
| Radü, EW | 1 |
| Gratzl, O | 1 |
| Green, BK | 1 |
| Gordon, GD | 1 |
| Horak, AR | 1 |
| Millar, RN | 1 |
| Commerford, PJ | 1 |
| Presbitero, P | 1 |
| Rabajoli, F | 1 |
| Paolillo, V | 1 |
| Kleiman, N | 1 |
| Aguirre, F | 1 |
| Chaitman, BR | 1 |
| Ross, AM | 1 |
| Théroux, P | 1 |
| Waters, D | 1 |
| Lam, J | 1 |
| Juneau, M | 1 |
| McCans, J | 1 |
| van Oppen, J | 1 |
| van Ommen, V | 1 |
| Bär, FW | 1 |
| de Swart, JB | 1 |
| van der Veen, FH | 1 |
| Wellens, HJ | 1 |
| Alexander, HM | 1 |
| Steele, PL | 1 |
| Malcolm, JA | 1 |
| Rosove, MH | 1 |
| Brewer, PM | 1 |
| Lange, J | 1 |
| Alter, M | 1 |
| Lai, SM | 1 |
| Friday, GH | 1 |
| Sobel, E | 1 |
| Toedter, LJ | 1 |
| Beaufils, M | 2 |
| Bazin, B | 2 |
| Capitant, C | 1 |
| Paris, J | 1 |
| Papa, G | 1 |
| Schinco, G | 1 |
| Fais, G | 1 |
| Dunbabin, D | 1 |
| Gibson, RS | 2 |
| Franzosi, MG | 1 |
| Malacrida, R | 1 |
| Rübsamen, K | 1 |
| Eschenfelder, V | 1 |
| Beisiegel, B | 1 |
| Hafner, G | 1 |
| Pop, T | 1 |
| Treese, N | 1 |
| Thomassin, JM | 1 |
| Korchia, D | 1 |
| Yu, Q | 1 |
| Kou, W | 1 |
| Lu, Z | 1 |
| Yao, K | 1 |
| Gao, R | 1 |
| Jia, Y | 1 |
| Duan, B | 1 |
| Bulbena, O | 1 |
| Bravo, ML | 1 |
| Navarro, C | 1 |
| de Bono, DP | 2 |
| Hoffman, W | 1 |
| Schanzenbächer, P | 2 |
| Pilger, E | 1 |
| Lammer, J | 1 |
| Bertuch, H | 1 |
| Stark, G | 1 |
| Decrinis, M | 1 |
| Pfeiffer, KP | 1 |
| Krejs, GJ | 1 |
| Hershey, LA | 1 |
| Rutsch, W | 1 |
| Heyndrickx, GR | 1 |
| Mast, EG | 1 |
| Wijns, W | 1 |
| Rensing, BJ | 1 |
| Vos, J | 1 |
| Stibbe, J | 1 |
| Mase, K | 1 |
| Yasunaga, K | 1 |
| Taussig, AS | 1 |
| Cowley, M | 3 |
| Ahmadi, R | 3 |
| Altmann, E | 1 |
| Spranger, C | 1 |
| Schweizer, J | 1 |
| Hoffmann, A | 1 |
| Schmidt, PK | 1 |
| Bourassa, MG | 3 |
| Lespérance, J | 3 |
| Eastwood, C | 2 |
| Schwartz, L | 3 |
| Côté, G | 1 |
| Kazim, F | 3 |
| Hudon, G | 1 |
| Himmelreich, G | 1 |
| Riess, H | 1 |
| Mohler, ER | 1 |
| Stark, KS | 1 |
| Haskel, EJ | 2 |
| Rogers, WJ | 1 |
| Babb, JD | 1 |
| Frederick, M | 1 |
| Passamani, ER | 1 |
| Pfisterer, M | 1 |
| Wenzel, R | 1 |
| Petch, MC | 1 |
| Domoto, DT | 1 |
| Bauman, JE | 1 |
| Joist, JH | 1 |
| Taylor, RR | 1 |
| Gibbons, FA | 1 |
| Cope, GD | 1 |
| Cumpston, GN | 1 |
| Mews, GC | 1 |
| Luke, P | 1 |
| Weller, M | 1 |
| Leo-Kottler, B | 1 |
| Berg, PA | 1 |
| Wiethölter, H | 1 |
| Johansson, SR | 1 |
| Wiklund, O | 1 |
| Karlsson, T | 1 |
| Hjalmarson, A | 1 |
| Emanuelsson, H | 1 |
| Neri Serneri, GG | 1 |
| Poggesi, L | 1 |
| Trotta, F | 1 |
| Modesti, PA | 1 |
| Boddi, M | 1 |
| Ieri, A | 1 |
| Margheri, M | 1 |
| Casolo, GC | 1 |
| Bini, M | 1 |
| Lien, IN | 1 |
| Ryu, SJ | 1 |
| Tchen, PH | 1 |
| Chen, CJ | 1 |
| Wu, SC | 1 |
| Chen, YC | 1 |
| Schatz, RA | 1 |
| Leon, M | 1 |
| Ellis, SG | 1 |
| Hirshfeld, JW | 2 |
| Cabin, HS | 1 |
| Walker, C | 1 |
| Stagg, J | 1 |
| O'Keefe, JH | 1 |
| Giorgi, LV | 1 |
| Hartzler, GO | 1 |
| Good, TH | 1 |
| Ligon, RW | 1 |
| Webb, DL | 1 |
| McCallister, BD | 1 |
| Grimme, M | 1 |
| Walter, U | 1 |
| Kochsiek, K | 1 |
| Hoffmann, W | 3 |
| Nitschke, M | 1 |
| Muche, J | 1 |
| Kampe, W | 1 |
| Handreg, W | 1 |
| Prentice, CR | 1 |
| Knudtson, ML | 1 |
| Flintoft, VF | 1 |
| Roth, DL | 1 |
| Hansen, JL | 1 |
| Duff, HJ | 1 |
| Reece, EA | 1 |
| Gabrielli, S | 1 |
| Cullen, MT | 1 |
| Zheng, XZ | 1 |
| Hobbins, JC | 1 |
| Yasuda, T | 1 |
| Gold, HK | 1 |
| Yaoita, H | 1 |
| Leinbach, RC | 1 |
| Guerrero, JL | 1 |
| Holt, R | 1 |
| Fallon, JT | 1 |
| Collen, D | 1 |
| Heiss, HW | 1 |
| Just, H | 1 |
| Middleton, D | 1 |
| Deichsel, G | 1 |
| Schmidt, T | 1 |
| Tebbe, U | 1 |
| Schrader, J | 1 |
| Brune, S | 1 |
| Kreuzer, H | 1 |
| van der Laarse, A | 1 |
| Funke-Küpper, AJ | 1 |
| Sterkman, LG | 1 |
| Galema, TW | 2 |
| Roos, JP | 2 |
| Henderson, MA | 1 |
| Goldberg, SH | 1 |
| Whitworth, H | 1 |
| Nye, ER | 1 |
| Ablett, MB | 1 |
| Robertson, MC | 1 |
| Ilsley, CD | 1 |
| Sutherland, WH | 1 |
| Sigwart, U | 1 |
| Hawkins, L | 1 |
| Bach, M | 1 |
| Dahn, G | 1 |
| Kothe, K | 1 |
| Schlake, HP | 1 |
| Vlot, AJ | 1 |
| Hené, RJ | 1 |
| Sixma, JJ | 1 |
| Ricou, F | 1 |
| Nukta, E | 1 |
| Holman, RA | 1 |
| Davis, M | 1 |
| Gough, KR | 1 |
| Gartell, P | 1 |
| Britton, DC | 1 |
| Smith, RB | 1 |
| Wille, B | 1 |
| Klein, W | 1 |
| Luha, H | 1 |
| Eber, B | 1 |
| Dusleag, J | 1 |
| Brussee, H | 1 |
| Rotman, B | 1 |
| Arafah, M | 1 |
| Ganassin, L | 1 |
| Vinazzer, H | 1 |
| Cox, JL | 1 |
| Gotlieb, AI | 1 |
| Barbash, GI | 1 |
| Rath, S | 1 |
| Miller, HI | 1 |
| Roth, A | 1 |
| Har-Zahav, Y | 1 |
| Modan, M | 1 |
| Rotstein, Z | 1 |
| Batler, A | 1 |
| Zivelin, A | 1 |
| Adams, SP | 1 |
| Feigen, LP | 1 |
| Saffitz, JE | 1 |
| Gorczynski, RJ | 1 |
| Penston, JG | 1 |
| Wormsley, KG | 1 |
| Dudczak, R | 2 |
| Leitha, T | 1 |
| Jung, M | 2 |
| Mordel, N | 1 |
| Sadovsky, E | 1 |
| Schenker, JG | 1 |
| Chrobocek, J | 1 |
| Zichner, R | 1 |
| Weihrauch, TR | 1 |
| Biller, J | 1 |
| Adams, HP | 1 |
| Godersky, JC | 1 |
| Loftus, CM | 1 |
| Mitchell, VL | 1 |
| Banwart, KJ | 1 |
| Jones, MP | 1 |
| Danays, T | 1 |
| Leor, Y | 1 |
| Feldman, S | 1 |
| Rabinowitz, B | 1 |
| Wilhelm, OG | 1 |
| Clayman, MD | 1 |
| Castaigne, A | 1 |
| Duval-Moulin, AM | 1 |
| Dutoit, C | 1 |
| Schlant, RC | 1 |
| Johnson, MW | 1 |
| Flynn, HW | 1 |
| Gass, JD | 1 |
| Salenius, JP | 1 |
| Haapanen, A | 1 |
| Harju, E | 1 |
| Jokela, H | 1 |
| Riekkinen, H | 1 |
| Schreiber, TL | 1 |
| Macina, G | 1 |
| McNulty, A | 1 |
| Bunnell, P | 1 |
| Kikel, M | 1 |
| Miller, DH | 1 |
| Devereux, RB | 1 |
| Tenney, R | 1 |
| Zola, B | 1 |
| Dehmer, GJ | 1 |
| van den Berg, EK | 1 |
| Eichhorn, EJ | 1 |
| Prewitt, JB | 1 |
| Campbell, WB | 1 |
| Jennings, L | 1 |
| Schmitz, JM | 1 |
| Borhani, NO | 1 |
| Caneschi, S | 1 |
| Bonaventi, C | 1 |
| Finzi, F | 1 |
| Knatterud, GL | 1 |
| Stamler, J | 1 |
| Meier, P | 1 |
| Bamford, J | 1 |
| Starkey, I | 1 |
| Evans, AE | 1 |
| Follath, F | 1 |
| Arnold, AE | 1 |
| Betriu, A | 1 |
| Col, J | 1 |
| Dougherty, FC | 1 |
| von Essen, R | 1 |
| Lambertz, H | 1 |
| Lubsen, J | 1 |
| Davenport, J | 1 |
| Whittaker, K | 1 |
| Cohen, LS | 1 |
| Hood, K | 1 |
| Gleeson, D | 1 |
| Ruppin, DC | 1 |
| Dowling, RH | 1 |
| Schöfl, R | 1 |
| Lockshin, MD | 1 |
| Druzin, ML | 1 |
| Qamar, T | 1 |
| Goldberg, RK | 1 |
| Levine, S | 1 |
| Fenster, PE | 1 |
| Weber, MA | 1 |
| Lorenz, RL | 1 |
| Schramm, W | 1 |
| Lam, JY | 1 |
| Roubin, GS | 1 |
| Bussmann, WD | 1 |
| Vallbracht, C | 2 |
| Austin, GE | 1 |
| Lynn, M | 1 |
| Aldridge, HE | 1 |
| Salvatori, VA | 1 |
| Henderson, M | 1 |
| Bonan, R | 1 |
| David, PR | 1 |
| Vahanian, A | 1 |
| Wilhelmsen, L | 1 |
| Pion, PD | 1 |
| Shimizu, Y | 1 |
| Tanaka, T | 1 |
| Takayama, Y | 1 |
| Hayashi, T | 1 |
| Ito, Y | 1 |
| Abe, M | 1 |
| Matsuda, M | 1 |
| Ida, T | 1 |
| Sakakibara, T | 1 |
| Obunai, Y | 1 |
| Tomaru, T | 1 |
| Uchida, Y | 1 |
| Sonoki, H | 1 |
| Sugimoto, T | 1 |
| Meek, AC | 1 |
| Chidlow, A | 1 |
| Greenhalgh, RM | 1 |
| McCollum, CN | 1 |
| Romano, PE | 1 |
| Küpper, AJ | 1 |
| Marcus, M | 1 |
| Biedner, B | 1 |
| Lifshitz, T | 1 |
| Yassur, Y | 1 |
| Spławińska, B | 1 |
| Spławiński, J | 1 |
| Wallenburg, HC | 1 |
| Rotmans, N | 1 |
| Rumore, MM | 1 |
| Goldstein, GS | 1 |
| Matthewson, K | 1 |
| Pugh, S | 1 |
| Northfield, TC | 1 |
| Hays, LJ | 1 |
| Beller, GA | 1 |
| Moore, CA | 1 |
| Burwell, LR | 1 |
| Craddock, GB | 1 |
| Gascho, JA | 1 |
| Smucker, ML | 1 |
| Tedesco, C | 1 |
| Nygaard, TW | 1 |
| Meikle, D | 1 |
| De Martiis, M | 1 |
| Parenzi, A | 1 |
| Barlattani, A | 1 |
| De Martiis, A | 1 |
| Phillips, BM | 1 |
| David, TJ | 1 |
| West, CD | 1 |
| Głab-Kordecka, E | 1 |
| Khalfen, ESh | 1 |
| Ivanova, IA | 1 |
| Feild, C | 1 |
| Brady, S | 1 |
| Lowe, B | 1 |
| Wohns, RN | 1 |
| Dupont, C | 1 |
| Suarez, M | 1 |
| Krieger, BP | 1 |
| Long, JB | 1 |
| Lynch, TG | 1 |
| Karanfilian, RG | 1 |
| Hobson, RW | 1 |
| Herskovits, E | 1 |
| Famulari, A | 1 |
| Tamaroff, L | 1 |
| Gonzalez, AM | 1 |
| Dominguez, R | 1 |
| Fraiman, H | 1 |
| Vila, J | 1 |
| Collins-Williams, C | 1 |
| Shekelle, RB | 1 |
| Gale, M | 1 |
| Norusis, M | 1 |
| Rühle, H | 1 |
| Bunt, TJ | 1 |
| Haynes, JL | 1 |
| Rubin, JR | 1 |
| Goldstone, J | 1 |
| Bollinger, A | 1 |
| Brunner, U | 1 |
| Witteman, GJ | 1 |
| Brubaker, SJ | 1 |
| Johnson, M | 1 |
| Marks, RG | 1 |
| Gorichkina, LA | 1 |
| Frolova, MK | 1 |
| Kuria, VF | 1 |
| Lowe, GD | 1 |
| Machado, SG | 1 |
| Krol, WF | 1 |
| Barton, BA | 1 |
| Harrison, MJ | 1 |
| Marshall, J | 1 |
| Meadows, JC | 1 |
| Russell, RW | 1 |
| Guiraud, B | 1 |
| Pris, J | 1 |
| Sheffer, AL | 1 |
| Miller, GC | 1 |
| Witham, AC | 1 |
| Bock, OA | 2 |
| Timaffy, M | 1 |
| Búzás, J | 1 |
| Chrisman, OD | 1 |
| Snook, GA | 1 |
| Wilson, TC | 1 |
| Cochrane, AL | 1 |
| Burr, ML | 1 |
| Sweetnam, PM | 1 |
| Williams, G | 1 |
| Welsby, E | 1 |
| Hughes, SJ | 1 |
| Renton, R | 1 |
| Mirić, V | 1 |
| Tomasević, M | 1 |
| Rybkin, LI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embol[NCT02239120] | Phase 3 | 5,390 participants (Actual) | Interventional | 2014-11-27 | Completed | ||
| Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS),[NCT02313909] | Phase 3 | 7,213 participants (Actual) | Interventional | 2014-12-23 | Terminated (stopped due to Study halted early due to no efficacy improvement over aspirin at an interim analysis and very little chance of showing overall benefit if study were completed) | ||
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589] | Phase 3 | 5,100 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| International Multicenter Registry on Takotsubo Cardiomyopathy[NCT01947621] | 4,000 participants (Anticipated) | Observational | 2011-01-31 | Recruiting | |||
| Ticagrelor Versus Clopidogrel in Ischemic Stroke. a Randomized Double-blinded Controlled Trial[NCT05553613] | Phase 3 | 900 participants (Actual) | Interventional | 2022-10-01 | Completed | ||
| Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke, a Randomized Controlled Trial[NCT06120725] | Phase 3 | 580 participants (Actual) | Interventional | 2021-09-01 | Completed | ||
| Novel Biomarkers of Thrombotic Risk[NCT02505217] | 200 participants (Actual) | Observational | 2015-07-31 | Completed | |||
| "RCT of an Intervention to Enable Stroke Survivors in Los Angeles County Hospitals to Stay Within the Guidelines (SUSTAIN)"[NCT00861081] | 410 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Int[NCT02415400] | Phase 4 | 4,614 participants (Actual) | Interventional | 2015-06-04 | Completed | ||
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Safety and Efficacy of Century Clot-Guided Prophylactic Rivaroxaban Therapy for Post ST-Segment Elevation Myocardial Infarction Complicating Left Ventricular Thrombus Compared With Conventional Antiplatelet Therapy[NCT06013020] | Phase 4 | 374 participants (Anticipated) | Interventional | 2023-08-28 | Recruiting | ||
| Antithrombotic Drug Use in Patients With Ischemic Stroke and Microbleeds[NCT05032053] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2022-03-01 | Recruiting | |||
| CRYptogenic STroke And underLying AF Trial[NCT00924638] | Phase 4 | 447 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke and Death in Patients With Acute Ischaemic Stroke or Tra[NCT03354429] | Phase 3 | 11,016 participants (Actual) | Interventional | 2018-01-22 | Completed | ||
| A Double-blind Randomized Comparison of Celecoxib Plus Esomeprazole Versus Naproxen Plus Esomeprazole for Prevention of Recurrent Ulcer Bleeding in Patients With Arthritis and Cardiothrombotic Diseases (NSAID#8 Study)[NCT00153660] | Phase 3 | 514 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623] | Phase 3 | 1,899 participants (Actual) | Interventional | 2008-03-01 | Completed | ||
| Low-dose Aspirin Therapy in Patients With Non-Cardioembolic Ischemic Stroke and Microbleeds[NCT04504864] | Phase 4 | 400 participants (Anticipated) | Interventional | 2020-10-01 | Recruiting | ||
| A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA.[NCT01994720] | Phase 3 | 13,307 participants (Actual) | Interventional | 2014-01-07 | Completed | ||
| A Prospective Evaluation of a Standardized Strategy for the Use of Bioresorbable Vascular Scaffold in ST-segment Elevation Myocardial Infarction: the BVS STEMI STRATEGY-IT Registry[NCT02601781] | Phase 4 | 500 participants (Actual) | Interventional | 2015-10-31 | Active, not recruiting | ||
| SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial[NCT02959606] | Phase 4 | 272 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Lo[NCT01452763] | Phase 3 | 621 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase 3, Multicenter, Single-blind, AG-1749-controlled, Parallel-group, Long-term Extension Study to Evaluate the Safety and Efficacy of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-[NCT01456247] | Phase 3 | 439 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Feasibility of Applying Remote Ischemic Conditioning in Secondary Prevention in Patients With Minor Ischemic Stroke or Transient Ischemic Attack -A Single-arm Futility Study[NCT03004820] | 167 participants (Actual) | Interventional | 2016-12-06 | Completed | |||
| A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention[NCT01802775] | Phase 2 | 203 participants (Actual) | Interventional | 2013-02-06 | Completed | ||
| Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events[NCT02616497] | Phase 4 | 1,220 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Impact of Perioperative Maintenance or Interruption of Low-dose Aspirin on Recurrence Rate and Thrombotic Events After Burr-hole Drainage of Chronic Subdural Hematoma: a Randomized, Placebo Controlled, Double Blinded Study[NCT03120182] | 142 participants (Anticipated) | Interventional | 2018-02-19 | Recruiting | |||
| The Origin and Role of Thromboembolism in the Pathogenesis of Ischaemic Stroke[NCT05636748] | 120 participants (Anticipated) | Observational | 2023-02-28 | Recruiting | |||
| Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the SWEDEHEART Platform[NCT02311231] | Phase 4 | 6,012 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Dupilumab as add-on Therapy for Aspirin-exacerbated Respiratory Disease (AERD)[NCT03595488] | Phase 2 | 11 participants (Actual) | Interventional | 2018-09-05 | Completed | ||
| Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment[NCT00912756] | Phase 4 | 200 participants (Anticipated) | Interventional | 2009-03-31 | Recruiting | ||
| Follow-up Management of Peripheral Arterial Intervention With Clopidogrel MIRROR-Study[NCT00163267] | Phase 2/Phase 3 | 80 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients[NCT01623700] | 78,000 participants (Actual) | Observational | 2006-01-31 | Active, not recruiting | |||
| Secondary Prevention of Small Subcortical Strokes (SPS3) Trial[NCT00059306] | Phase 3 | 3,020 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Prasugrel in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients[NCT04445623] | Phase 3 | 128 participants (Anticipated) | Interventional | 2020-07-31 | Not yet recruiting | ||
| Multicenter Randomized, Double-blind, Placebo-controlled, Clinical Trial of Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients (Asperum)[NCT04808895] | Phase 3 | 204 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| Cilostazol Stroke Prevention Study for Antiplatelet Combination[NCT01995370] | Phase 4 | 1,884 participants (Actual) | Interventional | 2013-12-13 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism[NCT02064439] | Phase 3 | 3,365 participants (Actual) | Interventional | 2014-03-05 | Completed | ||
| Randomized,Double-blind Trial Comparing the Effects of a Rivaroxaban Regimen During the First 30 Days,Versus Aspirin for the Acute Treatment of TIA or Minor Stroke[NCT01923818] | Phase 2/Phase 3 | 3,700 participants (Anticipated) | Interventional | 2013-09-30 | Not yet recruiting | ||
| Carotid Stenosis Management During COVID-19 Era - Best Medical Intervention Alone (CASCOM Pilot Study): A Prospective Observational Study[NCT04947046] | 120 participants (Anticipated) | Observational | 2020-03-11 | Recruiting | |||
| A Multicenter, Randomized, Controlled, Superiority Clinical Trial to Evaluate the Safety and Efficacy of Drug-eluting Peripheral Arterial Stent System（G-stream） in the Treatment of the Above-the-knee Femoropopliteal Artery Stenosis or Occlusion[NCT05780359] | 280 participants (Anticipated) | Interventional | 2022-05-27 | Recruiting | |||
| Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery[NCT00120406] | 474 participants (Actual) | Interventional | 2005-03-31 | Completed | |||
| A Prospective Multicenter Clinical Study of Aspirin for Prophylaxis in Patients With Hereditary or Acquired Thrombotic Thrombocytopenic Purpura[NCT05568147] | Phase 2/Phase 3 | 100 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| Histamine-2 Receptor Antagonist Versus Proton-Pump Inhibitor for the Prevention of Recurrent Upper Gastrointestinal Bleeding (UGI) in High-risk Users of Low-dose Aspirin (ASA)[NCT01408186] | Phase 3 | 264 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)[NCT01777503] | Phase 4 | 2,000 participants (Anticipated) | Interventional | 2012-11-30 | Recruiting | ||
| The Optimal Regimen of Medical Treatment in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance[NCT01925872] | 2,000 participants (Anticipated) | Observational | 2013-05-31 | Enrolling by invitation | |||
| The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases[NCT01867281] | Phase 4 | 32 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Challenge Test for Acetylsalicylic Acid Hypersensitivity[NCT01681615] | 50 participants (Anticipated) | Interventional | 2012-09-30 | Not yet recruiting | |||
| Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452] | Phase 3 | 25,086 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Implantation of CERENOVUS ENTERPRISE 2 Intracranial Stent in Patients With Severe Symptomatic Intracranial Atherosclerotic Stenosis: A Multicenter, Prospective and Single-Arm Study in China[NCT05316311] | 194 participants (Anticipated) | Interventional | 2022-05-24 | Recruiting | |||
| The Predictive Value of Retinal Vascular Signs for Patients With Intracranial Artery Stenosis: A Prospective, Continuity Study, Cross-sectional Study[NCT05270746] | 1,000 participants (Anticipated) | Observational | 2022-02-27 | Not yet recruiting | |||
| A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Subjects With Acute Coron[NCT00402597] | Phase 2 | 3,490 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [NCT00153725] | 156 participants | Interventional | 2003-02-28 | Completed | |||
| CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-05-01 | Recruiting | |||
| Sclerotherapy With Polidocanol Foam In The Management Of First, Second And Third-Grade Hemorrhoidal Disease In Patients With Bleeding Disorders: A Prospective Cohort Study[NCT04188171] | Phase 2/Phase 3 | 150 participants (Anticipated) | Interventional | 2018-08-01 | Active, not recruiting | ||
| Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma. A Double-blind, Placebo-controlled, Multicentre, Randomized Controlled Clinical Trial[NCT03582293] | Phase 3 | 140 participants (Anticipated) | Interventional | 2018-06-19 | Recruiting | ||
| To Scan or Not to Scan: The Role of Follow-up CT Scanning for Management of Chronic Subdural Hematoma After Neurosurgical Evacuation - a Prospective, Randomized, Controlled Trial[NCT01624545] | 368 participants (Actual) | Interventional | 2012-06-01 | Completed | |||
| A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969] | Phase 4 | 2,200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Antithrombotic Therapy After Left Atrial Appendage Occlusion: Double Antiplatelet Therapy vs Apixaban[NCT05632445] | Phase 4 | 160 participants (Actual) | Interventional | 2019-05-01 | Completed | ||
| PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062] | Phase 4 | 20,332 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| "PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314] | 142 participants (Actual) | Interventional | 2019-11-20 | Completed | |||
| A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591] | Phase 3 | 13,619 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?[NCT02550301] | 100 participants (Anticipated) | Observational | 2015-09-30 | Not yet recruiting | |||
| Biological Efficacy of Clopidogrel 600 mg Loading Dose Followed by 75 mg Maintenance Dose After Implantation of Drug-eluting Stents in Patients With Diabetes Mellitus or Metabolic Syndrome (SPACE)[NCT00298428] | 159 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| Chewing Clopidogrel in Addition to Regular Oral Clopidogrel Treatment to Improve Platelets Aggregation in Patient With NON ST ELEVATION MI[NCT00889044] | Phase 3 | 30 participants (Anticipated) | Interventional | 2009-04-30 | Recruiting | ||
| Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435] | 889 participants (Actual) | Interventional | 2013-06-30 | Terminated (stopped due to Ethics Committe decision) | |||
| Patent Foramen Ovale in Cryptogenic Stroke Study[NCT00697151] | Phase 4 | 630 participants (Actual) | Interventional | 1993-06-30 | Completed | ||
| Medical Treatment With or Without Transcatheter Patent Foramen Ovale CloSure for Older Patients With CrypTogenic StrOke and Patent Foramen Ovale. The STOP Trial[NCT05907694] | 714 participants (Anticipated) | Interventional | 2023-12-01 | Active, not recruiting | |||
| European Registry on the Management of Helicobacter Pylori Infection[NCT02328131] | 10,000 participants (Anticipated) | Observational | 2013-06-30 | Recruiting | |||
| Focal Cerebral Arteriopathy Steroid Trial[NCT06040255] | Phase 4 | 80 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| [NCT00000614] | Phase 3 | 0 participants | Interventional | 1998-09-30 | Completed | ||
| Retrospective Review on Patients With Recurrent Asthmatic Attacks Requiring Hospitalizations[NCT04479501] | 2,280 participants (Actual) | Observational | 2017-12-01 | Completed | |||
| A 3 Year Longitudinal Study of the Level of Asthma Control and Treatment of Asthma Patients in Hong Kong[NCT03239431] | 400 participants (Anticipated) | Observational [Patient Registry] | 2017-09-15 | Recruiting | |||
| Prevalence of Aspirin Resistance in Ischemic Stroke Patients at Assiut University Hospital[NCT05151263] | 133 participants (Anticipated) | Observational | 2023-11-01 | Not yet recruiting | |||
| Outcomes of Low-dose Colchicine in Patients With Myocardial Infarction: A Randomized Controlled Trial[NCT04218786] | Phase 2 | 0 participants (Actual) | Interventional | 2025-12-31 | Withdrawn (stopped due to Due to the pandemic, there were logistical issues in continuing the study.) | ||
| Antiplatelet Activity of Aspirin in Infants After Aortopulmonary and Cavopulmonary Shunts[NCT01656993] | 25 participants (Actual) | Observational | 2012-11-30 | Completed | |||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| Clopidogrel Hyper-Responsiveness: Incidence and Associated Outcomes in Patients With Cerebral Aneurysms[NCT05945563] | 208 participants (Anticipated) | Observational [Patient Registry] | 2023-01-17 | Recruiting | |||
| Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin[NCT01931852] | 312 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
| [NCT00000491] | Phase 3 | 0 participants | Interventional | 1974-10-31 | Completed | ||
| Improvements of Hand Function in Chronic Stroke Related to Upper Arm Anesthesia[NCT00006414] | 12 participants | Observational | 2000-10-31 | Completed | |||
| Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome[NCT02295475] | Phase 4 | 48 participants (Actual) | Interventional | 2014-12-10 | Completed | ||
| [NCT00000490] | Phase 3 | 0 participants | Interventional | 1973-06-30 | Completed | ||
| Smartwatches for Detection of Atrial Fibrillation (AFib) in Secondary Prevention of Cryptogenic Stroke - WATCH AFib A Prospective, Intraindividual-controlled, Multicenter Clinical Study[NCT06005233] | 400 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | |||
| A Sequential Phase I - Phase II Pilot Study to Compare Cardiac Imaging Capabilities of ICE With TEE Followed by a Randomized Comparison of ICE Guided Cardioversion With Conventional Cardioversion Strategy in Patients With Atrial Fibrillation[NCT00281073] | Phase 1/Phase 2 | 95 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)[NCT00430612] | 7,057 participants (Actual) | Observational [Patient Registry] | 2009-05-31 | Completed | |||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Early and Long-Term Outcome of Elective Stenting of the Infarct-Related Artery in Patients With Viability in the Infarct-Area Early After Acute Myocardial Infarction. The VIAMI-Trial.[NCT00149591] | 300 participants | Interventional | 2001-04-30 | Active, not recruiting | |||
| A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
| Evaluation of Neurological Outcome in Patients Undergoing Cerebral Angiography and Revascularization Using Angioplasty and Stent-Supported Angioplasty[NCT00597974] | 108 participants (Actual) | Observational | 2003-09-30 | Completed | |||
| Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation[NCT03021928] | Phase 3 | 200 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| A Multi-center Randomised Controlled Trial to Explore the Ideal Individualized Anti-hypertension Strategies in Patients With Severe Stroke at Acute Stage[NCT02982655] | 500 participants (Anticipated) | Interventional | 2017-01-31 | Completed | |||
| Phase II Dose-finding Open Study of Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) Injection Administered Within 3 Hours After Onset of Hyperacute Ischemic Stroke[NCT04676659] | Phase 2 | 240 participants (Actual) | Interventional | 2018-05-12 | Completed | ||
| Thrombolysis Treated by TNK-tPA in Acute Ischemic Stroke Patients: a Multi-center, Block Randomized, Positive Drug Parallel Control and Non-inferior Phase Ⅲ Trial, 3T Stroke-Ⅲ[NCT05745259] | Phase 3 | 1,630 participants (Anticipated) | Interventional | 2022-10-26 | Recruiting | ||
| Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients: a Multi-center, Block Randomized, Positive Drug Parallel Controlled Phase II Trial[NCT05281549] | Phase 2 | 225 participants (Anticipated) | Interventional | 2021-05-02 | Active, not recruiting | ||
| Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680] | 11,976 participants (Actual) | Interventional | 2016-03-23 | Completed | |||
| French Registry to Evaluate the Safety and Efficacy of the Diamondback 360TM Orbital Atherectomy System in the Preparation of Calcified Coronary Lesions Before Implantation of a Coronary Endoprothesis[NCT05417022] | 300 participants (Anticipated) | Observational [Patient Registry] | 2022-06-15 | Recruiting | |||
| Rotational Atherectomy Prior to Taxus Stent Treatment for Complex Native Coronary Artery Disease. A Multicenter, Prospective, Randomized Controlled Trial.[NCT00380809] | Phase 4 | 240 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients With Embolic Stroke Due to Atrial Fibrillation[NCT02159287] | Phase 2 | 80 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| [NCT00005196] | 0 participants | Observational | 1986-12-31 | Completed | |||
| First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment[NCT04037397] | Phase 3 | 120 participants (Anticipated) | Interventional | 2019-09-24 | Active, not recruiting | ||
| Silent Atrial Fibrillation - Screening of High-risk Groups for Atrial Fibrillation (The Silence Study)[NCT02893215] | 1,622 participants (Anticipated) | Observational [Patient Registry] | 2016-11-30 | Recruiting | |||
| Laryngeal Manifestations of Connective Tissue Diseases[NCT04582292] | 50 participants (Anticipated) | Observational [Patient Registry] | 2020-11-01 | Not yet recruiting | |||
| [NCT00000527] | Phase 2 | 0 participants | Interventional | 1986-08-31 | Completed | ||
| [NCT00000505] | Phase 3 | 0 participants | Interventional | 1983-04-30 | Completed | ||
| [NCT00000500] | Phase 3 | 0 participants | Interventional | 1981-09-30 | Completed | ||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)[NCT00272311] | Phase 4 | 70 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)[NCT00272337] | Phase 4 | 37 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268] | Phase 4 | 72 participants (Actual) | Interventional | 2019-04-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Adjudicated composite of non-fatal stroke, non-fatal myocardial infarction (MI), or cardiovascular death is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 4.80 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 5.40 |
Adjudicated fatal bleeding was defined as a bleeding event which the Independent Event Adjudication Committee (IAC) determined as the primary cause of death or contributed directly to death. The annualised event rate represents the average number of events per patient during a 1-year period. Because there were 0 events in one treatment group, the hazard ratio is unable to be calculated. (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.00 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.05 |
"Adjudicated intracranial haemorrhage comprised the subtypes of intracerebral bleeds, intraventricular bleeds, subdural bleeds, epidural bleeds, and subarachnoid bleeds. Microbleeds did not qualify as intracranial haemorrhage, except when they were symptomatic.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.67 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.63 |
Adjudicated ischaemic stroke is a key secondary endpoint. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 3.97 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 4.71 |
"Major bleeds were to be classified as life-threatening if they met one or more of the following criteria: fatal bleed, symptomatic intracranial bleed, reduction in haemoglobin of at least 5 grams/ deciliter (g/dL), transfusion of at least 4 units of packed red blood cells (equivalent to 9 units in Japan), associated with hypotension requiring the use of intravenous inotropic agents, or necessitated surgical intervention.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.76 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.91 |
Adjudicated recurrent stroke (ischemic, hemorrhagic, or unspecified) is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, approximately 43 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 4.09 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 4.80 |
All-cause death is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 1.24 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 1.28 |
"This was the sum of all major and minor bleeds (Minor bleeds were clinical bleeds that did not fulfil the criteria for major bleeds), regardless of severity.~The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 15.21 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 11.64 |
Disabling stroke (modified Rankin Scale greater than or equal to 4, as determined 3 months after recurrent stroke) is presented. The annualised event rate represents the average number of events per patient during a 1-year period. (NCT02239120)
Timeframe: From randomisation until full follow up period, up to 43 months
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 0.55 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 0.93 |
"First major bleed is primary safety endpoint. Major bleeds were defined according to the International Society of Thrombosis and Haemostasis (ISTH) definition as follows:~Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome and/or,~Bleeding (which should be overt) associated with a reduction in haemoglobin of at least 2 grams/ decilitre (g/dL) (1.24 millimoles Per Litre (mmol/L)), or leading to transfusion of ≥2 units of blood or packed cells (equivalent to ≥4.5 units in Japan); the haemoglobin drop should be considered to be due to and temporally related to the bleeding event and/or,~Fatal bleed. The annualised event rate represents the average number of events per patient during a 1-year period." (NCT02239120)
Timeframe: Between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months.
| Intervention | Annualised event rate (%/ year) (Number) |
|---|---|
| Dabigatran Etexilate 110 or 150 Milligram (mg) | 1.84 |
| Acetylsalicylic Acid, Aspirin (ASA) 100 mg | 1.33 |
Major bleeding event (as per ISTH), defined as bleeding event that met at least one of following: fatal bleeding; symptomatic bleeding in a critical area or organ (intraarticular, intramuscular with compartment syndrome, intraocular, intraspinal, pericardial, or retroperitoneal); symptomatic intracranial haemorrhage; clinically overt bleeding associated with a recent decrease in the hemoglobin level of greater than or equal to (>=) 2 grams per decilitre (g/dL) (20 grams per liter [g/L]; 1.24 millimoles per liter [mmol/L]) compared to the most recent hemoglobin value available before the event; clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. The results were based on classification of events that have been positively adjudicated as major bleeding events. Incidence rate estimated as number of subjects with incident events divided by cumulative at-risk time, where subject is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.82 |
| Acetylsalicylic Acid 100 mg OD | 0.67 |
All-cause mortality includes all deaths of participants due to any cause. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.88 |
| Acetylsalicylic Acid 100 mg OD | 1.50 |
Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. Cardiovascular death includes death due to hemorrhage and death with undetermined/unknown cause. Systemic embolism is defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms. The diagnosis of myocardial infarction requires the combination of: 1)evidence of myocardial necrosis (either changes in cardiac biomarkers or post-mortem pathological findings); and 2)supporting information derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 6.20 |
| Acetylsalicylic Acid 100 mg OD | 5.85 |
Non-major clinically relevant bleeding was defined as non-major overt bleeding but required medical attention (example: hospitalization, medical treatment for bleeding), and/or was associated with the study drug interruption of more than 14 days. The results were based on the outcome events at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 3.52 |
| Acetylsalicylic Acid 100 mg OD | 2.32 |
Intracranial hemorrhage included all bleeding events that occurred in intracerebral, sub arachnoidal as well as subdural or epidural sites. The below table displays results for all randomized participants and the outcomes at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 0.70 |
| Acetylsalicylic Acid 100 mg OD | 0.35 |
Life-threatening bleeding was defined as a subset of major bleeding that met at least one of the following criteria: 1) fatal bleeding; 2) symptomatic intracranial haemorrhage; 3) reduction in hemoglobin of at least 5 g/dl (50 g/l; 3.10 mmol/L); 4) transfusion of at least 4 units of packed red cells or whole blood; 5) associated with hypotension requiring the use of intravenous inotropic agents; 6) necessitated surgical intervention. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.02 |
| Acetylsalicylic Acid 100 mg OD | 0.43 |
Components of composite efficacy outcome (adjudicated) includes stroke (ischemic, hemorrhagic, and undefined stroke, TIA with positive neuroimaging) and systemic embolism. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 5.14 |
| Acetylsalicylic Acid 100 mg OD | 4.78 |
"Disabling stroke is defined as stroke with modified Rankin score (mRS) greater than or equal to (>=) 4 as assessed by investigator. mRS spans 0-6, running from perfect health to death. A score of 0-3 indicates functional status ranging from no symptoms to moderate disability (defined in the mRS as requiring some help, but able to walk without assistance); mRS 4-6 indicates functional status ranging from moderately severe disability (unable to walk or to attend to own bodily needs without assistance)through to death. CV death includes death due to hemorrhage and death with undetermined/unknown cause. Diagnosis of myocardial infarction requires combination of: 1) evidence of myocardial necrosis either changes in cardiac biomarkers or post-mortem pathological findings); 2) supporting information derived from clinical presentation, electrocardiographic changes, or results of myocardial or coronary artery imaging." (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) | ||||
|---|---|---|---|---|---|
| Stroke | Ischemic stroke | Disabling stroke | CV death(includes death due to hemorrhage) | Myocardial infarction | |
| Acetylsalicylic Acid 100 mg OD | 4.71 | 4.56 | 0.84 | 0.66 | 0.67 |
| Rivaroxaban 15 mg OD | 5.11 | 4.71 | 1.20 | 0.99 | 0.49 |
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
number of participants with the occurrence of a bleeding event leading the participant to seek medical attention (NCT02505217)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| High FcγRIIa Expression | 6 |
| Low FcγRIIa Expression | 6 |
number of participants with myocardial infarction, stroke, and/or death (NCT02505217)
Timeframe: average duration of follow-up 19 months
| Intervention | Participants (Count of Participants) |
|---|---|
| High FcγRIIa Expression | 17 |
| Low FcγRIIa Expression | 6 |
"Time to first occurrence during the time the participants were treated with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 24.66 |
| Vitamin K Antagonist | 35.79 |
"Time to first death or ischenic event during the 6-month treatment period with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with death or ischemic events in each treatment group during the 6-month treatment period.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 15.28 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 17.73 |
"Time to first all-cause death or all-cause hospitalization during the during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 57.24 |
| Vitamin K Antagonist | 69.19 |
"Time to first all-cause death or all-cause hospitalization during the 6-month period of treatment with aspirin or placebo.~N is the number of participants treated with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with all-cause death or all-cause hospitalization in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with all-cause death or all-cause hospitalization divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 65.72 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 60.56 |
"Time to first ISTH major or CRNM bleeding during the 6-month period of treatment with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with major or CRNM bleeding divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 24.66 |
| Vitamin K Antagonist | 35.79 |
"Time to first ISTH major or CRNM bleeding during the treatment period of 6 months with aspirin or placebo.~N is the number of participants with aspirin or placebo.~n is the number of participants treated with aspirin or placebo with major or CRNM bleeding in each treatment group during the 6-month period of treatment.~Event rates are calculated based on the number of participants with event of interest divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Acetylsalicylic Acid Film Coated Tablet | 40.51 |
| Placebo Matching Acetylsalicylic Acid Film Coated Tablet | 21.03 |
"Time to first occurrence during the 6-month treatment period with Apixaban or VKA.~N is the number of participants treated with Apixaban or VKA.~n is the number of participants treated with Apixaban or VKA with death or ischemic events in each treatment group during the during the 6-month period of treatment.~Event rates are calculated based on the number of participants with death or ischemic events divided by the sum of the number of days from the first dose of study drug to the event date or censoring date and expressed as percentage per year." (NCT02415400)
Timeframe: Approximately 6 months
| Intervention | Percentage per year (Number) |
|---|---|
| Apixaban | 15.85 |
| Vitamin K Antagonist | 17.17 |
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
Percentage of subjects with AF detected within 12 months of follow-up (NCT00924638)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Continuous Monitoring | 12.4 |
| Control Arm | 2.0 |
Percentage of subjects with AF detected within 6 months of follow-up (NCT00924638)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Continuous Monitoring | 8.9 |
| Control Arm | 1.4 |
Incidence of cardiovascular (CV) or stroke/TIA related hospitalizations within 12 months (NCT00924638)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Continuous Monitoring | 10.5 |
| Control Arm | 7.2 |
EQ-5D VAS (visual analog scale) quality of life score, which is a continuous measure of quality of life ranging from 0 (worst) to 100 (perfect health). (NCT00924638)
Timeframe: 12 months
| Intervention | units on a scale of 0 to 100 (Mean) |
|---|---|
| Continuous Monitoring | 78.9 |
| Control Arm | 76.3 |
Percentage of subjects with recurrent stroke or TIA within 12 months of follow-up (NCT00924638)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Continuous Monitoring | 7.1 |
| Control Arm | 9.1 |
Percentage of subjects who were using antiarrhythmic drugs at the 12 months follow-up visit (NCT00924638)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Continuous Monitoring | 2.0 |
| Control Arm | 1.6 |
Percentage of subjects who were using OAC drugs at the 12 months follow-up visit (NCT00924638)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Continuous Monitoring | 14.7 |
| Control Arm | 6.0 |
AF detection lag (days from AF occurrence to AF diagnosis) characterized by patient assistant (PA) use frequency (NCT00924638)
Timeframe: Follow-up closure
| Intervention | days from AF occurrence to AF diagnosis (Mean) | |||||
|---|---|---|---|---|---|---|
| PA used everyday | PA used most of the time (5-6 days/week) | PA used sometimes (3-4 days/week) | PA used rarely (1-2 days/week) | PA never used | PA use frequency not reported | |
| Continuous Monitoring | 14.0 | 25.0 | 174.8 | 15.3 | 92.0 | 20.0 |
Participants with bleeding event that fulfils serious adverse event criteria and is categorised as GUSTO Moderate/Severe. GUSTO is a bleeding scale (GUSTO = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries). GUSTO Severe bleeding is defined as any of the following: (1) fatal bleeding, (2) intracranial bleeding, or (3) bleeding that caused haemodynamic compromise requiring intervention. GUSTO Moderate bleeding is a bleeding requiring transfusion of whole blood or packed red blood cells without haemodynamic compromise (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 36 |
| PLACEBO | 11 |
Participants with bleeding event that fulfils serious adverse event criteria and is categorised as GUSTO Severe. GUSTO is a bleeding scale (GUSTO = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries). GUSTO Severe bleeding is defined as any of the following: (1) fatal bleeding, (2) intracranial bleeding, or (3) bleeding that caused haemodynamic compromise requiring intervention (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 28 |
| PLACEBO | 7 |
Participants with subsequent stroke or death (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 303 |
| PLACEBO | 362 |
Participants with ICH or fatal bleeding event (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 22 |
| PLACEBO | 6 |
Number of participants with ischaemic stroke (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 276 |
| PLACEBO | 345 |
The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.0 - No symptoms,1 - No significant disability. Able to carry out all usual activities, despite some symptoms. 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3 - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. (NCT03354429)
Timeframe: Visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 1282 |
| PLACEBO | 1284 |
Participants with premature permanent discontinuation of IP due to bleeding (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 152 |
| PLACEBO | 32 |
This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 50 |
| Primary PCI (Group B) | 43 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 59 |
| Primary PCI (Group B) | 73 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 100 |
| Primary PCI (Group B) | 123 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 117 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 77 |
| Primary PCI (Group B) | 85 |
This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 43 |
| Primary PCI (Group B) | 42 |
The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 116 |
| Primary PCI (Group B) | 135 |
This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 31 |
| Primary PCI (Group B) | 32 |
This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 41 |
| Primary PCI (Group B) | 56 |
This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 57 |
| Primary PCI (Group B) | 72 |
This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 9 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 6 |
| Primary PCI (Group B) | 3 |
This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 61 |
| Primary PCI (Group B) | 45 |
This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 206 |
| Primary PCI (Group B) | 191 |
This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 23 |
| Primary PCI (Group B) | 21 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 45 |
| Primary PCI (Group B) | 41 |
This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 19 |
| Primary PCI (Group B) | 11 |
This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 1 |
| Primary PCI (Group B) | 2 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 32 |
| Primary PCI (Group B) | 38 |
This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 10 |
| Primary PCI (Group B) | 29 |
This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 2 |
| Primary PCI (Group B) | 0 |
This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 7 |
| Primary PCI (Group B) | 4 |
This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 8 |
| Primary PCI (Group B) | 1 |
This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 267 |
| Primary PCI (Group B) | 236 |
This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tenecteplase (Group A) | 15 |
| Primary PCI (Group B) | 5 |
"EQ-5D index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: End of treatment visit (Day 90+-7d)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.85 |
| ASA 100 mg | 0.84 |
"EQ-5D index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Premature treatment discontinuation visit(<15 days after last dose)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.72 |
| ASA 100 mg | 0.68 |
"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Visit 1 (Enrolment)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.70 |
| ASA 100 mg | 0.70 |
"EQ-5D (EuroQol five dimensions questionnaire) index score using the UK tariff.~EQ-5D is a self assessment of 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. For each dimension responders are asked to state their status on a three level ordinal scale; whether they experience no problems (Level 1), some problems (Level 2) or severe problems (Level 3). Health states defined by the 5 dimensions can be converted into a weighted health state index (health state utility) by applying scores from the EQ-5D value sets elicited from general population samples.~The higher the index score the better the health state. In this study index scores ran from -0.59 to 1." (NCT01994720)
Timeframe: Visit 2 (Day 7+-2d)
| Intervention | Index score (Mean) |
|---|---|
| Ticagrelor 90 mg | 0.80 |
| ASA 100 mg | 0.79 |
Participants with stroke, MI, death or life-threatening bleeding. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 457 |
| ASA 100 mg | 508 |
"Analysis of severity of stroke and overall disability of patients, using the modified Rankin Score, mRS.~Modified Rankin Score:~0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead.~Disability defined as mRS > 1.~Odds ratio and p-value are calculated for ticagrelor versus ASA from a logistic regression model with treatment group, history of stroke and NIHSS (National Institutes of Health Stroke Scale) at baseline as explanatory variables." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 1107 |
| ASA 100 mg | 1194 |
Participants with all-cause death. If no event, censoring at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 68 |
| ASA 100 mg | 58 |
Participants with ischaemic stroke, MI or CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 423 |
| ASA 100 mg | 475 |
Participants with stroke, MI or death. If no event, censoring occures at the minimum of (last date of event assessment, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 442 |
| ASA 100 mg | 497 |
Participants with CV death. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 41 |
| ASA 100 mg | 35 |
Participants with disabling stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 277 |
| ASA 100 mg | 307 |
Participants with fatal stroke. If no event, censoring at the minimum of (last date of event assessment, date of death from non-CV causes, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 18 |
| ASA 100 mg | 17 |
Participants with ischaemic stroke. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 385 |
| ASA 100 mg | 441 |
Participants with MI. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97) (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 25 |
| ASA 100 mg | 21 |
"Participants with PLATO Major bleeding. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97).~PLATO Major bleeding is defined as a bleed that is any one of:~Fatal~Intracranial (excluding asymptomatic haemorrhagic transformations of ischemic brain infarctions and excluding micro-hemorrhages <10 mm evident only on gradient-echo MRI)~Intrapericardial bleed with cardiac tamponade~Hypovolaemic shock or severe hypotension due to bleeding and requiring pressors or surgery~Significantly disabling (eg. intraocular with permanent vision loss)~Clinically overt or apparent bleeding associated with a decrease in Hb of more than 30 g/L (1.9 mmol/L; 0.465 mmol/L)~Transfusion of 2 or more units (whole blood or packed red blood cells [PRBCs]) for bleeding." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 31 |
| ASA 100 mg | 38 |
Participants discontinuation of study drug due to any bleeding adverse event. If no event, censoring occures at the minimum of (last date of event assessment, date of death, end of treatment date, day 97). (NCT01994720)
Timeframe: Time from first dose and up to and including 7 days following the date of last dose of the study
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 82 |
| ASA 100 mg | 37 |
Participants with stroke. If no event, censoring at the minimum of (last date of event assessment, date of death, end of treatment date, day 97) (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg | 390 |
| ASA 100 mg | 450 |
"Change from baseline to end of treatment visit in NIHSS (National Institutes of Health Stroke Scale):~0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke." (NCT01994720)
Timeframe: From randomization up to 97 days
| Intervention | Participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=-5 | -4 | -3 | -2 | -1 | 0 | 1 | 2 | 3 | 4 | 5 | >5 | Missing | |
| ASA 100 mg | 127 | 438 | 810 | 1073 | 1131 | 683 | 79 | 31 | 16 | 11 | 6 | 14 | 450 |
| Ticagrelor 90 mg | 132 | 403 | 779 | 1088 | 1099 | 681 | 67 | 28 | 18 | 13 | 6 | 10 | 474 |
Number of Adjudicated Major Adverse Cardiovascular Events (MACE) which is a composite of non-fatal myocardial infarction (MI), non-fatal stroke and cardiovascular death (NCT01802775)
Timeframe: within 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 1 |
| Edoxaban | 3 |
Number of participants with amputations within 6 months (NCT01802775)
Timeframe: within 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 3 |
| Edoxaban | 1 |
Percentage of participants with re-stenosis/re-occlusion during treatment within 6 months - only the first occurrence of re-stenosis / re-occlusion was counted for each participant (NCT01802775)
Timeframe: within 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Clopidogrel | 34.7 |
| Edoxaban | 30.9 |
"Number of participants with serious adverse events (SAEs) within 6 months~Note: Based on changes to the database structure, clinically significant changes in physical or laboratory parameters are recorded as adverse events (AEs). Details of non-serious adverse events are reported at the 5% reporting threshold in the AE module, as is all-cause mortality." (NCT01802775)
Timeframe: within 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 30 |
| Edoxaban | 31 |
Percentage of participants with clinically relevant bleeding, defined as major bleeding or clinical relevant non-major bleeding, in the on-treatment period based on International Society of Thrombosis and Haemostasis (ISTH) (NCT01802775)
Timeframe: at 3 months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Including Access Site Bleeding (IASB) | Excluding Access Site Bleed (EASB) | |
| Clopidogrel | 8 | 6 |
| Edoxaban | 11 | 6 |
The percentage of participants with major, clinically relevant non-major, and minor bleeding occurring during treatment, within 3 months (NCT01802775)
Timeframe: within 3 months
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| IASB : Major Bleeding | IASB: CRNM Bleeding | IASB: Minor Bleeding | EASB : Major Bleeding | EASB : CRNM Bleeding | EASB : Minor Bleeding | |
| Clopidogrel | 5 | 4 | 20.8 | 4 | 3 | 17.8 |
| Edoxaban | 1 | 10 | 20 | 1 | 5 | 19 |
The secondary safety outcome was clinically relevant non-major (CRNM) bleeding, which was adjudicated by the CIAC using the ASA criteria: the bleeding was non-major and the bleeding was associated with a study medication interruption of more than 14 days. (NCT02064439)
Timeframe: Up to 12 months, at least 6 months
| Intervention | participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | 12 |
| Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | 17 |
| Acetylsalicylic (ASA) 100 mg, OD | 12 |
"The principal safety outcome was major bleeding which was defined according to the criteria of the International Society on Thrombosis and Hemostasis (ISTH) as clinically overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or whole blood, or occurring in a critical site, e.g. intracranial, intraspinal, intraocular, pericardial, intra articular, intramuscular with compartment syndrome, retroperitoneal, or contributing to death.~Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant." (NCT02064439)
Timeframe: Up to 12 months, at least 6 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Any major bleeding | Fatal bleeding | Non-fatal critical organ bleed | Non-fatal non-critical organ bleeding | |
| Acetylsalicylic (ASA) 100 mg, OD | 3 | 1 | 1 | 1 |
| Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | 5 | 0 | 2 | 3 |
| Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | 6 | 1 | 4 | 1 |
"The primary efficacy outcomes (i.e., recurrent venous thromboembolism [VTE] defined as composite of fatal or non-fatal symptomatic recurrent VTE, including unexplained death for which pulmonary embolism [PE] could not be ruled out) as confirmed by the central independent adjudication committee (CIAC) were considered up to the end of the individual intended duration of treatment.~Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant." (NCT02064439)
Timeframe: Up to 12 months, at least 6 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Composite | Symptomatic recurrent Deep vein thrombosis (DVT) | Symptomatic recurrent PE | Death (PE) | Death (unexplained and PE cannot be ruled out) | |
| Acetylsalicylic (ASA) 100 mg, OD | 50 | 29 | 19 | 1 | 1 |
| Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | 13 | 8 | 5 | 0 | 0 |
| Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | 17 | 9 | 6 | 0 | 2 |
The secondary efficacy outcome is the composite of the primary efficacy outcome, myocardial infarction (MI), ischemic stroke or non-central nervous system (CNS) systemic embolism. Incidence of the composite of the primary and secondary efficacy outcome and its components are based on the first occurrence to participant. (NCT02064439)
Timeframe: Up to 12 months, at least 6 months
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Composite | Ischemic stroke | Non-CNS systemic embolism | Myocardial infarction | Symptomatic recurrent DVT | Symptomatic recurrent PE | Death (PE) | Death (unexplained and PE cannot be ruled out) | Death (cardiovascular: myocardial infarction) | Death (cardiovascular: ischemic stroke) | |
| Acetylsalicylic (ASA) 100 mg, OD | 56 | 2 | 1 | 4 | 29 | 18 | 1 | 1 | 0 | 0 |
| Rivaroxaban (Xarelto, BAY59-7939) 10 mg, OD | 18 | 4 | 1 | 0 | 8 | 5 | 0 | 0 | 0 | 0 |
| Rivaroxaban (Xarelto, BAY59-7939) 20 mg, OD | 19 | 2 | 0 | 1 | 9 | 6 | 0 | 1 | 0 | 0 |
"Event-free survival is defined as freedom from the major adverse events of death, target lesion revascularization, target limb ischemia requiring surgical intervention (bypass or amputation of toe, foot or leg), surgical repair of the target vessel (e.g., dissection requiring surgery), and from worsening of the Rutherford classification by 2 classes or to class 5 or 6.~Participant flow is based on initial randomization of Zilver PTX or PTA (Percutaneous balloon angioplasty), and Event-free survival is based on Per-Protocol analysis where only patients who were treated according to their initial randomization are counted." (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 90.4 |
| PTA (Control) | 83.9 |
Primary patency is defined as a Peak systolic velocity (PSV) ratio < 2.0 or angiographic percent diameter stenosis < 50%. (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 82.7 |
| PTA (Control) | 32.7 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Clopidogrel 300/75/75 mg + ASA Low Dose | 267 |
| Clopidogrel 300/75/75 mg + ASA High Dose | 290 |
| Clopidogrel 600/150/75 mg + ASA Low Dose | 282 |
| Clopidogrel 600/150/75 mg + ASA High Dose | 240 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel + ASA High Dose | 527 | 211 | 251 | 65 |
| Clopidogrel + ASA Low Dose | 546 | 231 | 260 | 55 |
"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 557 | 222 | 274 | 61 |
| Clopidogrel 600/150/75 mg + ASA | 522 | 226 | 237 | 59 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 392 | 132 | 225 | 35 |
| Clopidogrel 600/150/75 mg + ASA | 330 | 130 | 172 | 28 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel + ASA High Dose | 282 | 216 | 73 |
| Clopidogrel + ASA Low Dose | 285 | 215 | 74 |
Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel 300/75/75 mg + ASA | 255 | 195 | 65 |
| Clopidogrel 600/150/75 mg + ASA | 313 | 236 | 83 |
This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Stent trombosis | - Definite | - Probable | |
| Clopidogrel 300/75/75 mg + ASA | 200 | 111 | 89 |
| Clopidogrel 600/150/75 mg + ASA | 135 | 58 | 77 |
The number of patients who died due to any cause or had a first occurrence of MI (including repeat MI) or stroke (ischemic, hemorrhagic or unknown) or severe recurrent ischemia requiring revascularization from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 83 |
| Riva 5 mg Total Daily Dose (TDD) | 23 |
| Riva 10 mg TDD | 55 |
| Riva 15 mg TDD | 27 |
| Riva 20 mg TDD | 36 |
The number of patients with the composite endpoint of cardiovascular death or MI or stroke that occurred from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 63 |
| Riva 5 mg Total Daily Dose (TDD) | 18 |
| Riva 10 mg TDD | 40 |
| Riva 15 mg TDD | 21 |
| Riva 20 mg TDD | 21 |
The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI), or stroke, or severe recurrent ischemia requiring revascularization, or TIMI (major or minor bleeding) from the time of randomization to the last date of patient contact to assess the net clinical benefit of rivaroxaban. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 88 |
| Riva 5 mg Total Daily Dose (TDD) | 24 |
| Riva 10 mg TDD | 71 |
| Riva 15 mg TDD | 35 |
| Riva 20 mg TDD | 48 |
The number of patients who died due to any cause or had a first occurrence of MI (or repeat MI) or stroke from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 66 |
| Riva 5 mg Total Daily Dose (TDD) | 18 |
| Riva 10 mg TDD | 40 |
| Riva 15 mg TDD | 21 |
| Riva 20 mg TDD | 22 |
The number of patients who died due to any cause from the time of randomization to the last date of patient contact. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 18 |
| Riva 5 mg Total Daily Dose (TDD) | 11 |
| Riva 10 mg TDD | 9 |
| Riva 15 mg TDD | 4 |
| Riva 20 mg TDD | 9 |
The number of patients with a first occurrence of a TIMI clinically significant bleeding event that occurred from the time of randomization to the time of the last patient contact. TIMI clinically significant bleeding events included TIMI minor bleeding events, TIMI major bleeding events, or any bleeding that required medical attention. (NCT00402597)
Timeframe: Day 1 to Day 210
| Intervention | Patients (Number) |
|---|---|
| Placebo | 36 |
| Riva 5 mg Total Daily Dose (TDD) | 17 |
| Riva 10 mg TDD | 109 |
| Riva 15 mg TDD | 43 |
| Riva 20 mg TDD | 89 |
Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 1333 |
| Clopidogrel | 1333 |
Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 1367 |
| Placebo | 1463 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 916 |
| Clopidogrel | 898 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 880 |
| Placebo | 934 |
(NCT00153062)
Timeframe: Randomization to final patient contact
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 125 |
| Placebo | 151 |
The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 692 |
| Clopidogrel | 822 |
The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 797 |
| Clopidogrel | 938 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 502 | 573 |
| Prasugrel | 389 | 462 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) | ||
|---|---|---|---|
| UA/NSTEMI (n=5044, n=5030) | STEMI (n=1769, n=1765) | All ACS (n=6813, n=6795) | |
| Clopidogrel | 565 | 216 | 781 |
| Prasugrel | 469 | 174 | 643 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 504 | 588 |
| Prasugrel | 399 | 472 |
TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TIMI Major or Minor Bleeding | TIMI Major Bleeding | TIMI Major Bleeding - Life-threatening (LT) | LT - Fatal | LT - Symptomatic intracranial hemorrage (ICH) | LT - Requiring inotropes | LT - Requiring surgical intervention | LT - Requiring transfusion (>=4 units) | TIMI Minor Bleeding | |
| Clopidogrel | 231 | 111 | 56 | 5 | 17 | 8 | 19 | 30 | 125 |
| Prasugrel | 303 | 146 | 85 | 21 | 19 | 21 | 19 | 45 | 164 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 189 |
| Placebo Arm | 230 |
- Birth weight <2500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1078 |
| Placebo Arm | 1153 |
- Birth weight <1500g (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 78 |
| Placebo Arm | 101 |
- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 303 |
| Placebo Arm | 353 |
- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 134 |
| Placebo Arm | 152 |
- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 141 |
| Placebo Arm | 166 |
- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 42 |
| Placebo Arm | 30 |
- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 352 |
| Placebo Arm | 325 |
- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 264 |
| Placebo Arm | 309 |
The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 668 |
| Placebo Arm | 754 |
- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 1506 |
| Placebo Arm | 1564 |
- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 214 |
| Placebo Arm | 246 |
- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 26 |
| Placebo Arm | 25 |
- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 54 |
| Placebo Arm | 43 |
- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 9 |
| Placebo Arm | 12 |
- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 23 |
| Placebo Arm | 30 |
Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 290 |
| Placebo Arm | 333 |
Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Arm | 8 |
| Placebo Arm | 21 |
Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation. (NCT00272311)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| Arm 1 of 5 Randomized Treatment Arms | 27.6 |
| Arm 2 of 5 Randomized Treatment Arms | 27.0 |
| Arm 3 of 5 Randomized Treatment Arms | 31.4 |
| Arm 4 of 5 Randomized Treatment Arms | 25.7 |
| Arm 5 of 5 Randomized Treatment Arms | 28.3 |
Heme oxygenase a downstream target of nitric oxide formation (NCT00272337)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| 1 of 5 Randomized Treatment Arms | 10.0 |
| 2 of 5 Randomized Treatment Arms | 11.2 |
| 3 of 5 Randomized Treatment Arms | 10.0 |
| 4 of 5 Randomized Treatment Arms | 11.0 |
| 5 of 5 Randomized Treatment Arms | 9.6 |
234 reviews available for aspirin and Recrudescence
| Article | Year |
|---|---|
Comparison of Ticagrelor vs Clopidogrel in Addition to Aspirin in Patients With Minor Ischemic Stroke and Transient Ischemic Attack: A Network Meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Humans; Ischemic Attack | 2022 |
[Idiopathic recurrent pericarditis: review of the literature and the Geneva experience].
Topics: Aspirin; Chronic Disease; Colchicine; Humans; Pericarditis; Recurrence | 2022 |
[Dual antiplatelet therapy for secondary stroke prevention in patients with acute ischemic stroke. CIERTO group recommendation].
Topics: Aspirin; Benzodiazepines; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient | 2019 |
Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Intracranial He | 2019 |
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc | 2019 |
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc | 2019 |
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc | 2019 |
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc | 2019 |
Comparison of therapeutic interventions for recurrent pregnancy loss in association with antiphospholipid syndrome: A systematic review and network meta-analysis.
Topics: Abortion, Spontaneous; Animals; Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecular-W | 2020 |
Managing acute and recurrent idiopathic pericarditis.
Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Azathiopri | 2020 |
Direct Oral Anticoagulants and Coronary Artery Disease: The Debacle of the Aspirin Era?
Topics: Administration, Oral; Animals; Aspirin; Blood Coagulation; Coronary Artery Disease; Coronary Thrombo | 2020 |
Should Aspirin Be Prescribed to Prevent Recurrence in Nonarteritic Anterior Ischemic Optic Neuropathy?
Topics: Aspirin; Humans; Optic Neuropathy, Ischemic; Platelet Aggregation Inhibitors; Prescription Drugs; Re | 2020 |
Aspirin or anticoagulation after cryptogenic stroke with patent foramen ovale: systematic review and meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Foramen Ovale, Patent; Humans; Ischemic Stroke; Middle Aged; Randomized Con | 2020 |
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atherosclerosis; Dose-Response Relationship, Drug; | 2020 |
Essential Thrombocythemia Presenting with Recurrent Priapism: A Case Report and Review of Literature.
Topics: Adult; Antineoplastic Agents; Aspirin; Cytoreduction Surgical Procedures; Humans; Hydroxyurea; Male; | 2020 |
Aspirin after Acute Ischemic Stroke.
Topics: Aspirin; Hemorrhage; Humans; Intracranial Hemorrhages; Ischemic Stroke; Mortality; Odds Ratio; Plate | 2020 |
Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis.
Topics: Aged; Anti-Inflammatory Agents; Aspirin; Cilostazol; Female; Humans; Intracranial Hemorrhages; Ische | 2021 |
Recurrence Risk of Fetal Growth Restriction: Management of Subsequent Pregnancies.
Topics: Adult; Anticoagulants; Aspirin; Delivery, Obstetric; Female; Fetal Growth Retardation; Gestational A | 2021 |
[Pericarditis].
Topics: Aspirin; Colchicine; Humans; Interleukin 1 Receptor Antagonist Protein; Pericarditis; Prospective St | 2021 |
Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2017 |
Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Plat | 2017 |
Acute and Recurrent Pericarditis.
Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chest Pain | 2017 |
Recurrent Ischemic Stroke: Strategies for Prevention.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; P | 2017 |
Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Randomized | 2017 |
Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Aspirin; Biomarker | 2018 |
Meta-analysis of efficacy and safety of dual antiplatelet therapy versus aspirin monotherapy after coronary artery bypass grafting.
Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Thrombosis; Dual Anti-Platelet Therapy; Female; Graf | 2019 |
Is Medication Overuse Drug Specific or Not? Data from a Review of Published Literature and from an Original Study on Italian MOH Patients.
Topics: Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Aspiri | 2018 |
The prevention of venous thromboembolism recurrence in the elderly: a still open issue.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clinical Trials as Topic; Humans; Inc | 2018 |
Optimal Antiplatelet Therapy in Moderate to Severe Asymptomatic and Symptomatic Carotid Stenosis: A Comprehensive Review of the Literature.
Topics: Aspirin; Asymptomatic Diseases; Carotid Stenosis; Clopidogrel; Dipyridamole; Drug Therapy, Combinati | 2019 |
Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemor | 2019 |
Care prior to and during subsequent pregnancies following stillbirth for improving outcomes.
Topics: Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Infant, Newborn; Parent | 2018 |
Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack | 2018 |
Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials.
Topics: Anticoagulants; Aspirin; Canada; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Rea | 2019 |
Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Dabigatran; Glycosaminoglycans; Hemorrhage; Hum | 2020 |
Treatment of acute and recurrent idiopathic pericarditis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Colchicine; Dis | 2013 |
Antiplatelet therapy for preventing stroke in patients with chronic kidney disease.
Topics: Aspirin; Cerebrovascular Circulation; Cohort Studies; Endothelium, Vascular; Female; Hemorrhage; Hum | 2013 |
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis.
Topics: Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Morpholines; | 2013 |
[Acute herpes simplex virus type 1 retinal necrosis three years after herpes simplex encephalitis].
Topics: Acyclovir; Antiviral Agents; Aspirin; Cataract Extraction; Causality; Drug Therapy, Combination; Enc | 2014 |
Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence.
Topics: Animals; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Recurrence; Stroke; Ticlopid | 2014 |
Colchicine for pericarditis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colchicine; Humans; Ibuprofen; Indo | 2014 |
Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid.
Topics: Animals; Aspirin; Blood Coagulation; Blood Platelets; Fibrin; Fibrinolytic Agents; Humans; Platelet | 2014 |
Idiopathic recurrent pericarditis as an immune-mediated disease: current insights into pathogenesis and emerging treatment options.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Aspirin; Colchicine; Drug Therapy, Co | 2014 |
Recurrent Kawasaki disease in a child with retropharyngeal involvement: a case report and literature review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Humans; Immunoglobulins, Intravenous; Male; | 2014 |
Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; Pla | 2015 |
Pharmacotherapy update of acute idiopathic pericarditis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; C-Reactive Protein; Clinical Trials | 2015 |
Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials.
Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Placebos; Platelet Aggr | 2015 |
Aspirin in secondary prevention of recurrent venous thromboembolism.
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Recurrence; | 2015 |
Does aspirin reduce recurrence after completing anticoagulant treatment for an idiopathic thromboembolic event?
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Randomized Controlled | 2015 |
Pharmacotherapeutic considerations for using colchicine to treat idiopathic pericarditis in the USA.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colchicine; Dose-Response Relationship, Drug; Drug | 2015 |
Recurrent pericarditis: new and emerging therapeutic options.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Aspirin; Azathioprine; Colchicine; Gl | 2016 |
Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Drug-Elut | 2015 |
[Gastrointestinal bleeding].
Topics: Anemia; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Blood Transfusion; Celecox | 2015 |
Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Aspirin; Data Collection; Drug Administration Schedule; Female; Hemorrhage; Humans; | 2015 |
[Meta-analysis on the efficacy and adverse events of aspirin plus clopidogrel versus aspirin-monotherapy in patients with ischemic stroke or transient ischemic attack].
Topics: Aspirin; Clopidogrel; Databases, Factual; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic At | 2015 |
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage | 2016 |
Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? The duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Recurrenc | 2016 |
Recurrent Pericarditis: Modern Approach in 2016.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Azathioprine; Colchicine; Drug Therapy, Combinatio | 2016 |
Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Random | 2016 |
Patent foramen ovale and cryptogenic stroke: from studies to clinical practice: Position paper of the Italian Chapter, International Society Cardiovascular Ultrasound.
Topics: Anticoagulants; Aspirin; Cardiac Catheterization; Echocardiography; Embolism, Paradoxical; Foramen O | 2016 |
Adherence to therapies for secondary prevention of cardiovascular disease: a focus on aspirin.
Topics: Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Humans; Medication Adherence; Recurrence; R | 2016 |
Management of idiopathic venous thromboembolism.
Topics: Anticoagulants; Aspirin; Fibrin Fibrinogen Degradation Products; Fibrinolytic Agents; Hemorrhage; Hu | 2016 |
Recurrent pericarditis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Pericarditis; Pro | 2017 |
Anticoagulants to prevent recurrent placenta-mediated pregnancy complications: Is it time to put the needles away?
Topics: Anticoagulants; Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Placent | 2017 |
PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-analysis of 19 studies comprising 3,003 patients.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Odds Ratio; Platelet Aggregation; Platele | 2008 |
Prediction and prevention of recurrent preeclampsia.
Topics: Adult; Antihypertensive Agents; Aspirin; Calcium, Dietary; Female; Fetal Growth Retardation; Heparin | 2008 |
Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Drug | 2009 |
Predicting poor outcome from acute upper gastrointestinal hemorrhage.
Topics: Aging; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Endoscopy, Gastrointestinal; Esophageal and | 2009 |
Anti-phospholipid antibodies and other immunological causes of recurrent foetal loss--a review of literature of various therapeutic protocols.
Topics: Abortion, Spontaneous; Anti-Inflammatory Agents; Antibodies, Antiphospholipid; Aspirin; Clinical Tri | 2009 |
[Chronic rhinosinusitis in morbus widal: clinical aspects and therapeutic options].
Topics: Adrenal Cortex Hormones; Aspirin; Asthma; Chronic Disease; Desensitization, Immunologic; Drug Hypers | 2009 |
Aspirin and clopidogrel hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Resistance; Huma | 2009 |
Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Interactions; Dr | 2010 |
Aspirin resistance: fact or fiction?
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregatio | 2010 |
[Actual review of diagnostics and endovascular therapy of intracranial arterial stenoses].
Topics: Angiography, Digital Subtraction; Angioplasty; Aspirin; Brain Infarction; Brain Ischemia; Cerebral A | 2011 |
[Dilemma between gastroprotection and cardiovascular prevention].
Topics: Alleles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; | 2010 |
[What's new in recurrent pericarditis in 2011?].
Topics: Acute Disease; Algorithms; Aspirin; Colchicine; Disease Progression; Humans; Pericarditis; Recurrenc | 2011 |
Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Headache; Hemorrhage; Humans; Ischemi | 2011 |
Patent foramen ovale and recurrent transient neurological symptoms: a case report and review of literature.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac Surgical Procedures; Echocardiography, Tra | 2011 |
[Decreasing incidence of stent thrombosis].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap | 2011 |
Promises of PAR-1 inhibition in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Female; Humans; Imines; Lactones; Male; Myocardial Ischemia; Plate | 2012 |
Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Datab | 2012 |
[Patent foramen ovale and stroke].
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Foramen Ovale, Patent; Humans; Platelet Aggregation In | 2012 |
The management of stroke patients by neurologists: common questions and new observations.
Topics: Angioplasty; Anticoagulants; Antihypertensive Agents; Aspirin; Carotid Stenosis; Case Management; Cl | 2002 |
Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome).
Topics: Acute Disease; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Monitoring; Heparin, Low-Mol | 2002 |
Interventional therapy for coronary artery disease.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Atherectomy, Coronary; B | 2002 |
State of the art--a journey through the world of antithrombotic therapy.
Topics: Ambulatory Care; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Coronary Disease; Fibrinolytic A | 2002 |
[Secondary and primary prevention of coronary heart disease: platelet aggregation inhibitors and anticoagulants].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Dose-Respon | 2002 |
[Antiphospholipid syndrome].
Topics: Adult; Aged; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Femal | 2002 |
[Antithrombotic therapy for ischemic cerebrovascular accident].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Fibrinolytic Agents; Humans; Recurrenc | 2002 |
[Etiology and pathogenesis of inflammatory bowel diseases].
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Co | 2002 |
[Therapy of chronic inflammatory bowel diseases].
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2002 |
[The best of thrombosis in 2002].
Topics: Abciximab; Angioplasty; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Ster | 2003 |
[Secondary prevention after ischemic stroke].
Topics: Administration, Oral; Angioplasty, Balloon; Anticholesteremic Agents; Anticoagulants; Aspirin; Atorv | 2003 |
[Secondary prevention after acute myocardial infarction: aspirin, warfarin or both?].
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Coronary Thrombosis; Drug Therapy, Combination; Fi | 2003 |
Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyc | 2003 |
[Secondary and primary prophylaxis of gastropathy associated with nonsteroidal antiinflammatory drugs or low-dose-aspirin: a review based on four clinical scenarios].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Gastrointestinal | 2003 |
Evidence-based management of thrombosis in the antiphospholipid antibody syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Evidence-Based Medicine; Humans; International N | 2003 |
[Which antithrombotic treatment should be used in the treatment of an elderly patient with chronic atrial fibrillation?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibril | 2003 |
[Stenosis of the carotid arteries].
Topics: Angioplasty, Balloon; Aspirin; Brain Ischemia; Carotid Stenosis; Endarterectomy; Humans; Recurrence; | 2003 |
[Lacunar infarcts].
Topics: Adult; Aged; Aspirin; Autopsy; Brain; Carotid Stenosis; Cerebral Infarction; Dementia; Female; Fibri | 2003 |
[Cryptogenic stroke and patent foramen ovale].
Topics: Administration, Oral; Adult; Anticoagulants; Aspirin; Echocardiography, Transesophageal; Follow-Up S | 2003 |
[Carotid stenosis: diagnosis, patient selection, therapy].
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Angioplasty, Balloon; Aspirin; Carotid St | 2003 |
Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Helicobacter Infections; Helicobacter pylori; Huma | 2004 |
Refractory Kawasaki disease.
Topics: Anti-Inflammatory Agents; Aspirin; Cyclosporine; Drug Therapy, Combination; Fever; Humans; Immunoglo | 2004 |
Antiphospholipid syndrome and second- or third-trimester fetal death: follow-up in the next pregnancy.
Topics: Adult; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Arteries; Aspirin; Female; Fetal Deat | 2004 |
Nasal polyps.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bacterial Infections; Drug Hypersensitivit | 2004 |
Clopidogrel: how good is it and how does it work?
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; | 2004 |
Comparison of bilateral thoracic artery grafting with percutaneous coronary interventions in diabetic patients.
Topics: Abciximab; Aged; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspir | 2004 |
Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Comorbidity; Diabetes Mellitus; Humans; Hypercholesterolemia | 2004 |
[Treatment and prophylaxis of an acute migraine attack].
Topics: Acupuncture Therapy; Acute Disease; Administration, Oral; Adrenergic beta-Antagonists; Analgesics; A | 2004 |
Stroke prevention. MATCHing therapy to the patient with TIA.
Topics: Aspirin; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Recurrenc | 2005 |
Post-varicella arteriopathy of childhood: natural history of vascular stenosis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angiog | 2005 |
[Digestive bleeding and anti-inflammatory drugs at the teaching hospital of Brazzaville].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Comorbidity; Congo; Femal | 2004 |
[Patent foramen ovale and stroke].
Topics: Adult; Age of Onset; Aspirin; Heart Septal Defects, Atrial; Humans; Middle Aged; Platelet Aggregatio | 2004 |
Anticoagulation therapy in the antiphospholipid syndrome: recent advances.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Humans; Kidney Transplantation; Pregnanc | 2005 |
Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Recurrence; Salicylates | 2005 |
[Preventing cerebrovascular accidents during atrial fibrillation].
Topics: Administration, Oral; Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conver | 2005 |
[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; | 2005 |
[Atheromatosis of the thoracic aorta and risk of stroke].
Topics: Anticoagulants; Aorta, Thoracic; Aortic Diseases; Aspirin; Atherosclerosis; Clopidogrel; Controlled | 2006 |
Major arterial involvement and review of Behcet's disease.
Topics: Adrenal Cortex Hormones; Adult; Aneurysm, False; Anticoagulants; Aortic Aneurysm, Abdominal; Arteria | 2007 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
[Aspirin].
Topics: Aspirin; Humans; Recurrence; Stroke | 2006 |
Antiplatelet therapy for atherothrombotic disease: an update for the primary care physician.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial | 2007 |
Independent predictors of stroke in patients with atrial fibrillation: a systematic review.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Case-Control Studies; Cohort Stu | 2007 |
[The antiphospholipid syndrome, an update].
Topics: Abortion, Spontaneous; Acenocoumarol; Adult; Antibodies, Anticardiolipin; Anticoagulants; Antiphosph | 2007 |
PRO: Should aspirin be used in all women older than 65 years to prevent stroke?
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Cost of Illness; Evidence-Based Practice; Femal | 2007 |
[Antiplatelet and anticoagulant treatment after percutaneous transluminal angioplasty for peripheral arteriosclerosis. Survey of a Cochrane review].
Topics: Angioplasty, Balloon; Anticoagulants; Arteriosclerosis; Aspirin; Dipyridamole; Evidence-Based Medici | 2007 |
[Latest developments: management and treatment of preeclampsia].
Topics: Adrenal Cortex Hormones; Antihypertensive Agents; Aspirin; Calcium; Calcium Channel Blockers; Female | 2008 |
Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review.
Topics: Adult; Aged; Aspirin; Blood Platelets; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Tolerance; E | 2008 |
Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events--a meta-analysis.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Coronary Disease; Drug Resistance; Humans; Platel | 2008 |
Chronic antithrombotic therapy in post-myocardial infarction patients.
Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Clopidogrel; Humans; Myocardial Infarction; Perip | 2008 |
Update in treatment of peptic ulcer disease.
Topics: Adult; Aged; Alcohol Drinking; Aluminum; Antacids; Anti-Ulcer Agents; Aspirin; Bismuth; Cimetidine; | 1984 |
Cardiac death prevention in post-myocardial infarction patients: a review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Anticoagu | 1980 |
[Secondary prevention following myocardial infarct. Platelet aggregation inhibitors, beta receptor blockers, antiarrhythmics].
Topics: Adrenergic beta-Antagonists; Alprenolol; Anti-Arrhythmia Agents; Aspirin; Dipyridamole; Female; Fibr | 1981 |
"But will it help my patients with myocardial infarction?" The implications of recent trials for everyday country folk.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Care Units; Fe | 1982 |
[Prevention of myocardial infarction by chemotherapy].
Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Blood Platelets | 1982 |
Cardiovascular involvement in Kawasaki syndrome.
Topics: Adrenal Cortex Hormones; Age Factors; Arrhythmias, Cardiac; Arteritis; Aspirin; Cardiovascular Disea | 1983 |
Changing concepts of pathophysiology, prognosis, and therapy in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aspirin; Coronary Disease; Coronary Vasospasm; Death, Sudden; Dipyridam | 1983 |
Percutaneous transluminal coronary angioplasty.
Topics: Angina, Unstable; Angioplasty, Balloon; Animals; Aspirin; Calcium Channel Blockers; Coronary Artery | 1984 |
[Allergic and pseudoallergic skin reactions to drugs and food additives].
Topics: Aspirin; Chronic Disease; Dermatitis, Contact; Drug Hypersensitivity; Drug Tolerance; Female; Food A | 1983 |
Platelet inhibitors for TIAs. A review of prospective drug trial results.
Topics: Aged; Aspirin; Clofibrate; Dipyridamole; Drug Therapy, Combination; Female; Humans; Ischemic Attack, | 1984 |
Gastroduodenal damage due to drugs, alcohol and smoking.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents; Aspirin; Ethanol; Gastric Mucosa; Gastrointestinal | 1984 |
[Primary thrombocyte reactions in hemostasis and thrombogenesis and the possibilities of influencing them by drugs].
Topics: Animals; Aspirin; Blood Platelets; Dipyridamole; Dose-Response Relationship, Drug; Drug Evaluation; | 1984 |
[Treatment of thrombosis and prevention of recurrence].
Topics: Aspirin; Heparin; Humans; Prognosis; Recurrence; Thrombosis | 1980 |
[Interference in platelet-fibrinogen system for prevention and therapy of myocardial infarct].
Topics: Angina Pectoris; Anticoagulants; Aspirin; Fibrinolysis; Humans; Myocardial Infarction; Recurrence | 1982 |
[Evaluation of the results of using aspirin in preventing recurrence of myocardial infarct].
Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial | 1981 |
Some issues concerning treatment in patients after myocardial infarction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Humans; Myocardial Infarction; Recurrence; Time F | 1995 |
[Radiofrequency ablation in permanent ectopic left atrial tachycardia].
Topics: Adult; Aspirin; Catheter Ablation; Chemotherapy, Adjuvant; Electrocardiography; Female; Follow-Up St | 1995 |
[Prevention of reinfarction with 100 mg or 30 mg ASS daily?].
Topics: Animals; Aspirin; Dose-Response Relationship, Drug; Epoprostenol; Humans; Myocardial Infarction; Pla | 1995 |
What do we really know about secondary prevention after myocardial infarction?
Topics: Adrenergic beta-Antagonists; Aspirin; Clinical Competence; Humans; Life Style; Myocardial Infarction | 1995 |
Medical treatment for stroke prevention.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard | 1994 |
Prevention of myocardial reinfarction. Recommendations based on results of drug trials.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1993 |
[Coronary disease: benefits of aspirin. What dose for which disease?].
Topics: Adult; Aged; Angina, Unstable; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Female; | 1994 |
Maintenance therapy for peptic ulcer--who needs it?
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Helicobacter Infections; Heli | 1993 |
The use of aspirin in cardiovascular disease.
Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Posto | 1993 |
The role of dipyridamole in the therapy of vascular disease.
Topics: Animals; Aspirin; Coronary Artery Bypass; Dipyridamole; Graft Survival; Heart Valve Prosthesis; Huma | 1993 |
When do vascular surgeons prescribe antiplatelet therapy? Current attitudes.
Topics: Angioplasty, Balloon; Arteriosclerosis; Aspirin; Dipyridamole; Graft Occlusion, Vascular; Humans; Is | 1993 |
Kawasaki disease in Adelaide: a review.
Topics: Adolescent; Anti-Bacterial Agents; Aspirin; Cardiovascular Diseases; Child; Child, Preschool; Female | 1993 |
Incidence, natural history, and risk factors in lacunar infarction.
Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Cerebral Infarction; Diabetic Angiopathies; Fem | 1993 |
[Secondary prevention of ischemic cardiopathy].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; | 1995 |
Pharmacologic treatment of recurrent pediatric headache.
Topics: Acetaminophen; Adolescent; Adrenal Cortex Hormones; Analgesics; Aspirin; Child; Child, Preschool; Er | 1995 |
Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: a clinical study of 16 pregnancies.
Topics: Adrenal Cortex Hormones; Adult; Aspirin; Combined Modality Therapy; Diagnostic Errors; Dipyridamole; | 1996 |
Oral anticoagulant treatment with and without aspirin.
Topics: Administration, Oral; Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Dipyridam | 1995 |
[High dosage acetylsalicylic acid administration for prevention of acute cerebral ischemia].
Topics: Aspirin; Cerebral Infarction; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Ischemi | 1995 |
[Aspirin dosage for prevention of cerebral infarct: arguments for low dosage].
Topics: Aspirin; Cerebral Infarction; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administra | 1995 |
Prehospital administration of aspirin in patients with unstable angina and acute myocardial infarction.
Topics: Angina, Unstable; Animals; Aspirin; Clinical Trials as Topic; Hospitalization; Humans; Myocardial In | 1996 |
Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Hemorrhage; He | 1996 |
Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials.
Topics: Anticoagulants; Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Heparin; Humans; Myoc | 1996 |
Coronary heart disease, unstable angina, PTCA: new indications for low molecular weight heparins?
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Coronary Disease | 1996 |
Pharmacologic therapies after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1996 |
[The use of acetylsalicylic acid in IHD].
Topics: Angina, Unstable; Aspirin; Coronary Vessels; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 1996 |
Stent thrombosis. Closing in on the best preventive treatment.
Topics: Aspirin; Atherectomy; Coronary Disease; Humans; Platelet Aggregation Inhibitors; Recurrence; Stents; | 1997 |
[Low molecular weight heparin in unstable angina].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Dalteparin; Dose-Response Relationship, Drug; Drug Therap | 1996 |
[Antiplatelet therapy during coronary endoprosthesis placement].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combin | 1996 |
Recent advances in stroke management.
Topics: Aged; Aged, 80 and over; Aspirin; Cerebrovascular Disorders; Female; Fibrinolytic Agents; Humans; In | 1997 |
Aspirin in the treatment and prevention of cardiovascular disease.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Female; Humans; Male; Middle Aged | 1997 |
Antiplatelet agents prevent cardiac events in patients with coronary artery disease.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Europe; Humans; Japan; Myocardial Infarction; P | 1998 |
[Secondary prevention following cerebral ischemia: is monotherapy with acetylsalicylic acid still first choice?].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel | 1998 |
Alkalinization and hemodialysis in severe salicylate poisoning: comparison of elimination techniques in the same patient.
Topics: Acute Disease; Adult; Alcoholic Intoxication; Aspirin; Bipolar Disorder; Drug Overdose; Epilepsy, To | 1998 |
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I | 1998 |
Management of thrombosis and pregnancy loss in the antiphospholipid syndrome.
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin | 1998 |
Antithrombotic therapy in patients undergoing coronary angioplasty.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Coronary | 1998 |
Clinical profile of saruplase: angiographic findings.
Topics: Aspirin; Clinical Trials as Topic; Coronary Angiography; Fibrinolytic Agents; Heparin; Humans; Myoca | 1998 |
Management of atrial fibrillation: out-of-hospital approach.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Electric Countershock; Heart | 1999 |
Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors | 1999 |
[Acute pericarditis: etiology, diagnosis, course, complications and treatment].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac Tamponade; Diagnosis, Diffe | 1999 |
Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggr | 2000 |
Ischemic stroke. Clinical strategies based on mechanisms and risk factors.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Brai | 2000 |
[Aspirin and cerebral ischemic accidents].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Cerebral Infarction; Clinica | 2000 |
[Aspirin and antiphospholipid syndrome].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antiphospholipid Syndrome; Arteriosc | 2000 |
Thrombolysis and percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Antithrombins; Aspirin; Cerebral Hemorrhage; Clinical Trials, Phase | 2000 |
Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups.
Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrha | 2000 |
Failed thrombolysis in myocardial infarction.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Antithrombins; As | 2000 |
[Low molecular weight heparin in the treatment of acute coronary syndromes without ST-segment elevation: unstable angina and non-Q-wave myocardial infarction].
Topics: Angina, Unstable; Anticoagulants; Aspirin; Clinical Trials as Topic; Confidence Intervals; Daltepari | 2000 |
Aspirin in the treatment and prevention of cardiovascular disease.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Case-Control Studie | 2000 |
Stroke prevention: antiplatelet and antithrombolytic therapy.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Carotid Stenosis; Clinical Trials as Topic; Clopidog | 2000 |
Post myocardial infarction treatment in the older adult.
Topics: Adrenergic beta-Antagonists; Aftercare; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; | 2001 |
The epidemiology of the antiphospholipid syndrome: who is at risk?
Topics: Adolescent; Adult; Age Factors; Aged; Animals; Antibodies, Anticardiolipin; Antibodies, Antiphosphol | 2001 |
Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Drug Th | 2002 |
[Is chronic or recurrent idiopathic pericarditis an autonomous inflammatory disease?].
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; As | 2001 |
From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Drug Therapy, Combination; Heparin; Humans; Intracranial Art | 2002 |
[Heparin or aspirin in the treatment of acute cerebral infarction?].
Topics: Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Fibrinolytic Agents; Heparin; Humans; Patient Sel | 2001 |
Thrombotic thrombocytopenic purpura and pregnancy: a case report and a review of the literature.
Topics: Adult; Aspirin; Disease Management; Female; Heparin; Humans; Practice Guidelines as Topic; Pregnancy | 2002 |
Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cyclooxygenase Inhibitors; Dose | 2002 |
[Anticoagulation therapy in myocardial infarction (author's transl)].
Topics: Anticoagulants; Aspirin; Coumarins; Dipyridamole; Fibrinolysis; Heparin; Humans; Leg; Myocardial Inf | 1975 |
[Prevention of complications and the methods of increasing the safety of percutaneous transluminal coronary angioplasty (PTCA)].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Catheterization; Coronary Disease; Extracorporeal Circulati | 1992 |
The secondary prevention of myocardial infarction by drug treatment; excluding lipid lowering agents.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Aspirin; Cardiovascular Agents; Humans; Hypert | 1992 |
[Isolated atrial fibrillation. The risk of embolism and its prevention].
Topics: 4-Hydroxycoumarins; Adult; Aged; Aged, 80 and over; Amiodarone; Anticoagulants; Aspirin; Atrial Fibr | 1992 |
[Aspirin and heparin in the fibrinolytic treatment of acute myocardial infarction].
Topics: Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; | 1992 |
Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis.
Topics: Angina Pectoris; Aspirin; Chemotherapy, Adjuvant; Coronary Thrombosis; Female; Humans; Male; Meta-An | 1992 |
[Can coronary "restenosis" after percutaneous angioplasty be prevented?].
Topics: Adrenal Cortex Hormones; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Disease; Coronary | 1992 |
[Embolic complications of chronic atrial fibrillation].
Topics: Aspirin; Atrial Fibrillation; Chronic Disease; Heart Valve Diseases; Humans; Primary Prevention; Pro | 1992 |
[Angioplasty in unstable angina].
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Combined Modali | 1992 |
Management of acute non-Q-wave myocardial infarction. The role of prophylactic diltiazem therapy and indications for predischarge coronary arteriography.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Coronary Angiography; Diltiazem; Ele | 1991 |
Perspectives on therapeutic interventions in patients with acute myocardial infarction: viewpoints after the GISSI-2 results.
Topics: Aspirin; Drug Therapy, Combination; Heparin; Humans; Myocardial Infarction; Recurrence; Streptokinas | 1991 |
[Nasosinusal polyposis. Indications. Results. Apropos of 222 ethmoidectomies].
Topics: Adult; Aged; Aspirin; Asthma; Drug Hypersensitivity; Ethmoid Sinus; Female; Humans; Male; Middle Age | 1991 |
What is the role of invasive intervention after coronary thrombolysis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Heparin; Humans; Myocardial Infa | 1991 |
Stroke prevention in women: role of aspirin versus ticlopidine.
Topics: Aspirin; Cerebrovascular Disorders; Female; Humans; Meta-Analysis as Topic; Recurrence; Sex Factors; | 1991 |
A review of secondary coronary prevention with dipyridamole and aspirin.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Myocardial Infar | 1990 |
Recurrent adverse pregnancy outcome and antiphospholipid antibodies.
Topics: Adrenal Cortex Hormones; Antibodies; Aspirin; Blood Coagulation Factors; Cardiolipins; Female; Human | 1990 |
Review of antiplatelet drug use in preventing restenosis following percutaneous transluminal coronary angioplasty.
Topics: Angioplasty, Balloon; Aspirin; Calcium Channel Blockers; Coronary Disease; Cyclooxygenase Inhibitors | 1988 |
Management of acute non-Q-wave myocardial infarction: role of prophylactic pharmacotherapy and indications for predischarge coronary arteriography.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Coronary Angiography; Electrocardiog | 1989 |
[Optimal dosage of acetylsalicylic acid. I: Use in primary and secondary prevention of myocardial infarct and following aortocoronary bypass operation].
Topics: Aspirin; Coronary Artery Bypass; Dose-Response Relationship, Drug; Humans; Myocardial Infarction; Po | 1989 |
[Aspirin in coronary heart disease].
Topics: Aspirin; Coronary Disease; Humans; Myocardial Infarction; Recurrence | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease.
Topics: Aspirin; Biomechanical Phenomena; Cardiovascular Diseases; Gastrointestinal Diseases; Humans; Myocar | 1989 |
After coronary thrombolysis and reperfusion, what next?
Topics: Animals; Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Myoca | 1989 |
[Platelet antiaggregants and coronary pathology].
Topics: Angina, Unstable; Aspirin; Coronary Disease; Humans; Myocardial Infarction; Recurrence | 1989 |
Usefulness of calcium entry blockers during and after percutaneous transluminal coronary artery angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Calcium Channel Blockers; Clinical Trials as Topic; Coronar | 1989 |
Prevention of restenosis after coronary angioplasty: a pharmacological approach.
Topics: Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical | 1989 |
Secondary prevention in elderly survivors of heart attacks.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Cholesterol; Female; Humans; Hypertension; Male; Myocard | 1988 |
Medical prophylaxis for the post myocardial infarct patient.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical Trials as T | 1988 |
Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty.
Topics: Angioplasty, Balloon; Animals; Arterial Occlusive Diseases; Aspirin; Clinical Trials as Topic; Dipyr | 1987 |
Influence of the methodology of percutaneous transluminal coronary angioplasty on restenosis.
Topics: Angioplasty, Balloon; Aspirin; Calcium Channel Blockers; Coronary Disease; Coronary Thrombosis; Huma | 1987 |
[Pharmacological prevention of coronary thrombosis].
Topics: Aspirin; Blood Coagulation; Coronary Disease; Coronary Thrombosis; Humans; Recurrence | 1987 |
Prevention of recurrent myocardial infarction and sudden death with aspirin therapy.
Topics: Aspirin; Death, Sudden; Humans; Myocardial Infarction; Prognosis; Recurrence | 1987 |
Pathogenesis and management of arthropathy in cystic fibrosis.
Topics: Adolescent; Adult; Aspirin; Child; Child, Preschool; Cystic Fibrosis; Female; Humans; Joint Diseases | 1986 |
Asymptomatic carotid disease.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disor | 1985 |
Clinical spectrum of adverse reactions to tartrazine.
Topics: Angioedema; Aspirin; Asthma; Azo Compounds; Child; Child, Preschool; Dermatitis, Contact; Diet; Food | 1985 |
340 trials available for aspirin and Recrudescence
| Article | Year |
|---|---|
Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial.
Topics: Administration, Oral; Age Factors; Aged; Aspirin; Atrial Fibrillation; Body Mass Index; Dabigatran; | 2021 |
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Topics: Adult; Aged; Aspirin; Double-Blind Method; Embolic Stroke; Factor Xa Inhibitors; Female; Humans; Mal | 2021 |
Dabigatran versus aspirin for stroke prevention after cryptogenic stroke with patent foramen ovale: A prospective study.
Topics: Aspirin; Dabigatran; Foramen Ovale, Patent; Humans; Ischemic Stroke; Prospective Studies; Recurrence | 2022 |
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
Topics: Aged; Anticoagulants; Aspirin; Chronic Disease; Coronary Artery Disease; Double-Blind Method; Drug T | 2020 |
Post-stroke cognitive impairment as an independent predictor of ischemic stroke recurrence: PICASSO sub-study.
Topics: Aged; Aspirin; Cilostazol; Cognitive Dysfunction; Female; Fibrinolytic Agents; Humans; Male; Middle | 2020 |
Impact of established cardiovascular disease on outcomes in the randomized global leaders trial.
Topics: Aged; Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female | 2020 |
Homocysteine Level Predicts Response to Dual Antiplatelet in Women With Minor Stroke or Transient Ischemic Attack: Subanalysis of the CHANCE Trial.
Topics: Aged; Aspirin; Biomarkers; China; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Femal | 2020 |
Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; China; Clopidogrel; Drug Substi | 2020 |
Higher early recurrence risk and potential benefit of dual antiplatelet therapy for minor stroke with watershed infarction: subgroup analysis of CHANCE.
Topics: Aspirin; Drug Therapy, Combination; Female; Humans; Infarction; Male; Middle Aged; Platelet Aggregat | 2020 |
Comparison of Antiplatelet Therapies for Prevention of Patent Foramen Ovale-Associated Stroke.
Topics: Adolescent; Adult; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Foramen Ov | 2020 |
Association of Black Race With Early Recurrence After Minor Ischemic Stroke or Transient Ischemic Attack: Secondary Analysis of the POINT Randomized Clinical Trial.
Topics: Aged; Aspirin; Black or African American; Clopidogrel; Female; Humans; Ischemic Attack, Transient; I | 2020 |
Antithrombotic Treatment of Embolic Stroke of Undetermined Source: RE-SPECT ESUS Elderly and Renally Impaired Subgroups.
Topics: Aged; Aged, 80 and over; Aspirin; Dabigatran; Double-Blind Method; Female; Fibrinolytic Agents; Huma | 2020 |
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Beverages; Caffeine; Double-Blind Method; Dual Anti-Platelet Therapy; Dyspnea; Female | 2020 |
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Aspirin; Brain Ischemia; Double-Blind Method; Embolic Stroke; Factor Xa Inhibitors; Female; Hu | 2020 |
Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy.
Topics: Aged; Aspirin; Double-Blind Method; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Intra | 2020 |
Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: an Exploratory Analysis of The POINT Randomized Clinical Trial.
Topics: Aged; Aspirin; Carotid Artery Diseases; Clopidogrel; Comorbidity; Double-Blind Method; Dual Anti-Pla | 2020 |
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Double-Blind Method; Embolic Stroke; Female; Hum | 2021 |
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Double-Blind Method; Embolic Stroke; Female; Hum | 2021 |
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Double-Blind Method; Embolic Stroke; Female; Hum | 2021 |
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Double-Blind Method; Embolic Stroke; Female; Hum | 2021 |
Dabigatran or Aspirin in East Asian Patients With Embolic Stroke of Undetermined Source: RE-SPECT ESUS Subgroup Analysis.
Topics: Asia, Eastern; Asian People; Aspirin; Cohort Studies; Dabigatran; Double-Blind Method; Embolic Strok | 2021 |
Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Carotid Stenosis; Clopidogrel; Dual Anti-Platelet | 2021 |
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cardiovascular | 2017 |
Microbleeds in the Secondary Prevention of Small Subcortical Strokes Trial: Stroke, mortality, and treatment interactions.
Topics: Aspirin; Cerebral Hemorrhage; Clopidogrel; Double-Blind Method; Female; Humans; Magnetic Resonance I | 2017 |
Low dose aspirin in the prevention of recurrent spontaneous preterm labour - the APRIL study: a multicenter randomized placebo controlled trial.
Topics: Adolescent; Adult; Aspirin; Cost-Benefit Analysis; Double-Blind Method; Female; Gestational Age; Hum | 2017 |
Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.
Topics: Adenosine; Aged; Aortic Diseases; Aspirin; Atherosclerosis; Carotid Stenosis; Female; Humans; Intrac | 2017 |
SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial.
Topics: Amputation, Surgical; Aspirin; Clinical Protocols; Clopidogrel; Computed Tomography Angiography; Con | 2017 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double | 2018 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double | 2018 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double | 2018 |
Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Double | 2018 |
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb | 2018 |
Rationale and Study Design for a Single-Arm Phase IIa Study Investigating Feasibility of Preventing Ischemic Cerebrovascular Events in High-Risk Patients with Acute Non-disabling Ischemic Cerebrovascular Events Using Remote Ischemic Conditioning.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Ther | 2018 |
Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA: a subgroup analysis of the CHANCE trial.
Topics: Aged; Aspirin; China; Clopidogrel; Double-Blind Method; Dual Anti-Platelet Therapy; Female; Humans; | 2017 |
Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Endovascular Procedures; Europe; Factor Xa In | 2018 |
Risk of recurrent venous thromboembolism according to baseline risk factor profiles.
Topics: Adult; Aged; Aspirin; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Midd | 2018 |
Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Cyclooxygenase Inhibitors; Female; Greece; H | 2019 |
Oxidized low-density lipoprotein predicts recurrent stroke in patients with minor stroke or TIA.
Topics: Aged; Aspirin; Blood Pressure; Body Mass Index; Clopidogrel; Double-Blind Method; Female; Follow-Up | 2018 |
Low-dose aspirin and burr-hole drainage of chronic subdural hematoma: study protocol for a randomized controlled study.
Topics: Aspirin; Confidentiality; Data Interpretation, Statistical; Double-Blind Method; Drainage; Hematoma, | 2019 |
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Chronic Disease; Corona | 2019 |
Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Endpoint Determination; Female; Hemorrhage; Humans; Ischemic Attac | 2019 |
Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection: The Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Carotid Artery, Internal, Disse | 2019 |
The influence of mean arterial pressure on the efficacy and safety of dual antiplatelet therapy in minor stroke or transient ischemic attack patients.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arterial Pressure; Aspirin; Blood Pressure; Case-Cont | 2019 |
Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Intracr | 2019 |
Effect of dual versus mono antiplatelet therapy on recurrent stroke modulated by activated partial thromboplastin time.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle | 2019 |
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence | 2019 |
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence | 2019 |
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence | 2019 |
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.
Topics: Aged; Antithrombins; Aspirin; Dabigatran; Double-Blind Method; Female; Hemorrhage; Humans; Incidence | 2019 |
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind Method; Factor Xa Inhibitors; Female; Hu | 2019 |
Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease.
Topics: Adult; Aspirin; Desensitization, Immunologic; Drug Hypersensitivity; Female; Follow-Up Studies; Huma | 2013 |
Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.
Topics: Aged; Aged, 80 and over; Alloys; Angioplasty; Aspirin; Cardiovascular Diseases; Cilostazol; Constric | 2013 |
Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Clopidogrel; Double-Blind Method; Drug Thera | 2013 |
[Acetylsalicylic acid non-responders after ischemic insult in geriatric patients].
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Female; Humans; Male; Platelet Aggregation Inhibit | 2014 |
Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up.
Topics: Aged; Aspirin; Brain Ischemia; Dyspepsia; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; | 2014 |
C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study.
Topics: Aged; Antihypertensive Agents; Aspirin; Biomarkers; Blood Pressure; C-Reactive Protein; Clopidogrel; | 2014 |
A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke.
Topics: Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Endpoint Determination; Female; Humans; Intra | 2014 |
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial.
Topics: Administration, Oral; Aged; Aspirin; Clopidogrel; Epidemiologic Methods; Female; Hemorrhage; Humans; | 2014 |
Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin.
Topics: Aged; Anti-Ulcer Agents; Aspirin; Double-Blind Method; Duodenal Ulcer; Female; Fibrinolytic Agents; | 2014 |
Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; H | 2014 |
Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; H | 2014 |
Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; H | 2014 |
Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; H | 2014 |
Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial.
Topics: Aged; Anticoagulants; Aspirin; Female; Fibrinolytic Agents; Heart Failure; Humans; Male; Middle Aged | 2014 |
Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Stud | 2014 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Glyc | 2015 |
Left Ventricular Geometry on Transthoracic Echocardiogram and Prognosis after Lacunar Stroke: The SPS3 Trial.
Topics: Aged; Aspirin; Clopidogrel; Echocardiography; Female; Heart Ventricles; Humans; Magnetic Resonance I | 2015 |
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study.
Topics: Aspirin; Clinical Protocols; Double-Blind Method; Drug Administration Schedule; Fibrinolytic Agents; | 2015 |
Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A Double-Blind, Randomized, Crossover Trial.
Topics: Adult; Aspirin; Cardiovascular Diseases; Cross-Over Studies; Double-Blind Method; Female; Humans; In | 2015 |
Dual antiplatelet therapy in stroke and ICAS: Subgroup analysis of CHANCE.
Topics: Aged; Aspirin; Clopidogrel; Constriction, Pathologic; Double-Blind Method; Drug Therapy, Combination | 2015 |
Treatment of Rivaroxaban versus Aspirin for Non-disabling Cerebrovascular Events (TRACE): study protocol for a randomized controlled trial.
Topics: Adult; Aspirin; Clinical Protocols; Factor Xa Inhibitors; Female; Humans; Ischemic Attack, Transient | 2015 |
Achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial.
Topics: Aspirin; Blood Pressure; Blood Pressure Determination; Clopidogrel; Drug Therapy, Combination; Femal | 2016 |
Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Australia; Drug Therapy, Co | 2016 |
Morphological classification of penetrating artery pontine infarcts and association with risk factors and prognosis: The SPS3 trial.
Topics: Antihypertensive Agents; Aspirin; Cerebral Infarction; Clopidogrel; Constriction, Pathologic; Double | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack.
Topics: Aged; Aspirin; Chi-Square Distribution; China; Clopidogrel; Disease Progression; Double-Blind Method | 2016 |
Aspirin in venous leg ulcer study (ASPiVLU): study protocol for a randomised controlled trial.
Topics: Aspirin; Australia; Clinical Protocols; Combined Modality Therapy; Cyclooxygenase Inhibitors; Double | 2016 |
The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial.
Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Arterial Diseases; Clopidogrel; Drug Therapy, Co | 2016 |
Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA.
Topics: Aged; Aspirin; Blood Glucose; Brain Ischemia; Clopidogrel; Diabetes Complications; Double-Blind Meth | 2016 |
Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
Topics: Aged; Aged, 80 and over; Aspirin; Double-Blind Method; Famotidine; Female; Hemoglobins; Histamine H2 | 2017 |
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy | 2016 |
Impact of Glycemic Control on Efficacy of Clopidogrel in Transient Ischemic Attack or Minor Stroke Patients With
Topics: Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind Method; Female; Glycated Serum Al | 2017 |
Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Desensitization, | 2008 |
Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Desensitization, | 2008 |
Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Desensitization, | 2008 |
Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Desensitization, | 2008 |
Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle A | 2008 |
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopi | 2008 |
Failure of antithrombotic therapy and risk of stroke in patients with symptomatic intracranial stenosis.
Topics: Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Constriction, Pathologic; Double-Blind Met | 2009 |
Prolonged anticoagulation therapy adjunctive to aspirin after successful fibrinolysis: from early reduction in reocclusion to improved long-term clinical outcome.
Topics: Aged; Anticoagulants; Aspirin; Coronary Occlusion; Coumarins; Hemorrhage; Humans; International Norm | 2009 |
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde | 2009 |
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde | 2009 |
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde | 2009 |
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde | 2009 |
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Chest Pain; Dose-Response Relationship, Drug | 2009 |
Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Dis | 2009 |
Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Agents; Clopidogrel; Coronary Angiography; C | 2009 |
Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2010 |
Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardi
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiograp | 2009 |
Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Embolism; Feasibility Studies | 2010 |
Safety and feasibility of a novel intravitreal tamponade using a silicone oil/acetyl-salicylic acid suspension for proliferative vitreoretinopathy: first results of the Austrian Clinical Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Austria; Double-Blind Method; Drainage; Drug Combinations; | 2010 |
Factors responsible for "aspirin resistance" - can we identify them?
Topics: Aged; Aged, 80 and over; Aspirin; Coronary Disease; Drug Resistance; Female; Humans; Male; Middle Ag | 2010 |
The International Stroke Trial database.
Topics: Access to Information; Activities of Daily Living; Aged, 80 and over; Anticoagulants; Asia; Aspirin; | 2011 |
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose- | 2011 |
Influence of aspirin therapy in the ulcer associated with chronic venous insufficiency.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Bandages, Hydrocolloid; Cardiovascular Agents; Chi-Square D | 2012 |
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause | 2012 |
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.
Topics: Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hem | 2012 |
CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment.
Topics: Adenoma; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Chemoprevention; Colorectal Neoplasms; Cytoch | 2013 |
Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry.
Topics: Antineoplastic Agents, Phytogenic; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Rela | 2013 |
Aspirin resistance in Chinese stroke patients increased the rate of recurrent stroke and other vascular events.
Topics: Aged; Asian People; Aspirin; Cardiovascular Diseases; Drug Resistance; Female; Humans; Male; Myocard | 2013 |
Baseline dietary fiber intake and colorectal adenoma recurrence in the wheat bran fiber randomized trial.
Topics: Adenoma; Aged; Aspirin; Colorectal Neoplasms; Dietary Fiber; Educational Status; Exercise; Female; F | 2002 |
The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
Topics: Angina, Unstable; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Female; Heart Failure | 2003 |
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
Topics: Abciximab; Administration, Cutaneous; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood F | 2003 |
Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial.
Topics: Aged; Aspirin; Black or African American; Double-Blind Method; Female; Humans; Male; Middle Aged; Pl | 2003 |
Effect of site of venous protamine administration, previously alleged risk factors, and preoperative use of aspirin on acute protamine-induced pulmonary vasoconstriction.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Cardiopulmonary Bypass; Constriction, Pathol | 2003 |
Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke.
Topics: Adult; Aged; Aspirin; Cerebral Infarction; Drug Therapy, Combination; Female; Humans; Ischemic Attac | 2003 |
The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial
Topics: Administration, Oral; Aspirin; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; | 2003 |
Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Ambulances; Angioplasty, Balloon, Coronary; Aspirin; Emergency Medic | 2003 |
Serial urinary 11-dehydrothromboxane B2, aspirin dose, and vascular events in blacks after recent cerebral infarction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Black People; Cerebral Infarction; Dose-Response R | 2004 |
Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study.
Topics: Aged; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; | 2004 |
Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Arachidonic Acid; Aspiri | 2004 |
Leukocyte count as an independent predictor of recurrent ischemic events.
Topics: Aspirin; Biomarkers; Brain Ischemia; Cause of Death; Clopidogrel; Female; Humans; Inflammation; Leuk | 2004 |
Effect of aspirin and warfarin therapy in stroke patients with valvular strands.
Topics: Adult; Aged; Aortic Valve; Aspirin; Echocardiography, Transesophageal; Endpoint Determination; Fibri | 2004 |
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M | 2004 |
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M | 2004 |
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M | 2004 |
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M | 2004 |
Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
Topics: Adolescent; Adult; Aged; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Celec | 2004 |
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome.
Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypa | 2004 |
High-grade infarct-related stenosis after successful thrombolysis: strong predictor of reocclusion, but not of clinical reinfarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Restenosis; Coronary S | 2004 |
Effects of probucol versus aspirin and versus brachytherapy on restenosis after femoropopliteal angioplasty: the PAB randomized multicenter trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon; Arterial Occlusive Diseases; As | 2004 |
Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Angiography; Coronary Diseas | 2005 |
Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agent | 2005 |
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).
Topics: Administration, Oral; Adult; Algorithms; Antibodies, Anticardiolipin; Anticoagulants; Antiphospholip | 2005 |
Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs.
Topics: Acetaminophen; Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anal | 2005 |
Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: the PREVENT Trial [corrected].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biocompatibl | 2005 |
Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial.
Topics: Adult; Aged; Anti-Inflammatory Agents; Aspirin; Colchicine; Female; Humans; Male; Middle Aged; Peric | 2005 |
Does adding misoprostol to standard intravenous proton pump inhibitor protocol improve the outcome of aspirin/NSAID-induced upper gastrointestinal bleeding?: a randomized prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2007 |
Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Biomarkers; Cardiac Catheterization; C | 2007 |
Impact of valvular thickness on stroke recurrence in medically treated patients with stroke.
Topics: Adult; Aged; Aortic Valve; Aspirin; Brain Ischemia; Double-Blind Method; Echocardiography, Transesop | 2007 |
Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study.
Topics: 3' Untranslated Regions; Activated Protein C Resistance; Adult; Aspirin; Double-Blind Method; Drug A | 2007 |
Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events.
Topics: Age Factors; Aged; Anti-Inflammatory Agents; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel | 2008 |
Cardiac death prevention in post-myocardial infarction patients: a review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Animals; Anti-Arrhythmia Agents; Anticoagu | 1980 |
"But will it help my patients with myocardial infarction?" The implications of recent trials for everyday country folk.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Care Units; Fe | 1982 |
[Aftercare of heart infarct patients to reduce the risk of a subsequent infarction].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Clinical Trials as Top | 1983 |
The role of pharmacotherapy in secondary prevention of myocardial infarction and death.
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Fem | 1984 |
Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study.
Topics: Adult; Aged; Angina Pectoris; Angioplasty, Balloon; Aspirin; Coumarins; Follow-Up Studies; Humans; M | 1984 |
British studies of aspirin and myocardial infarction.
Topics: Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial Infarction; P | 1983 |
[Low-dose acetylsalicylic acid (100 mg/day) following aortocoronary bypass operation].
Topics: Aspirin; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Bypass; Coronary Circulatio | 1984 |
[Results of ambulatory follow-up of patients after myocardial infarction treated with platelet aggregation inhibitors and antithrombotic drugs].
Topics: Acenocoumarol; Adult; Ambulatory Care; Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyrida | 1983 |
Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs. conventional antiaggregants: a six-month randomized follow-up study.
Topics: Aged; Aspirin; Dipyridamole; Drug Tolerance; Female; Follow-Up Studies; Humans; Male; Middle Aged; P | 1984 |
[Secondary prevention of ischemic cardiopathy with anti-platelet aggregates in the post-infarct patient. Review].
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation | 1982 |
[The treatment of transitory ischemic attacks with acetylsalicylic acid: results of a double-blind-study (author's transl)].
Topics: Aspirin; Cerebral Infarction; Humans; Ischemic Attack, Transient; Placebos; Recurrence; Vertebrobasi | 1980 |
The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group.
Topics: 4-Hydroxycoumarins; Aged; Anticoagulants; Aspirin; Austria; Clinical Trials as Topic; Death, Sudden; | 1980 |
[Persantin and aspirin in coronary heart disease. The persantin-aspirin reinfarction study group (PARIS)].
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Disease; Dipyridamole; Drug Therapy, Combin | 1980 |
[Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial].
Topics: Aspirin; Clinical Trials as Topic; Dihydroergotoxine; Dipyridamole; Humans; Ischemic Attack, Transie | 1982 |
A randomized, controlled trial of aspirin in persons recovered from myocardial infarction.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial Infarc | 1980 |
Aspirin and recurrent myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Female; Humans; Male; Middle Aged; Myocardial Infar | 1980 |
Secondary prevention of myocardial infarction--the present state of the ART.
Topics: Anticoagulants; Aspirin; Blood Platelets; Clinical Trials as Topic; Dipyridamole; Humans; Myocardial | 1980 |
Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials.
Topics: Adult; Angina Pectoris; Angina Pectoris, Variant; Arteries; Aspirin; Clinical Trials as Topic; Coron | 1981 |
[The platelet inhibitor problem].
Topics: Aspirin; Blood Transfusion; Brain Ischemia; Clinical Trials as Topic; Female; Humans; Male; Myocardi | 1981 |
[Results of prevention of second myocardial infarct with syncumar or aspirin].
Topics: Acenocoumarol; Aged; Aspirin; Clinical Trials as Topic; Follow-Up Studies; Humans; Middle Aged; Myoc | 1981 |
Can aspirin prevent recurrence of heart attacks and strokes?
Topics: Adult; Aged; Antithrombins; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Female; Hu | 1982 |
Anti platelet agents for strokes and myocardial infarction: a critical appraisal of recent clinical trials.
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Collagen; Coronary Disease; Dipyridamo | 1981 |
E.P.S.I.M., the French oral anticoagulant--aspirin trial in post-myocardial infarction patients: design, organization and quality control procedures.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Data Collectio | 1981 |
[Evaluation of the results of using aspirin in preventing recurrence of myocardial infarct].
Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Myocardial | 1981 |
A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Death, Sudden; | 1982 |
[Long term prophylaxis of re-infarct. Results of the persantin-acetylsalicylic acid re-infarct study].
Topics: Adult; Aged; Aspirin; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; Female; Humans; | 1980 |
A randomized trial of E5510 versus aspirin in patients with transient ischemic attacks. The Japanese E5510 TIA study-1 (JETS-1) Group.
Topics: Aged; Aspirin; Double-Blind Method; Fatty Acids, Monounsaturated; Female; Humans; Incidence; Ischemi | 1995 |
The diagnostic and prognostic importance of ambulatory ST recording compared to a predischarge exercise test after an episode of unstable angina or non-Q wave myocardial infarction.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Angina, Unstable; Aspirin; Coronary Disease; Dos | 1995 |
Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Female; Glutathione; Heparin; Human | 1994 |
Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II)
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Double-Blind Method | 1995 |
Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Chi-Square Distribution; Drug Therapy, Combination; Female; | 1995 |
Recurrent stroke after transient ischaemic attack or minor ischaemic stroke: does the distinction between small and large vessel disease remain true to type? Dutch TIA Trial Study Group.
Topics: Aged; Aspirin; Atenolol; Cerebral Arteries; Cerebrovascular Disorders; Double-Blind Method; Female; | 1995 |
Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Combined Modality Therapy; Dose-Re | 1995 |
Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy.
Topics: Aspirin; Coronary Angiography; Coronary Disease; Coronary Vessels; Dipyridamole; Double-Blind Method | 1995 |
Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilazapril; Coronary Angiography; Coronary Disease; Double- | 1995 |
Audit of secondary prophylaxis after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aftercare; Aspirin; Community Health Services; England; Hospitalization | 1994 |
Effect of aspirin use on death and recurrent myocardial infarction in current and former cigarette smokers. Program on the Surgical Control of the Hyperlipidemias Group.
Topics: Aspirin; Cohort Studies; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hypercholestero | 1995 |
Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Calcium Channel Blockers; Drug Therapy | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Double-Blind Method; | 1993 |
[Effect of captopril on mortality and morbidity in patients with dysfunction of the left ventricle after myocardial infarction. Results on survival and hypertrophic studies].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Captopril; Cardiac Output, Low | 1993 |
[Unstable angina: effect of aspirin and heparin on treatment outcome in hospital patients (a double-blind, placebo-controlled study)].
Topics: Administration, Oral; Adult; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Female; Follow-Up | 1993 |
[Sumatriptan in the treatment of acute migraine: its role in primary health care].
Topics: Acute Disease; Administration, Oral; Algorithms; Aspirin; Caffeine; Double-Blind Method; Drug Therap | 1994 |
The role of autopsy findings in multicenter treatment evaluations as exemplified by two aspirin trials.
Topics: Aspirin; Autopsy; Cause of Death; Cerebral Infarction; Death, Sudden, Cardiac; Diagnostic Errors; Do | 1993 |
Comparison of symptomatic and asymptomatic reinfarctions after small subcortical stroke.
Topics: Aged; Aspirin; Cerebral Angiography; Cerebral Infarction; Cholesterol, HDL; Female; Fibrinogen; Foll | 1994 |
Can aspirin prevent gallstone recurrence after successful extracorporeal shockwave lithotripsy?
Topics: Adult; Aged; Aspirin; Cholelithiasis; Female; Follow-Up Studies; Humans; Life Tables; Lithotripsy; M | 1994 |
Acetylsalicylic acid in the prevention of early stenosis and occlusion of transjugular intrahepatic portal-systemic stent shunts: a controlled study.
Topics: Aged; Aspirin; Constriction, Pathologic; Female; Follow-Up Studies; Humans; Liver; Liver Transplanta | 1994 |
Secondary prevention after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Cholesterol; Exercise; Female; Humans; Male; Midd | 1993 |
Effect on early acute occlusion rate of adjunctive antithrombotic treatment with intravenously administered dipyridamole during percutaneous transluminal coronary angioplasty.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Chemotherapy, Adjuvant; Coronary Thrombosis; | 1994 |
Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Dipyridamole; | 1994 |
Acetylsalicylic acid--reocclusion--prophylaxis after angioplasty (ARPA-study). A randomized double-blind trial of two different dosages of ASA in patients with peripheral occlusive arterial disease.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Combined Modality Therapy; Dose-Response | 1994 |
Culprit lesion morphology and stenosis severity in the prediction of reocclusion after coronary thrombolysis: angiographic results of the APRICOT study. Antithrombotics in the Prevention of Reocclusion in Coronary Thrombolysis.
Topics: Aspirin; Coronary Angiography; Coronary Thrombosis; Female; Humans; Male; Middle Aged; Multivariate | 1993 |
The challenge of maintaining coronary arterial patency with intravenous heparin following tissue plasminogen activator administration.
Topics: Administration, Oral; Aspirin; Coronary Angiography; Drug Administration Schedule; Drug Therapy, Com | 1993 |
Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Double-Blind Method | 1994 |
Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Electrocardiography; Female; Fibrinolytic Agen | 1994 |
Platelet inhibition with ASA/dipyridamole after percutaneous balloon angioplasty in patients with symptomatic lower limb arterial disease. A prospective double-blind trial. Study group on pharmacological treatment after PTA.
Topics: Aged; Angiography; Angioplasty, Balloon; Aspirin; Dipyridamole; Double-Blind Method; Drug Combinatio | 1994 |
Can recurrent stenosis after carotid endarterectomy be prevented by low-dose acetylsalicylic acid? A double-blind, randomised and placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Carotid Artery, Internal; Carotid Stenosis; Dose-Response R | 1993 |
European Stroke Prevention Study (ESPS): antithrombotic therapy is also effective in the elderly.
Topics: Actuarial Analysis; Aged; Aspirin; Cause of Death; Cerebral Infarction; Cerebrovascular Disorders; D | 1993 |
Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Thrombosis; Female; Fibrinolytic Agents; Humans; Male; | 1993 |
Influence on early outcome and restenosis of urokinase before elective coronary angioplasty.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Coronary | 1993 |
Subacute occlusion, bleeding complications, hospital stay and restenosis after Palmaz-Schatz coronary stenting under a new antithrombotic regimen.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Aspirin; Coronary Angiography; | 1996 |
[Drug prescription in the postinfarction period; results of the EPPI II (Study of Postinfarct Prescription). A French cooperative study].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Aspirin; Calcium Channel Blockers; Drug Prescr | 1995 |
Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Coronary Disease; Daltepa | 1996 |
Intranasal lysine aspirin in recurrent nasal polyposis.
Topics: Administration, Intranasal; Adult; Aspirin; Drug Combinations; Humans; Lysine; Male; Middle Aged; Na | 1995 |
[Low molecular weight heparin (Fraxiparine) as adjunctive therapy with thrombolysis for acute myocardial infarction: a pilot study with a one year follow up].
Topics: Adult; Aged; Aspirin; Echocardiography; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male | 1996 |
Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group.
Topics: Aspirin; Cerebrovascular Disorders; Diastole; Female; Humans; Hypertension; Male; Middle Aged; Recur | 1996 |
Comparison of aspirin with a thromboxane antagonist for patients with prolonged chest pain and ST segment depression.
Topics: Aged; Aspirin; Biphenyl Compounds; Coronary Care Units; Double-Blind Method; Electrocardiography; Fe | 1996 |
Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators.
Topics: Abciximab; Aged; Angioplasty; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Transfusion; Co | 1996 |
Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Feasibility | 1996 |
[The effect of Taprostene on platelet activation and clinical course after percutaneous transluminal angioplasty].
Topics: Administration, Oral; Adult; Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Cardi | 1996 |
Antiplatelet therapy in therapy-resistant unstable angina. A pilot study with REO PRO (c7E3).
Topics: Abciximab; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; As | 1995 |
A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial.
Topics: Anistreplase; Anticoagulants; Aspirin; Death, Sudden, Cardiac; Female; Heparin; Humans; Male; Myocar | 1996 |
Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy.
Topics: Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Heparin; | 1997 |
Comparison of heparin therapy for < or = 48 hours to > 48 hours in unstable angina pectoris.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Case-Control Studies; Coronary Angi | 1997 |
Control of bias in dietary trial to prevent coronary recurrences: The Lyon Diet Heart Study.
Topics: Adrenergic beta-Antagonists; Adult; Alcohol Drinking; Angiotensin-Converting Enzyme Inhibitors; Anti | 1997 |
Aspirin plus either dipyridamole or ticlopidine is effective in preventing recurrent myocardial infarction. Secondary Prevention Group.
Topics: Aged; Aspirin; Dipyridamole; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mid | 1997 |
Healing with basic fibroblast growth factor is associated with reduced indomethacin induced relapse in a human model of gastric ulceration.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Cimetidine; Cross-Over S | 1997 |
We need stronger predictors of major vascular events in patients with a recent transient ischemic attack or nondisabling stroke. Dutch TIA Trial Study Group.
Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Dose-Response Relationship, Drug; | 1997 |
Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISA
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardiovascular Diseases; Combined Modality | 1997 |
The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cerebrovascular Disorders; Clinical | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Cerebrovascul | 1997 |
Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Ca | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
Coronary stenting after rotational atherectomy in calcified and complex lesions. Angiographic and clinical follow-up results.
Topics: Aged; Aspirin; Atherectomy, Coronary; Calcinosis; Coronary Angiography; Coronary Disease; Coronary T | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; | 1997 |
The effects of platelet inhibitors on platelet uptake and restenosis after femoral angioplasty.
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Constriction, Pathologic; Female; | 1997 |
Effectiveness of low-dose ASA in prevention of secondary ischemic stroke, the ASA Study Group in Taiwan.
Topics: Aged; Aspirin; Brain Ischemia; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggr | 1997 |
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.
Topics: Analysis of Variance; Antithrombins; Aspirin; Cardiac Catheterization; Double-Blind Method; Drug Adm | 1997 |
[Immediate and long-term clinical and angiographic results of the Wiktor stent in the treatment of chronic coronary occlusions].
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Chronic Disease; Coro | 1997 |
Wiktor stent for treatment of chronic total coronary artery occlusions: short- and long-term clinical and angiographic results from a large multicenter experience.
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Catheterization, Peri | 1998 |
PAMI (Primary Angioplasty in Myocardial Infarction) Stent Pilot Trial.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Follow-Up Studies; Humans; Myoca | 1998 |
Prevalence of late potentials after myocardial infarction treated with systemic thrombolysis or primary percutaneous transluminal coronary angioplasty.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Co | 1998 |
[Intracoronary dipyridamole reduces the incidence of acute coronary vessel occlusion in percutaneous transluminal coronary angioplasty--a prospective randomized study].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Coro | 1997 |
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Atherectomy; Blood Coagu | 1998 |
Incidence and prognosis of early primary ventricular fibrillation in acute myocardial infarction--results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI-2) database.
Topics: Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atenolol; Drug Administration Routes; Electrocardio | 1998 |
Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Double-Blind Method; Drug Administration Routes; D | 1998 |
Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE).
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 1998 |
The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Aspirin; Cerebrovascular Disorders; Clopidogrel; Double-Blind Method; Humans; Ischemia; Myocardial I | 1998 |
Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Delayed-Action Preparations; Dipyridamole; Disease-Free Su | 1998 |
The trapidil restenosis trial (STARC study): background, methods and clinical characteristics of the patient population.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clinical Protocols; Cohort Studies; Coronary D | 1994 |
Advances in post stenting medication protocol.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Drug Therapy, Combination | 1995 |
Attenuated severity of new acute ischemic events in patients with previous coronary heart disease receiving long-acting nitrates.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Calcium Channel Blo | 1999 |
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
Topics: Acute Disease; Age Factors; Aged; Angina, Unstable; Aspirin; Brain Damage, Chronic; Cerebral Hemorrh | 1999 |
Transesophageal echocardiography and unexplained cerebral ischemia: a multicenter follow-up study. The STEPS Investigators. Significance of Transesophageal Echocardiography in the Prevention of Recurrent Stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Cerebrovascular Disorders; Echocardiography | 1999 |
[Secondary prevention after ischemic cerebral infarct. The ESPRIT Study: low dose anticoagulation, combined therapy with acetylsalicylic acid/dipyridamole or monotherapy with acetylsalicylic acid?].
Topics: Anticoagulants; Aspirin; Australia; Cerebral Infarction; Dipyridamole; Dose-Response Relationship, D | 1999 |
Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Coagulation Factors; Chondroitin Sulf | 1999 |
Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Calcium; Cell Division; Cilostazol; Combined Modality | 1999 |
Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG St
Topics: Adult; Analgesics; Aspirin; Double-Blind Method; Female; Humans; Infusions, Intravenous; Injections, | 1999 |
Comparison of cilostazol versus ticlopidine therapy after stent implantation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Disease; Coronary Thrombo | 1999 |
Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial.
Topics: Adult; Angina, Unstable; Anticoagulants; Aspirin; Death, Sudden, Cardiac; Double-Blind Method; Drug | 1999 |
The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study: evaluation of acute and long-term therapies for patients with acute coronary syndromes without ST elevation.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Aspirin; Canada; Death, Sudden, Cardiac; Dose | 1999 |
Vitamin E, a modifier of platelet function: rationale and use in cardiovascular and cerebrovascular disease.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Double-Blind Method; H | 1999 |
Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aged; Aspirin; Dose-Response Rel | 1999 |
Changes in levels of factor VII and protein S after acute myocardial infarction: effects of low-dose warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antigens; Aspirin; Brain Ischemia; Death, Sudden, Ca | 1999 |
Usefulness of cilostazol versus ticlopidine in coronary artery stenting.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Cilostazol; Coronary Angiograp | 1999 |
Chest pain--a strong predictor of adverse cardiac events following precutaneous intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial [EPISENT])].
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Chest Pain; Corona | 1999 |
Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Cohort Studies; Dose-Re | 2000 |
Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coron
Topics: Administration, Oral; Aged; Angina, Unstable; Aspirin; Double-Blind Method; Female; Humans; Male; Mi | 2000 |
Randomized comparative trial of triflusal and aspirin following acute myocardial infarction.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; My | 2000 |
Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; | 2000 |
Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy.
Topics: Aged; Angina, Unstable; Aspirin; Drug Administration Routes; Drug Therapy, Combination; Electrocardi | 2000 |
Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups.
Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrha | 2000 |
A randomized comparison of elective high-pressure stenting with balloon angioplasty: six-month angiographic and two-year clinical follow-up. On behalf of AS (Angioplasty or Stent) trial investigators.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coronary D | 2000 |
Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Female; Fibrinolytic Agents; F | 2000 |
Effects of lysine-acetylsalicylate (LAS) treatment in nasal polyposis: two controlled long term prospective follow up studies.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2000 |
Effects of cilostazol on angiographic restenosis after coronary stent placement.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cilostazol; Coronary Angiography; Coronary Disease; Disease | 2000 |
Piracetam versus acetylsalicylic acid in secondary stroke prophylaxis. A double-blind, randomized, parallel group, 2 year follow-up study.
Topics: Aspirin; Blood Platelets; Demography; Double-Blind Method; Endpoint Determination; Female; Follow-Up | 2000 |
Sustained benefit over four years from an initial combined antiplatelet regimen after coronary stent placement in the ISAR trial. Intracoronary Stenting and Antithrombotic Regimen.
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Coronary Angiography; Coronary Disease; Drug Therapy, | 2001 |
[Efficacy of colchicine in recurrent acute idiopathic pericarditis].
Topics: Acute Disease; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Colchicin | 2000 |
Aspirin does not influence the effect of angiotensin-converting enzyme inhibition on left ventricular ejection fraction 3 months after acute myocardial infarction.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Dose-Response Relationship, Drug; Dr | 2001 |
Ticlopidine versus aspirin after myocardial infarction (STAMI) trial.
Topics: Adult; Aged; Aspirin; Cause of Death; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; | 2001 |
The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment.
Topics: Adult; Aged; Anticoagulants; Aspirin; Coronary Artery Bypass; Coronary Disease; Dose-Response Relati | 2001 |
[Does early high dosage dipyridamole in prevention of secondary stroke induce cardiac events?].
Topics: Administration, Oral; Angina Pectoris; Aspirin; Cause of Death; Cerebral Infarction; Delayed-Action | 2001 |
Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study.
Topics: Adolescent; Aspirin; Brain Ischemia; Child; Child, Preschool; Fibrinolytic Agents; Follow-Up Studies | 2001 |
Insights from CURE: using clopidogrel on top of standard therapy.
Topics: Aged; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Hepari | 2002 |
Efficacy of n-3 polyunsaturated fatty acids after myocardial infarction: results of GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2001 |
Cessation of embolic signals after antithrombotic prevention is related to reduced risk of recurrent arterioembolic transient ischaemic attack and stroke.
Topics: Aged; Aspirin; Clopidogrel; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Intracranial Emb | 2002 |
Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction.
Topics: Acute Disease; Aspirin; Double-Blind Method; Drug Costs; Humans; Myocardial Infarction; Platelet Agg | 2002 |
Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Topics: Ambulatory Care; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Cost-Benefit Analysis; Dal | 2002 |
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer A | 2002 |
[Prevention of reinfarction with acetylsalicylic acid].
Topics: Adult; Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Placebos; Prospectiv | 1979 |
[Course control of platelet function and blood lipid levels during a 2 years prospective study on the prevention of reinfarction with acetylsalicylic acid, phenprocoumon and placebo].
Topics: 4-Hydroxycoumarins; Aged; Aspirin; Clinical Trials as Topic; Humans; Lipids; Longitudinal Studies; M | 1978 |
A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction.
Topics: Aspirin; Clinical Trials as Topic; Female; Humans; Male; Myocardial Infarction; Random Allocation; R | 1979 |
Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective study.
Topics: 4-Hydroxycoumarins; Aged; Aspirin; Austria; Blood Platelets; Double-Blind Method; Evaluation Studies | 1979 |
[Prevention of re-occlusion after recanalisation of occluded arteries by the catheter method (author's transl)].
Topics: Arterial Occlusive Diseases; Aspirin; Dipyridamole; Double-Blind Method; Drug Therapy, Combination; | 1978 |
Editorial: aspirin and myocardial infarction: a new national cooperative trial.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Informed Consent; Male; Middle Aged; | 1975 |
A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aspirin; Double-Blind Method; Drug Therapy, Combinati | 1992 |
Ticlopidine versus aspirin for the prevention of recurrent stroke. Analysis of patients with minor stroke from the Ticlopidine Aspirin Stroke Study.
Topics: Adult; Aspirin; Cerebrovascular Disorders; Diarrhea; Double-Blind Method; Female; Humans; Male; Midd | 1992 |
[Dose-dependent inhibition of plaque growth in the carotid artery by acetylsalicylic acid].
Topics: Angioplasty, Balloon; Aspirin; Carotid Stenosis; Dose-Response Relationship, Drug; Double-Blind Meth | 1992 |
[Comparison of 50 mg and 900 mg/day acetylsalicylic acid for prevention of recurrence after percutaneous transluminal angioplasty of the lower extremities: results of the LARA study].
Topics: Aged; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Combined Modality Therapy; Dose-Re | 1992 |
A comparison between intravenous streptokinase and tissue plasminogen activator with early intravenous heparin in acute myocardial infarction.
Topics: Aspirin; Cardiac Catheterization; Drug Therapy, Combination; Electrocardiography; Heparin; Humans; I | 1992 |
Failure of aspirin plus dipyridamole to prevent restenosis after carotid endarterectomy.
Topics: Aged; Aspirin; Carotid Stenosis; Combined Modality Therapy; Dipyridamole; Drug Therapy, Combination; | 1992 |
Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
Topics: Aspirin; Coronary Angiography; Coronary Vessels; Hemorrhage; Heparin; Humans; Myocardial Infarction; | 1992 |
Reactivation of unstable angina after the discontinuation of heparin.
Topics: Acute Disease; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; He | 1992 |
[More about aspirin in cardiology].
Topics: Anticoagulants; Aspirin; Blood Coagulation; Humans; International Cooperation; Myocardial Infarction | 1992 |
Prevention of fetal growth retardation with low-dose aspirin: findings of the EPREDA trial.
Topics: Adult; Aspirin; Birth Weight; Dipyridamole; Double-Blind Method; Drug Administration Schedule; Drug | 1991 |
Prevention of relapse in nasal polyposis.
Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Evaluat | 1991 |
Management of acute non-Q-wave myocardial infarction. The role of prophylactic diltiazem therapy and indications for predischarge coronary arteriography.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Coronary Angiography; Diltiazem; Ele | 1991 |
[Modification of thrombocyte function in diagnostic and therapeutic interventions in cardiology].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Double- | 1991 |
Secondary prevention of myocardial reinfarction with low dose aspirin.
Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Plate | 1991 |
Ticlopidine, a new anti-thrombotic drug.
Topics: Aspirin; Dipyridamole; Humans; Intracranial Embolism and Thrombosis; Long-Term Care; Recurrence; Tic | 1991 |
Two year Cottbus reinfarction study with 30 mg aspirin per day.
Topics: Aged; Aspirin; Dinoprost; Follow-Up Studies; Gastrointestinal Diseases; Germany; Hospitals, District | 1991 |
Nd:YAG laser with sapphire tip combined with balloon angioplasty in peripheral arterial occlusions. Long-term results.
Topics: Aged; Angioplasty, Balloon; Angioplasty, Laser; Arterial Occlusive Diseases; Aspirin; Dipyridamole; | 1991 |
Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARP
Topics: Angioplasty, Balloon, Coronary; Aspirin; Biphenyl Compounds; Constriction, Pathologic; Coronary Dise | 1991 |
Multi-Hospital Eastern Atlantic Restenosis Trial. II: A placebo-controlled trial of thromboxane blockade in the prevention of restenosis following coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Double-Blind Method | 1991 |
[Randomized comparative study of the recurrence rate following femoro-popliteal PTA: high (1.0 g/die) vs low (0.1 g/die) acetylsalicylic acid dose].
Topics: Angioplasty, Balloon; Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Femoral | 1991 |
Clinical, physiologic, anatomic and procedural factors predictive of restenosis after percutaneous transluminal coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Dipyridamole; Double-Blind Method; Female | 1991 |
Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II Investigators.
Topics: Aged; Aspirin; Coronary Angiography; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Co | 1991 |
Prolonged myocardial stunning after thrombolysis: can left ventricular function be assessed definitely at hospital discharge?
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Artery Byp | 1991 |
Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis.
Topics: Aspirin; Blood Coagulation Tests; Blood Platelets; Catheters, Indwelling; Drug Evaluation; Drug Ther | 1991 |
Effects of low-dose aspirin on restenosis after coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Constriction, Pathologic; Coronary Angiography; Coron | 1991 |
Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina.
Topics: Administration, Oral; Aged; Analysis of Variance; Angina Pectoris; Angina, Unstable; Aspirin; Double | 1990 |
Secondary prevention of ischemic stroke with low dose acetylsalicylic acid.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Female; Follow-Up Studies; Humans; Male; Middle Ag | 1990 |
Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Dipyridamole; Equipment Design; Female; F | 1991 |
Effects of diltiazem on complications and restenosis after coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Constriction, Pathologic; Coronary Angiography; Coronary Di | 1991 |
[Effects of high and low doses of acetylsalicylic acid on the restenosis rate after initially successful coronary angioplasty].
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Female; Humans; Male; Middle Aged; | 1991 |
Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Angiography; Coro | 1990 |
Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Arteriosclerosis Obliterans; Aspirin; Dipyrida | 1990 |
Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Female; Follow-Up Studies; Hu | 1990 |
European Stroke Prevention Study. ESPS Group.
Topics: Age Factors; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical T | 1990 |
Low-dose aspirin for migraine prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chi-Square Distribution; Double-Blind Method; Drug Administ | 1990 |
Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Disease; Dipyridamole; Drug Th | 1990 |
Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group).
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Artery | 1990 |
Acetylsalicylic acid vs. metoprolol in migraine prophylaxis--a double-blind cross-over study.
Topics: Adult; Aspirin; Double-Blind Method; Female; Humans; Male; Metoprolol; Migraine Disorders; Recurrenc | 1990 |
The role of antiplatelet agents in modifying the extent of restenosis following percutaneous transluminal coronary angioplasty.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Dipyridamole; Double-Blind Method; | 1990 |
[Prevention of recurrence of cerebrovascular thromboses. A randomized comparative study of acetylsalicylic acid and sodium pentosan polysulfate].
Topics: Aged; Aspirin; Clinical Trials as Topic; Female; Humans; Intracranial Embolism and Thrombosis; Ische | 1987 |
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Aspirin; Cardiac Catheterization; Combined Modali | 1989 |
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Aspirin; Cardiac Catheterization; Combined Modali | 1989 |
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Aspirin; Cardiac Catheterization; Combined Modali | 1989 |
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon; Aspirin; Cardiac Catheterization; Combined Modali | 1989 |
A randomized trial of aspirin or heparin in hospitalized patients with recent transient ischemic attacks. A pilot study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cerebral Infarction; Clinical Trials as Topic; | 1989 |
Idiopathic recurrent fetal growth retardation and aspirin-dipyridamole therapy.
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Female; Fetal Growth Ret | 1989 |
Aspirin for prevention of myocardial infarction and stroke.
Topics: Angina, Unstable; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Ischemic Att | 1989 |
Usefulness of calcium entry blockers during and after percutaneous transluminal coronary artery angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Calcium Channel Blockers; Clinical Trials as Topic; Coronar | 1989 |
Prevention of restenosis after coronary angioplasty: a pharmacological approach.
Topics: Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical | 1989 |
Superior prevention of reinfarction by 30 mg per day aspirin compared with 1000 mg: results of a two years follow-up study in Cottbus.
Topics: Aged; Aspirin; Female; Follow-Up Studies; Germany, East; Humans; Male; Middle Aged; Myocardial Infar | 1989 |
Urokinase plus heparin versus aspirin in unstable angina and non-Q-wave myocardial infarction.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Coronary Angiography; Drug Therapy, Combination; Electro | 1989 |
Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-3 fatty acids.
Topics: Angioplasty, Balloon; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Angiography; Coro | 1988 |
Prevention of coronary heart disease in practice. Implications of the results of recent clinical trials.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina, Unstable; Aspirin; Blood Platelets; Cholesterol; C | 1985 |
Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin.
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Clinical Trials as Topic; Dig | 1986 |
Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon; Aspirin; Clinical Trials as Topic; Combined Modality Therapy; Cor | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.
Topics: Administration, Oral; Aged; Aged, 80 and over; Aspirin; Cause of Death; Cerebral Hemorrhage; Clinica | 1988 |
Medical prophylaxis for the post myocardial infarct patient.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Calcium Channel Blockers; Clinical Trials as T | 1988 |
Prevention of gallstone recurrence by non-steroidal anti-inflammatory drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cholelithiasis; Dr | 1988 |
Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty.
Topics: Angioplasty, Balloon; Animals; Arterial Occlusive Diseases; Aspirin; Clinical Trials as Topic; Dipyr | 1987 |
Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.
Topics: Administration, Oral; Angioplasty, Balloon; Aspirin; Clinical Trials as Topic; Coronary Angiography; | 1988 |
[Advantages of immediate coronary dilatation after thrombolysis using tissue-type plasminogen activator in acute myocardial infarction. A European Cooperative Group trial].
Topics: Angioplasty, Balloon; Aspirin; Coronary Angiography; Coronary Disease; Coronary Vessels; Heparin; Hu | 1988 |
[ISIS-2--a study of patients with myocardial infarction. A combination of streptokinase and acetylsalicylic acid diminishes mortality risk, reinfarction and stroke].
Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Myo | 1988 |
Superior prevention of reinfarction by 30 mg/d aspirin compared with 1000 mg/d: results of a two years follow-up study in Cottbus.
Topics: Aged; Aspirin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Middle Aged; Myoc | 1988 |
Low dose aspirin after early thrombolysis in anterior wall acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Double-Blind | 1988 |
Aspirin and secondary bleeding after traumatic hyphema.
Topics: Adult; Aspirin; Clinical Trials as Topic; Eye Injuries; Hemorrhage; Humans; Hyphema; Recurrence; Wou | 1988 |
Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole.
Topics: Adult; Aspirin; Birth Weight; Clinical Trials as Topic; Dipyridamole; Epoprostenol; Female; Fetal Gr | 1987 |
Aspirin to prevent myocardial infarction and death.
Topics: Angina Pectoris; Angina, Unstable; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Myocardi | 1986 |
[Randomized clinical study of the efficacy of buflomedil in the prevention of recurrence of cerebral ischemia in comparison with anti-platelet aggregation agents].
Topics: Aspirin; Clinical Trials as Topic; Dipyridamole; Humans; Ischemic Attack, Transient; Pyrrolidines; R | 1986 |
[Secondary prevention of ischemic heart disease. Evaluation of platelet function in patients treated with anticoagulants and cod liver oil].
Topics: Adult; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Cod Liver Oil; Coronary Disease; Dip | 1986 |
[Prevention of recurrent myocardial infarcts by long-term aspirin therapy].
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Death, Sudden; Female; Follow-Up Studies; Humans; Ma | 1986 |
Asymptomatic carotid disease.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disor | 1985 |
Preventive treatment of cerebral transient ischemia: comparative randomized trial of pentoxifylline versus conventional antiaggregants.
Topics: Aged; Aspirin; Clinical Trials as Topic; Dipyridamole; Drug Combinations; Female; Humans; Ischemic A | 1985 |
Type A score (Jenkins Activity Survey) and risk of recurrent coronary heart disease in the aspirin myocardial infarction study.
Topics: Adult; Aged; Analysis of Variance; Aspirin; Clinical Trials as Topic; Coronary Disease; Double-Blind | 1985 |
[Anticoagulants and thrombocyte aggregation inhibitors in or following myocardial infarct].
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Dipyridamole; Double-Blind Method; Fibrinolytic A | 1985 |
The protective effect of aspirin against degeneration of human articular cartilage.
Topics: Aspirin; Cartilage Diseases; Cartilage, Articular; Clinical Trials as Topic; Humans; Joint Dislocati | 1972 |
A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction.
Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Follow-Up Studies; Humans; Male; Middle Aged; | 1974 |
[Follow-up of a course of intermittent rheumatism].
Topics: Adult; Aspirin; Chloroquine; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Hydrarthro | 1974 |
674 other studies available for aspirin and Recrudescence
| Article | Year |
|---|---|
Application of Age, Body Mass Index, Chronic Kidney Disease, Diabetes, and Genotyping Score for Efficacy of Clopidogrel: Secondary Analysis of the CHANCE Trial.
Topics: Age Factors; Aged; Aspirin; Body Mass Index; Cerebrovascular Disorders; Clopidogrel; Cytochrome P-45 | 2022 |
Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cy | 2022 |
Hyperglycemia, Risk of Subsequent Stroke, and Efficacy of Dual Antiplatelet Therapy: A Post Hoc Analysis of the POINT Trial.
Topics: Aspirin; Blood Glucose; Clopidogrel; Humans; Hyperglycemia; Ischemic Attack, Transient; Ischemic Str | 2022 |
A dual treatment blocks alcohol binge-drinking relapse: Microbiota as a new player.
Topics: Acetylcysteine; Alcohol Drinking; Alcohol-Related Disorders; Alcoholism; Animals; Aspirin; Chronic D | 2022 |
No rebound effect after a course of clopidogrel in patients with acute TIA or minor stroke.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Humans; Ischemic Attack, | 2022 |
The pattern of epistaxis recurrence in patients taking prophylactic acetylsalicylic acid (ASA) from a 10 year cohort.
Topics: Anticoagulants; Aspirin; Cardiovascular Diseases; Epistaxis; Humans; Recurrence; Retrospective Studi | 2023 |
How to prevent recurrence of acute pericarditis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Pericarditis; Recurrence | 2024 |
Aspirin use is associated with reduced risk for recurrence of pyogenic liver abscess: a propensity score analysis.
Topics: Adult; Aged; Aspirin; Cohort Studies; Female; Humans; Liver Abscess, Pyogenic; Male; Middle Aged; Re | 2019 |
Review: After stroke or TIA, adding clopidogrel to aspirin for ≤ 1 month reduces recurrence and MACE.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib | 2019 |
The Dilemma of Resuming Antithrombotic Therapy After Intracranial Hemorrhage in Patients With Left Ventricular Assist Devices.
Topics: Aged; Anticoagulants; Aspirin; Deprescriptions; Female; Fibrinolytic Agents; Heart Failure; Heart-As | 2020 |
Antiplatelet agents for the secondary prevention of ischaemic stroke in patients with or without renal dysfunction.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Glomerular Filtrat | 2020 |
Aspirin and N-acetylcysteine co-administration markedly inhibit chronic ethanol intake and block relapse binge drinking: Role of neuroinflammation-oxidative stress self-perpetuation.
Topics: Acetylcysteine; Alcohol Drinking; Alcoholism; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspi | 2021 |
Lp-PLA
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Aspirin; Cerebrovascular Disorders; Clopidogre | 2020 |
CSPS.com Trial of Adding Cilostazol to Antiplatelet Therapy to Reduce Recurrent Stroke.
Topics: Aspirin; Cerebral Infarction; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middle Ag | 2020 |
Impact of aspirin on takotsubo syndrome: a propensity score-based analysis of the InterTAK Registry.
Topics: Aspirin; Heart Failure; Humans; Ischemic Attack, Transient; Myocardial Infarction; Platelet Aggregat | 2020 |
[Recurrent pericarditis: New treatment].
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Colchicine; | 2020 |
Assessment of Cardiovascular Risk by the Combination of Clinical Risk Scores Plus Platelet Expression of FcγRIIa.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Cohort Studies; Drug Therapy, Combination; Flow C | 2020 |
Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Child, Preschool; Coronary Arte | 2020 |
Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopi | 2020 |
Extracting the benefits of berberine for colorectal cancer.
Topics: Adenoma; Antineoplastic Agents, Phytogenic; Aspirin; Berberine; Cardiovascular Diseases; Case-Contro | 2020 |
Association of aspirin resistance with 4-hydroxynonenal and its impact on recurrent cerebral infarction in patients with acute cerebral infarction.
Topics: Aged; Aldehydes; Aspirin; Cerebral Infarction; Drug Resistance; Female; Humans; Male; Middle Aged; P | 2020 |
Disability After Minor Stroke and Transient Ischemic Attack in the POINT Trial.
Topics: Aged; Aspirin; Clopidogrel; Disability Evaluation; Double-Blind Method; Female; Humans; Intracranial | 2020 |
Derivation and Application of a Tool to Estimate Benefits From Multiple Therapies That Reduce Recurrent Stroke Risk.
Topics: Aged; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Aspirin; Diet Therapy; Exer | 2020 |
Focal Cerebral Arteriopathy in Young Adult Patients With Stroke.
Topics: Acyclovir; Adult; Antibodies, Viral; Antiviral Agents; Aspirin; Carotid Artery, Internal; Carotid St | 2020 |
Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Thrombosis; Fa | 2020 |
Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Bacteria; Case-Control Studies; Dual Anti-Platelet Therapy; Female; Gastrointestinal | 2020 |
Impact of Flow Dynamics on Device-Related Thrombosis After Left Atrial Appendage Occlusion.
Topics: Aged; Antithrombins; Aspirin; Atrial Appendage; Atrial Fibrillation; Cardiac Catheterization; Comput | 2020 |
Higher neutrophil-to-lymphocyte ratio (NLR) increases the risk of suboptimal platelet inhibition and major cardiovascular ischemic events among ACS patients receiving dual antiplatelet therapy with ticagrelor.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Dual Anti-Platelet Therapy; Female; Human | 2020 |
Age- and sex-based differences in patients with acute pericarditis.
Topics: Acute Disease; Adult; Age Distribution; Age Factors; Aged; Anti-Inflammatory Agents; Anti-Inflammato | 2021 |
A multicenter approach to evaluate omalizumab effectiveness in Samter's triad.
Topics: Adult; Aged; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Asthma | 2020 |
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Algorithms; Aspirin; Case-Control Studies; | 2020 |
Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; At | 2020 |
Comparative Effectiveness of Dual Antiplatelet Therapy With Aspirin and Clopidogrel Versus Aspirin Monotherapy in Mild-to-Moderate Acute Ischemic Stroke According to the Risk of Recurrent Stroke: An Analysis of 15 000 Patients From a Nationwide, Multicent
Topics: Aged; Aspirin; Clopidogrel; Comparative Effectiveness Research; Databases, Factual; Dual Anti-Platel | 2020 |
Cilostazol Addition to Aspirin could not Reduce the Neurological Deterioration in TOAST Subtypes: ADS Post-Hoc Analysis.
Topics: Aged; Aspirin; Cilostazol; Disease Progression; Dual Anti-Platelet Therapy; Female; Humans; Japan; M | 2021 |
Level of sex hormones and their association with acetylsalicylic acid intolerance and nasal polyposis.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Cone-Beam Computed Tomography; Drug Hypers | 2020 |
Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged | 2020 |
Low miR-19b-1-5p Expression Is Related to Aspirin Resistance and Major Adverse Cardio- Cerebrovascular Events in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Asia; Aspirin; Biomarkers; Blood Platelets; Drug Resistance; Female; Gene E | 2021 |
The efficacy and safety of Hirudin plus Aspirin versus Warfarin in the secondary prevention of Cardioembolic Stroke due to Nonvalvular Atrial Fibrillation: A multicenter prospective cohort study.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Embolic Stroke; Female; Follow-Up Studies; Hirud | 2021 |
Two-State Kinetic Model of Rates of Stroke Recurrence in the POINT Study Population.
Topics: Aspirin; Double-Blind Method; Fibrinolytic Agents; Humans; Ischemic Stroke; Kinetics; Nonlinear Dyna | 2021 |
Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clinical Trials as Topic; Cost-Benefit Analysis; Dabi | 2021 |
Dual Antiplatelet Therapy Duration After Venous Sinus Stenting for Idiopathic Intracranial Hypertension and Stent Survival-Is Longer Necessarily Better? A Meta-Regression.
Topics: Adult; Aspirin; Central Venous Pressure; Clopidogrel; Drug Therapy, Combination; Female; Graft Occlu | 2021 |
A risk score for pericarditis recurrence.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chest Pain; Colchicine; | 2021 |
Evaluation of Systolic Blood Pressure, Use of Aspirin and Clopidogrel, and Stroke Recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial.
Topics: Aged; Aspirin; Blood Pressure; Clopidogrel; Cohort Studies; Dual Anti-Platelet Therapy; Female; Huma | 2021 |
Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; Intracranial Hemorrhages; Isc | 2021 |
Venous thromboembolism: Risk of recurrence lower with rivaroxaban than aspirin.
Topics: Anticoagulants; Aspirin; Humans; Recurrence; Rivaroxaban; Venous Thromboembolism | 2017 |
The association between high on-treatment platelet reactivity and early recurrence of ischemic events after minor stroke or TIA.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Ischem | 2017 |
Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Diabetes Mellitus, Type 2; | 2017 |
Numerous Fusiform and Saccular Cerebral Aneurysms in Central Nervous System Lupus Presenting with Ischemic Stroke.
Topics: Adult; Antihypertensive Agents; Aspirin; Brain Ischemia; Cerebral Angiography; Diffusion Magnetic Re | 2017 |
Aspirin and the risk of cardiovascular events in atherosclerosis patients with and without prior ischemic events.
Topics: Aged; Aspirin; Chi-Square Distribution; Coronary Artery Disease; Female; Humans; Male; Middle Aged; | 2017 |
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F | 2016 |
Platelet distribution width as the prognostic marker in coronary bifurcation treatment.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug-Eluting Stents; Female; H | 2017 |
The efficacy and safety of naproxen in acute rheumatic fever: The comparative results of 11-year experience with acetylsalicylic acid and naproxen.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Female; Follow-Up Studies; Huma | 2016 |
In VTE, extending anticoagulation with rivaroxaban vs aspirin reduced recurrence without increasing bleeding.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Recurrence; Rivaroxaban; Venous Thromboembolism | 2017 |
Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Vessels; Drug Hypersensitivity; Humans; Male; Middle Aged; | 2017 |
Anticoagulation withdrawal in antiphospholipid syndrome: a retrospective matched-control study.
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Blood Coagu | 2018 |
High On-Treatment Platelet Reactivity to Adenosine Diphosphate Predicts Ischemic Events of Minor Stroke and Transient Ischemic Attack.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Resi | 2017 |
Conservative treatment of patients with thromboangiitis obliterans or cannabis-associated arteritis presenting with critical lower limb ischaemia.
Topics: Adult; Amputation, Surgical; Ankle Brachial Index; Anticoagulants; Arteritis; Aspirin; Cardiovascula | 2017 |
Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Diabetes Mel | 2017 |
Association between platelet function and recurrent ischemic vascular events after TIA and minor stroke
.
Topics: Alleles; Aspirin; Blood Coagulation Tests; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; F | 2017 |
Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Follow-Up Studies; Humans; Logistic Models; | 2017 |
Analysis of risk factors for colonic diverticular bleeding and recurrence.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Ca | 2017 |
A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction: The BVS STEMI STRATEGY-IT Study.
Topics: Absorbable Implants; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Thrombosis; | 2017 |
Isolated left ventricular non-compaction (LVNC) and recurrent strokes: to anticoagulate or not to anticoagulate, that is the question.
Topics: Aged; Anticoagulants; Aspirin; Clopidogrel; Diagnosis, Differential; Humans; Isolated Noncompaction | 2017 |
Regulatory T cells improve pregnancy rate in RIF patients after additional IVIG treatment.
Topics: Adult; Aspirin; Cytokines; Embryo Implantation; Embryo Transfer; Female; Fertilization in Vitro; Gen | 2017 |
Clinical characteristics and outcomes of patients with coronary artery spasm who initially presented with acute myocardial infarction.
Topics: Adult; Aged; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Dise | 2018 |
Does colchicine decrease the rate of recurrence of acute idiopathic pericarditis treated with glucocorticoids?
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; | 2018 |
Etiology and long-term rebleeding of endoscopic ulcerative lesions in the small bowel in patients with obscure gastrointestinal bleeding: A multicenter cohort study.
Topics: Aged; Aspirin; Capsule Endoscopy; Cohort Studies; Endoscopy, Gastrointestinal; Female; Follow-Up Stu | 2018 |
Internal Carotid Artery Web as the Cause of Recurrent Cryptogenic Ischemic Stroke.
Topics: Adult; Aspirin; Atorvastatin; Biopsy; Brain Ischemia; Cardiovascular Agents; Carotid Artery Diseases | 2018 |
[Prolonged Secondary Prevention After Venous Thromboembolism].
Topics: Administration, Oral; Anticoagulants; Aspirin; Humans; Recurrence; Risk Factors; Secondary Preventio | 2018 |
Recurrent Iliofemoral Venous Thrombosis in the Setting of May-Thurner Syndrome as the Presenting Symptom of Behcet's Disease.
Topics: Aspirin; Behcet Syndrome; Endovascular Procedures; Factor Xa Inhibitors; Femoral Vein; Humans; Iliac | 2018 |
Scoring system to predict early carotid restenosis after eversion endarterectomy by analysis of inflammatory markers.
Topics: Aged; Algorithms; Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Agents; Carotid Stenosis; | 2018 |
Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction.
Topics: Age Factors; Aged; Aspirin; Case-Control Studies; Clopidogrel; Drug Therapy, Combination; Female; Fr | 2018 |
Prevention of recurrent venous thrombosis and post-thrombotic syndrome.
Topics: Aspirin; Drug Therapy, Combination; Female; Fibrinolytic Agents; Flavonoids; Glycosaminoglycans; Hum | 2018 |
Clinical efficacy of aspirin with identification of intimal morphology by optical coherence tomography in preventing event recurrence in patients with vasospasm-induced acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aspirin; Coronary Angiography; Coronary Vasospasm; Coronary Vessels; | 2018 |
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myeloproliferative Disorders; Recurre | 2018 |
Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.
Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Pe | 2018 |
Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Aged; Aryldialkylphosphatase; Aspirin; Biotransformation; Clopidogrel; Cyto | 2019 |
Association between aspirin dose and subarachnoid hemorrhage from saccular aneurysms: A case-control study.
Topics: Aneurysm; Aneurysm, Ruptured; Aspirin; Case-Control Studies; Dose-Response Relationship, Drug; Femal | 2018 |
[ADP-Induced Recalcified Blood Clotting Time as a Marker of Rethrombosis Risk and Effectiveness of Antiplatelet Therapy in Acute Coronary Syndrome].
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aspirin; Biomarkers; Humans; Male; Platelet A | 2018 |
Comparison Between Aspirin and Clopidogrel in Secondary Stroke Prevention Based on Real-World Data.
Topics: Aged; Aspirin; Clopidogrel; Female; Follow-Up Studies; Humans; Incidence; Male; Platelet Aggregation | 2018 |
Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
Topics: Aged; Aspirin; Australia; Carotid Artery Diseases; Cost-Benefit Analysis; Decision Support Technique | 2019 |
Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib | 2018 |
Oral anticoagulation and left atrial appendage closure: a new strategy for recurrent cardioembolic stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Appendage; Cardiac Surgical Procedures; Ech | 2019 |
Recurrent Stroke in a Ghanaian Patient With Polycythemia.
Topics: Aphasia, Broca; Aspirin; Clopidogrel; Ghana; Humans; Hydroxyurea; Infarction, Middle Cerebral Artery | 2019 |
Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
Topics: Aspirin; Blood Coagulation; Cardiovascular Diseases; Drug Interactions; Drug Therapy, Combination; F | 2018 |
Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack: Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Aspirin; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cytochrome P-450 CYP2C19; | 2019 |
Stroke prevention in patients with acute ischemic stroke and atrial fibrillation in Germany - a cross sectional survey.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cross-Sectional Studies; Female; Germany; Humans | 2019 |
Management of idiopathic recurrent pericarditis during pregnancy.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Disease Management; Female; | 2019 |
Optimal stroke prevention in patients with PFO.
Topics: Aspirin; Foramen Ovale, Patent; Humans; Recurrence; Rivaroxaban; Stroke | 2019 |
Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Administration Schedule; Dual Anti-Platelet Therapy; Eu | 2020 |
Recurrent retinal vein thrombosis: prevention with Aspirin, Pycnogenol®, ticlopidine, or sulodexide.
Topics: Adult; Aspirin; Female; Fibrinolytic Agents; Flavonoids; Glycosaminoglycans; Humans; Incidence; Male | 2019 |
Aspirin reduced recurrent stroke risk in patients with lacunar stroke.
Topics: Adult; Aged; Aspirin; Cohort Studies; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Plat | 2019 |
A Unique Recurrent Stroke Case due to Bilateral Vertebral Artery Dissection with Familial Hirschsprung Disease.
Topics: Adult; Aspirin; Cerebral Angiography; Cerebral Infarction; Cilostazol; Diffusion Magnetic Resonance | 2019 |
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54.
Topics: Aged; Aspirin; Drug Approval; Drug Labeling; Drug Therapy, Combination; Europe; Female; Hemorrhage; | 2019 |
Impact of Baseline Anemia in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A Prespecified Analysis From the VALIDATE-SWEDEHEART Trial.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anemia; Aspirin; Case-Control Studies; Dual Anti-P | 2019 |
[3-year follow-up after endovascular aneurysm treatment with Silk® flow diverter].
Topics: Adult; Aged; Aspirin; Cerebral Angiography; Clopidogrel; Embolization, Therapeutic; Equipment Design | 2013 |
Catheter ablation of atrial fibrillation in patients at low thrombo-embolic risk: efficacy and safety of a simplified periprocedural anticoagulation strategy.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Echocardiography, Transesophageal; | 2013 |
An unusual cause of recurrent chest pain in an adult woman: a case of recurrent stress-induced (Takotsubo) cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Chest Pain; D | 2013 |
Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Brain Ischemia; Cerebral Hemorrhage; Heart Failure; | 2013 |
[Thrombosis risk during pregnancy after history of cerebral venous thrombosis].
Topics: Adult; Anticoagulants; Aspirin; Chemoprevention; Family Health; Female; Humans; Intracranial Thrombo | 2015 |
Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; | 2014 |
Aspirin resistant patients with recent ischemic stroke.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Humans; Platelet Aggregation Inhibitors; Rec | 2014 |
Thrombotic aortic restenosis after transapical SAPIEN valve implantation.
Topics: Aged, 80 and over; Anticoagulants; Aortic Valve Stenosis; Aspirin; Bioprosthesis; Clopidogrel; Echoc | 2014 |
Presentation of untreated systemic mastocytosis as recurrent, pulseless-electrical-activity cardiac arrests resistant to cardiac pacemaker.
Topics: Acetates; Aged, 80 and over; Aspirin; Cromolyn Sodium; Cyclopropanes; Death, Sudden, Cardiac; Drug T | 2014 |
[From apixaban to aspirin in the prevention of recurrent venous thromboembolism].
Topics: Anticoagulants; Antithrombins; Aspirin; Clinical Trials as Topic; Factor Xa Inhibitors; Heparin, Low | 2013 |
Predictors of favourable outcome in non-variceal upper gastrointestinal bleeding: implications for early discharge?
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Blood Transfusion; Endoscopy, Digestive System; Esoph | 2014 |
[Rescue treatment in acute thrombosis of intracranial stents].
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Basilar Artery; Capillary Permeability; Cerebral Angiogr | 2014 |
Secondary prevention of atherothrombotic or cryptogenic stroke.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Clopidogrel; Drug Th | 2014 |
Positive clinical response to clopidogrel is independent of paraoxonase 1 Q192R and CYP2C19 genetic variants.
Topics: Aged; Alleles; Angina Pectoris; Aryldialkylphosphatase; Aspirin; Clopidogrel; Cohort Studies; Corona | 2014 |
Cardiac tamponade due to low-volume effusive constrictive pericarditis in a patient with uncontrolled type II autoimmune polyglandular syndrome.
Topics: Aspirin; Cardiac Tamponade; Cardiotonic Agents; Colchicine; Combined Modality Therapy; Glucocorticoi | 2014 |
Opposing effects of aspirin and anticoagulants on morbidity and mortality in patients with upper gastrointestinal bleeding.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Female; H | 2014 |
Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate | 2014 |
Pharmacologic strategy for one repeated stent thrombosis patient with hyporesponsiveness to standard dual antiplatelet therapy.
Topics: Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Electrocardiography; Huma | 2015 |
Recurrence and mortality among patients hospitalized for acute lower gastrointestinal bleeding.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Fema | 2015 |
Otologic manifestation of Samter triad.
Topics: Aspirin; Asthma, Aspirin-Induced; Female; Hearing Loss; Humans; Middle Aged; Nasal Polyps; Otitis Me | 2014 |
Chronic histiocytic intervillositis: outcome, associated diseases and treatment in a multicenter prospective study.
Topics: Abortion, Habitual; Adult; Aspirin; Autoantibodies; Autoimmune Diseases; Cell Movement; Chorionic Vi | 2015 |
Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis.
Topics: Aged; Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; | 2014 |
Antithrombotic therapy for secondary stroke prevention in bacterial meningitis in children.
Topics: Adolescent; Aspirin; Brain; Child; Child, Preschool; Diagnostic Imaging; Female; Fibrinolytic Agents | 2014 |
Aspirin may reduce liver fibrosis progression: Evidence from a multicenter retrospective study of recurrent hepatitis C after liver transplantation.
Topics: Aspirin; Disease Progression; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplan | 2014 |
T2238C ANP gene variant and risk of recurrent acute coronary syndromes in an Italian cohort of ischemic heart disease patients.
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Unstable; Aspirin; Atrial Natriuretic Factor; Female | 2016 |
Effects of anticoagulant therapy on pregnancy outcomes in patients with thrombophilia and previous poor obstetric history.
Topics: Abortion, Habitual; Anticoagulants; Apgar Score; Aspirin; Birth Weight; Blood Coagulation Factors; D | 2015 |
Rebleeding after initial endoscopic hemostasis in peptic ulcer disease.
Topics: Antithrombins; Aspirin; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hemostasis, Endoscopic; Hum | 2014 |
Kawasaki shock syndrome complicating a recurrence of Kawasaki disease.
Topics: Aspirin; Child; Combined Modality Therapy; Diagnosis, Differential; Dose-Response Relationship, Drug | 2014 |
The mystery of recurrent idiopathic cerebrovascular and coronary arterial thrombosis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Coronary Thrombosis; Diagnosis, Differential; Electrocardio | 2014 |
Long-Term Outcomes of NSAID-Induced Small Intestinal Injury Assessed by Capsule Endoscopy in Korea: A Nationwide Multicenter Retrospective Study.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Capsule Endoscopy; Female; Huma | 2015 |
Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
Topics: Administration, Oral; Anticoagulants; Aspirin; Female; Hemorrhage; Humans; Male; Middle Aged; Mortal | 2015 |
Endovascular treatment of internal carotid artery pseudo-aneurysm presenting with epistaxis. A case report.
Topics: Angiography, Digital Subtraction; Aspirin; Carotid Artery Injuries; Carotid Artery, Internal; Clopid | 2014 |
Moyamoya disease associated with aortic coarctation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aortic Coarctation; Aspirin; Calcium Channel Blocker | 2014 |
Recurrent ischaemic stroke unveils polycythaemia vera.
Topics: Aspirin; Atorvastatin; Bloodletting; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutar | 2015 |
Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers | 2015 |
Effects of platelet infusion, anticoagulant and other risk factors on the rehaemorrhagia after surgery of hypertensive cerebral hemorrhage.
Topics: Aged; Anticoagulants; Aspirin; Blood Loss, Surgical; Female; Hematoma; Humans; Intracranial Hemorrha | 2015 |
Stroke mimicking relapse in a patient with CLIPPERS syndrome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Brain Stem; Encephalomye | 2015 |
Clinical outcomes of nonvariceal upper gastrointestinal bleeding in Kosova.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; An | 2014 |
Recurrence of retinal vein thrombosis with Pycnogenol® or Aspirin® supplementation: a registry study.
Topics: Adult; Aspirin; Female; Fibrinolytic Agents; Flavonoids; Humans; Incidence; Italy; Male; Middle Aged | 2015 |
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Topics: Activation, Metabolic; Acute Coronary Syndrome; Aged; Alleles; Angina Pectoris; Aspirin; Clopidogrel | 2015 |
High Residual Collagen-Induced Platelet Reactivity Predicts Development of Restenosis in the Superficial Femoral Artery After Percutaneous Transluminal Angioplasty in Claudicant Patients.
Topics: Aged; Angiography; Angioplasty; Aspirin; Blood Platelets; Collagen; Female; Femoral Artery; Hemodyna | 2016 |
[Diagnosis and treatment of aspirin--and NSAID-induced peptic ulcers].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastric Mucosa; Humans; Peptic Ulcer; Practice Gui | 2015 |
Clinical characteristics of Helicobacter pylori-negative drug-negative peptic ulcer bleeding.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Breath Tests; Endoscopy, Gast | 2015 |
Computational fluid dynamics evaluation of flow reversal treatment of giant basilar tip aneurysm.
Topics: Aspirin; Basilar Artery; Blood Flow Velocity; Computer Simulation; Contraindications; Endovascular P | 2015 |
Dual Antiplatelet Therapy Prior to Expedited Carotid Surgery Reduces Recurrent Events Prior to Surgery without Significantly Increasing Peri-operative Bleeding Complications.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Loss, Surgical; Carotid Stenosis; Clopidogrel; Drug A | 2015 |
[Comparison between Endoscopic Therapy and Medical Therapy in Peptic Ulcer Patients with Adherent Clot: A Multicenter Prospective Observational Cohort Study].
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Female; H | 2015 |
Recurrent myocardial infarctions and premature coronary atherosclerosis in a 23-year-old man with antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Coronary Angiography; Coronary Artery Disease; H | 2016 |
Elevated levels of antibodies against phosphatidylserine/prothrombin complex and/or cardiolipin associated with infection and recurrent purpura in a child: a forme fruste of antiphospholipid syndrome?
Topics: Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Aspirin; Autoantibodies; Bacterial Infection | 2015 |
A Patient Guide: Managing Diverticulitis.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonosco | 2015 |
Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug Resis | 2015 |
Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Cohort Studies; | 2015 |
[Recurrence of Cerebral Infarction Associated Aspirin Resistance or Chinese Medical Constitutions: a Correlation Study].
Topics: Aspirin; Body Constitution; Cerebral Infarction; Drug Resistance; Humans; Medicine, Chinese Traditio | 2015 |
Successful Management of Recurrent Colon Ulcer in Hemodialysis Patient after Conversion to Peritoneal Dialysis.
Topics: Aspirin; Colon; Colonic Diseases; Colonoscopy; Drug Therapy, Combination; Gastrointestinal Hemorrhag | 2015 |
Clopidogrel Versus Aspirin as an Antiplatelet Monotherapy After 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents.
Topics: Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug-Eluting Stents; Female; Humans; I | 2016 |
Risk of early recurrent stroke in symptomatic carotid stenosis after best medical therapy and before endarterectomy.
Topics: Aged; Aged, 80 and over; Aspirin; Carotid Arteries; Carotid Stenosis; Clopidogrel; Endarterectomy, C | 2016 |
Treatment and outcomes of patients with recurrent myocardial infarction: A prospective observational cohort study.
Topics: Age Factors; Aged; Aspirin; Cohort Studies; Comorbidity; Drug Utilization; Female; Guideline Adheren | 2016 |
Continuation and adherence rates on initially-prescribed intensive secondary prevention therapy after Rapid Access Stroke Prevention (RASP) service assessment.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Dipyr | 2016 |
Presumed bilateral cilioretinal artery occlusion related to relapsing white dot syndrome.
Topics: Arterial Occlusive Diseases; Aspirin; Ciliary Arteries; Coloring Agents; Drug Therapy, Combination; | 2016 |
Proton pump inhibitors and other disease-based factors in the recurrence of adverse cardiovascular events following percutaneous coronary angiography: A long-term cohort.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Drug Combinations; Female; Foll | 2016 |
High on-treatment platelet reactivity and outcomes after percutaneous endovascular procedures in patients with peripheral artery disease.
Topics: Aged; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Drug Resistance; Drug Therapy, | 2016 |
Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Cardiovascular Diseases; Cohort Studies; C | 2016 |
Subdural haematoma complicating shunting for normal pressure hydrocephalus in the setting of concomitant antiplatelet medication - a report of 11 cases.
Topics: Aged; Aged, 80 and over; Aspirin; Female; Hematoma, Subdural, Chronic; Humans; Hydrocephalus, Normal | 2016 |
[After the first stroke, acetylsalicylic acid is no longer enough].
Topics: Aged; Aspirin; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Humans; Recurrence; Stroke | 2016 |
Risks of Bleeding Recurrence and Cardiovascular Events With Continued Aspirin Use After Lower Gastrointestinal Hemorrhage.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Female; Gastrointes | 2016 |
Complication of Stenting in Intracranial Arterial Stenosis.
Topics: Age Factors; Aged; Angioplasty; Aspirin; China; Clopidogrel; Computed Tomography Angiography; Constr | 2016 |
Recurrent Kawasaki Disease: Mind the Age, But It Does Not Matter.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Immunoglobulins, Intravenous; Male; Mucocu | 2016 |
PPM1A Methylation Is Associated With Vascular Recurrence in Aspirin-Treated Patients.
Topics: Aspirin; Brain Ischemia; CpG Islands; DNA Methylation; Follow-Up Studies; Genetic Association Studie | 2016 |
[Retrospective cohort study for the impact on readmission of patients with ischemic stroke after treatment of aspirin plus clopidogrel or aspirin mono-therapy].
Topics: Aspirin; Beijing; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; | 2016 |
High-Sensitive C-Reactive Protein Predicts Recurrent Stroke and Poor Functional Outcome: Subanalysis of the Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events Trial.
Topics: Aged; Aspirin; C-Reactive Protein; Clopidogrel; Drug Therapy, Combination; Female; Humans; Incidence | 2016 |
Three episodes of Kawasaki disease including one after the Pneumo 23 vaccine in a child with a family history of Kawasaki disease.
Topics: Aspirin; Child, Preschool; Family Health; Humans; Immunoglobulins, Intravenous; Male; Mucocutaneous | 2016 |
Does Early Resumption of Low-Dose Aspirin After Evacuation of Chronic Subdural Hematoma With Burr-Hole Drainage Lead to Higher Recurrence Rates?
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Craniotomy; Drainage; Female; Hematoma, S | 2016 |
Aspirin for Primary and Secondary Prevention of Cardiovascular Disease.
Topics: Aged; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Female; Hemorrhage; Humans; Male; Mid | 2016 |
Risk factors influencing the outcome of peptic ulcer bleeding in chronic kidney disease after initial endoscopic hemostasis: A nationwide cohort study.
Topics: Adult; Age Factors; Aged; Aspirin; Female; Hemostasis, Endoscopic; Hospital Costs; Humans; Intubatio | 2016 |
Aspirin is Key to Reducing Risk of Early Stroke Recurrence.
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Recurrence; Risk Reduction Behavior; Stroke | 2016 |
Effect of Low-Dose Aspirin on Midluteal Phase Uterine Artery Blood Flow in Patients With Recurrent Pregnancy Loss.
Topics: Abortion, Spontaneous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Flow Velocity; | 2016 |
TRIAD system catalase, insulin, and low dose aspirin neutralize the effect of dermcidin isoform-2 and prevent cell death in acute myocardial infarction and recurrence of the disease.
Topics: Aspirin; Catalase; Cell Death; Humans; Hypoglycemic Agents; Insulin; Myocardial Infarction; Peptides | 2016 |
Aspirin Blocks Orthodontic Relapse via Inhibition of CD4
Topics: Animals; Aspirin; CD4-Positive T-Lymphocytes; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Int | 2017 |
Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.
Topics: Acute Coronary Syndrome; Adenosine; Anti-HIV Agents; Aspirin; Blood Platelets; Clopidogrel; Cross-Se | 2017 |
Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox?
Topics: Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat | 2017 |
Burr-Hole Drainage for Chronic Subdural Hematoma Under Low-Dose Acetylsalicylic Acid: A Comparative Risk Analysis Study.
Topics: Aged; Aspirin; Cardiovascular Diseases; Decompressive Craniectomy; Dose-Response Relationship, Drug; | 2017 |
Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Drug Therapy, Combination; | 2017 |
Association of genetic variant and platelet function in patients undergoing neuroendovascular stenting.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Aspirin; Brain Ischemia; Clopidogrel; Female; Genetic Varia | 2017 |
Cryptogenic stroke in a patient with a PFO: a decision analysis.
Topics: Anticoagulants; Aspirin; Cardiac Catheterization; Decision Trees; Foramen Ovale, Patent; Humans; Int | 2008 |
[Secondary stroke prevention according to the PRoFESS Study. What are the sequelae for practical therapy?].
Topics: Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Germany; Humans; Multicenter Studies | 2008 |
Relationship between haemoglobin A1C values and recurrent cardiac events: A retrospective, longitudinal cohort study.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascula | 2008 |
Reversible clopidogrel resistance due to right ventricular myocardial infarction: risk factor of recurrent stent thrombosis?
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Stenosis; Coronary Thrombosis; Drug R | 2008 |
45-year-old woman with recurrent headache and photophobia.
Topics: Acyclovir; Anti-Bacterial Agents; Antiviral Agents; Aspirin; Diagnosis, Differential; Female; Headac | 2008 |
Does Aggrenox (aspirin/dipyridamole) reduce the risk of recurrent stroke to a greater degree than aspirin alone?
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Platelet A | 2008 |
Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
Topics: Age Factors; Aged; Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combi | 2006 |
[Digital ischemia in a gardener: is rose cutting a vascular risk factor?].
Topics: Alprostadil; Aneurysm; Anticoagulants; Aspirin; Diagnosis, Differential; Female; Finger Injuries; Fi | 2008 |
Cardiovascular outcomes after a change in prescription policy for clopidogrel.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Co | 2008 |
Recurrent perimesencephalic subarachnoid hemorrhage during antithrombotic therapy.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Cerebral Angiography; Fatal Outcome; Female; Hepar | 2009 |
Aspirin resistance in South African Caucasian patients with thrombotic cerebrovascular events.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Resistance; Female; Humans; Intracranial Thrombosis; M | 2009 |
[Brain hypoperfusion revealed by an ocular ischemic syndrome].
Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Brain Ischemia; Carotid Artery Thrombosis; Ciliary B | 2008 |
Recurrent stroke in a child with incontinentia pigmenti.
Topics: Aspirin; Brain; Female; Humans; Incontinentia Pigmenti; Infant, Newborn; Magnetic Resonance Imaging; | 2009 |
Risk stratification after coronary artery bypass surgery by a point-of-care test of platelet function.
Topics: Aged; Aspirin; Cohort Studies; Coronary Artery Bypass; Coronary Stenosis; Dose-Response Relationship | 2009 |
[Recurrent idiopathic cerebral infarction in a 5-year-old boy, with emphasis on the importance of platelet aggregation analysis for appropriate selection of anti-platelet drugs].
Topics: Adenosine Diphosphate; Aspirin; Blood Coagulation Tests; Cerebral Infarction; Child, Preschool; Cilo | 2009 |
Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2009 |
Is steroid therapy enough to reverse complete atrioventricular block after percutaneous perimembranous ventricular septal defect closure?
Topics: Anti-Inflammatory Agents; Aspirin; Atrioventricular Block; Cardiac Catheterization; Cardiac Pacing, | 2009 |
Degos' disease: a rare condition simulating rheumatic diseases.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diagnosis, Differential; Fatal Outcome; Fem | 2009 |
Aspirin vs anticoagulation in carotid artery dissection: a study of 298 patients.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal, Dissection; Female; Follow-Up Stu | 2009 |
[Postoperative ischemic acute stroke and thrombolytic therapy].
Topics: Acute Disease; Aged; Anticoagulants; Aphasia, Broca; Aspirin; Cholesteatoma; Ear Diseases; Ear, Exte | 2009 |
[Factors influencing development of atrial fibrillation after implantation of cardiac pacemaker for sinus node dysfunction].
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Data | 2009 |
Recurrent pericarditis due to natalizumab treatment.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aspirin; Chest Pain; Colchicine; D | 2009 |
[Therapy of atrial fibrillation. Heart rate or rhythm control, marcumar or acetylsalicylic acid?].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Catheter Ablation; Humans; Patient Education as Topic; | 2009 |
Acknowledging a failed strategy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Clopidogrel. Patients with peptic ulcers.
Topics: Aspirin; Clopidogrel; Histamine H2 Antagonists; Humans; Peptic Ulcer Hemorrhage; Platelet Aggregatio | 2009 |
Retinal artery embolization during carotid angioplasty and carotid artery stenting: case report.
Topics: Aged; Angioplasty, Balloon; Anticoagulants; Antipyrine; Aspirin; Carotid Artery, External; Carotid S | 2009 |
Recurrent Kawasaki disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diagnosis, Differential; Humans; Immunoglobulins, | 2009 |
Anti-interleukin-5 therapy and severe asthma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aspirin; Asthma; Eosinophilia; Humans; In | 2009 |
[The concept of aspirin "resistance": mechanisms and clinical relevance].
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Resistance; Huma | 2009 |
Recurrent hematospermia due to aspirin.
Topics: Adult; Aspirin; Hemospermia; Humans; Male; Platelet Aggregation Inhibitors; Recurrence | 2009 |
[Frosted-branch angiitis revealing Behçet's disease].
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Behcet Syndrome; | 2009 |
The prescribing patterns of antithrombotic agents for prevention of recurrent ischemic stroke.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Drug Utilization; Female; Fibrinolytic Agents; Humans; Male; M | 2009 |
JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis.
Topics: Aspirin; Child; Clone Cells; Cytotoxins; Diagnosis, Differential; Female; Headache; Humans; Hydroxyu | 2009 |
Redo surgery or carotid stenting for restenosis after carotid endarterectomy: results of two different treatment strategies.
Topics: Aged; Aged, 80 and over; Angioplasty; Aspirin; Carotid Stenosis; Endarterectomy, Carotid; Feasibilit | 2010 |
Acetylsalicylic acid use in patients with acute myocardial infarction and peptic ulcer bleeding.
Topics: Aged; Aspirin; Blood Transfusion; Endoscopy, Digestive System; Female; Gastrointestinal Hemorrhage; | 2009 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Antiplatelet agents in stroke prevention: acute and long-term treatment strategies.
Topics: Aged; Aspirin; Female; Humans; Ischemic Attack, Transient; Male; Platelet Aggregation Inhibitors; Pr | 2009 |
Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aspirin; Beclomethasone; Cohort Studies; Colitis, Ulc | 2010 |
Aspirin withdrawal in acute peptic ulcer bleeding: are we harming patients?
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Gastrointestinal Hemorrhage; Humans; Pe | 2010 |
Summaries for patients. Benefits and risks of continuing aspirin in patients with peptic ulcer bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2010 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.
Topics: Adult; Aged; Aspirin; Clopidogrel; Denmark; Drug Therapy, Combination; Female; Follow-Up Studies; He | 2009 |
Long-term clinical course of patients with isolated myocardial bridge.
Topics: Aged; Angina Pectoris; Aspirin; Coronary Angiography; Coronary Vasospasm; Female; Follow-Up Studies; | 2010 |
A 19-month-old boy with recurrent respiratory distress.
Topics: Acid-Base Equilibrium; Albuterol; Alkalosis, Respiratory; Aspirin; Asthma; Bicarbonates; Bites, Huma | 2010 |
Ultrasound evaluation of early changes in arterial dissection.
Topics: Aspirin; Blood Proteins; Carotid Artery, Internal; Carotid Artery, Internal, Dissection; Cerebrovasc | 2010 |
Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Fema | 2010 |
Stroke recurrence in an elderly CADASIL patient on aspirin discontinuation due to severe auto-immune thrombocytopenia.
Topics: Aged, 80 and over; Aspirin; Autoimmune Diseases; CADASIL; Exons; Humans; Male; Receptor, Notch3; Rec | 2010 |
Spontaneous coronary dissection as cause of recurring myocardial infarction.
Topics: Anticoagulants; Aortic Dissection; Aspirin; Coronary Aneurysm; Coronary Angiography; Drug Therapy, C | 2011 |
Influence of age on long-term outcome after emergent percutaneous coronary intervention for ST-elevation myocardial infarction.
Topics: Age Distribution; Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary | 2010 |
Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Ischemic A | 2010 |
[Case of branch atheromatous disease presenting capsular warning syndrome].
Topics: Anticoagulants; Aspirin; Atherosclerosis; Atorvastatin; Dextrans; Diffusion Magnetic Resonance Imagi | 2010 |
[Sporadic hemiplegic migraine-like headache in a patient with systemic lupus erythematosus].
Topics: 1-Naphthylamine; Adult; Aspirin; Calcium Channel Blockers; Diagnosis, Differential; Female; Hemipleg | 2010 |
The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chi-Square Distribution; Female | 2010 |
The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chi-Square Distribution; Female | 2010 |
The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chi-Square Distribution; Female | 2010 |
The influence of preoperative anticoagulation on outcome and quality of life after surgical treatment of chronic subdural hematoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Chi-Square Distribution; Female | 2010 |
Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diffusion Magnetic Resonance Imaging; | 2010 |
Platelet function testing for aspirin resistance is reasonable to do: yes!
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Recurrence; Stroke | 2010 |
The use of platelet function assays may help to determine appropriate antiplatelet treatment options in a patient with recurrent stroke on baby aspirin: against.
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Recurrence; Stroke | 2010 |
Neurosonographic monitoring of 105 spontaneous cervical artery dissections: a prospective study.
Topics: Administration, Oral; Adult; Anticoagulants; Aspirin; Carotid Artery, Internal, Dissection; Drug Adm | 2010 |
[Risk factors for development and recurrence of peptic ulcer disease].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Endoscopy, Gastrointestinal; Female; | 2010 |
Ischaemic stroke--prevention is better than cure.
Topics: Adult; Age Factors; Aged; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Blo | 2010 |
What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?
Topics: Aspirin; Cilostazol; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Female; Follow-Up Studie | 2011 |
Recurrent episodes of very late stent thrombosis in a patient with aspirin hypersensitivity, stent fracture and malapposition.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Occlusion; Coronary Thrombosis; Drug | 2011 |
Relapsed spontaneous spinal epidural hematoma associated with aspirin and clopidogrel.
Topics: Aspirin; Clopidogrel; Hematoma, Epidural, Spinal; Humans; Magnetic Resonance Imaging; Male; Middle A | 2011 |
[Beyond coronary artery disease: interventional approach to carotid occlusive disease].
Topics: Aged; Aged, 80 and over; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carotid Arte | 2010 |
Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Denmark; Drug Interactions; Humans; Kaplan-Meier Esti | 2011 |
[Kawasaki disease in older children and young adults: 10 years of experience in Marseille, France].
Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Age Factors; Anti-Inflammatory Agents, No | 2011 |
Fabry disease and Factor V Leiden: a potent vascular risk combination.
Topics: Activated Protein C Resistance; alpha-Galactosidase; Aspirin; Atorvastatin; Coronary Stenosis; Defib | 2011 |
Impact of coronary computed tomographic angiography results on patient and physician behavior in a low-risk population.
Topics: Acute Disease; Adult; Aged; Aspirin; Baltimore; Cardiovascular Agents; Case-Control Studies; Confoun | 2011 |
[Intracerebral hemorrhage in anticoagulated patients: what do we do afterwards?].
Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Clopidogrel; Female; Follow-Up Studies; Humans; | 2012 |
Ischemic stroke in patients receiving aspirin.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Argentina; Aspirin; Brain Ischemia; Chi-Square Dis | 2012 |
Patent foramen ovale may be causal for the first stroke but unrelated to subsequent ischemic events.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Foramen Ovale, Patent; | 2011 |
Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clop | 2011 |
Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Angioplasty, B | 2011 |
Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers.
Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Emergency T | 2012 |
The HEART study: a real-world experience using the CID Chrono Carbostent in primary and rescue PCI.
Topics: Aged; Aspirin; Chi-Square Distribution; Chromium Alloys; Clopidogrel; Coated Materials, Biocompatibl | 2012 |
[Aspirin versus anticoagulation in young patients with cerebral infarction secondary to primary antiphospholipid syndrome].
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Cerebral Infarction; Female; Follow-Up St | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Use of aspirin in Chinese after recovery from primary intracranial haemorrhage.
Topics: Age Factors; Aspirin; Female; Follow-Up Studies; Humans; Intracranial Hemorrhages; Male; Middle Aged | 2012 |
Microtrauma-induced recurrent hyphema and secondary glaucoma associated with chronic acetylsalicylic acid use.
Topics: Administration, Oral; Adult; Angina Pectoris; Antihypertensive Agents; Aspirin; Diagnosis, Different | 2012 |
Recurrent cerebral infarction in Klippel-Trenaunay-Weber syndrome.
Topics: Aspirin; Cerebral Angiography; Cerebral Infarction; Dysarthria; Female; Fibromuscular Dysplasia; Gai | 2012 |
Sinonasal outcome under aspirin desensitization following functional endoscopic sinus surgery in patients with aspirin triad.
Topics: Adult; Aspirin; Asthma, Aspirin-Induced; Desensitization, Immunologic; Drug Hypersensitivity; Endosc | 2013 |
Recurrent pediatric thrombosis: the effect of underlying and/or coexisting factors.
Topics: Adolescent; Adult; Anticoagulants; Aspirin; Child; Child, Preschool; Chronic Disease; Factor VIII; F | 2012 |
Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study.
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Brain Ische | 2012 |
Diagnosis and management of giant cell arteritis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Aspirin; Biopsy; Giant Cell Arteritis; Glucocorticoi | 2012 |
Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atherosclerosis; Female; Fibrinolytic Agents; Huma | 2012 |
Recurrent aortic aneurysm due to Behcet's disease: a case report from China.
Topics: Adult; Anticoagulants; Aortic Aneurysm; Aortography; Aspirin; Behcet Syndrome; China; Glucocorticoid | 2013 |
Treatment of blood blister-like aneurysms of the internal carotid artery with stent-assisted coil embolization.
Topics: Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Cerebral Angiography; Clopidogrel; Embol | 2013 |
Clinical and biochemical aspirin resistance in patients with recurrent cerebral ischemia.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Brain Ischemia; Drug Resistance; Female; Hum | 2013 |
Treatment of a pediatric recurrent fusiform middle cerebral artery (MCA) aneurysm with a flow diverter.
Topics: Adolescent; Aspirin; Cerebral Angiography; Clopidogrel; Embolization, Therapeutic; Humans; Intracran | 2012 |
Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry).
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Atherectomy; Atorvastatin; Cardiovasc | 2013 |
[Correlation between antiplatelet resistance and recurrent cardiac ischemic events of patients with acute myocardial infarction].
Topics: Aged; Aspirin; Clopidogrel; Drug Resistance; Electric Impedance; Female; Humans; Male; Middle Aged; | 2012 |
Low-dose aspirin use and recurrent gout attacks.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiotonic Agents; Cardiovascular Diseases; Cross-Over Stu | 2014 |
Recurrent thromboembolism in a patient with beta-thalassemia major associated with double heterozygosity for factor V R506Q and prothrombin G20210A mutations.
Topics: 3' Untranslated Regions; Activated Protein C Resistance; Adult; Anticoagulants; Aspirin; beta-Thalas | 2002 |
[Long-term anticoagulation after bypass operation].
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Humans; Long-Term Care; Platelet Aggregation Inhi | 2002 |
Anticoagulation therapy in cerebral sinovenous thrombosis and ulcerative colitis in children.
Topics: Adolescent; Adult; Antibodies, Anticardiolipin; Anticoagulants; Aspirin; Child; Colitis, Ulcerative; | 2002 |
[Platelet aggregation inhibitor in general practice. Every 3rd infarct prevented--reinfarction rate cut in half].
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Survival Rate; | 2002 |
How to keep chest pain from cramping your style. If you are one of the millions of Americans for whom chest pain is part of daily life, here are some ABCs for getting it under control.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina Pectoris; Aspirin; Chest Pain; Diet; Exercise; Fema | 2002 |
[Embolism prevention in atrial fibrillation with heparin?].
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Heparin; Heparin, Low-Molecul | 2002 |
Ischaemic stroke in young people: a prospective and long-term follow-up study.
Topics: Acenocoumarol; Adolescent; Adult; Anticoagulants; Aspirin; Brain Ischemia; Disability Evaluation; Ec | 2003 |
Aspirin or warfarin: what's best after a heart attack? Risk of bleeding counters warfarin's edge in efficacy.
Topics: Anticoagulants; Aspirin; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; | 2002 |
Aspirin-responsive painful red, blue, black toe, or finger syndrome in polycythemia vera associated with thrombocythemia.
Topics: Aged; Aspirin; Busulfan; Erythromelalgia; Female; Fingers; Hematocrit; Humans; Male; Middle Aged; Pl | 2003 |
[Anticoagulation and antiaggregation in neurological patients].
Topics: Acute Disease; Administration, Oral; Aged; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopid | 2003 |
Heart failure as a cause for hospitalization in chronic dialysis patients.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular | 2003 |
Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Alleles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 2003 |
Why are eligible patients not prescribed aspirin in primary care? A qualitative study indicating measures for improvement.
Topics: Aspirin; Attitude of Health Personnel; Drug Prescriptions; Humans; Patient Compliance; Physicians, F | 2003 |
High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; | 2003 |
High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; | 2003 |
High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; | 2003 |
High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.
Topics: Aged; Aspirin; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; | 2003 |
Successful perinatal outcome following recurrent idiopathic cerebrovascular strokes in pregnancy: a case report.
Topics: Adult; Aspirin; Cerebral Infarction; Delivery, Obstetric; Diagnosis, Differential; Drug Therapy, Com | 2003 |
Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke.
Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; China; Cohort Stu | 2003 |
[How should anticoagulants be used in recurrent, ischemic and hemorrhagic brain infarctions?].
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Hemo | 2003 |
[PRoFESS study presented. Change in secondary prevention].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Aspirin, Dipyridamole Drug Combination; Benzimida | 2003 |
[ASS and dipyridamole combination. A decisive contribution to secondary prevention after stroke].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Clinical Trials as Topic; Delayed-Action Preparatio | 2003 |
[Secondary prevention of ischemic insult and transient cerebral ischemia. Is ASS alone enough?].
Topics: Aspirin; Controlled Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; Ische | 2003 |
Regression of collateral function after recanalization of chronic total coronary occlusions: a serial assessment by intracoronary pressure and Doppler recordings.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Collateral Circulation; | 2003 |
[Heartburn without esophagitis. Symptoms more important than the finding?].
Topics: Androstadienes; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ul | 2003 |
A case of frequently recurring amaurosis fugax with atherothrombotic ophthalmic artery occlusion.
Topics: Amaurosis Fugax; Angiography, Digital Subtraction; Arterial Occlusive Diseases; Arteriosclerosis; As | 2004 |
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Comorbid | 2004 |
The specificity of prescription patterns in secondary stroke prevention.
Topics: Accidental Falls; Anticoagulants; Aspirin; Cognition Disorders; Geriatric Assessment; Humans; Patien | 2004 |
Does cardiovascular therapy affect the onset and recurrence of preretinal and vitreous haemorrhage in diabetic eye disease?
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; Cardiovascula | 2004 |
Aspirin resistance.
Topics: Aspirin; Drug Resistance; Humans; Ischemia; Platelet Aggregation Inhibitors; Recurrence | 2004 |
Day-hospital treatment of acute pericarditis: a management program for outpatient therapy.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Day Care, Medical; Decision Tree | 2004 |
Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke.
Topics: Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Case-Control Studies; Cyclooxygenase 1; DNA Muta | 2003 |
Is the endovascular treatment of carotid stenosis in high-risk patients really safer than carotid endarterectomy?
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Carotid Stenosis; Endarterectomy, Car | 2004 |
Lepirudin therapy for thrombotic complications in congenital afibrinogenaemia.
Topics: Afibrinogenemia; Aspirin; Blood Coagulation Tests; Drug Therapy, Combination; Heparin; Hirudins; Hum | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
Topics: Adenosine Diphosphate; Aged; Aspirin; Biotransformation; Clopidogrel; Combined Modality Therapy; Cor | 2004 |
Different treatments and outcomes of consecutive patients with non-ST-elevation myocardial infarction depending on initial electrocardiographic changes (results of the Acute Coronary Syndromes [ACOS] Registry).
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converti | 2004 |
Paroxysmal dysarthria and ataxia after midbrain infarction.
Topics: Aged; Anticoagulants; Aspirin; Cerebellum; Diplopia; Dysarthria; Gait Ataxia; Humans; Infarction, Mi | 2004 |
Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Biomarkers; Brain Infarction; Brain Ischemia; Coho | 2004 |
[Ulcerative colitis. Acute episode].
Topics: Acute Disease; Administration, Oral; Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammator | 2004 |
[Clopidogrel protection is not increased further by ASS!].
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ische | 2004 |
[Use of assessment of aggregation of thrombocytes induced by cationic propyl gallate to estimate recurrence of cardiovascular complications].
Topics: Adult; Aged; Angina, Unstable; Aspirin; Drug Resistance; Female; Humans; Male; Myocardial Infarction | 2004 |
Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cause of Death; | 2005 |
Influence of aspirin on outcome following aneurysmal subarachnoid hemorrhage.
Topics: Adult; Aged; Aspirin; Female; Humans; Incidence; Male; Medical Records; Middle Aged; Platelet Aggreg | 2004 |
Long-term combination therapy with aspirin and clopidogrel.
Topics: Angina, Unstable; Arteriosclerosis; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Double-Blind Me | 2004 |
[Stroke prevention in atrial fibrillation -- transfer of study results to the practice].
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrilla | 2004 |
A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
Topics: Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Computer Simulation; Cost-Benefit A | 2005 |
Clinical characteristics of patients with ischemic ocular nerve palsies and lacunar brain infarcts: a retrospective comparative study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Brain I | 2005 |
Exercise and aspirin increase levels of circulating gliadin peptides in patients with wheat-dependent exercise-induced anaphylaxis.
Topics: Adolescent; Adult; Allergens; Anaphylaxis; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Exercis | 2005 |
Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No.
Topics: Administration, Oral; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Trials as Topic; | 2005 |
A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugs.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Endoscopy, Gastroi | 2005 |
S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits.
Topics: Animals; Aortic Diseases; Aspirin; Atherosclerosis; Catheterization; Diet, Atherogenic; Drug Evaluat | 2005 |
Characterisation of patients with frequent exacerbation of asthma.
Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As | 2006 |
Characterisation of patients with frequent exacerbation of asthma.
Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As | 2006 |
Characterisation of patients with frequent exacerbation of asthma.
Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As | 2006 |
Characterisation of patients with frequent exacerbation of asthma.
Topics: Adrenal Cortex Hormones; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; As | 2006 |
Link between platelet activity and outcomes after an ischemic stroke.
Topics: Aged; Aspirin; Blood Platelets; Endpoint Determination; Female; Flow Cytometry; Humans; Logistic Mod | 2005 |
Weight restoration in a patient with anorexia nervosa on dialysis.
Topics: Adult; Anorexia Nervosa; Aspirin; Barbiturates; Body Mass Index; Body Weight; Caffeine; Combined Mod | 2005 |
Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aspirin; Cardiac Catheterization; Clopidogrel; Co | 2006 |
Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Bypass, Off-Pum | 2006 |
Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease.
Topics: Acetaminophen; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Butanones; Colitis, Ul | 2006 |
[Percutaneous closure of patent foramen ovale-- Against].
Topics: Aspirin; Evidence-Based Medicine; Heart Septal Defects, Atrial; Humans; Platelet Aggregation Inhibit | 2006 |
Combined aspirin and clopidogrel resistance associated with recurrent coronary stent thrombosis.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Rest | 2006 |
Acute migraine treatment: patterns of use and satisfaction in a clinical population.
Topics: Acetaminophen; Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Caffein | 2006 |
Large subcortical infarcts: clinical features, risk factors, and long-term prognosis compared with cortical and small deep infarcts.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain; Cerebral Cortex; Cerebral Infarction; Cohort Studies | 2006 |
Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Clopidogrel; Coronary Artery Disease; Cyclooxygena | 2006 |
The aspirin resistance controversy: clinical entity or platelet heterogeneity?
Topics: Aspirin; Coronary Artery Disease; Cyclooxygenase 1; Cyclooxygenase 2; Dose-Response Relationship, Dr | 2006 |
A new theory of cryptogenic stroke and its relationship to patent foramen ovale; or, the puzzle of the missing extra risk.
Topics: Adult; Aged; Aspirin; Databases, Factual; Foramen Ovale, Patent; Humans; Middle Aged; Recurrence; Ri | 2006 |
Flexible versus nonflexible mitral valve rings for congestive heart failure: differential durability of repair.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiomyopathy, Dilated; Combined Modality | 2006 |
[Gastroenterology in family practice. Updates for your "stomach patient"].
Topics: Anti-Ulcer Agents; Aspirin; Clopidogrel; Dyspepsia; Esophagitis, Peptic; Family Practice; Heartburn; | 2006 |
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Enoxapari | 2006 |
The significance of incomplete stent apposition in patients undergoing stenting of internal carotid artery stenosis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Brain Ischemia; Carotid Arteries; Carotid St | 2006 |
[Treating ischemic stroke as an emergency to prevent cerebral infarction or limit its spread].
Topics: Aspirin; Cerebral Infarction; Emergencies; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; | 2006 |
[Transient ischemic stroke].
Topics: Administration, Oral; Anticoagulants; Aspirin; Diagnosis, Differential; Female; Fibrinolytic Agents; | 2006 |
[Prevention of vascular events after transient ischemic attack or cerebral infarct].
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Cerebral Infarction; Clopidogrel; Dipyridamole; Drug | 2006 |
Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aspirin; Clopidogrel; Coronary Disease; Diabetes Complic | 2006 |
Effects of policosanol on patients with ischemic stroke: a pilot open study.
Topics: Aged; Anticholesteremic Agents; Aspirin; Fatty Alcohols; Female; Follow-Up Studies; Humans; Lipids; | 2006 |
Platelet activation and cardiovascular outcomes in acute coronary syndromes.
Topics: Acute Disease; Aspirin; Coronary Disease; Humans; Platelet Activation; Platelet Aggregation Inhibito | 2006 |
Platelet hyperactivity and risk of recurrent thrombosis.
Topics: Aspirin; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Pred | 2006 |
[Antiplatelet therapy after aspirin-induced upper gastrointestinal bleeding].
Topics: Anti-Ulcer Agents; Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combinatio | 2006 |
Clinical trials and dipyridamole formulation selection.
Topics: Aspirin; Brain Ischemia; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dipyridamole; Drug | 2007 |
Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States).
Topics: Adenomatous Polyps; Aspirin; Body Mass Index; Colorectal Neoplasms; Confidence Intervals; Female; Hu | 2006 |
A current problem in cardiology: very late thrombosis after implantation of sirolimus eluting stent.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Drug-Eluting Stents; Huma | 2007 |
Clopidogrel response variability and future therapies: clopidogrel: does one size fit all?
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chest Pain; Clopidogrel; Coronary Angiography; Electr | 2006 |
Treatment practices and outcomes of patients with established peripheral arterial disease hospitalized with acute myocardial infarction in a community setting.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Female; Hospit | 2007 |
The effect of glycoprotein IIIa A1/A2 gene polymorphism on one-year outcome in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Electrocardiography; Female; Genetic Markers; Humans; | 2006 |
Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2007 |
Non-ST-elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Aspirin; Cardiac Catheterization; Coronary Angiograph | 2007 |
Factitious anticoagulant-resistance as a cause of recurrent arterial bypass graft occlusions.
Topics: Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Co | 2007 |
Myopericarditis versus viral or idiopathic acute pericarditis.
Topics: Acute Disease; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiac T | 2008 |
Aspirin can elicit the recurrence of gastric ulcer induced with acetic acid in rats.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Base Sequence; Cyclooxygenas | 2007 |
Successful pregnancy with the use of nitric oxide donors and heparin after recurrent severe preeclampsia in a woman with scleroderma.
Topics: Adult; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Nitric Oxide Donors; Pre-Eclampsia; P | 2007 |
The prevalence of Samter's triad in patients undergoing functional endoscopic sinus surgery.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Asthma; Child; Child, Preschool; Chronic Diseas | 2007 |
Dual antiplatelet agent failure: a new syndrome or clinical nonentity?
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Hum | 2007 |
Redo pedal bypass surgery after pedal graft failure: gain or gadget?
Topics: Aged; Anastomosis, Surgical; Anticoagulants; Arteries; Aspirin; Blood Vessel Prosthesis; Blood Vesse | 2007 |
[Antithrombotic therapy in ischemic stroke and transient ischemic attack].
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; | 2007 |
Optical platelet aggregometry does not appear useful as a means of assessing the risk of recurrent vascular events in aspirin-treated patients.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Electronic Data Processing; Female; Humans; Ischemic | 2008 |
[A study on the recurrence of ischemic stroke in nonvalvular atrial fibrillation].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Cohort Studies; Female; Follow-Up Stud | 2007 |
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2008 |
Prediction and prevention of stroke in patients with symptomatic carotid stenosis: the high-risk period and the high-risk patient.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Endarterectomy, Carotid; Humans; Ischemic Attack, Transient; | 2008 |
Comment on "hyperresponsiveness of platelets in ischemic stroke" by Fateh-Moghadam et al.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Epine | 2008 |
Therapy with statins and aspirin enhances long-term outcome of percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Drug Therapy, Combi | 2008 |
Laboratory-defined aspirin resistance and recurrent cardiovascular events.
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Platelet Aggregation Inhibitors; Recurren | 2008 |
Is aspirin resistance due to noncompliance?
Topics: Aspirin; Cardiovascular Diseases; Drug Resistance; Humans; Patient Compliance; Platelet Aggregation | 2008 |
[Thromboprophylaxis for cerebrovascular disorders: acetylsalicylic acid remains the cornerstone].
Topics: Aspirin; Cerebrovascular Disorders; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Re | 2008 |
Single antiplatelet therapy for patients with previous gastrointestinal bleeds.
Topics: Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Female; Gastrointest | 2008 |
Failure of aspirin to prevent myocardial infarction and adverse outcome during follow-up - a large series of all-comers.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Coronary Disease; Disease-Free Survival; Female; | 2008 |
Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Sectional Studies; Dyspepsia | 2008 |
Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2.
Topics: Animals; Aspirin; Base Sequence; Blood Vessels; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase I | 2008 |
Antiplatelet drugs in the secondary prevention of myocardial infarction. One view of the present position.
Topics: Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Humans; Myocardial Infarction; Recurrence; | 1980 |
[Prevention of recurrent myocardial infarct].
Topics: Adrenergic beta-Antagonists; Aspirin; Humans; Myocardial Infarction; Recurrence; Sulfinpyrazone | 1981 |
Overview of recent clinical and methodological advances from clinical trials of cardiovascular disease.
Topics: Adrenergic beta-Antagonists; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Di | 1982 |
[Second prevention following myocardial infarct].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Humans; Myocardial Inf | 1984 |
Secondary prevention of coronary heart disease.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Disease; Diabetes Mellitus; Feeding B | 1984 |
[Postoperative antithrombotic therapy in acute occlusion of the major arteries of the extremities].
Topics: Acute Disease; Adolescent; Adult; Aged; Arm; Arterial Occlusive Diseases; Aspirin; Dextrans; Female; | 1980 |
Antithrombotic treatment.
Topics: Ancrod; Aspirin; Cerebrovascular Disorders; Dextrans; Dipyridamole; Drug Administration Schedule; He | 1983 |
[Acetylsalicylic acid--additive intolerance phenomenon in chronic recurring urticaria].
Topics: Adolescent; Adult; Aged; Aspirin; Drug Eruptions; Female; Food Coloring Agents; Food Preservatives; | 1982 |
[Incidence of recurrence after successful transluminal coronary angioplasty].
Topics: Angioplasty, Balloon; Aspirin; Coronary Disease; Exercise Test; Humans; Isosorbide Dinitrate; Premed | 1983 |
Effect of antiplatelet therapy on restenosis after experimental angioplasty.
Topics: Angioplasty, Balloon; Animals; Arteriosclerosis; Aspirin; Blood Platelets; Dipyridamole; Iliac Arter | 1984 |
Role of percutaneous transluminal coronary angioplasty in patients with variant angina and coexistent coronary stenosis refractory to maximal medical therapy.
Topics: Adult; Angina Pectoris, Variant; Angiography; Angioplasty, Balloon; Aspirin; Constriction, Pathologi | 1984 |
[Anticoagulants or thrombocyte aggregation inhibitors in the prevention of recurrent heart infarction?].
Topics: Anticoagulants; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence | 1983 |
Lupus anticoagulant in pregnancy.
Topics: Aspirin; Blood Coagulation Disorders; Blood Coagulation Factors; Chorea; Drug Therapy, Combination; | 1984 |
[Acetosal and the heart].
Topics: Aspirin; Coronary Disease; Humans; Myocardial Infarction; Platelet Aggregation; Recurrence | 1984 |
Aspirin and recurrent hyphema after blunt ocular trauma.
Topics: Adolescent; Adult; Aspirin; Child; Child, Preschool; Eye Injuries; Female; Humans; Hyphema; Male; Mi | 1983 |
[Platelet antiaggregants in post-myocardial infarct patients: why, which and in what doses?].
Topics: Aspirin; Dipyridamole; Humans; Myocardial Infarction; Platelet Aggregation; Recurrence; Sulfinpyrazo | 1983 |
Aspirin and recurrent hyphema after blunt ocular trauma.
Topics: Aspirin; Eye Injuries; Humans; Hyphema; Recurrence | 1984 |
Aspirin in the prevention of myocardial infarction. Current status.
Topics: Angina Pectoris; Aspirin; Cerebrovascular Disorders; Fibrinolytic Agents; Humans; Myocardial Infarct | 1984 |
Anticoagulants and platelet-active agents in the secondary prevention of coronary artery disease.
Topics: Aged; Anticoagulants; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Epoprostenol; Humans | 1982 |
Non-surgical reperfusion in acute myocardial infarction.
Topics: Aspirin; Coronary Circulation; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heparin; Human | 1981 |
Etiologic factors for recurrent carotid artery stenosis.
Topics: Anesthesia; Arteriosclerosis; Aspirin; Carotid Artery Diseases; Constriction, Pathologic; Coronary D | 1983 |
Analgesic ingestion and other factors preceding relapse in ulcerative colitis.
Topics: Acetaminophen; Adult; Aged; Analgesics; Aspirin; Colitis, Ulcerative; Female; Humans; Male; Middle A | 1983 |
Myocardial infarction and aspirin.
Topics: Aspirin; Humans; Myocardial Infarction; Recurrence; Sulfinpyrazone | 1980 |
Analgesic abuse and the kidney.
Topics: Aged; Analgesics; Aspirin; Caffeine; Codeine; Drug Combinations; Humans; Kidney; Kidney Diseases; Ki | 1980 |
[Pro and con: Aggregation inhibitors in the prophylaxis of myocardial infarct. Arguments in favor of aggregation inhibitors].
Topics: Aspirin; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Male; Myocardial Infarction; Plat | 1980 |
[Pro and con: Anticoagulation or thrombocyte function inhibitors in the prophylaxis of myocardial infarct? Arguments in favor of thrombocyte function inhibitors].
Topics: Aged; Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Phenprocoumon; Platelet Agg | 1980 |
[Summary: Secondary prophylaxis following myocardial re-infarct. Anticoagulants or thrombocyte function inhibitors?].
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Myocardial Infarction; Platelet Aggregation; R | 1980 |
Secondary prevention in myocardial infarction survivors.
Topics: Anticoagulants; Aspirin; Diabetes Mellitus; Diet, Reducing; Humans; Hypertension; Lipids; Myocardial | 1982 |
The use of indomethacin in the treatment of pericarditis in childhood.
Topics: Adolescent; Aspirin; Child; Female; Humans; Indomethacin; Male; Pericarditis; Prednisone; Radiograph | 1982 |
Shock syndrome associated with mastocytosis: pharmacologic reversal of the acute episode and therapeutic prevention of recurrent attacks.
Topics: Aspirin; Chlorpheniramine; Cimetidine; Epinephrine; Humans; Hypotension; Infusions, Parenteral; Pros | 1982 |
Preventing death after myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Platelet Aggregation; Recurrence; Sulfinpyrazone | 1980 |
Aspirin intolerance and recurrent urticaria in normal adults and children. Epidemiology and review.
Topics: Adolescent; Adult; Age Factors; Aged; Aspirin; Bronchial Spasm; Child; Child, Preschool; Drug Hypers | 1980 |
Hyperlipidaemia advances and retreats.
Topics: Aspirin; Humans; Myocardial Infarction; Recurrence | 1980 |
[Sulfinpyrazone (Anturan) after myocardial infarction].
Topics: Aspirin; Female; Humans; Male; Middle Aged; Myocardial Infarction; Recurrence; Sulfinpyrazone | 1980 |
Fever caused by hydroxyurea.
Topics: Aspirin; Female; Fever; Humans; Hydroxyurea; Middle Aged; Psoriasis; Recurrence | 1981 |
Early reactivation of ischaemia after abrupt discontinuation of heparin in acute myocardial infarction.
Topics: Aspirin; Drug Administration Schedule; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myoc | 1995 |
Inhibition of restenosis by beraprost sodium (a prostaglandin I2 analogue) in the atherosclerotic rabbit artery after angioplasty.
Topics: Administration, Oral; Angioplasty, Balloon; Animals; Arteriosclerosis; Aspirin; Cholesterol, Dietary | 1995 |
Immunosuppressive therapy prevents recurrent pericarditis.
Topics: Adolescent; Adult; Aged; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immu | 1995 |
[Aspirin--yes, but 30 mg??].
Topics: Animals; Aspirin; Dose-Response Relationship, Drug; Epoprostenol; Humans; Myocardial Infarction; Rec | 1995 |
Choosing drugs for secondary prevention after myocardial infarction: a pragmatic approach.
Topics: Algorithms; Anticoagulants; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Recur | 1995 |
[Results of endoprostheses in the iliac arteries; an experience apropos of 47 implantations].
Topics: Angiography; Angioplasty, Balloon; Aortic Dissection; Aspirin; Blood Vessel Prosthesis; Female; Foll | 1994 |
[Prevention of reinfarction with 100 mg or 30 mg aspirin daily?].
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Myocardial Infarcti | 1995 |
Beneficial effect of nitroglycerin on arterial rethrombosis after thrombolysis. Results from a rabbit thrombosis model.
Topics: Animals; Aspirin; Blood Flow Velocity; Blood Pressure; Disease Models, Animal; Drug Therapy, Combina | 1995 |
[Can early recurrent hemorrhage in gastroduodenal ulcer be predicted?].
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Duodenal Ulcer; En | 1994 |
Coronary stenting without anticoagulation.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aortic Dissection; Aspirin; Coronary An | 1995 |
Effect of intraventricular haemorrhage and rebleeding following subarachnoid haemorrhage on CSF eicosanoids.
Topics: 6-Ketoprostaglandin F1 alpha; Aspirin; Brain Damage, Chronic; Cerebral Ventricles; Dexamethasone; Di | 1994 |
[Intracranial hemorrhage following second thrombolytic treatment of myocardial reinfarction].
Topics: Aged; Aspirin; Cerebral Hemorrhage; Female; Heparin; Humans; Male; Myocardial Infarction; Recurrence | 1994 |
The management of thrombosis in the antiphospholipid-antibody syndrome.
Topics: Adolescent; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Follow-Up Studies; Hu | 1995 |
The management of thrombosis in the antiphospholipid-antibody syndrome.
Topics: Adolescent; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Follow-Up Studies; Hu | 1995 |
The management of thrombosis in the antiphospholipid-antibody syndrome.
Topics: Adolescent; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Follow-Up Studies; Hu | 1995 |
The management of thrombosis in the antiphospholipid-antibody syndrome.
Topics: Adolescent; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Follow-Up Studies; Hu | 1995 |
Anticoagulant treatment or antiplatelet therapy after a single carotid TIA?
Topics: Aspirin; Carotid Artery Diseases; Cerebrovascular Disorders; Follow-Up Studies; Heparin; Humans; Isc | 1995 |
Anticoagulants for atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Middle Aged; | 1993 |
Aspirin and prevention of stroke.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Recurrence | 1994 |
[Sliding indications for balloon angioplasty].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspi | 1994 |
Acute myocardial infarction in women: survival analysis in first six months.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aspirin; Coronary Care Units; Female; Follow- | 1994 |
Antiphospholipid syndrome: clinical and therapeutic aspects.
Topics: Adolescent; Adult; Antiphospholipid Syndrome; Aspirin; Dose-Response Relationship, Drug; Female; Hum | 1994 |
Platelet activation and arterial thrombosis. Report of a meeting of Physicians and Scientists, University of Texas Health Science Center at Houston and Texas Heart Institute, Houston.
Topics: Aspirin; Hemorheology; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Activation; Platel | 1994 |
[Transthoracic and transesophageal follow-up in patients with left atrial thrombosis].
Topics: Aged; Aspirin; Combined Modality Therapy; Echocardiography; Echocardiography, Doppler, Color; Echoca | 1994 |
Development of aspirin resistance in persons with previous ischemic stroke.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular D | 1994 |
Clopidogrel is more effective than aspirin in preventing coronary artery reocclusion after thrombolysis.
Topics: Animals; Aspirin; Blood Coagulation; Clopidogrel; Coronary Thrombosis; Disease Models, Animal; Dogs; | 1993 |
Factors associated with failure of aspirin treatment.
Topics: Aspirin; Case-Control Studies; Cerebrovascular Disorders; Humans; Recurrence; Risk Factors | 1994 |
[Emergency intracoronary stent implantation: complications and experiences with 124 patients].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Blood Coagulation Tests; Co | 1994 |
Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis.
Topics: Animals; Aspirin; Clopidogrel; Coronary Thrombosis; Dogs; Drug Therapy, Combination; Fibrinolytic Ag | 1994 |
[Intranasal provocation with lysine acetylsalicylic acid].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Child; Drug Hyper | 1993 |
Patent foramen ovale and brain infarct. Echocardiographic predictors, recurrence, and prevention.
Topics: Adult; Aged; Aspirin; Cerebral Infarction; Cerebrovascular Disorders; Echocardiography, Transesophag | 1994 |
Guidelines for medical treatment for stroke prevention. American College of Physicians.
Topics: Aspirin; Atrial Fibrillation; Cerebrovascular Disorders; Humans; Ischemic Attack, Transient; Myocard | 1994 |
Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Coagulation Disorders; Brain Ischemia; Cerebral Infar | 1994 |
[Chronic recurrent thrombotic thrombocytopenic purpura (Moschcowitz disease). An unusual long-term course in a 43-year-old patient].
Topics: Adult; Aspirin; Biopsy; Cerebral Angiography; Cerebral Infarction; Combined Modality Therapy; Female | 1993 |
Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Carotid Artery, Internal; Cerebrovascular Disorders; | 1993 |
Does external ultrasound accelerate thrombolysis? Results from a rabbit model.
Topics: Animals; Aspirin; Femoral Artery; Platelet Activation; Rabbits; Recurrence; Regional Blood Flow; Rep | 1994 |
Branch retinal artery occlusion in pregnancy.
Topics: Adult; Aspirin; Female; Headache; Humans; Pregnancy; Pregnancy Complications, Cardiovascular; Recurr | 1994 |
[Hereditary spherocytosis].
Topics: Aspirin; Combined Modality Therapy; Erythrocyte Count; Humans; Recurrence; Spherocytosis, Hereditary | 1994 |
Recent developments in secondary prevention of stroke.
Topics: Aspirin; Cerebrovascular Disorders; Endarterectomy, Carotid; Humans; Hypercholesterolemia; Myocardia | 1993 |
Anticoagulants, antiaggregants or nothing following carotid endarterectomy?
Topics: Aged; Aspirin; Carotid Stenosis; Cause of Death; Endarterectomy, Carotid; Female; Follow-Up Studies; | 1993 |
Indications and results after Strecker-stent-application in iliac and SFA.
Topics: Arterial Occlusive Diseases; Aspirin; Female; Femoral Artery; Follow-Up Studies; Heparin; Humans; Il | 1993 |
Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis.
Topics: Age Factors; Aged; Aspirin; Female; Humans; London; Male; Middle Aged; Myocardial Infarction; Progno | 1993 |
Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated with antiphospholipid antibodies.
Topics: Abortion, Spontaneous; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Drug | 1993 |
Aspirin versus coumadin.
Topics: Aspirin; Humans; Myocardial Infarction; Recurrence; Thrombolytic Therapy; Warfarin | 1993 |
Retreatment with alteplase for early signs of reocclusion after thrombolysis. The European Cooperative Study Group.
Topics: Adult; Aged; Aspirin; Coronary Angiography; Drug Therapy, Combination; Electrocardiography; Female; | 1993 |
Ischemic stroke, Part 2: Optimal treatment and prevention.
Topics: Aged; Aspirin; Brain Edema; Brain Ischemia; Cerebral Infarction; Heparin; Humans; Recurrence; Risk F | 1993 |
Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model.
Topics: Animals; Aspirin; Coronary Thrombosis; Dogs; Drug Therapy, Combination; Epoprostenol; Myocardial Inf | 1993 |
Ulcer risk factors: interactions between Helicobacter pylori infection, nonsteroidal use, and age.
Topics: Adult; Age Factors; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Fema | 1993 |
Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets.
Topics: Animals; Aspirin; Blood Platelets; Coronary Disease; Dogs; Drug Therapy, Combination; Hirudin Therap | 1993 |
Migraine after electroconvulsive therapy.
Topics: Antidepressive Agents; Aspirin; Combined Modality Therapy; Depressive Disorder; Dose-Response Relati | 1995 |
Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes.
Topics: Aged; Aspirin; Contraindications; Female; Health Status Indicators; Humans; Male; Multivariate Analy | 1996 |
Effective treatment with interferon-alpha in chronic recurrent multifocal osteomyelitis.
Topics: Adult; Aspirin; Chronic Disease; Drug Therapy, Combination; Humans; Interferon alpha-2; Interferon-a | 1995 |
[Response to the letter by K. Schrör on: Prevention of reinfarction with 100 mg or 30 mg ASS daily].
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Myocardial Infarcti | 1995 |
[Response to the editorial by J. C. Frölich: Aspirin--yes, but 30 mg??].
Topics: Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Myocardial Infarcti | 1995 |
Uterine Doppler wave form and the prediction of the recurrence of pre-eclampsia and intra-uterine growth retardation in patients treated with low-dose aspirin.
Topics: Adult; Aspirin; Dose-Response Relationship, Drug; Female; Fetal Growth Retardation; Follow-Up Studie | 1995 |
[Drug therapy as secondary prevention following myocardial infarction].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antic | 1996 |
A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aspirin; Cardiac Care Facilities; Cardiology; Cholesterol; | 1996 |
[Response to the letter by W. Förster on: prevention of reinfarction with 100 mg or 30 mg aspirin daily].
Topics: Aspirin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Myocardial Infarction; | 1996 |
Elective implantation of intracoronary stents without intravascular ultrasound guidance or subsequent warfarin.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Combined Modality Therapy; Cor | 1996 |
Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.
Topics: Animals; Aspirin; Coronary Circulation; Coronary Thrombosis; Dogs; Drug Synergism; Drug Therapy, Com | 1995 |
Pathogenetic factors in chronic subdural haematoma and causes of recurrence after drainage.
Topics: Adult; Aged; Aspirin; Chronic Disease; Drainage; Female; Hematoma, Subdural; Humans; Male; Middle Ag | 1995 |
Primary stent implantation without coumadin in acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Case-Control Studies; Coronary Angiography; | 1996 |
Stenting in the carotid artery: initial experience in 110 patients.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Carotid Artery | 1996 |
ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Coronary Angiography; Coronary Circulation; Dose-Response Relationship, Drug; | 1996 |
Inhibitory effect of a novel orally active GP IIb/IIIa inhibitor, SC-54684A on intimal thickening in the guinea pig femoral artery.
Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Benzamidines; Cell Movement; Cells, Cultured; Coro | 1996 |
Fraud and ethics charges hit stroke drug trial.
Topics: Aspirin; Brain Diseases; Cerebrovascular Disorders; Controlled Clinical Trials as Topic; Dipyridamol | 1996 |
Anticoagulants in acute MI.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Heparin; Humans; Meta-Analysis as Topic; Myocard | 1997 |
Ticlopidine and aspirin interactions.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, C | 1997 |
[The in-vivo test of the inhibition of leukocyte natural migration with aspirin and analgin in the specific diagnosis of the asthmatic triad].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cell Migration Inhibition; Dipyrone | 1996 |
[Single-center experience with the Palmaz-Schatz intracoronary stent: the immediate results and medium- and long-term follow-up].
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Combined Modality Therapy; Coronary | 1996 |
Aspirin after thrombolysis for MI.
Topics: Anistreplase; Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Multicenter Studies as Topic; My | 1997 |
Therapeutic options in atrial flutter and fibrillation.
Topics: Aged; Algorithms; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive | 1997 |
[Recurrent infarct during aspirin therapy].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Cerebral Infarction; Dose-Response Relationship, Drug; | 1997 |
[Cost-effectiveness analysis of prevention of reinfarction using low-dose acetylsalicylic acid; model calculation].
Topics: Adult; Aspirin; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Humans; Middle Aged; Models | 1997 |
Mobile thromboses of the aortic arch without aortic debris. A transesophageal echocardiographic finding associated with unexplained arterial embolism. The Filiale Echocardiographie de la Société Française de Cardiologie.
Topics: Adult; Aorta, Thoracic; Arteriosclerosis; Aspirin; Blood Coagulation Tests; Diabetes Complications; | 1997 |
Obstetric outcome in antiphospholipid syndrome.
Topics: Abortion, Spontaneous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Anticardiolipin; | 1997 |
Stroke recurrence among 30 days survivors of ischemic stroke in a prospective community-based study.
Topics: Aged; Angina Pectoris; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Cohort Studies; Female; F | 1997 |
Prevention of subsequent coronary events.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Asp | 1997 |
[Acute glaucoma caused by massive subretinal hemorrhage in age-related macular degeneration and disordered thrombocyte function].
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Eye Enucleation; Female; Glau | 1997 |
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Topics: Adenosine Diphosphate; Animals; Aspirin; Bleeding Time; Collagen; Coronary Thrombosis; Dogs; Drug Ev | 1997 |
A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow | 1997 |
[Recurrent fetal death and antiphospholipid antibody syndrome. A case report].
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiphospholipid Syndrome; | 1997 |
[Superaspirin in the platelet aggregation inhibitor therapy].
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Aspirin; Fibrinolytic Agents; Humans; Immunoglobulin Fa | 1997 |
Aspirin in the management of recurrent herpes simplex virus infection.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Herpes Genitalis; Herpes Labialis; | 1998 |
Carotid artery dissection presenting as a painless Horner's syndrome in a pilot: fit to fly?
Topics: Aerospace Medicine; Aortic Dissection; Aspirin; Carotid Artery, Internal; Cerebrovascular Disorders; | 1998 |
[Coronary stents].
Topics: Aspirin; Belgium; Coronary Disease; Humans; Myocardial Revascularization; Platelet Aggregation Inhib | 1998 |
Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer.
Topics: Aspirin; Female; Humans; Intestinal Diseases; Male; Middle Aged; Peptic Ulcer; Postoperative Complic | 1998 |
Titration of antiplatelet treatment in pregnant women at risk of preeclampsia.
Topics: Abortion, Spontaneous; Adult; Aspirin; Birth Weight; Female; Fetal Death; Fetal Growth Retardation; | 1998 |
A late complication of internal carotid artery stenting.
Topics: Angioplasty; Anticoagulants; Aspirin; Carotid Artery Diseases; Carotid Artery, Internal; Carotid Ste | 1998 |
Underutilization of aspirin in older patients with prior myocardial infarction at the time of admission to a nursing home.
Topics: Aged; Aged, 80 and over; Aspirin; Drug Utilization; Female; Humans; Male; Middle Aged; Myocardial In | 1998 |
Clinical and angiographic outcome of Micro Stent II implantation in native coronary arteries.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Blood Vessel Prosthesis Implantation; Coro | 1998 |
[Secondary prevention of recurrent transient ischemic attacks].
Topics: Anticoagulants; Aspirin; Cerebral Infarction; Drug Therapy, Combination; Female; Humans; Ischemic At | 1998 |
Cogan's syndrome with Takayasu's arteritis.
Topics: Angiography; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents | 1998 |
Micro stent implantation in patients with acute myocardial infarction without anticoagulation: clinical experience with two different antithrombotic protocols.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiograp | 1998 |
[Wiktor coronary stent for elective placement with an antiaggregation regimen. WINE study. WINE Group Study].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Catheterization; Coronary Disease; Female; | 1998 |
[An acetylsalicylic acid-dypiridamole combination (Asasantine) in the prevention of the recurrence of cerebrovascular accidents (a cost-effectiveness analysis)].
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Belgium; Cerebrovascular Disorders; Cost-Benefit An | 1998 |
Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study.
Topics: Aspirin; Drug Therapy, Combination; Female; Fetal Growth Retardation; Gestational Age; Heparin, Low- | 1998 |
Aspirin and newer orally active antiplatelet agents in the treatment of the post-myocardial infarction patient.
Topics: Administration, Oral; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhi | 1998 |
[When salicylates do not help. Practice in recurrent TIA (Transient Ischemic Attack) varies at Swedish hospitals].
Topics: Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient | 1998 |
Procedural results and long-term clinical outcomes following coronary stenting in perimyocardial infarction syndromes.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Disease-Free Survival; Female; Follow | 1998 |
Limitations of acetaminophen, aspirin, and caffeine in alleviating migraine.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Caffeine; | 1998 |
Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Aspirin; Co | 1998 |
A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation Tests; Coronary Disease; Cost-Benef | 1998 |
Intracoronary Multi-link stents: experience in 218 patients using aspirin alone.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Combined Modality Therapy; Coronary Disease; Coronary Vesse | 1998 |
Gallstone recurrence after successful shock wave therapy: the magnitude of the problem and the predictive factors.
Topics: Actuarial Analysis; Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Aci | 1999 |
Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention?
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Female; Fibrinolytic Agents; Humans; Hypolipidemic Agent | 1999 |
Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebrovascular Disorder | 1999 |
Detection of activated eosinophils in nasal polyps of an aspirin-induced asthma patient.
Topics: Adrenal Cortex Hormones; Aspirin; Asthma; Biopsy, Needle; Eosinophilia; Eosinophils; Follow-Up Studi | 1999 |
[Does idiopathic naso-sinusal polyposis exist in children?].
Topics: Adolescent; Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bacterial | 1999 |
[A case of aspirin triad].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Drug Hypersensitivity; Follow-Up | 1999 |
[Significance of eosinophilic granulocytes in relation to allergy and aspirin intolerance in patients with sinusitis polyposa].
Topics: Adult; Aged; Aspirin; Drug Hypersensitivity; Eosinophilia; Eosinophils; Female; Humans; Male; Middle | 1999 |
Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Dise | 1999 |
A 42-year-old man with recurrent myocardial infarction and normal appearing coronary arteries.
Topics: Adult; Aspirin; Coronary Thrombosis; Humans; Male; Microvascular Angina; Myocardial Infarction; Plat | 1999 |
Persistent atrial standstill in a cat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Arrhythmias, Cardiac; Asp | 1999 |
Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy.
Topics: Adult; Age Factors; Aged; Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Follow-Up | 1999 |
Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; C | 1999 |
[Bone marrow transplantation-associated thrombotic microangiopathy manifested by visual disturbance].
Topics: Adult; Aspirin; Bone Marrow Transplantation; Dipyridamole; Female; Humans; Leukemia, Myeloid, Acute; | 2000 |
Outcome of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in Japan.
Topics: Adolescent; Adult; Aged; Aspirin; Bacterial Toxins; Child; Child, Preschool; Clinical Trials as Topi | 1999 |
Saphenous vein graft disease treated with the Wiktor Hepamed stent: procedural outcome, in-hospital complications and six-month angiographic follow-up.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Artery Bypass; Female; Fibrinolytic Agents; Follow-Up | 2000 |
[Prevention of embolism in atrial septal defects?].
Topics: Adult; Age Factors; Anticoagulants; Aspirin; Coumarins; Embolism; Female; Fibrinolytic Agents; Heart | 2000 |
Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; | 2000 |
Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
Topics: Aspirin; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Drug Therapy, Combination; Humans; Platel | 2000 |
Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.
Topics: Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Dipyridamole; Drug Therapy, Combi | 2000 |
[Undertreatment in secondary prevention of patients with coronary heart disease after revascularization].
Topics: Adrenergic beta-Antagonists; Aftercare; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic | 2000 |
Transient ischemic attacks after dipyridamole-aspirin therapy.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dipyridamole; Drug The | 2000 |
[A case of choanal polyp in a man with aspirin triad and pollinosis].
Topics: Adult; Aspirin; Drug Hypersensitivity; Humans; Male; Nasal Polyps; Recurrence; Rhinitis, Allergic, S | 2000 |
Multifocal pyogranulomatous osteomyelitis resembling chronic recurrent multifocal osteomyelitis in a lemur.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy, Needle; Chronic Disease; Femur; F | 2001 |
Coexistence of factor V Leiden and primary antiphospholipid syndrome: a patient with recurrent myocardial infarctions and thrombocytopenia.
Topics: Activated Protein C Resistance; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Blood Coagulatio | 2000 |
Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice.
Topics: Animals; Aspirin; Constriction, Pathologic; Hypercholesterolemia; Mice; Mice, Inbred C57BL; Mice, Kn | 2001 |
ASA or low-molecular-weight heparin in the initial management of acute ischemic stroke complicating atrial fibrillation?
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2001 |
[Late stent thrombosis after intracoronary brachytherapy. A case report and review of the literature].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Brachytherapy; Clinical Trials as Topic; C | 2001 |
Heparin and aspirin in stroke.
Topics: Aspirin; Heparin, Low-Molecular-Weight; Humans; Recurrence; Risk Factors; Stroke | 2001 |
Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antiphospholipid Syndrome; Asp | 2001 |
Antiphospholipid antibodies in women at risk for preeclampsia.
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Aspirin; Blood Pressure; Enzyme-Li | 2001 |
Short-term outcome of stent implantation in saphenous vein grafts: predictors of distal embolization and restenosis.
Topics: Aged; Anticoagulants; Aspirin; Catheterization; Combined Modality Therapy; Comorbidity; Coronary Ang | 2001 |
Involvement of aspirin-sensitive oxylipins in vulvovaginal candidiasis.
Topics: Antifungal Agents; Arachidonic Acids; Aspirin; Candida albicans; Candidiasis, Vulvovaginal; Clotrima | 2001 |
Edge stenosis after intracoronary radiotherapy: angiographic, intravascular, and histological findings.
Topics: Aged; Angioplasty, Balloon, Laser-Assisted; Anticoagulants; Aspirin; Brachytherapy; Clopidogrel; Com | 2001 |
Second stroke.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Chemoprevention; Dipyridamole; Drug Approval; Drug | 2000 |
Status of secondary prevention in patients undergoing coronary revascularization.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 2001 |
Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Cilos | 2001 |
Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibod | 2001 |
Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child, Preschool; Cyclos | 2001 |
Transient ischaemic attacks: a GP guide.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Carotid Arteries; Diagnosis, Differentia | 2001 |
Low-dose aspirin is effective for treatment of recurrent miscarriage in patients with decreased coagulation factor XII.
Topics: Abortion, Spontaneous; Adult; Aspirin; Dose-Response Relationship, Drug; Factor XII Deficiency; Fema | 2001 |
Nonsteroidal anti-inflammatory drug-associated colitis with a histology of collagenous colitis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colitis; Collagen; Colonoscopy; Diarrhea; Fe | 2001 |
Late acute thrombosis after paclitaxel eluting stent implantation.
Topics: Acute Disease; Angiogenesis Inhibitors; Aspirin; Coronary Disease; Coronary Thrombosis; Drug Implant | 2001 |
[Treatment of ASS-Associated Polyposis (ASSAP) with a cysteinyl leukotriene receptor antagonist - a prospective drug study on its antiinflammatory effects].
Topics: Acetates; Adult; Anti-Asthmatic Agents; Aspirin; Asthma; Cyclopropanes; Female; Humans; Leukotriene | 2001 |
Aspirin and warfarin equally good for stroke patients.
Topics: Anticoagulants; Aspirin; Humans; Platelet Aggregation Inhibitors; Recurrence; Stroke; Warfarin | 2001 |
Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.
Topics: Adolescent; Adult; Aspirin; Brain Ischemia; Echocardiography, Transesophageal; Female; Follow-Up Stu | 2001 |
Initiative raises use of interventions that prevent second heart attacks.
Topics: Adrenergic beta-Antagonists; Aspirin; Cholesterol; Humans; Hypolipidemic Agents; Myocardial Infarcti | 2000 |
Transcatheter closure of patent foramen ovale in patients with paradoxical embolism: intermediate-term risk of recurrent neurological events.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Catheters, Indwelling; Embolism, Paradoxical; Fema | 2002 |
[Long-term prophylaxis with omeprazol is superior to eradication therapy in H. pylori-positive NSAIDs taking patients].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dose-Response Relationship, Drug; Helicobacter Inf | 2002 |
Natural history of small and medium-sized side branches after coronary stent implantation.
Topics: Acute Disease; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary An | 2002 |
Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials.
Topics: Abortion, Spontaneous; Adult; Antibodies, Antiphospholipid; Aspirin; Controlled Clinical Trials as T | 2002 |
[Severe Reye syndrome: report of 14 cases managed in a pediatric intensive care unit over 11 years].
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Edema; Child; Child, Preschoo | 2002 |
Recurrent haemolytic uraemic syndrome.
Topics: Adenoviridae; Antibodies, Viral; Anticoagulants; Aspirin; Child, Preschool; Dicumarol; Diphtheria To | 1976 |
Aspirin for the treatment of recurrent toxaemia.
Topics: Adult; Aspirin; Female; Humans; Pre-Eclampsia; Pregnancy; Pregnancy Trimester, Third; Recurrence; Th | 1978 |
[Therapeutic effectiveness of aspirin].
Topics: Aspirin; Blood Platelets; Humans; Myocardial Infarction; Recurrence; Thromboembolism | 1978 |
The detrimental effect of aspirin on hyphema rebleed.
Topics: Adolescent; Adult; Aspirin; Child; Child, Preschool; Eye Injuries; Humans; Hyphema; Iris; Middle Age | 1979 |
Moves beginning to approve new indications for aspirin use.
Topics: Aspirin; Female; Humans; Ischemic Attack, Transient; Male; Recurrence; Sex Factors | 1979 |
Statistical evidence of the German-Austrian secondary prevention trial.
Topics: Actuarial Analysis; Aspirin; Austria; Germany; Humans; Myocardial Infarction; Phenprocoumon; Recurre | 1979 |
Prevention of subsequent infarctions and transient ischemic attacks.
Topics: Aged; Anticoagulants; Aspirin; Cerebral Infarction; Humans; Ischemic Attack, Transient; Middle Aged; | 1979 |
[Deforming, recurrent nasal polyposis in the adult].
Topics: Adrenal Cortex Hormones; Adult; Aspirin; Asthma; Child; Cystic Fibrosis; Drug Hypersensitivity; Huma | 1979 |
TIA, stroke, and mitral valve prolapse.
Topics: Adult; Aged; Aspirin; Carotid Artery Thrombosis; Cerebrovascular Disorders; Dipyridamole; Echocardio | 1979 |
Chronic and recurrent urticaria: new concepts of drug-group sensitivity.
Topics: Aspirin; Barbiturates; Blood Coagulation Tests; Chronic Disease; Cross Reactions; Dose-Response Rela | 1977 |
Influence of aspirin on healing of chronic gastric ulcers in dogs.
Topics: Acetates; Animals; Aspirin; Chronic Disease; Dogs; Gastric Mucosa; Gastroscopy; Male; Peptic Ulcer P | 1977 |
Antiplatelet agents in coronary disease: are they of prophylactic value?
Topics: Angina Pectoris; Aspirin; Cardiopulmonary Bypass; Clofibrate; Coronary Disease; Dipyridamole; Fibrin | 1978 |
[Treatment of recurrent rheumatism with acetylsalicylic acid and its pharmacokinetics].
Topics: Adult; Aspirin; Humans; Middle Aged; Recurrence; Rheumatic Fever | 1978 |
Cricoarytenoid arthritis and airway obstruction in juvenile rheumatoid arthritis.
Topics: Airway Obstruction; Arthritis, Juvenile; Aspirin; Child, Preschool; Dexamethasone; Humans; Laryngeal | 1977 |
[Modern aspects in the pathogenesis of urticaria with special reference to intolerance phenomena].
Topics: Anaphylaxis; Antigen-Antibody Reactions; Aspirin; Autoantigens; Chronic Disease; Cold Temperature; D | 1977 |
The effect of aspirin on rebleeding in traumatic hyphema.
Topics: Aspirin; Child; Hemorrhage; Humans; Hyphema; Recurrence | 1976 |
A follow-up study of patients with recurrent urticaria and hypersensitivity to aspirin, benzoates and azo dyes.
Topics: Adolescent; Adult; Aged; Aspirin; Azo Compounds; Benzoates; Drug Hypersensitivity; Female; Follow-Up | 1976 |
Effects of acetylsalicylic acid (ASA), ASA plus L-glutamine and L-glutamine on healing of chronic gastric ulcer in the rat.
Topics: Animals; Aspirin; Chronic Disease; Drug Evaluation, Preclinical; Glutamine; Male; Rats; Recurrence; | 1976 |
Primary and secondary prevention trials in coronary heart disease.
Topics: Adult; Aspirin; Coronary Disease; Diet; Diet, Atherogenic; Evaluation Studies as Topic; Humans; Male | 1976 |
Gastric devascularization: an alternate approach to the surgical treatment of massive, diffuse hemorrhage from gastritis.
Topics: Adult; Age Factors; Alcoholism; Aspirin; Burns; Child, Preschool; Female; Gastrectomy; Gastritis; Ga | 1976 |
[The antithrombotic treatment and prevention of recurrence with acetylsalicylic acid in myocardial infarct].
Topics: Animals; Anticoagulants; Aspirin; Dogs; Drug Hypersensitivity; Gastrointestinal Hemorrhage; Humans; | 1976 |
Increased platelet aggregability in young patients with stroke. Diagnosis and therapy.
Topics: Adult; Aspirin; Blood Coagulation Tests; Blood Platelet Disorders; Cell Survival; Cerebrovascular Di | 1975 |
The effect of aspirin on rebleeding in traumatic hyphema.
Topics: Aspirin; Eye Injuries; Hemorrhage; Humans; Hyphema; Platelet Adhesiveness; Recurrence | 1975 |
Factors relevant to the prognosis of chronic gastric ulcer.
Topics: Age Factors; Aspirin; Chronic Disease; Female; Follow-Up Studies; Humans; Male; Prognosis; Recurrenc | 1975 |
[Proceedings: Case of acute idiopathic recurring pericarditis].
Topics: Acute Disease; Aspirin; Child; Cortisone; Humans; Indomethacin; Male; Pericarditis; Recurrence | 1975 |
Growing pains: fact or fiction?
Topics: Adolescent; Adult; Age Factors; Arthritis, Juvenile; Aspirin; Child; Diagnosis, Differential; Extrem | 1976 |
Platelet hyperaggregability in idiopathic recurrent deep vein thrombosis.
Topics: Adult; Aspirin; Blood Platelets; Dipyridamole; Female; Humans; Male; Methods; Middle Aged; Platelet | 1976 |
Recurring and chronic urticaria: identification of etiologies.
Topics: Aspirin; Barbiturates; Blood Coagulation Tests; Bromides; Chronic Disease; Drug Hypersensitivity; Hu | 1976 |
Secondary prevention of coronary heart disease in patients after acute myocardial infarction at the Soroka Medical Center.
Topics: Adrenergic beta-Antagonists; Adult; Aftercare; Aged; Aspirin; Calcium Channel Blockers; Clinical Pro | 1992 |
[Drug treatments of atrial fibrillation].
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Atrial Fibrillation; H | 1992 |
Residual platelet function under acetylsalicylic acid and the risk of restenosis after coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Disease; Cyclic AMP; Female; Humans; Male; Platele | 1992 |
Fixed drug eruption in a mother and her son.
Topics: Adult; Anxiety; Aspirin; Child; Dimenhydrinate; Drug Eruptions; Food Hypersensitivity; Humans; Male; | 1992 |
The effect of antiplatelet therapy on platelet accumulation after experimental angioplasty in the rabbit iliac model.
Topics: Angioplasty, Balloon; Animals; Arteriosclerosis; Aspirin; Dipyridamole; Disease Models, Animal; Drug | 1992 |
[Prevention of recurrence of myocardial infarction].
Topics: Age Factors; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Artery By | 1992 |
Dilated cardiomyopathy with recurrent intraventricular thrombosis.
Topics: Aspirin; Cardiomyopathy, Dilated; Coronary Thrombosis; Echocardiography; Electrocardiography; Heart | 1992 |
Gastric changes in coronary-operated patients with low-dose aspirin.
Topics: Adult; Aged; Aspirin; Coronary Artery Bypass; Coronary Disease; Dose-Response Relationship, Drug; Fe | 1992 |
Efficacy of cryotherapy in vernal catarrh.
Topics: Adolescent; Adult; Aspirin; Child; Conjunctiva; Conjunctivitis, Allergic; Cryosurgery; Female; Follo | 1992 |
Thrombolytic therapy: reocclusion rates with adjunctive aspirin and its relation to heparin therapy.
Topics: Aspirin; Chemotherapy, Adjuvant; Coronary Thrombosis; Heparin; Humans; Recurrence; Streptokinase; Th | 1992 |
Aspirin as a risk factor for hemorrhage in patients with head injuries.
Topics: Adult; Aged; Aspirin; Brain Concussion; Cerebral Hemorrhage; Female; Hematoma, Epidural, Cranial; He | 1992 |
Safety of combined intravenous beta-adrenergic blockade (atenolol or metoprolol) and thrombolytic therapy in acute myocardial infarction.
Topics: Administration, Oral; Adult; Aspirin; Atenolol; Combined Modality Therapy; Female; Humans; Infusions | 1992 |
Complications after intracoronary stent implantation: three cases.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Disease; Coumarins; Di | 1992 |
[Strategies for antiplatelet therapy-drug-fixed method and suppression-fixed method].
Topics: Aspirin; Cerebral Infarction; Dipyridamole; Drug Therapy, Combination; Humans; Myocardial Infarction | 1992 |
Changes in drug treatment and case fatality of patients with acute myocardial infarction. Observations from the Newcastle MONICA Project, 1984/1985 to 1988/1990.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Blockers; Diuretics; | 1992 |
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
Topics: Aged; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hepa | 1992 |
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
Topics: Aged; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hepa | 1992 |
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
Topics: Aged; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hepa | 1992 |
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients.
Topics: Aged; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hepa | 1992 |
Adjunctive therapies in thrombolysis. Introduction.
Topics: Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Heparin; Humans; Myocardial Infarcti | 1991 |
Aspirin, warfarin, and recurrent stroke.
Topics: Aged; Aspirin; Cerebrovascular Disorders; Female; Humans; Male; Middle Aged; Recurrence; Warfarin | 1991 |
Aspirin, warfarin, and recurrent stroke.
Topics: Aspirin; Cerebrovascular Disorders; Humans; Recurrence; Warfarin | 1991 |
Reocclusion after thrombolysis: a problem solved by hirudin?
Topics: Animals; Aspirin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heparin; Hirudin Therapy; H | 1991 |
Experimental reactivation of chronic gastric lesions exposed to different aggressive conditions.
Topics: Acetates; Animals; Aspirin; Chronic Disease; Ethanol; Female; Gastric Acid; Gastric Mucosa; Random A | 1991 |
[Clinical interventions for prevention and therapy of restenosis of coronary heart disease].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Follow-Up Stud | 1991 |
[A clinical trial of the secondary prevention of reinfarction with low dose aspirin].
Topics: Aged; Aspirin; China; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; R | 1991 |
[Effect of antiplatelet therapy on prevention of thrombotic diseases].
Topics: Arachidonic Acid; Arterial Occlusive Diseases; Aspirin; Cerebral Infarction; Humans; Myocardial Infa | 1991 |
[Rate of recurrence following PTA of pelvic-leg arteries in relation to selected risk factors and antithrombotic after care].
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Combined Modality Therapy; Coumarins; Fo | 1991 |
[Recurrent thromboembolism due to increased acetylsalicylic acid-resistant platelet aggregation].
Topics: Aspirin; Fibrin; Humans; Male; Middle Aged; Platelet Aggregation; Recurrence; Thromboembolism; Ticlo | 1991 |
Conservative management complications after thrombolytic therapy.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Drug Therapy, Combination; | 1991 |
Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
Topics: Animals; Aspirin; Coronary Thrombosis; Dogs; Fibrinolytic Agents; Heparin; Hirudin Therapy; Hirudins | 1991 |
Coronary bypasses 10 years on.
Topics: Aspirin; Coronary Artery Bypass; Coronary Disease; Female; Graft Occlusion, Vascular; Humans; Male; | 1991 |
[The antiphospholipid syndrome. The neurological complications and the therapeutic possibilities].
Topics: Adult; Antibodies; Antiphospholipid Syndrome; Aspirin; Blindness; Female; Humans; Nervous System Dis | 1991 |
Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cholesterol; Cholesterol, HDL; Cholesterol, LD | 1991 |
Reevaluation of the Cottbus Reinfarction Study with 30 mg aspirin per day 4 years after the end of the study.
Topics: Aspirin; Dose-Response Relationship, Drug; Follow-Up Studies; Germany; Humans; Middle Aged; Myocardi | 1991 |
Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation
Topics: Animals; Antibodies, Monoclonal; Antithrombins; Arginine; Aspirin; Coronary Circulation; Coronary Di | 1990 |
Pharmacological therapy after coronary angioplasty. Early experience with low molecular weight heparin for prophylaxis of reocclusion.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Coronary Disease; Heparin, Low-M | 1990 |
Patient-related variables and restenosis after percutaneous transluminal coronary angioplasty--a report from the M-HEART Group.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Constriction, Pathologic; C | 1990 |
[Coronary endoprostheses (stents)].
Topics: Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Aspirin; Coronary Angiography; Coronary Dis | 1990 |
[Experiences from general practice: use of acetylsalicylic acid and anticoagulants in patients following acute myocardial infarct].
Topics: Aged; Aspirin; Berlin; Blood Coagulation Tests; Follow-Up Studies; Humans; Middle Aged; Myocardial I | 1990 |
[Thrombotic thrombocytopenic purpura: a benign disease with a very severe acute phase].
Topics: Adult; Aspirin; Combined Modality Therapy; Drug Therapy, Combination; Female; Humans; Plasmapheresis | 1990 |
Acute infarction during triple-vessel coronary angioplasty due to acute occlusion of a nonattempted vessel.
Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Cardiac Catheterization; Combined Modality Therapy; | 1990 |
Value of a centralised approach in the management of haematemesis and melaena: experience in a district general hospital.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Femal | 1990 |
[Late results following thrombendarterectomy of the carotid artery].
Topics: Aged; Aspirin; Carotid Artery Thrombosis; Endarterectomy; Female; Humans; Male; Middle Aged; Postope | 1990 |
[The patient following PTCA].
Topics: Angioplasty, Balloon, Coronary; Aspirin; Calcium Channel Blockers; Coronary Disease; Exercise Test; | 1990 |
Intermittent, dose-related fluctuations of pain and ST elevation during infusion of recombinant tissue plasminogen activator during acute myocardial infarction.
Topics: Adult; Aged; Aspirin; Blood Coagulation; Electrocardiography; Heparin; Humans; Middle Aged; Myocardi | 1989 |
Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors.
Topics: Amino Acid Sequence; Animals; Aspirin; Dogs; Femoral Artery; Microscopy, Electron, Scanning; Molecul | 1989 |
Ranitidine maintenance treatment of non-steroidal anti-inflammatory drug-induced duodenal ulceration.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Duodenal Ulcer; Du | 1989 |
Platelet deposition at angioplasty sites and its relation to restenosis in human iliac and femoropopliteal arteries.
Topics: Angioplasty, Balloon; Arterial Occlusive Diseases; Aspirin; Blood Platelets; Constriction, Pathologi | 1989 |
Successful pregnancies of two patients with relapsing thrombotic thrombocytopenic purpura.
Topics: Adult; Aspirin; Blood Transfusion; Combined Modality Therapy; Dipyridamole; Drug Therapy, Combinatio | 1989 |
[The effectiveness of antiplatelet therapy in ischemic cerebrovascular attacks in the chronic stage].
Topics: Aspirin; Brain Ischemia; Dipyridamole; Female; Hemiplegia; Humans; Male; Middle Aged; Pentoxifylline | 1989 |
Idiopathic recurrent branch retinal arterial occlusion.
Topics: Adult; Aspirin; Female; Fluorescein Angiography; Fundus Oculi; Humans; Recurrence; Retina; Retinal A | 1989 |
Late carotid restenosis: aetiologic factors for recurrent carotid artery stenosis during long-term follow-up.
Topics: Adult; Aged; Aspirin; Carotid Artery Diseases; Cholesterol; Cholesterol, HDL; Constriction, Patholog | 1989 |
[Ischemic cerebrovascular disease: treatment with various anti-platelet aggregation drugs. Clinical follow-up of 80 patients (22-34 months)].
Topics: Adenosine Diphosphate; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Isoxsuprine; Male; Oxa | 1985 |
Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile?
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Anticoagulants; Aspirin; Atrial Fibrillatio | 1986 |
Secondary prevention after myocardial infarction.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Coronary Artery Bypass; Humans; Lipids; Myocar | 1986 |
[Secondary prevention following myocardial infarct].
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Death, Sudden; Humans; Myocardial Infarction; | 1986 |
Indium-111-labeled platelet scintigraphy in carotid atherosclerosis.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Aspirin; Blood Platelets; Carotid Artery Diseases; | 1989 |
Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody.
Topics: Aspirin; Autoantibodies; Female; Fetal Death; Humans; Lupus Erythematosus, Systemic; Phospholipids; | 1989 |
Management of patients after thrombolytic therapy for acute myocardial infarction.
Topics: Angioplasty, Balloon; Aspirin; Combined Modality Therapy; Coronary Artery Bypass; Coronary Circulati | 1985 |
[Prevention of thrombosis in the after-care of coronary dilatation and thrombolysis].
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Combined Modality Therapy; Coronary Circulation; Coro | 1986 |
Reocclusions after percutaneous transluminal coronary angioplasty.
Topics: Angioplasty, Balloon; Animals; Aspirin; Constriction, Pathologic; Coronary Disease; Dipyridamole; Hu | 1987 |
Restenosis after arterial angioplasty: a hemorrheologic response to injury.
Topics: Angioplasty, Balloon; Animals; Arterial Occlusive Diseases; Arteries; Aspirin; Microscopy, Electron, | 1987 |
The Frankfurt experience in restenosis after coronary angioplasty.
Topics: Angioplasty, Balloon; Aspirin; Calcium Channel Blockers; Coronary Disease; Follow-Up Studies; German | 1987 |
Laboratory test results as predictors of recurrent coronary artery stenosis following angioplasty.
Topics: Aged; Angioplasty, Balloon; Aspirin; Cholesterol; Clinical Laboratory Techniques; Coronary Disease; | 1987 |
Feline aortic thromboemboli: t-PA thrombolysis followed by aspirin therapy and rethrombosis.
Topics: Animals; Aortic Diseases; Aspirin; Cat Diseases; Cats; Female; Recurrence; Thromboembolism; Tissue P | 1988 |
Recurrence rate after successful coronary angioplasty.
Topics: Angiography; Angioplasty, Balloon; Aspirin; Calcium Channel Blockers; Combined Modality Therapy; Con | 1985 |
Clinical experience of percutaneous transluminal coronary angioplasty--technique and results.
Topics: Adult; Aged; Angina Pectoris; Angioplasty, Balloon; Aspirin; Coronary Angiography; Coronary Disease; | 1985 |
Preventive effects of batroxobin on experimental canine coronary thrombosis.
Topics: Animals; Aspirin; Batroxobin; Coronary Disease; Coronary Thrombosis; Disease Models, Animal; Dogs; E | 1988 |
Platelet kinetics following carotid endarterectomy: the effect of aspirin and patch angioplasty.
Topics: Aspirin; Blood Vessel Prosthesis; Carotid Arteries; Carotid Artery Diseases; Dipyridamole; Endartere | 1988 |
Aspirin and secondary bleeding after traumatic hyphema.
Topics: Aspirin; Eye Injuries; Humans; Hyphema; Recurrence; Statistics as Topic | 1988 |
Which peptic ulcer patients bleed?
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Male; Mi | 1988 |
Short-term infarct vessel patency with aspirin and dipyridamole started 24 to 36 hours after intravenous streptokinase.
Topics: Angiography; Aspirin; Dipyridamole; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardi | 1988 |
Aspirin sensitivity and recurrent polyposis.
Topics: Aspirin; Asthma; Drug Hypersensitivity; Humans; Nasal Polyps; Recurrence | 1988 |
Childhood membranoproliferative glomerulonephritis: an approach to management.
Topics: Aspirin; Azathioprine; Child; Cyclophosphamide; Dipyridamole; Drug Administration Schedule; Drug The | 1986 |
Relapsing Kawasaki's disease.
Topics: Aspirin; Dermatitis; Female; Fever; Humans; Infant; Mucocutaneous Lymph Node Syndrome; Recurrence | 1987 |
Transient ischemic attacks at high altitude.
Topics: Adult; Altitude Sickness; Aspirin; Fluid Therapy; Humans; Hypoxia; Ischemic Attack, Transient; Male; | 1986 |
Exacerbating factors in recurrent urticaria.
Topics: Adult; Angioedema; Aspirin; Chronic Disease; Female; Hot Temperature; Humans; Male; Recurrence; Urti | 1986 |
Bronchoalveolar lavage in recurrent aspirin-induced adult respiratory distress syndrome.
Topics: Aspirin; Humans; Leukocytes; Male; Middle Aged; Pulmonary Alveoli; Pulmonary Edema; Recurrence; Resp | 1986 |
Carotid endarterectomy. One solution to the stroke problem.
Topics: Adult; Aged; Arterial Occlusive Diseases; Aspirin; Carotid Arteries; Carotid Artery Diseases; Cerebr | 1985 |
Peripheral vascular disease: treatment and referral of the elderly. Part II.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular | 1985 |
Antiplatelet drugs improve the patency rates after femoro-popliteal endarterectomy.
Topics: Arterial Occlusive Diseases; Aspirin; Blood Platelets; Dipyridamole; Endarterectomy; Female; Femoral | 1985 |
The incidence of rebleeding in traumatic hyphema.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Age Factors; Aged; Analysis of Variance; Aspirin; Child; | 1985 |
[Diagnostic and therapeutic methods in the asthmatic triad].
Topics: Adolescent; Adult; Aspirin; Asthma; Bronchial Provocation Tests; Child; Desensitization, Immunologic | 1985 |
White blood cell count and haematocrit as predictors of coronary recurrence after myocardial infarction.
Topics: Adult; Aged; Aspirin; Cholesterol; Coronary Disease; Dipyridamole; Diuretics; Female; Hematocrit; Hu | 1985 |
Effect of aspirin in amaurosis fugax.
Topics: Aspirin; Blindness; Dipyridamole; Recurrence; Retinal Vessels; Thrombosis | 1971 |
Aspirin and recurrent painful toes and fingers in thrombocythaemia.
Topics: Aged; Aspirin; Blood Platelet Disorders; Fingers; Humans; Male; Middle Aged; Pain; Platelet Adhesive | 1972 |
Urticaria and angioedema.
Topics: Adult; Anaphylaxis; Angioedema; Aspirin; Cold Temperature; Female; Histamine Release; Humans; Male; | 1972 |
Delayed febrile pleuropericarditis after sepsis. A possible analogue of the postcardiotomy syndrome.
Topics: Adult; Aspirin; Blood Sedimentation; Cardiomegaly; Erythrocytes; Female; Fever; Heart Auscultation; | 1973 |
The natural history of duodenal ulceration.
Topics: Aspirin; Duodenal Ulcer; Female; Gastric Acidity Determination; Gastric Juice; Gastrointestinal Hemo | 1972 |
[Recurrent gastric hemorrhage caused by salicylic acid].
Topics: Aspirin; Gastric Mucosa; Gastrointestinal Hemorrhage; Gastroscopy; Hematemesis; Humans; Male; Melena | 1974 |
The management of a patient with a duodenal ulcer.
Topics: Adult; Alcohol Drinking; Alkalies; Aspirin; Chronic Disease; Diet Therapy; Duodenal Ulcer; Humans; P | 1972 |
[Comparative evaluation of different methods of secondary prevention of rheumatism].
Topics: Aspirin; Disability Evaluation; Humans; Laryngitis; Penicillin G Benzathine; Penicillins; Recurrence | 1973 |